WorldWideScience

Sample records for breast cancer sentinel

  1. Radiation protection for the sentinel node procedure in breast cancer

    NARCIS (Netherlands)

    de Kanter, AY; Arends, PPAM; Eggermont, AMM; Wiggers, T

    2003-01-01

    Aims: The purpose of our study was to determine the radiation dose for those who are involved in the sentinel node procedure in breast cancer patients and testing of a theoretical model. Methods: We studied 12 consecutive breast cancer patients undergoing breast surgery, and a sentinel node dissecti

  2. Sentinel Lymph Node Dissection in Locally Recurrent Breast Cancer

    DEFF Research Database (Denmark)

    Uth, Charlotte Caspara; Christensen, Mette Haulund; Oldenbourg, Mette Holmqvist

    2015-01-01

    BACKGROUND: The aim of this study was to investigate the use of sentinel lymph node dissection (SLND) in the treatment of patients with locally recurrent breast cancer. METHODS: A total of 147 patients with locally recurrent breast cancer were included from five different breast surgery departments...

  3. Assessment of Risk Reduction for Lymphedema Following Sentinel Lymph Noded Guided Surgery for Primary Breast Cancer

    Science.gov (United States)

    2006-10-01

    Lymphedema Following Sentinel Lymph Noded Guided Surgery for Primary Breast Cancer PRINCIPAL INVESTIGATOR: Andrea L. Cheville, M.D...5a. CONTRACT NUMBER Assessment of Risk Reduction for Lymphedema Following Sentinel Lymph Noded Guided Surgery for Primary Breast Cancer 5b...14. ABSTRACT Lymphedema is a common complication of primary breast cancer therapy. It is a chronic, insidiously progressive, and potentially

  4. Nanoparticles in Sentinel Lymph Node Assessment in Breast Cancer

    OpenAIRE

    Michael Douek; Geoff Charles-Edwards; Laura Johnson

    2010-01-01

    The modern management of the axilla in breast cancer relies on surgery for accurate staging of disease and identifying those patients at risk who would benefit from adjuvant chemotherapy. The introduction of sentinel lymph node biopsy has revolutionized axillary surgery, but still involves a surgical procedure with associated morbidity in many patients with no axillary involvement. Nanotechnology encompasses a broad spectrum of scientific specialities, of which nanomedicine is one. The potent...

  5. [Sentinel lymph node biopsy in breast cancer. Experience of the Rome Breast Cancer Study Group].

    Science.gov (United States)

    Fortunato, Lucio; Drago, Stefano; Vitelli, Carlo Eugenio; Santoni, Marcello; Gucciardo, Giacomo; Cabassi, Alessandro; Farina, Massimo; La Pinta, Massimo; Remedi, Massimiliano; Pagano, Giovanni; Silipod, Teresa; Terribile, Daniela; Stagnitto, Daniela; Grassi, Giovanni Battista

    2006-01-01

    We report our multicentric experience with sentinel lymph node biopsy for breast cancer patients. Patients with breast cancer operated on from January 1999 to March 2005 in 6 different institutions in the Rome area were retrospectively reviewed. All patients gave written informed consent. 1440 consecutive patients were analysed, with a median age of 59 years (range: 33-81) and a median tumour diameter of 1.3 cm (range: 0.1-5). Patients underwent lymphatic mapping with Tc99 nanocolloid (N = 701; 49%), with Evans Blue (N = 70; 5%), or with a combined injection (N = 669, 46%). The majority of patients were mapped with an intradermal or subdermal injection (N = 1193; 84%), while an intraparenchymal or peritumoral injection was used in 41 (3%) and 206 patients (13%), respectively. Sentinel lymph nodes were identified in 1374/1440 cases (95.4%), and 2075 sentinel lymph nodes were analysed (average 1.5/patient). A total of 9305 additional non-sentinel lymph-nodes were removed (median 6/patient). Correlations between sentinel lymph nodes and final lymph node status were found in 1355/1374 cases (98.6%). There were 19 false-negative cases (5%). Lymph node metastases were diagnosed in 325 patients (24%). In this group, micrometastases (< 2 mm in diameter) were diagnosed in 103 cases (7.6%). Additionally, isolated tumour cells were reported in 61 patients (4,5%). In positive cases, additional metastases in non-sentinel lymph-nodes were identified in 117/325 cases after axillary dissection (36%). Axillary dissection was avoided in 745/1440 patients (52%). At a median follow-up of 36 months, only 1 axillary recurrence has been reported. Sentinel lymph node biopsy improves staging in women with breast cancer because it is accurate and reproducible, and allows detection of micrometastases and isolated tumour cells that would otherwise be missed. Our multicentric study confirms that this is the preferred axillary staging procedure in women with breast cancer.

  6. Sentinel lymph node biopsy indications and controversies in breast cancer.

    Science.gov (United States)

    Wiatrek, Rebecca; Kruper, Laura

    2011-05-01

    Sentinel lymph node biopsy (SLNB) has become the standard of care for early breast cancer. Its use in breast cancer has been evaluated in several randomized controlled trials and validated in multiple prospective studies. Additionally, it has been verified that SLNB has decreased morbidity when compared to axillary lymph node dissection (ALND). The technique used to perform sentinel lymph node mapping was also evaluated in multiple studies and the accuracy rate increases when radiocolloid and blue dye are used in combination. As SLNB became more accepted, contraindications were delineated and are still debated. Patients who have clinically positive lymph nodes or core biopsy-proven positive lymph nodes should not have SLNB, but should have an ALND as their staging procedure. The safety of SLNB in pregnant patients is not fully established. However, patients with multifocal or multicentric breast cancer and patients having neoadjuvant chemotherapy are considered candidates for SLNB. However, the details of which specific neoadjuvant patients should have SLNB are currently being evaluated in a randomized controlled trial. Patients with ductal carcinoma in situ (DCIS) benefit from SLNB when mastectomy is planned and when there is a high clinical suspicion of invasion. With the advent of SLNB, pathologic review of breast cancer lymph nodes has evolved. The significance of occult metastasis in SLNB patients is currently being debated. Additionally, the most controversial subject with regards to SLNB is determining which patients with positive SLNs benefit from further axillary dissection.

  7. The clinical value of hybrid sentinel lymphoscintigraphy to predict metastatic sentinel lymph nodes in breast cancer

    Energy Technology Data Exchange (ETDEWEB)

    Na, Cang Ju; Kim, Jeong Hun; Choi, Se Hun; Han, Yeon Hee; Jeong, Hwan Jeong; Sohn, Myung Hee; Youn, Hyun Jo; Lim, Seok Tae [Chonbuk National University Medical School and Hospital, Jeonju (Korea, Republic of)

    2015-03-15

    Hybrid imaging techniques can provide functional and anatomical information about sentinel lymph nodes in breast cancer. Our aim in this study was to evaluate which imaging parameters on hybrid sentinel lymphoscintigraphy predicted metastatic involvement of sentinel lymph nodes (SLNs) in patients with breast cancer. Among 56 patients who underwent conventional sentinel lymphoscintigraphy, 45 patients (age, 53.1 ± 9.5 years) underwent hybrid sentinel lymphoscintigraphy using a single-photon emission computed tomography (SPECT)/computed tomography (CT) gamma camera. On hybrid SPECT/CT images, we compared the shape and size (long-to-short axis [L/S] ratio) of the SLN, and SLN/periareolar injection site (S/P) count ratio between metastatic and non-metastatic SLNs. Metastatic involvement of sentinel lymph nodes was confirmed by pathological biopsy. Pathological biopsy revealed that 21 patients (46.7 %) had metastatic SLNs, while 24 (53.3 %) had non-metastatic SLNs. In the 21 patients with metastatic SLNs, the SLN was mostly round (57.1 %) or had an eccentric cortical rim (38.1 %). Of 24 patients with non-metastatic SLNs, 13 patients (54.1 %) had an SLN with a C-shape rim or eccentric cortex. L/S ratio was 2.04 for metastatic SLNs and 2.38 for non-metastatic SLNs. Seven (33 %) patients had T1 primary tumors and 14 (66 %) had T2 primary tumors in the metastatic SLN group. In contrast, 18 (75 %) patients had T1 primary tumors and six (25 %) had T2 tumors in the non-metastatic SLN group. S/P count ratio was significantly lower in the metastatic SLN group than the non-metastatic SLN group for those patients with a T1 primary tumor (p = 0.007). Hybrid SPECT/CT offers the physiologic data of SPECT together with the anatomic data of CT in a single image. This hybrid imaging improved the anatomic localization of SLNs in breast cancer patients and predicted the metastatic involvement of SLNs in the subgroup of breast cancer patients with T1 primary tumors.

  8. Sentinel lymph node biopsy in pregnant patients with breast cancer

    Energy Technology Data Exchange (ETDEWEB)

    Gentilini, Oreste; Toesca, Antonio; Sangalli, Claudia; Veronesi, Paolo; Galimberti, Viviana [European Institute of Oncology, Division of Senology, Milan (Italy); Cremonesi, Marta; Pedroli, Guido [European Institute of Oncology, Unit of Medical Physics, Milan (Italy); Colombo, Nicola [European Institute of Oncology, Unit of Cardiology, Milan (Italy); Peccatori, Fedro [European Institute of Oncology, Division of Haematology-Oncology, Milan (Italy); Sironi, Roberto [S. Pio X Hospital, Unit of Obstetrics and Gynecology, Milan (Italy); Rotmensz, Nicole [European Institute of Oncology, Division of Epidemiology and Biostatistics, Milan (Italy); Viale, Giuseppe [European Institute of Oncology, Division of Pathology, Milan (Italy); University of Milan School of Medicine, Milan (Italy); Goldhirsch, Aron [European Institute of Oncology, Department of Medicine, Milan (Italy); Veronesi, Umberto [European Institute of Oncology, Division of Senology, Milan (Italy); European Institute of Oncology, Milan (Italy); Paganelli, Giovanni [European Institute of Oncology, Division of Nuclear Medicine, Milano (Italy)

    2010-01-15

    Sentinel lymph node biopsy (SLNB) is currently not recommended in pregnant patients with breast cancer due to radiation concerns. Twelve pregnant patients with breast cancer received low-dose (10 MBq on average) lymphoscintigraphy using {sup 99m}Tc human serum albumin nanocolloids. The sentinel lymph node (SLN) was identified in all patients. Of the 12 patients, 10 had pathologically negative SLN. One patient had micrometastasis in one of four SLN. One patient had metastasis in the SLN and underwent axillary clearance. From the 12 pregnancies, 11 healthy babies were born with no malformations and normal weight. One baby, whose mother underwent lymphatic mapping during the 26th week of gestation, was operated on at the age of 3 months for a ventricular septal defect and at 43 months was in good health. This malformation was suspected at the morphological US examination during week 21, well before lymphoscintigraphy, and was confirmed a posteriori by a different observer based on videotaped material. No overt axillary recurrence appeared in the patients with negative SLNs after a median follow-up of 32 months. Our experience supports the safety of SLNB in pregnant patients with breast cancer, when performed with a low-dose lymphoscintigraphic technique. (orig.)

  9. The role of sentinel node biopsy in male breast cancer.

    Science.gov (United States)

    Maráz, Róbert; Boross, Gábor; Pap-Szekeres, József; Markó, László; Rajtár, Mária; Ambrózay, Éva; Bori, Rita; Cserni, Gábor

    2016-01-01

    Sentinel lymph node biopsy (SLNB) is a standard procedure in women with breast cancer. The risk of morbidity related to axillary lymph node dissection (ALND) is similar for men and women with breast cancer and SLNB could minimize this risk. Between January 2004 and August 2013, 25 men with primary breast cancer were operated on at the Bács-Kiskun County Teaching Hospital. These were reviewed retrospectively. SLNB was performed following lymphoscintigraphy with intraoperative gamma probe detection and blue dye mapping. SLNB was successful in all 16 male patients (100 %), in whom it was attempted. The SLNs were negative in 4 cases (25 %) and were involved in 12. Intraoperative imprint cytology was positive in 9 of the 12 involved cases (75 %) and resulted immediate completion ALND. In 7 patients, the intraoperative imprint cytology was negative, with 3 false-negative results that resulted in delayed completion ALND. After a median follow-up of 48 months, there was only one axillary recurrence after ALND and none in the SLNB group. SLNB is successful and accurate in male breast cancer patients too. Although compared to women a larger proportion of men have positive nodes, for men with negative nodes, ALND-related morbidity may be reduced by SLNB. We recommend SLNB in male patients with breast cancer and clinically negative axilla.

  10. Intraoperative immunohistochemistry staining of sentinel nodes in breast cancer: Clinical and economical implications

    DEFF Research Database (Denmark)

    Holm, M.; Paaschburg, B.; Balslev, E.;

    2008-01-01

    The study aimed to evaluate intraoperative immunohistochemistry (IHC) staining of sentinel nodes in primary breast cancer surgery. We analysed retrospectively 1209 consecutive sentinel node procedures and compared the rate of late positive metastases in sentinel node biopsy (SNB) and the duration...

  11. [Sentinel node in melanoma and breast cancer. Current considerations].

    Science.gov (United States)

    Vidal-Sicart, S; Vilalta Solsona, A; Alonso Vargas, M I

    2015-01-01

    The main objectives of sentinel node (SN) biopsy is to avoid unnecessary lymphadenectomies and to identify the 20-25% of patients with occult regional metastatic involvement. This technique reduces the associated morbidity from lymphadenectomy and increases the occult lymphatic metastases identification rate by offering the pathologist the or those lymph nodes with the highest probability of containing metastatic cells. Pre-surgical lymphoscintigraphy is considered a "road map" to guide the surgeon towards the sentinel nodes and to localize unpredictable lymphatic drainage patterns. The SPECT/CT advantages include a better SN detection rate than planar images, the ability to detect SNs in difficult to interpret studies, better SN depiction, especially in sites closer to the injection site and better anatomic localization. These advantages may result in a change in the patient's clinical management both in melanoma and breast cancer. The correct SN evaluation by pathology implies a tumoral load stratification and further prognostic implication. The use of intraoperative imaging devices allows the surgeon a better surgical approach and precise SN localization. Several studies reports the added value of such devices for more sentinel nodes excision and a complete monitoring of the whole procedure. New techniques, by using fluorescent or hybrid tracers, are currently being developed. Copyright © 2014 Elsevier España, S.L.U. and SEMNIM. All rights reserved.

  12. Nanoparticles in Sentinel Lymph Node Assessment in Breast Cancer

    Directory of Open Access Journals (Sweden)

    Michael Douek

    2010-11-01

    Full Text Available The modern management of the axilla in breast cancer relies on surgery for accurate staging of disease and identifying those patients at risk who would benefit from adjuvant chemotherapy. The introduction of sentinel lymph node biopsy has revolutionized axillary surgery, but still involves a surgical procedure with associated morbidity in many patients with no axillary involvement. Nanotechnology encompasses a broad spectrum of scientific specialities, of which nanomedicine is one. The potential use of dual-purpose nanoprobes could enable imaging the axilla simultaneous identification and treatment of metastatic disease. Whilst most applications of nanomedicine are still largely in the laboratory phase, some potential applications are currently undergoing clinical evaluation for translation from the bench to the bedside. This is an exciting new area of research where scientific research may become a reality.

  13. Sentinel Lymph Node Occult Metastases Have Minimal Survival Effect in Some Breast Cancer Patients

    Science.gov (United States)

    Detailed examination of sentinel lymph node tissue from breast cancer patients revealed previously unidentified metastases in about 16% of the samples, but the difference in 5-year survival between patients with and without these metastases was very small

  14. Impact of non-axillary sentinel node biopsy on staging and treatment of breast cancer patients

    Science.gov (United States)

    Tanis, P J; Nieweg, O E; Valdés Olmos, R A; Peterse, J L; Rutgers, E J Th; Hoefnagel, C A; Kroon, B B R

    2002-01-01

    The purpose of this study was to evaluate the occurrence of lymphatic drainage to non-axillary sentinel nodes and to determine the implications of this phenomenon. A total of 549 breast cancer patients underwent lymphoscintigraphy after intratumoural injection of 99mTc-nanocolloid. The sentinel node was intraoperatively identified with the aid of intratumoural administered patent blue dye and a gamma-ray detection probe. Histopathological examination of sentinel nodes included step-sectioning at six levels and immunohistochemical staining. A sentinel node outside level I or II of the axilla was found in 149 patients (27%): internal mammary sentinel nodes in 86 patients, other non-axillary sentinel nodes in 44 and both internal mammary and other non-axillary sentinel nodes in nineteen patients. The intra-operative identification rate was 80%. Internal mammary metastases were found in seventeen patients and metastases in other non-axillary sentinel nodes in ten patients. Staging improved in 13% of patients with non-axillary sentinel lymph nodes and their treatment strategy was changed in 17%. A small proportion of clinically node negative breast cancer patients can be staged more precisely by biopsy of sentinel nodes outside level I and II of the axilla, resulting in additional decision criteria for postoperative regional or systemic therapy. British Journal of Cancer (2002) 87, 705–710. doi:10.1038/sj.bjc.6600359 www.bjcancer.com © 2002 Cancer Research UK PMID:12232750

  15. Factors influencing sentinel lymph node identification failure in breast cancer surgery

    DEFF Research Database (Denmark)

    Straalman, Kristina; Kristoffersen, Ulrik S; Galatius, Hanne

    2008-01-01

    The purpose of this study was to investigate potential risk factors for failed sentinel lymph node identification in breast cancer surgery. Patient characteristics, tumour characteristics, surgeon experience and detection success/failure were registered at 748 sentinel lymph node biopsy procedures...

  16. Frozen section investigation of the sentinel node in malignant melanoma and breast cancer

    NARCIS (Netherlands)

    Tanis, PJ; Boom, RPA; Faneyte, IF; Peterse, JL; Nieweg, OE; Rutgers, EJT; Tiebosch, ATMG; Kroon, BBR; Schraffordt Koops, H.

    2001-01-01

    Background: Intraoperative frozen section investigation allows immediate regional lymph node dissection when the sentinel node contains tumor. The purpose of this study was to determine the sensitivity of frozen section diagnosis of the sentinel node in melanoma and breast cancer patients. Methods:

  17. High risk of non-sentinel node metastases in a group of breast cancer patients with micrometastases in the sentinel node

    DEFF Research Database (Denmark)

    Tvedskov, Tove Filtenborg; Jensen, Maj-Britt; Lisse, Ida Marie;

    2012-01-01

    for ALND. 1577 breast cancer patients with micrometastases and 304 with ITC in sentinel nodes, treated by sentinel lymph node dissection and ALND in 2002-2008, were identified in the Danish Breast Cancer Cooperative Group database. Risk of NSN metastases was calculated according to clinicopathological...

  18. Factors influencing sentinel lymph node identification failure in breast cancer surgery

    DEFF Research Database (Denmark)

    Straalman, K.; Kristoffersen, U.S.; Galatius, H.;

    2008-01-01

    The purpose of this study was to investigate potential risk factors for failed sentinel lymph node identification in breast cancer surgery. Patient characteristics, tumour characteristics, surgeon experience and detection success/failure were registered at 748 sentinel lymph node biopsy procedures...... at our inpatient clinic. Data were analysed with backward stepwise multiple logistic regression with a cut-off point of psentinel lymph node detection rate....... Tumour size, palpability and biopsy method were not significantly associated with the sentinel lymph node detection rate. In conclusion, it is possible to identify patients with a higher risk of sentinel lymph node identification failure and we recommend that these patients are operated by experienced...

  19. Sentinel node detection and radioguided occult lesion localization in breast cancer.

    Science.gov (United States)

    Trifirò, Guiseppe; Lavinia Travaini, Laura; De Cicco, Concetta; Paganelli, Giovanni

    2006-01-01

    Sentinel lymph node biopsy might replace complete axillary dissection for staging of the axilla in clinically N0 breast cancer patients and represent a significant advantage as a minimally invasive procedure, considering that about 70% of patients are found to be free from metastatic disease, yet axillary node dissection can lead to significant morbidity. In our Institute, Radioguided Occult Lesion Localization is the standard method to locate non-palpable breast lesions and the gamma probes is very effective in assisting intra-operative localization and removal, as in sentinel node biopsy. The rapid spread of sentinel lymph node biopsy has led to its use in clinical settings previously considered contraindications to sentinel lymph node biopsy. In this contest, we evaluated in a large group of patients possible factors affecting sentinel node detection and the reliability of sentinel lymph node biopsy carried out after large excisional breast biopsy. Our data confirm that a previous breast surgery does not prohibit efficient sentinel lymph node localization and sentinel lymph node biopsy can correctly stage the axialla in these patients.

  20. Sentinel lymph node biopsy for breast cancer patients using fluorescence navigation with indocyanine green

    Directory of Open Access Journals (Sweden)

    Aoyama Kei

    2011-12-01

    Full Text Available Abstract Background There are various methods for detecting sentinel lymph nodes in breast cancer. Sentinel lymph node biopsy (SLNB using a vital dye is a convenient and safe, intraoperatively preparative method to assess lymph node status. However, the disadvantage of the dye method is that the success rate of sentinel lymph node detection depend on the surgeon's skills and preoperative mapping of the sentinel lymph node is not feasible. Currently, a vital dye, radioisotope, or a combination of both is used to detect sentinel nodes. Many surgeons have reported successful results using either method. In this study we have analyzed breast lymphatic drainage pathways using indocyanine green (ICG fluorescence imaging. Methods We examined the lymphatic courses, or lymphatic vessels, in the breast using ICG fluorescence imaging, and applied this method to SLNB in patients who underwent their first operative treatment for breast cancer between May 2006 and April 2008. Fluorescence images were obtained using a charge coupled device camera with a cut filter used as a detector, and light emitting diodes at 760 nm as a light source. When ICG was injected into the subareola and periareola, subcutaneous lymphatic vessels from the areola to the axilla became visible by fluorescence within a few minutes. The sentinel lymph node was then dissected with the help of fluorescence imaging navigation. Results The detection rate of sentinel nodes was 100%. 0 to 4 states of lymphatic drainage pathways from the areola were observed. The number of sentinel nodes was 3.41 on average. Conclusions This method using indocyanine green (ICG fluorescence imaging may possibly improve the detection rate of sentinel lymph nodes with high sensitivity and compensates for the deficiencies of other methods. The ICG fluorescence imaging technique enables observation of breast lymph vessels running in multiple directions and easily and accurately identification of sentinel lymph nodes

  1. Iatrogenic displacement of tumor cells to the sentinel node after surgical excision in primary breast cancer

    DEFF Research Database (Denmark)

    Tvedskov, Tove F; Jensen, Maj-Britt; Kroman, Niels;

    2012-01-01

    Isolated tumor cells (ITC) are more common in the sentinel node (SN) after needle biopsy of a breast cancer, indicating iatrogenic displacement of tumor cells. We here investigate whether similar iatrogenic displacement occurs after surgical excision of a breast tumor. We compared the incidence...

  2. Stage migration after introduction of sentinel lymph node dissection in breast cancer treatment in Denmark: a nationwide study

    DEFF Research Database (Denmark)

    Tvedskov, Tove Filtenborg; Jensen, Maj-Britt; Balslev, Eva

    2011-01-01

    To estimate the size and therapeutic consequences of stage migration after introduction of sentinel lymph node dissection (SLND) in breast cancer treatment in Denmark.......To estimate the size and therapeutic consequences of stage migration after introduction of sentinel lymph node dissection (SLND) in breast cancer treatment in Denmark....

  3. Staging of women with breast cancer after introduction of sentinel node guided axillary dissection

    DEFF Research Database (Denmark)

    Tvedskov, Tove Filtenborg

    2012-01-01

    Today, sentinel lymph node dissection (SLND) has replaced axillary lymph node dissection (ALND) as standard procedure for staging of the axilla in the treatment of breast cancer. SLND can accurately stage the axilla by removing on average only two lymph nodes. Only in case of metastatic spread...... to sentinel nodes an ALND is offered. Removing fewer nodes has made more extensive histopathological examinations of the lymph nodes possible and as a consequence more metastases are found. This has resulted in stage migration. Based on data from the nationwide Danish Breast Cancer Cooperative Group (DBCG.......8%, when estimated using today´s criteria for risk-allocation, because nodal status is now less important in risk-allocation. In general, only 15-20% of patients with micrometastases and 10-15% of patients with isolated tumor cells (ITC) in sentinel node have further metastatic spread to non-sentinel nodes...

  4. Axillary web syndrome following sentinel node biopsy for breast cancer.

    Science.gov (United States)

    Nieves Maldonado, S M; Pubul Núñez, V; Argibay Vázquez, S; Macías Cortiñas, M; Ruibal Morell, Á

    2016-01-01

    A 49 year-old woman diagnosed with infiltrating lobular breast carcinoma, underwent a right mastectomy and sentinel node biopsy (SLNB). The resected sentinel lymph nodes were negative for malignancy, with an axillary lymphadenectomy not being performed. In the early post-operative period, the patient reported an axillary skin tension sensation, associated with a painful palpable cord. These are typical manifestations of axillary web syndrome (AWS), a poorly known axillary surgery complication, from both invasive and conservative interventions. By presenting this case we want to focus the attention on a pathological condition, for which its incidence may be underestimated by not including it in SLNB studies. It is important for nuclear medicine physicians to be aware of AWS as a more common complication than infection, seroma, or lymphoedema, and to discuss this possible event with the patient who is consenting to the procedure. Copyright © 2016 Elsevier España, S.L.U. y SEMNIM. All rights reserved.

  5. Sentinel Lymph Node in Breast Cancer: Review Article from a Pathologist's Point of View.

    Science.gov (United States)

    Apple, Sophia K

    2016-03-01

    Breast cancer staging, in particular N-stage changed most significantly due to the advanced technique of sentinel lymph node biopsy two decades ago. Pathologists have more thoroughly examined and scrutinized sentinel lymph node and found increased number of small volume metastases. While pathologists use the strict criteria from the Tumor Lymph Node Metastasis (TNM) Classification, studies have shown poor reproducibility in the application of American Joint Committee on Cancer and International Union Against Cancer/TNM guidelines for sentinel lymph node classification in breast cancer. In this review article, a brief history of TNM with a focus on N-stage is described, followed by innate problems with the guidelines, and why pathologists may have difficulties in assessing lymph node metastases uniformly. Finally, clinical significance of isolated tumor cells, micrometastasis, and macrometastasis is described by reviewing historical retrospective data and significant prospective clinical trials.

  6. LYMPHATIC MAPPING AND SENTINEL LYMPH NODE BIOPSY IN THE PATIENTS WITH BREAST CANCER

    Institute of Scientific and Technical Information of China (English)

    2000-01-01

    Objective: To identify the feasibility of the lymphatic mapping and sentinel node biopsy (SNB) in patients with breast cancer and to examine whether the characteristics of the sentinel lymph node (SLN) accurately predict the status of axillary node. Methods: 33 patients with breast cancer intraoperatively and postoperatively underwent a lymphatic mapping and the SNB using Patent Blue. Results: The SLNs were found in 30 of 33 patients (90.9%), the SLN accurately predicted the status of the axillary in 29 (96.7%). In one case the SLN was negative, but other axillary nodes were tumor positive. Conclusion: This study confirmed that the procedure of lymphatic mapping and SNB in the patients with breast cancer is feasibility, and that the histological characteristics of the SLN accurately predict the status of the axillary node. We believe that this technique might replace axillary lymph node dissection for breast cancer patients with negative axillae in the future.

  7. [A Case of Male Hereditary Breast Cancer Involving a Sentinel Lymph Node Biopsy].

    Science.gov (United States)

    Tokunou, Kazuhisa; Yamamoto, Tatsuhito; Yamamoto, Hisato; Kamei, Ryoji; Kitamura, Yoshinori; Ando, Seiichirou

    2016-11-01

    We report a rare case of male hereditary breast cancer in which a sentinel lymph node biopsy was performed. A 62-yearold man was admitted to our hospital because of a palpable tumor in his right breast. Both his younger sister and daughter had had breast cancer. Genetic testing revealed a morbid mutation in the BRCA2 gene. The tumor was palpated to an elastic hard mass and had a clear border in the right DCE area. We performed a core needle biopsy and diagnosed invasive ductal carcinoma, specifically, cT1cN0cM0, cStage I hereditary breast cancer. The patient underwent mastectomy and a sentinel lymph node biopsy. Nine days later, tamoxifen therapy was initiated. There has been no sign of recurrence during the 9 months after the operation.

  8. Innovation in early breast cancer surgery: radio-guided occult lesion localization and sentinel node biopsy.

    Science.gov (United States)

    Paganelli, G; Veronesi, U

    2002-07-01

    The surgical management of non-palpable breast lesions remains controversial. At the European Institute of Oncology we have introduced a new technique, radio-guided occult lesion localization (ROLL) to replace standard methods and overcome their disadvantages. Regarding axillary dissection, probe-guided biopsy of the sentinel node (SN) is easy to apply, and the whole procedure is associated to a low risk of false negatives. We suggest that the SN technique should be widely adopted to stage the axilla in patients with breast cancer with clinically negative lymph nodes. Large-scale implementation of the sentinel node technique will reduce the cost of treatment as a result of shorter hospitalization times.

  9. Sentinel node biopsy in breast cancer: five years experience from Denmark

    DEFF Research Database (Denmark)

    Christiansen, Peter; Balslev, E.; Jensen, D.

    2008-01-01

    INTRODUCTION: Danish experience from the first five years with sentinel lymph node biopsy (SLNB) as a routine staging procedure in early breast cancer is reported. METHODS: During the period January 1, 2002 to December 31, 2006, 14 923 patients were diagnosed at Danish breast surgical centers...... certified for the sentinel node method. SLNB was performed in 8 338 patients (55.9%). The fraction increased steadily from 43% in 2002 to 67% in 2006. The median follow-up was 1.7 year (range 0-5.2 years). RESULTS: Patients staged with SLNB were younger, had more often BCS, had smaller tumor size, were more...

  10. Sentinel Lymph Node Biopsy and Isolated Tumor Cells in Invasive Lobular Versus Ductal Breast Cancer

    NARCIS (Netherlands)

    Truin, Wilfred; Roumen, Rudi M.; Siesling, Sabine; van der Heiden-van der Loo, Margriet; Lobbezoo, Dorien J.; Tjan-Heijnen, Vivianne C.G.; Voogd, Adri C.

    2016-01-01

    Background Sentinel lymph node (SLN) biopsy is the standard of care for axillary staging in invasive breast cancer. The introduction of SLN biopsy with an extensive pathology examination, in addition to the introduction of the 2002 TNM classification, led to different axillary classification

  11. Sentinel node localization in breast cancer patients using intradermal dye injection

    DEFF Research Database (Denmark)

    Ilum, Lars; Bak, Martin; Olsen, K E

    2000-01-01

    In a series of 161 consecutive breast cancer operations, intradermal injection of Patent Blue was used to localize the sentinel node (SN). The surgical localization rate was 60%. Including the blue lymph nodes found by the pathologist, localization rate was 70%. After the first 103 operations, th...

  12. Axillary recurrence rate 5 years after negative sentinel node biopsy for breast cancer

    NARCIS (Netherlands)

    Andersson, Y.; de Boniface, J.; Jonsson, P. -E.; Ingvar, C.; Liljegren, G.; Bergkvist, L.; Frisell, J.

    2012-01-01

    Background: Sentinel lymph node (SLN) biopsy has replaced axillary lymph node dissection (ALND) as the standard axillary staging procedure in breast cancer. Follow-up studies in SLN-negative women treated without ALND report low rates of axillary recurrence, but most studies have short follow-up, an

  13. Guideline adherence for early breast cancer before and after introduction of the sentinel node biopsy

    NARCIS (Netherlands)

    Schaapveld, M; de Vries, EGE; Otter, R; de Vries, J; Dolsma, WV; Willemse, PHB

    2005-01-01

    This population-based study aimed to analyse variations in surgical treatment and guideline compliance with respect to the application of radiotherapy and axillary lymph node dissection (ALND), for early breast cancer, before and after the sentinel node biopsy (SNB) introduction. The study included

  14. Cross-validation of three predictive tools for non-sentinel node metastases in breast cancer patients with micrometastases or isolated tumor cells in the sentinel node

    DEFF Research Database (Denmark)

    Tvedskov, T F; Meretoja, T J; Jensen, M B

    2014-01-01

    BACKGROUND: We cross-validated three existing models for the prediction of non-sentinel node metastases in patients with micrometastases or isolated tumor cells (ITC) in the sentinel node, developed in Danish and Finnish cohorts of breast cancer patients, to find the best model to identify patients...... who might benefit from further axillary treatment. MATERIAL AND METHOD: Based on 484 Finnish breast cancer patients with micrometastases or ITC in sentinel node a model has been developed for the prediction of non-sentinel node metastases. Likewise, two separate models have been developed in 1577...... metastases while less than 1% was identified by the Finish model. In contrast, the Finish model predicted a much larger proportion of patients being in the low-risk group with less than 10% risk of non-sentinel node metastases. CONCLUSION: The Danish model for micrometastases worked well in predicting high...

  15. [Interest of preoperative lymphoscintigraphy on sentinel lymph node identification in patients with breast cancer].

    Science.gov (United States)

    Tulpin, L; Morel, O; Akerman, G; Malartic, C; Desfeux, P; Barranger, E

    2008-01-01

    Sentinel lymph node biopsy is nowadays an accepted method of staging breast cancer patients. In case of an injection of radioactive colloid, preoperative lymphoscintigraphy is recommended to establish a lymphatic mapping and to predict the number of sentinel lymph nodes identified during surgery. Preoperative lymphoscintigraphy does not decrease the false-negative rate. However, positive preoperative lymphoscintigraphy significantly improves the identification rate of intraoperative sentinel nodes comparing with negative preoperative lymphoscintigraphy. Detecting extra-axillary sentinel lymph nodes, because of its minimal therapeutic consequences, does not appear to be an indication for preoperative lymphoscintigraphy. Given logistics and cost required, preoperative lymphoscintigraphy should be only performed for patients with a high risk of intraoperative failed localization. In case of negative preoperative lymphoscintigraphy, sentinel lymph node biopsy must be tried because sentinel nodes are still identified in the majority of these patients. Another possibility, with important cost and logistic, should consist in performing a later lymphoscintigraphy on the day after radioactive injection to ameliorate sentinel lymph nodes identification.

  16. Fallacies of preoperative lymphoscintigraphy in detecting sentinel node in breast cancer

    Directory of Open Access Journals (Sweden)

    Maharajan R

    2005-05-01

    Full Text Available Abstract Background Preoperative lymphoscintigraphy is one of the three methods of evaluating sentinel nodes in patients with breast cancer; however, it has been reported to have a high false negative rate. Case presentations We report here two cases where the preoperative lymphoscintigraphy was found to be fallacious. A 44-year-old female with T2N0 breast cancer underwent preoperative lymphoscintigraphy with Tc99 sulfur colloid which failed to show any uptake in axilla or internal mammary chain. Intraoperative scintigraphy with blue dye and hand held gamma probe identified sentinel lymph node in axilla. Another patient with T2N0 lesion underwent preoperative lymphoscintigraphy which showed a sentinel lymph node in axilla and another in supraclevicular fossa. Intraoperative scintigraphy failed to show supraclevicular node however axillary node was correctly identified. Conclusion These two cases further strengthen the need to carry out triple test in identification of sentinel lymph node in patients with breast cancer. It also demonstrates the fallacies of preoperative lymphoscintigraphy.

  17. Sentinel Node Biopsy Alone versus Completion Axillary Node Dissection in Node Positive Breast Cancer: Systematic Review and Meta-Analysis

    OpenAIRE

    Rachna Ram; Jasprit Singh; Eddie McCaig

    2014-01-01

    Introduction. There has been recent interest in validity of completion axillary node dissection after a positive sentinel node. This systematic review aims to ascertain if sentinel lymph node dissection alone was noninferior to axillary lymph node dissection for breast cancer patients who have a positive sentinel node. Method. A systematic review of the electronic databases Embase, MEDLINE, and Cochrane Register of Controlled Trials was carried out. Only randomised trials that had patients wi...

  18. Clinical outcomes after sentinel lymph node biopsy in clinically node-negative breast cancer patients

    Energy Technology Data Exchange (ETDEWEB)

    Han, Hee Ji; Keun Ki Chang; Suh, Chang Ok; Kim, Yong Bae [Dept.of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul (Korea, Republic of); Kim, Ju Ree [Dept.of Radiation Oncology, Cheil General Hospital, Seoul (Korea, Republic of); Nam, Hee Rim [Dept.of Radiation Oncology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul (Korea, Republic of)

    2014-09-15

    To evaluate non-sentinel lymph node (LN) status after sentinel lymph node biopsy (SNB) in patients with breast cancer and to identify the predictive factors for disease failure. From January 2006 to December 2007, axillary lymph node (ALN) dissection after SNB was performed for patients with primary invasive breast cancer who had no clinical evidence of LN metastasis. A total of 320 patients were treated with breast-conserving surgery and radiotherapy. The median age of patients was 48 years, and the median follow-up time was 72.8 months. Close resection margin (RM) was observed in 13 patients. The median number of dissected SNB was two, and that of total retrieved ALNs was 11. Sentinel node accuracy was 94.7%, and the overall false negative rate (FNR) was 5.3%. Eleven patients experienced treatment failure. Local recurrence, regional LN recurrence, and distant metastasis were identified in 0.9%, 1.9%, and 2.8% of these patients, respectively. Sentinel LN status were not associated with locoregional recurrence (p > 0.05). Close RM was the only significant factor for disease-free survival (DFS) in univariate and multivariate analysis. The 5-year overall survival, DFS, and locoregional DFS were 100%, 96.8%, and 98.1%, respectively. In this study, SNB was performed with high accuracy and low FNR and high locoregional control was achieved.

  19. Comparison between hemosiderin and Technetium-99 in sentinel lymph node biopsy in human breast cancer

    Energy Technology Data Exchange (ETDEWEB)

    Vasques, Paulo Henrique Diogenes; Aquino, Ranniere Gurgel Furtado de; Pinheiro, Luiz Gonzaga Porto, E-mail: luizgporto@uol.com.br [Universidade Federal do Ceara (UFC), Fortaleza, CE (Brazil). Departamento de Cirurgia; Alves, Mayara Maia [Rede Nordeste de Biotecnologia (RENORBIO/UFC), Fortaleza, CE (Brazil); Torres, Roberto Vitor Almeida; Bezerra, Jose Lucas Martins [Universidade Federal do Ceara (UFC), Fortaleza, CE (Brazil). Faculdade de Medicina; Brasileiro, Luis Porto [Faculdades INTA, Sobral, CE (Brazil). Faculdade de Medicina

    2015-11-15

    Purpose: To assess the safety and potential equivalence of the use of hemosiderin compared to the Technetium-99 in sentinel lymph node biopsy in human breast cancer. Methods: Non-random sample of 14 volunteer women diagnosed with breast cancer with primary tumors (T1/T2) and clinically tumor-free axilla were submitted to the identification of sentinel lymph node using hemosiderin obtained from autologous blood injected in the periareolar region 24h before surgery on an outpatient basis. Patients received preoperative subareolar intradermal injection of Technetium-99 in the immediate preoperative period. Patients were submitted to sentinel lymph node biopsy, with incision in the axillary fold guided by Gamma-Probe, dissection by planes until the identification of the point of maximum uptake of Technetium-99, identifying the marked nodes and their colors. All surgical specimens were sent for pathological and immunohistochemical study. Results: The results showed no evidence of side effects and/or allergic and non-allergic reactions in patients submitted to SLNB with hemosiderin. The SLN identification rate per patient was 100%. SLNB identification rate per patient with hemosiderin was the same as that of Technetium, with a concordance rate of 100% between the methods. Conclusion: Hemosiderin is a safe dye that is equivalent to Technetium in breast sentinel lymph node biopsy. (author)

  20. Sentinel Node Biopsy in Special Histologic Types of Invasive Breast Cancer.

    Science.gov (United States)

    Solà, Montserrat; Recaj, Mireia; Castellà, Eva; Puig, Pere; Gubern, Josep Maria; Julian, Juan Francisco; Fraile, Manel

    2016-04-01

    To assess the feasibility of sentinel node biopsy (SNB) in ductal and lobular invasive breast cancer, a group of tumors known as special histologic type (SHT) of breast cancer. Between January 1997 and July 2008, 2253 patients from 6 affiliated hospitals underwent SNB who had early breast cancer and clinically negative axilla. The patients' data were collected in a multicenter database. For lymphatic mapping, all patients received an intralesional dose of radiocolloid Tc-99m (4mCi in 0.4 mL saline), at least two hours before the surgical procedure. SNB was performed by physicians from the same nuclear medicine department in all cases. Of the 2253 patients in the database, the SN identification rate was 94.5% (no radiotracer migration in 123 patients), and positive sentinel node prevalence was 22%. SHT was reported in 144 patients (6.4%) of the whole series. In this subgroup, migration of radiotracer was unsuccessful in 8 patients (identification rate was 94.4%) and SNs were positive in 7.4%. SN positivity prevalence in these tumors was variable across the subtypes. Higher probability of lymphatic spread seemed to be related to tumor invasiveness (20% of positivity in micropapillary, 15% in cribriform subtypes, and 0% in adenoid-cystic). Sentinel node biopsy is feasible in special histologic subtypes of breast carcinoma with a good identification rate. Lower migration rates, however, might be associated with special histologic features (colloid subtype). Complete axillary dissection after a positive sentinel node cannot be omitted in patients with SHT breast cancer because they can be associated with further axillary disease; the reported very low incidence of axillary metastases would justify avoiding axillary dissection only in the adenoid-cystic subtype.

  1. Sentinel lymph node biopsy in breast cancer--the Aarhus experience

    DEFF Research Database (Denmark)

    Lauridsen, M C; Garne, J P; Hessov, I

    2000-01-01

    Eighty patients, with newly diagnosed unifocal breast cancer and with no axillary metastases verified by ultrasonography, underwent sentinel lymph node (SLN) and subsequent axillary lymph node dissection. To identify the SLN, we used a combination of Tc-99m labelled colloid (Albures) and blue dye...... as SLNs that tested negative but with higher nodes that tested positive. If SLN biopsy is accepted as a routine procedure and when the exact indications are defined, the method described probably could be offered to the majority of breast cancer patients....

  2. Comparison of radioactive tracer tin colloid and phytate for sentinel node biopsy in breast cancer

    Energy Technology Data Exchange (ETDEWEB)

    Yagata, Hiroshi; Suzuki, Masato; Nagashima, Takashi; Kasagawa, Takahiro; Sakakibara, Masahiro; Oshida, Keiko; Sangai, Takafumi; Nakano, S.; Miyazaki, Masaru [Chiba Univ. (Japan). Graduate School of Medicine

    2002-10-01

    Eighty-four consecutive sentinel node biopsies were performed using dye and radioactive tracer (tin colloid for 42 tumors and phytate for 42 tumors). They had subdermal injection on the morning of surgery or the afternoon before surgery. Maximum RI count of each sentinel node was recorded and classified {<=}5 counts per second (cps), 5-20, or 20<. In injection on the afternoon before surgery, 19 tumors had {<=}5 cps and 2 had 20 cps< in 24 of tin colloid, whereas 1 had {<=}5 cps and 18 had 20 cps< in 22 of phytate. In injection on the morning of surgery, 9 had {<=}5 and 20 had 20< in 18 of tin colloid, whereas 1 had {<=}5 and 18 had 20< in 20 of phytate. The injection of phytate tended to have higher RI count than tin colloid. Phytate is superior to tin colloid for sentinel node biopsy in breast cancer. (author)

  3. Axillary sentinel node identification in breast cancer patients: degree of radioactivity present at biopsy is critical

    DEFF Research Database (Denmark)

    Nielsen, Kristina R; Oturai, Peter S; Friis, Esbern

    2011-01-01

    The radioactivity present in the patient (Act(rem) ) at sentinel node (SN) biopsy will depend on injected activity amount as well as on the time interval from tracer injection to biopsy, which both show great variations in the literature. The purpose of this study was to analyse the influence...... of varying Act(rem) levels on the outcome of axillary SN biopsy in patients with breast cancer (BC)....

  4. Can methylene blue only be used in sentinel lymph node biopsy for breast cancer?

    Science.gov (United States)

    Golshan, Mehra; Nakhlis, Faina

    2006-01-01

    Sentinel lymph node biopsy (SLNB) has become an accepted standard of care to stage the axilla for clinically node-negative early stage breast cancer. In experienced hands, studies have shown an acceptable rate of identification of the sentinel lymph node (SLN) with blue dye only. Lymphazurin is occasionally associated with severe allergic reaction, including anaphylaxis and death. The use of methylene blue alone as a method of identifying the SLN in breast cancer has been reported once previously in the literature. Methylene blue may be an acceptable alternative with fewer deleterious side effects. Medical records of patients, who underwent sentinel node mapping between September 2003 and March 2005 by two surgeons at an academic medical center were reviewed. SLN mapping was performed by periareolar injection of 5 cc of 1% methylene blue. All patients with positive SLNs underwent completion axillary node dissection. During the study period, 141 consecutive patients with clinically node-negative axillas and without evidence of inflammatory breast cancer underwent SLNB with injection of methylene blue only. A SLN was identified in 136 of 141 patients (96.5%). Thirty-three of 136 SLNs (24%) harbored metastatic disease. No cases of anaphylaxis were noted. In experienced hands, methylene blue alone is a highly sensitive method of detecting SLNs. Avoiding the greater frequency of allergic reactions seen with lymphazurin is an important advantage of methylene blue.

  5. Sentinel node biopsy after neoadjuvant chemotherapy in cytologically proven node-positive breast cancer.

    Science.gov (United States)

    Yagata, Hiroshi; Yamauchi, Hideko; Tsugawa, Koichiro; Hayashi, Naoki; Yoshida, Atsushi; Kajiura, Yuka; In, Reika; Matsuda, Naoko; Nakamura, Seigo

    2013-12-01

    Several studies have assessed the feasibility of sentinel lymph node biopsy (SLNB) after NAC in patients with breast cancer, but diagnostic accuracy has varied. We prospectively evaluated the diagnostic accuracy of SLNB in detecting axillary lymph node (ALN) metastases after NAC in patients with cytologically proven positive nodes before chemotherapy. We studied 95 breast cancer patients with cytologically proven positive nodes and a partial or complete clinical response to NAC in the breast lesions confirmed using magnetic resonance imaging. Patients then underwent SLNB followed by ALN dissection. The identification rate of sentinel lymph nodes (SLNs) and the false negative rate of nodal metastases were assessed. Subgroup analysis was conducted according to several clinical factors. SLNs were successfully identified in 81 (85.3%) of the 95 patients. Among these 81 patients, 51 (63.0%) had ALN metastases on final pathologic examination after NAC. Eight of the 51 patients with ALN metastases had negative results on SLNB (false negative rate, 15.7%). Univariate analysis indicated that the false negative rate was significantly lower only in the HER2-negative group (P = .003). SLNB after NAC did not correctly predict the presence or absence of axillary node metastases in patients with breast cancer who had cytologically proven positive nodes before NAC. However, the diagnostic accuracy might be different in cancer subtypes, therapeutic effect of chemotherapy, or sentinel lymph node status after chemotherapy. Well-powered studies are needed to confirm diagnostic accuracy of SLNB after NAC according to subgroup in patients with breast cancer. Copyright © 2013 Elsevier Inc. All rights reserved.

  6. Sentinel Node Mapping for Breast Cancer: Current Situation

    Directory of Open Access Journals (Sweden)

    Sergi Vidal-Sicart

    2012-01-01

    Full Text Available Axillary node status is a major prognostic factor in early-stage disease. Traditional staging needs levels I and II axillary lymph node dissection. Axillary involvement is found in 10%–30% of patients with T1 (<2 cm tumours. Sentinel lymph node biopsy is a minimal invasive method of checking the potential nodal involvement. It is based on the assumption of an orderly progression of lymph node invasion by metastatic cells from tumour site. Thus, when sentinel node is free of metastases the remaining nodes are free, too (with a false negative rate lesser than 5%. Moreover, Randomized trials demonstrated a marked reduction of complications associated with the sentinel lymph node biopsy when compared with axillary lymph node dissection. Currently, the sentinel node biopsy procedure is recognized as the standard treatment for stages I and II. In these stages, this approach has a positive node rate similar to those observed after lymphadenectomy, a significant decrease in morbidity and similar nodal relapse rates at 5 years. In this review, the indications and contraindications of the sentinel node biopsy are summarized and the methodological aspects discussed. Finally, the new technologic and histologic developments allow to develop a more accurate and refinate technique that can achieve virtually the identification of 100% of sentinel nodes and reduce the false negative rate.

  7. Sentinel lymph node detection through radioguided surgery in patients with breast cancer

    Energy Technology Data Exchange (ETDEWEB)

    Abreu, Benedita Andrade Leal de; Santos, Adriana de Morais; Soares, Livia de Almeida; Santos, Antonio Ricardo dos; Barros, Idna de Carvalho; Abreu, Everardo Leal de; Cruz Filho, Alexandre Jorge Gomes da; Abreu, Joao Batista de; Vieira, Sabas Carlos [Universidade Estadual do Piaui, Teresina, PI (Brazil); Centro Federal de Educacao Tecnologica do Piaui (CEFET-PI), Teresina, PI (Brazil); Faculdade Sao Gabriel, PI (Brazil); Hospital Sao Marcos, PI (Brazil); Universidade Federal do Piaui (UFPI), Teresina, PI (Brazil)

    2008-12-15

    Biopsy of the sentinel lymphnode (SLNB), the first lymphnode to receive lymphatic drainage from the primary tumor, accurately predicts the axillary lymph node status and, when negative, obviates the need for axillary lymphadenectomy (AL). The aim of this study was, to verify the SLN localization in breast cancer through preoperative lymphoscintigraphy and intraoperative gamma-probe, as well as to demonstrate the benefits of such techniques in preventing complications of AL. Medical records of 228 patients with breast carcinoma, who were underwent SLN localization and, radioguided surgery, from March 2005 to December 2007 were analyzed retrospectively. Data regarding age, tumor characteristic, breast involved, type of surgery, radiopharmaceutical drainage pattern, axillary assessment (SLNB or AL) and number of lymph nodes dissected were collected. It was ascertained that radioguided surgery is a selective method of axillary assessment in breast cancer, which makes this technique a safe alternative to radical assessment of total dissection of axillary lymph nodes and its subsequent complications. (author)

  8. Photo guided sentinel node mapping in breast cancer using marker free photo gamma fusion lymphoscintigraphy

    Energy Technology Data Exchange (ETDEWEB)

    Lee, Eun Seong; Chun, In Kook; Ha, Seungn Gyun; Yoon, Hai Jeon; Jung, So Youn; Lee, See Youn; Kim, Seok Won; Lee, Eun Sook; Kim, Tae Yoon; Kim, Kwang Gi; Kim, Tae Sung; Kim, Seok Ki [National Cancer Center, Goyang (Korea, Republic of); Lee, Byung Il [Korea Photonics Technology Institute, Gwangju (Korea, Republic of)

    2012-03-15

    Photo gamma fusion lymphoscintigraphy (PGFLS) was developed by overlying a conventional planar gamma image on a photograph for the guidance of sentinel node biopsy. The feasibility and accuracy of PGFLS was assessed in breast cancer patients. A digital camera and a gamma camera were coordinated to obtain photograph and gamma images from the same angle. Using the distance to the object and calibration acquisition with a flat phantom and radioactive markers, PGFLS was performed both in phantom and in patients without fiducial markers. Marker free PGFLS was verified using flat phantom, anthropomorphic phantom with markers simulating sentinel nodes and breast cancer patients. In addition, the depth of the radioactive marker or sentinel node was calculated using two gamma images taken at right angles. The feasibility and accuracy of PGFLS were assessed in terms of mismatch errors of co registration and depth with reference to the data from SPECT/CT. The mismatch error was less than 6mm in the flat phantom image at a distance from 50 to 62cm without misalignment. In the anthropomorphic phantom study, co registration error was 0.42{+-}0.29cm; depth error was 0.51{+-}0.37cm, which was well correlated with the reference value on SPECT/CT (x scale: R'2'=0.99, p<0.01; y scale: R'2'=0.09, p<0.01; depth: R'2'=0.99, p<0.01). In ten patients with breast cancer referred for lympho SPECT/CT, PGFSL enabled photo guided sentinel lymph node mapping with acceptable accuracy (co-registration error, 0.47{+-}0.24cm; depth error, 1.20{+-}0.41cm). The results from PGFSL showed close correlation with those from SPECT/CT (x scale: R'2'=0.99, p<0.01; y scale: R'2'=0.98, p<0/01; depth: R'2'=0.77, p<0.01). The novel and convenient PGFLS technique is clinically feasible, showing acceptable accuracy and providing additional visual and quantitative information for sentinel lymph node mapping. This approach will facilitate photo guided

  9. PREDICTION OF NON-SENTINEL LYMPH NODE METASTASES IN BREAST CANCER

    Institute of Scientific and Technical Information of China (English)

    张杰; 沈坤炜; 尼尔马; 柳光宇; 吴炅; 邵志敏; 沈镇宙

    2003-01-01

    Objective. To identify a subset of breast cancer patients in whom metastatic disease is confined on- ly to the sentinel lymph node(SLn). Methods. Sentinel lymph node biopsy is performed with the injecetion of Tc99m-SC, and a gamma probe. Sentinel node biopsy was compared with standard axillary dissection for its ability to reflect the final pathological status of the axillary nodes. The factors associated with non-SLN metastases were assessed in the univariate and multivariate analysis. Result. We successfully identified 91 out of 95 patients for SLN(95.8%). The accuracy of sentinel lymph node to predict the axillary lymph node status was 93.4%. Clinical tumor size and tumor grade were proved to be the independent predictive factors for non-SLN metastases by logistic regression model. Conclusio.In most cases, the gamma probe guided method is technically feasible for detecting sentinel nodes, accurately predicting the axillary lymph node status. A subset of the patients identified who have a low risk of non-SLN metastases may not require axillary lymph node dissection.

  10. Predictors to assess non-sentinel lymph node status in breast cancer patients with only one sentinel lymph node metastasis

    Institute of Scientific and Technical Information of China (English)

    YANG Ben; YANG Li; ZUO Wen-shu; GE Wen-kai; ZHENG Gang; ZHENG Mei-zhu; YU Zhi-yong

    2013-01-01

    Background The purpose of this study was to investigate the feasibility of avoiding axillary lymph node dissection (ALND) for patients with only one sentinel lymph node (SLN) metastasis.The characteristics and predictive factors for non-sentinel lymph node (NSLN) metastasis of patients with single positive SLN were also analyzed.Methods Patients with no and only one SLN metastasis (0/n and 1/n group,n ≥2) were selected from 1228 cases of invasive breast carcinoma,who underwent axillary dissection in Shandong Cancer Hospital between November 1999 and December 2011,to compare the characteristics of NSLN metastasis between them.For the 1/n group,the factors that influenced the NSLN metastasis were analyzed by univariate and multivariate analysis.Results Differences of the NSLN metastasis between the 0/n and the 1/n groups were significant (P <0.001).There was no significant difference between the axillary lymph node metastasis on level Ⅲ in 1/n group and 0/n group (P=0.570).When the total SLN number was ≥4 and with one positive case,the NSLN metastasis was not significantly different from that in the 0/n group (P=0.118).In the 1/n group,clinical tumor size (P =0.012),over-expression of Her-2 (P=0.003),tumor grade (P=-0.018) and the total number of SLN (P=-0.047) significantly correlated with non-SLN metastasis.Clinical tumor size (P=-0.015) and the expression of Her-2 (P=0.01) were independent predictive factors for non-SLN metastasis by the Logistic regression model.Conclusion Under certain conditions,breast cancer patients with single SLN metastasis could avoid ALND.

  11. Combined Methylene Blue Dye andRadioactive Tracer Technique for Sentinel Lymph Node Localization in Early Breast Cancer

    Directory of Open Access Journals (Sweden)

    Abdolrasoul Talei

    2010-10-01

    Full Text Available Background: Sentinel lymph node biopsy is a technique used to identify the axillary node most likely to contain tumor cells that have metastasized from a primarycarcinoma of the breast. This technique provides accurate staging with fewer complications than axillary dissection and may result in decreased costs. We designed the present study to determine the accuracy and success rate of a combined blue dyeand radioactive tracer technique in sentinel node localization. Methods: This prospective study included 70 patients with early stage (tumor>5cm; T1, T2 operable breast cancer and nonpalpable axillary lymphadenopathy seen between 2005 and 2009. Patients underwent sentinel lymph node localization using 4mL of blue dye combined with radioactive colloid. After identification and removal of the sentinel node(s, the axilla was checked for any residual radioactivity. A sentinelnode was defined as any node that was hot, hot and blue or only blue.Results:The sentinel node was identified in 66 patients with a detection rate of 94.2%,and a mean of 1.5 sentinel nodes were identified and harvested (range of 1-4. In 23cases, the sentinel lymph node contained metastatic disease on pathological assessment.There was no pathological evidence of any metastases in the sentinel node in the remaining 43 patients. All sentinel lymph nodes were located in level I of the axillary region. In four patients, no sentinel lymph node was found, so axillary dissection was performed. The sensitivity of the procedure in predicting further axillary disease was 95.6% with a specificity of 97.6%.Conclusion: The present study describes the blue dye and radioisotope localization technique as successful in identifying the sentinel lymph node in early-stage breast cancer patients.

  12. Breast Cancer and Internal Mammary Sentinel Nodes: A Meta-Analysis

    Directory of Open Access Journals (Sweden)

    Khaldoun Bekdache

    2014-05-01

    Full Text Available Background: The management of internal mammary (IM nodes in breast cancer lacks a well-defined consensus. Lymphoscintigraphy identifies up to one-third of breast cancer patients with extra-axillary drainage, which is mainly located in the IM chain. Our aim in this meta-analysis is to identify the lymphoscintigraphy technique variables that effect IM node identification.Methods: An internet database was utilized to review articles concerning sentinel nodes and breast cancer from 1993 through the end of 2011; 74 articles met our inclusion criteria. The total number of patients included was 22959. We grouped the citations by injection location and injection material. We then analyzed the rate of identification of IM nodes according to these groupings and their subsets.Results: The overall IM identification rate using the random effect model was 9%. The injection location had the most significant impact on IM identification rate; the deeper injections were associated with the highest rate of identification. Variation in IM identification was associated with the particle size of injection material; the smaller particle size group had a higher rate of identification. Increased dose of the tracer was also associated with increased identification rate.Conclusions: The use of smaller particle size tracers and a deeper injection location achieve the highest IM identification rate. The dose of the tracer also increased the identification rate. These observations can help in the selection of patients for IM sentinel node biopsy, which can affect their prognosis and treatment management.

  13. A novel finding of sentinel lymphatic channels in early stage breast cancer patients: which may influence detection rate and false-negative rate of sentinel lymph node biopsy.

    Directory of Open Access Journals (Sweden)

    Minghai Wang

    Full Text Available BACKGROUND: The exact lymphatic drainage pattern of the breast hasn't been explained clearly. The aim of this study was to investigate the sentinel lymphatic channels (SLCs in the cancerous breast. Whether the type of SLCs influenced the detection rate and false-negative rate of SLNB was also assessed. METHODOLOGY AND PRINCIPAL FINDINGS: Mimic SLNB was performed in 110 early-stage breast cancer patients with subareolar injection of blue methylene dye intraoperatively. Postoperatively, 110 specimens of modified radical mastectomy were examined for all blue SLCs after additional injection of methylene dye in peritumoral parenchyma. Interestingly, three types of SLCs, including superficial sentinel lymphatic channel (SSLC, deep sentinel lymphatic channel (DSLC, and penetrating sentinel lymphatic channel (PSLC were found in 107 patients. Six lymphatic drainage patterns based on the three types of SLCs were observed in these 107 patients. The proportions of the drainage pattern SSLC, DSLC, PSLC, SSLC+DSLC, SSLC+PSLC, and DSLC+PSLC in the breast were 43%, 0.9%, 15.9%, 33.6%, 3.7% and 2.8%, respectively. The lymphatic drainage pattern in the breast was a significant risk factor for unsuccessful identification of sentinel lymph nodes (P<0.001 and false-negatives in SLNB (P = 0.034 with the subareolar injection technique. CONCLUSIONS: Three kinds of SLCs are the basis of six lymphatic drainage patterns from the breast to the axilla. The type of SLCs is the factor influencing the detection rate and false-negative rate of SLNB. These findings suggest the optimal injection technique of the combination of superficial and deep injection in SLNB procedures. Future clinical studies are needed to confirm our novel findings.

  14. Sentinel node biopsy using two kinds of radiopharmaceuticals in breast cancer

    Energy Technology Data Exchange (ETDEWEB)

    Hisamatsu, Kazutoshi; Ishine, Masahiro; Takiyama, Wataru [Hiroshima City Asa Hospital (Japan)] [and others

    2002-08-01

    Between June 2000 and May 2001, 37 consecutive patients with breast cancer received sentinel node biopsy (SNB) be the gamma-probe method using two kinds of radiopharmaceutical, Tin colloid in 11 patients (T-group) and Phytate in 26 patients (P-group). The differences in their clinical results were evaluated retrospectively. The identification rate of SN in the P-group was superior than that in the T-group (92% vs. 64%). Accuracy and false negative rates in the P-group vs. the T-group were 96% vs. 100% and 17% vs. 0%, respectively. From these results, Phytate was more useful than Tin colloid in the SNB using gamma-probe method for patients with breast cancer. (author)

  15. A new model for predicting non-sentinel lymph node status in Chinese sentinel lymph node positive breast cancer patients.

    Directory of Open Access Journals (Sweden)

    Miao Liu

    Full Text Available BACKGROUND: Our goal is to validate the Memorial Sloan-Kettering Cancer Center (MSKCC nomogram and Stanford Online Calculator (SOC for predicting non-sentinel lymph node (NSLN metastasis in Chinese patients, and develop a new model for better prediction of NSLN metastasis. METHODS: The MSKCC nomogram and SOC were used to calculate the probability of NSLN metastasis in 120 breast cancer patients. Univariate and multivariate analyses were performed to evaluate the relationship between NSLN metastasis and clinicopathologic factors, using the medical records of the first 80 breast cancer patients. A new model predicting NSLN metastasis was developed from the 80 patients. RESULTS: The MSKCC and SOC predicted NSLN metastasis in a series of 120 patients with an area under the receiver operating characteristic curve (AUC of 0.688 and 0.734, respectively. For predicted probability cut-off points of 10%, the false-negative (FN rates of MSKCC and SOC were both 4.4%, and the negative predictive value (NPV 75.0% and 90.0%, respectively. Tumor size, Kiss-1 expression in positive SLN and size of SLN metastasis were independently associated with NSLN metastasis (p<0.05. A new model (Peking University People's Hospital, PKUPH was developed using these three variables. The MSKCC, SOC and PKUPH predicted NSLN metastasis in the second 40 patients from the 120 patients with an AUC of 0.624, 0.679 and 0.795, respectively. CONCLUSION: MSKCC nomogram and SOC did not perform as well as their original researches in Chinese patients. As a new predictor, Kiss-1 expression in positive SLN correlated independently with NSLN metastasis strongly. PKUPH model achieved higher accuracy than MSKCC and SOC in predicting NSLN metastasis in Chinese patients.

  16. [METHODOLOGIC PROBLEMS OF SENTINEL LYMPH NODE BIOPSY IN PATIENTS WITH BREAST CANCER].

    Science.gov (United States)

    Krivorotko, P V; Kanaev, S V; Semiglazov, V F; Novikov, S N; Krzhivitsky, P I; Semenov, I I; Turkevich, E A; Busko, E A; Donskikh, R V; Bryantseva, Zh V; Piskunov, E A; Trufanova, E S; Chernaya, A V

    2015-01-01

    The study included data on 168 patients with breast cancer, surgical treatment of whom was supplemented by axillary dissection (133 patients or 79.2%) or biopsy of sentinel lymph nodes (35 patients or 20.8%). The examination included ultrasound, planar scintigraphy of the breast and zones of regional lymph drainage. In 122 patients with primary breast cancer stage cT1-2N0M0 retrospective analysis of radionuclide imaging sentinel lymph node was performed. In 89 patients the introduction of colloidal radiopharmaceutical was carried out using a particle diameter of not more than 80-100 nm, in 33 patients study was conducted after administration of radiocolloid with a particle diameter of 200 to 1000 nm. Based on the data obtained by scintigraphy and ultrasonography of zones of regional lymph drainage there were offered two diagnostics models: the first, in which the presence of metastatic axillary lymph nodes was established when there were changes according to at least one of the diagnostic methods--scintigraphy or ultrasound; the second, in which the defeat of lymph nodes was determined only in the case of simultaneous detection of ultrasound and scintigraphic evidence of axillary lymph nodes. Sensitivity, specificity, and overall accuracy of the combination of ultrasound and planar scintigraphy axillary lymph nodes using the first model accounted for 82.7%, 67.7% and 74.4%, respectively. In the second model, the specificity was 94.6%, sensitivity--56%. Rapid transport of radiopharmaceuticals from the injection site, a high gradient of radiopharmaceuticals accumulation in sentinel lymph nodes, effective their visualization, approaching to 100%, were undoubted advantages of radiocolloids having a particle diameter up to 100 nm.

  17. [Place of indocyanine green coupled with fluorescence imaging in research of breast cancer sentinel node].

    Science.gov (United States)

    Vermersch, Charlotte; Raia Barjat, Tiphaine; Perrot, Marianne; Lima, Suzanne; Chauleur, Céline

    2016-04-01

    The sentinel node has a fundamental role in the management of early breast cancer. Currently, the double detection of blue and radioisotope is recommended. But in common practice, many centers use a single method. However, with a single detection, the risk of false negatives and the identification failure rate increase to a significant extent and the number of sentinel lymph node detected and removed is not enough. Furthermore, the tracers used until now show inconveniences. The purpose of this work is to present a new method of detection, using the green of indocyanine coupled with fluorescence imaging, and to compare it with the already existing methods. The method combined by fluorescence and isotopic is reliable, sure, of fast learning and could constitute a good strategy of detection. The major interest is to obtain a satisfactory number of sentinel nodes. The profit could be even more important for overweight patients. The fluorescence used alone is at the moment not possible. Wide ranging studies are necessary. The FLUOTECH, randomized study of 100 patients, comparing the isotopic method of double isotope technique and fluorescence, is underway to confirm these data.

  18. Predicting non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement: evaluation of two scoring systems.

    Science.gov (United States)

    Sanjuán, Alex; Escaramís, Georgia; Vidal-Sicart, Sergi; Illa, Miriam; Zanón, Gabriel; Pahisa, Jaume; Rubí, Sebastià; Velasco, Martín; Santamaría, Gorane; Farrús, Blanca; Muñoz, Montse; García, Yolanda; Fernández, Pedro Luís; Pons, Francesca

    2010-01-01

    The aim of this study was to validate a nomogram and a scoring system to predict non-sentinel lymph node status in breast cancer patients with sentinel lymph node (SLN) involvement. A total of 516 breast cancer patients underwent sentinel lymph node biopsy at our institution from January 2001 to August 2006. A prospective database was used to identify breast cancer patients with a positive SLN biopsy examination who underwent a completion axillary lymph node dissection. A total of 114 patients were identified. The Memorial Sloan-Kettering Cancer Center (MSKCC) nomogram and an axilla scoring system from Paris (Hôpital Tenon) were used to predict the probability of having non-SLN involvement. One hundred fourteen patients were included in the study. The areas under the receiver operating characteristics (ROC) curves were 0.671 (95% CI: 0.552-0.790) for the MSKCC nomogram and 0.703 (95% CI: 0.596-0.811) for the Tenon score. The univariate analysis shows that size of SLN metastases, the number of positive and negative SLN and the proportion of positive SLN were statistically significant. On multivariate logistic regression analysis, the size of SLN metastases and the proportion of positive SLN were statistically significant. The two scoring systems are similar according to their area under ROC curves, but should be improved to be valid and determinant to the general population. Meanwhile, the use of scoring systems could be applied in an individual manner in some patients.

  19. Clinical axillary recurrence after sentinel node biopsy in breast cancer: a follow-up study of 220 patients

    Energy Technology Data Exchange (ETDEWEB)

    Sanjuan, A. [University of Barcelona, Department of Gynecology and Obstetrics, Breast Pathology Unit (Spain); Hospital Clinic Provincial, Barcelona (Spain); Vidal-Sicart, S.; Pons, F. [University of Barcelona, Department of Nuclear Medicine, Hospital Clinic (Spain); Zanon, G.; Pahisa, J.; Vanrell, J.A. [University of Barcelona, Department of Gynecology and Obstetrics, Breast Pathology Unit (Spain); Velasco, M.; Santamaria, G. [University of Barcelona, Department of Radiology, Breast Pathology Unit, Hospital Clinic (Spain); Fernandez, P.L. [University of Barcelona, Department of Pathology, Breast Pathology Unit, Hospital Clinic (Spain); Farrus, B. [University of Barcelona, Department of Radiation Oncology, Breast Pathology Unit, Hospital Clinic (Spain); Munoz, M.; Albanell, J. [University of Barcelona, Department of Medical Oncology, Breast Pathology Unit, Hospital Clinic (Spain)

    2005-08-01

    The aim of this study was to evaluate the frequency of false-negative (FN) sentinel node procedures in patients with breast cancer and the subsequent clinical outcome in such patients. A total of 325 breast cancer patients underwent sentinel lymph node biopsy at our institution between June 1998 and May 2004. A 2-day protocol was used to localise the sentinel node with the injection of{sup 99m}Tc-nanocolloid. There were two phases in the study: the learning phase (105 patients) and the application phase (220 patients). In the learning phase, a complete lymphadenectomy was always performed. In the application phase, sentinel nodes were studied intraoperatively and lymphadenectomy was performed when considered warranted by the pathological intraoperative results. The median follow-up duration in the 220 patients studied during the application phase was 21.2 months (range 4-45 months). In this phase a total of 427 sentinel nodes were obtained (range 1-5 per patient, median 1.99), with 66 positive sentinel nodes in 56 patients (26%). The lymphadenectomies performed were also positive in 25% of cases (14 patients). We observed a total of two false-negative sentinel lymph node results (3.45%). One of them was found during the surgical excision of non-sentinel nodes, and the other presented as an axillary recurrence 17 months postoperatively (1.72% clinical false-negative rate). The latter patient died 1 year after the first recurrence. After a median follow-up of 21.2 months we observed only one clinical recurrence among 220 patients. Our results indicate that adequate local control is achieved by application of the sentinel node protocol. (orig.)

  20. Reduction in the number of sentinel lymph node procedures by preoperative ultrasonography of the axilla in breast cancer.

    NARCIS (Netherlands)

    Deurloo, E.E.; Tanis, P.J.; Gilhuijs, K.G.; Muller, S.H.; Kroger, R.; Peterse, J.L.; Rutgers, E.; Valdes Olmos, R.A.; Schultze Kool, L.J.

    2003-01-01

    Currently, breast cancer patients without clinically suspicious lymph nodes are candidates for sentinel lymph node procedures (SLNPs). The aims of this study were to investigate whether preoperative axillary ultrasonography and fine-needle aspiration cytology (FNA) can reduce the number of the more

  1. Prognostic significance of axillary dissection in breast cancer patients with micrometastases or isolated tumor cells in sentinel nodes

    DEFF Research Database (Denmark)

    Tvedskov, Tove Filtenborg; Jensen, Maj-Britt; Ejlertsen, Bent;

    2015-01-01

    to identify patients with micrometastases or ITC in sentinel nodes following surgery for primary breast cancer between 2002 and 2008. A Cox proportional hazard regression model was developed to assess the hazard ratios (HR) for AR and OS between patients with and without ALND. We identified 2074 patients...

  2. Axillary and internal mammary sentinel lymph node biopsy in male breast cancer patients: case series and review

    Directory of Open Access Journals (Sweden)

    Cao X

    2015-06-01

    Full Text Available Xiaoshan Cao,1,2 Chunjian Wang,1 Yanbing Liu,1 Pengfei Qiu,1 Binbin Cong,1,2 Yongsheng Wang1 1Breast Cancer Center, Shandong Cancer Hospital and Institute, Jinan, Shandong, People’s Republic of China; 2School of Medicine and Life Sciences, Jinan University-Shandong Academy of Medical Sciences, Jinan, Shandong, People’s Republic of China Abstract: Male breast cancer (MBC is considered as a rare disease that accounts for less than 1% of all breast cancers, and its treatment has been based on the evidence available from female breast cancer. Axillary sentinel lymph node biopsy (SLNB is now regarded as the standard of care for both female and male patients without clinical and imaging evidence of axillary lymph node metastases, while internal mammary SLNB has rarely been performed. Internal mammary chain metastasis is an independent prognostic predictor. Internal mammary SLNB should be performed to complete nodal staging and guide adjuvant therapy in MBC patients with preoperative lymphoscintigraphic internal mammary chain drainage. We report both axillary and internal mammary SLNB in two cases with MBC. Internal mammary sentinel lymph node did contain metastasis in one case. Keywords: male breast cancer, internal mammary lymph node, sentinel lymph node biopsy, case report

  3. Clinicopathologic analysis of sentinel lymph node mapping in early breast cancer.

    Science.gov (United States)

    Choi, Seung-Hye; Barsky, Sanford H; Chang, Helena R

    2003-01-01

    Axillary nodal status is the most significant prognosticator for predicting survival and guiding adjuvant therapy in breast cancer patients. Sentinel lymph node biopsy (SLNB) represents a minimally invasive procedure with low morbidity for staging axillary nodal status. In this article we review and report our experiences in patients with early breast cancer who underwent SLNB at the Revlon/UCLA Breast Center. Between September 1998 and May 2000, a total 83 SLNBs were performed in 81 patients with proven breast cancer and negative axillary examination who elected to have SLNB as the first step of nodal staging. Two patients had bilateral breast cancer. SLNB was localized by using both 99Tc sulfur colloid (83 cases) and isosulfan blue dye (75 cases). Data of these patients were prospectively collected and analyzed. The clinical and pathologic characteristics of women with positive and negative sentinel lymph nodes (SLNs) were compared to identify features predictive of SLN metastasis. Of the 83 cases, the SLN was successfully localized in 82 (98.8%). Sixty-three percent of patients had SLNs found in level I only, 18.3% in both level I and II, and 4.9% in level II alone. The vast majority (84.3%) of these cases had T1 breast cancer with an average size of 1.55 cm for the entire series. Twenty-three patients (28%) had positive SLNs, with an average of 1.5 positive SLNs per patient. Fifteen had metastases detected by hematoxylin and eosin staining and 8 had micrometastases detected by immunohistochemistry (IHC) using anticytokeratin antibodies. Ten of the former group agreed to and 2 of the latter group opted for full axillary lymph node dissection (ALND). An average of 17.5 lymph nodes were removed from each ALND procedure. Additional metastases or micrometastases were found in seven patients (in a total of 28 lymph nodes). Three patients with completely negative SLNs experienced additional axillary lymph node removal due to their election of free flap reconstruction

  4. Near-infrared fluorescence sentinel lymph node mapping in breast cancer: a multicenter experience

    Science.gov (United States)

    Verbeek, Floris P.R.; Troyan, Susan L.; Mieog, J. Sven D.; Liefers, Gerrit-Jan; Moffitt, Lorissa A.; Rosenberg, Mireille; Hirshfield-Bartek, Judith; Gioux, Sylvain; van de Velde, Cornelis J.H.; Vahrmeijer, Alexander L.; Frangioni, John V.

    2014-01-01

    NIR fluorescence imaging using indocyanine green (ICG) has the potential to improve the SLN procedure by facilitating percutaneous and intraoperative identification of lymphatic channels and SLNs. Previous studies suggested that a dose of 0.62 mg (1.6 ml of 0.5 mM) ICG is optimal for SLN mapping in breast cancer. The aim of this study was to evaluate the diagnostic accuracy of near-infrared (NIR) fluorescence for sentinel lymph node (SLN) mapping in breast cancer patients when used in conjunction with conventional techniques. Study subjects were 95 breast cancer patients planning to undergo SLN procedure at either the Dana-Farber/Harvard Cancer Center (Boston, MA, USA) or the Leiden University Medical Center (Leiden, the Netherlands) between July 2010 and January 2013. Subjects underwent the standard-of-care SLN procedure at each institution using 99Technetium-colloid in all subjects and patent blue in 27 (28%) of the subjects. NIR fluorescence-guided SLN detection was performed using the Mini-FLARE imaging system. SLN identification was successful in 94 of 95 subjects (99%) using NIR fluorescence imaging or a combination of both NIR fluorescence imaging and radioactive guidance. In 2 of 95 subjects, radioactive guidance was necessary for initial in vivo identification of SLNs. In 1 of 95 subjects, NIR fluorescence was necessary for initial in vivo identification of SLNs. A total of 177 SLNs (mean = 1.9, range = 1–5) were resected: 100% NIR fluorescent, 88% radioactive, and 78% (of 40 nodes) blue. In 2 of 95 subjects (2.1%), SLNs containing macrometastases were found only by NIR fluorescence, and in 1 patient this led to upstaging to N1. This study demonstrates the safe and accurate application of NIR fluorescence imaging for the identification of SLNs in breast cancer patients, but calls into question what technique should be used as the gold standard in future studies. PMID:24337507

  5. SENTINEL NODE BIOPSY BY TWO KINDS OF BLUE DYES IN PATIENTS WITH BREAST CANCER

    Institute of Scientific and Technical Information of China (English)

    2001-01-01

    Objective To evaluate the identification successful rate of sentinel lymph node (SLN) with breast cancer and the accuracy to predict axillary lymph node status in different vital blue dyes.Methods 94 patients with breast cancer were recruited for the study between Oct. 1999 and Apr. 2001, of whom 32 and 62, respectively, were injected 0.028mmol*L-1 Methylene blue and 0.018mmol*L-1 Patent blue violet in breast parenchyma surrounding the primary tumor to identify SLN.All 94 patients underwent the axillary lymph node dissection.Results For Methylene blue group and Patent blue violet group, SLN identification successful rates were 65.6% (21/32) and 88.7% (55/62) (P=0.012) and accuracy rate to predict axillary lymph node status were 90.5% (19/21) and 98.2% (54/55) (P=0.183), respectively.Conclusion In identifying SLN,Patent blue violet is more ideal vital blue dye than Methylene blue, whereas the accuracy rate to predict axillary lymph node status had no significant difference.

  6. The use of indocyanine green in sentinel lymph node biopsy in patients with breast cancer

    Directory of Open Access Journals (Sweden)

    De-qiang KOU

    2015-06-01

    Full Text Available Objective To explore the prospect of clinical application of indocyanine green (ICG in sentinel lymph node biopsy (SLNB in patients with breast cancer. Methods Seventy-two female breast cancer patients were selected from those receiving surgery during July 2014 and December 2014, with an age range of 33-67 years and a median age of 50 years, and they were randomly divided into experimental group (n=35 and control group (n=37, ICG and methylene blue as tracers were used respectively for SLNB. The surgical specimens were submitted to frozen section for pathological examination. The patients with metastasis to SLN received axillary lymph node dissection. Results The successful detection rate of metastasis to SLN by ICG method was 94.3%, with a total of 111 SLNs, with an average of 3.17 SLNs for each patient, and the accuracy rate was 94.3%, the sensitivity and false negative rate were 100% and 0%, respectively. On the other hand, the detection rate with methylene blue method was 92.0%, including 78 SLNs, with an average of 2.1 SLNs for each patient, and the accuracy rate was 89.2%, the sensitivity and false negative rates were 92.9% and 7.7%, respectively. The differences between two methods in the average SLNs and false-negative rate were statistically significant (P0.05. Conclusion ICG method for SLNB in breast cancer shows a higher success rate and lower false negative rate, indicating that its clinical efficacy is superior to that of methylene blue, therefore it may be hopeful to be used alone in SLNB for breast cancer. DOI: 10.11855/j.issn.0577-7402.2015.05.12

  7. Measuring surgeon performance of sentinel lymph node biopsy in breast cancer treatment by cumulative sum analysis.

    Science.gov (United States)

    Lerch, Lindsey; Donald, James C; Olivotto, Ivo A; Lesperance, Mary; van der Westhuizen, Nick; Rusnak, Conrad; Biberdorf, Darren; Ross, Alison; Hayashi, Allen

    2007-05-01

    This study was performed to determine if surgeons' performance of sentinel lymph node biopsy (SLNB) for breast cancer varied with time and to devise a method to continuously evaluate that performance. We retrospectively examined the SLNB experience of 13 community surgeons performing 765 SLNBs and 579 concomitant axillary dissections. False-negative rates (FNRs) were assessed for individuals and cohorts defined by caseload. Performance with time was assessed using cumulative sum (CUSUM) analysis. Overall, the SLN identification rate was 94.3%, and FNR was 5.3%. Each surgeon demonstrated variation in identification rate and/or FNR with time. CUSUM analysis provided an effective means to demonstrate when surgeon variation breached performance standards. Surgeon performance of SLNB varied with time, independent of case load. CUSUM may prove to be a useful statistical tool to evaluate performance before adopting stand-alone SLNB.

  8. Detection of micrometastases in bone marrow and sentinel lymph nodes of breast cancer patients

    Institute of Scientific and Technical Information of China (English)

    Jia Zhao; Xiaoan Liu; Lijun Ling

    2007-01-01

    Objective: To study the sensitivity and clinical significance of HE-staining,IHC and RT-PCR in detecting breast cancer micrometastases in bone marrow and sentinel lymph nodes (SLNs). Methods:After general anesthesia, all patients underwent bone marrow puncture and sentinel lymph node biopsy (SLNB) by 1% isosulfan blue, and then HE-staining,IHC and RT-PCR were used to detect micrometastases. Results:Of 62 patients with breast cancer whose axillary lymph nodes showed negative HE-staining results, 15 cases presented with positive RT-PCR and 9 cases showed positive IHC results positive in bone marrow micrometastases detection. PT-PCR and IHC showed good uniformity(kappa=0.6945)and there was significant difference in detective rate between these two methods (χ2=4.1667,P=0.0412). In SLN samples, 13 showed positive RT-PCR results, while 7 showed positive IHC results. PT-PCR and IHC showed good uniformity (kappa=0.6483)and significant difference was also found in detective rate between these two methods (χ2=4.1667,P=0.0412). Both bone marrow and SLN samples were RT-PCR positive in 3 cases,which indicated that bone marrow micrometastases did not always accompany SLN micrometastases(χ2=0.067,P=0.796). Conclusion: Even if no axillary lymph node involvement or distant metastases are present in routine preoperative examination, micrometastases can still be detected in bone marrow or SLNs. Because the bone marrow micrometastases and axillary node micrometastses are not present simultaneously, combination test of multiple indicators will detect micrometastases more accurately.

  9. Recent Development of Sentinel Lymph Node Biopsy for Breast Cancer in Japan

    Directory of Open Access Journals (Sweden)

    Tadashi Ikeda

    2004-10-01

    Full Text Available The number of breast cancer cases undergoing sentinel lymph node biopsy (SLNB has been increasing with the number of articles published in Japan. SLNB using the dye method alone is performed in about one-third of patients. Analysis of questionnaire responses from 40 institutions in Japan revealed an identification rate by the dye method alone of 87%, compared with 96% using the combined method; the combined method is now recognized in Japan as superior to the dye method alone. No dyes have been specifically approved by the government for use in SLNB, and physicians have been using several inappropriate dyes as tracers for SLNB, such as indocyanine green, patent blue, indigo carmine, and isosulfan blue. The colloidal radiotracers used in Japan include tin colloid, stannous phytate, rhenium sulfate and human serum albumin. Albumin colloid and sulfur colloid are not commercially available in Japan. Small-size tin colloids, stannous phytate and rhenium sulfate all yield good results in terms of detection and false-negative rates. Provided that the surgeon has adequate experience in SLNB, a negative sentinel node can serve as a substitute for negative results from axillary lymph node dissection. Although many institutions have introduced SLNB, few reports have focused on the results of SLNB without axillary dissection because of short follow-up times and small number of patients. The final decision as to whether SLNB is an adequate substitute for axillary dissection awaits the results of prospective randomized trials.

  10. Intraoperative frozen section assessment of sentinel lymph nodes in the operative management of women with symptomatic breast cancer

    Directory of Open Access Journals (Sweden)

    Landers Rob

    2008-06-01

    Full Text Available Abstract Background Maximisation of the potential of sentinel lymph node biopsy as a minimally invasive method of axillary staging requires sensitive intraoperative pathological analysis so that rates of re-operation for lymphatic metastases are minimised. The aim of this study was to describe the test parameters of the frozen section evaluation of sentinel node biopsy for breast cancer compared to the gold standard of standard permanent pathological evaluation at our institution. Methods The accuracy of intraoperative frozen section (FS of sentinel nodes was determined in 94 consecutive women undergoing surgery for clinically node negative, invasive breast cancer (37:T1 disease; 43:T2; 14:T3. Definitive evidence of lymphatic spread on FS indicated immediate level II axillary clearance while sentinel node "negativity" on intraoperative testing led to the operation being curtailed to allow formal H&E analysis of the remaining sentinel nodal tissue. Results Intraoperative FS correctly predicted axillary involvement in 23/30 patients with lymphatic metastases (76% sensitivity rate permitting definitive surgery to be completed at the index operation in 87 women (93% overall. All SN found involved on FS were confirmed as harbouring tumour cells on subsequent formal specimen examination (100% specificity and positive predictive value with 16 patients having additional non-sentinel nodes found also to contain tumour. Negative Predictive Values were highest in women with T1 tumours (97% and lessened with more local advancement of disease (T2 rates: 86%; T3: 75%. Of those with falsely negative FS, three had only micrometastatic disease. Conclusion Intraoperative FS reliably evaluates the status of the sentinel node allowing most women complete their surgery in a single stage. Thus SN can be offered with increased confidence to those less likely to have negative axillae hence expanding the population of potential beneficiaries.

  11. An operative gamma camera for sentinel lymph node procedure in case of breast cancer

    CERN Document Server

    Salvador, S; Mathelin, C; Guyonne, J; Huss, D

    2007-01-01

    Large field of view gamma cameras are widely used to perform lymphoscintigraphy in the sentinel lymph nodes (SLN) procedure in case of breast cancer. However, they are not specified for this application and their sizes do not enable their use in the operative room to control the excision of the all SLN. We present the results obtained with a prototype of a new mini gamma camera developed especially for the operative lymphoscintigraphy of the axillary area in case of breast cancer. This prototype is composed of 10 mm thick parallel lead collimator, a 2 mm thick GSO:Ce inorganic scintillating crystal from Hitachi and a Hamamatsu H8500 flat panel multianode (64 channels) photomultiplier tube (MAPMT) equipped with a dedicated electronics. Its actual field of view is 50 × 50mm2. The gamma interaction position in the GSO scintillating plate is obtained by calculating the center of gravity of the fired MAPMT channels. The measurements performed with this prototype demonstrate the usefulness of this mini gamma camer...

  12. Application of biomarkers in sentinel lymph node biopsy for the management of breast cancer

    Institute of Scientific and Technical Information of China (English)

    Qing Liu; Wings Tjing Yung Loo; Adrian Yun San Yip; Louis Wing Cheong Chow; Elizabeth Lam Yan Ng; Mary Ngan Bing Cheung

    2012-01-01

    Objective Sentinel lymph node in breast cancer is a predictor of the tumor's metastatic potential. Cytokines emerging from antitumor immune response might also target sentinel lymph node (SLN). In this study, we evaluated the cytokine profile including interleukin-8 (IL-8), interleukin-12 (IL-12), interferon-gamma (IFN-γ), and tumor necrosis factor alpha (TNF-α) for the T-cell response.Methods From January 2008 to August 2010, 35 patients with breast mass underwent SLN biopsy in UNIMED Medical Institute. The specimens were formalin-fixed and paraffin-embedded for hematoxylin and eosin staining and immunohistochemistry with following markers: IL-8, IL-12, IFN-γ and TNF-α. The staining intensity was scored according to four grades: negative (-), weak expression (+), moderately positive expression (++), strong positive expression (+++). The correlation between the expression of cytokines and pathological characteristics were also analyzed using the Spearman Rank Correlation test. Results Out of 35 patients, SLN metastases were observed in 20 patients and among them, 75% (15/20) were strongly stained (+++) with IL-8 and moderately stained (++) with IL-12, but only 25% (5/20) were strongly stained (+++) with IFN-γ and TNF-α. The expression of IL-8 was significantly associated with all tumor grades (r=0.639, P=0.00), estrogen receptor (r=0.778, P=0.01), progesterone receptor (r=0.759 P=0.00) and HER-2/neu receptor (r=0.863 P=0.00). Conclusion The strong association between IL-8 expression and SLN metastases might highlight the prognostic significance of IL-8 in SLN.

  13. Breast cancer lymphoscintigraphy: Factors associated with sentinel lymph node non visualization.

    Science.gov (United States)

    Vaz, S C; Silva, Â; Sousa, R; Ferreira, T C; Esteves, S; Carvalho, I P; Ratão, P; Daniel, A; Salgado, L

    2015-01-01

    To evaluate factors associated with non identification of the sentinel lymph node (SLN) in lymphoscintigraphy of breast cancer patients and analyze the relationship with SLN metastases. A single-center, cross-sectional and retrospective study was performed. Forty patients with lymphoscintigraphy without sentinel lymph node identification (negative lymphoscintigraphy - NL) were enrolled. The control group included 184 patients with SLN identification (positive lymphoscintigraphy - PL). Evaluated factors were age, body mass index (BMI), tumor size, histology, localization, preoperative breast lesion hookwire (harpoon) marking and SLN metastases. The statistical analysis was performed with uni- and multivariate logistic regression models and matched-pairs analysis. Age (p=0.036) or having BMI (p=0.047) were the only factors significantly associated with NL. Being ≥60 years with a BMI ≥30 increased the odds of having a NL 2 and 3.8 times, respectively. Marking with hookwire seems to increase the likelihood of NL, but demonstrated statistical significance is lacking (p=0.087). The other tested variables did not affect the examination result. When controlling for age, BMI and marking with the harpoon, a significant association between lymph node metastization and NL was not found (p=0.565). The most important factors related with non identification of SLN in the patients were age, BMI and marking with hook wire. However, only the first two had statistical importance. When these variables were controlled, no association was found between NL and axillary metastases. Copyright © 2015 Elsevier España, S.L.U. and SEMNIM. All rights reserved.

  14. Sentinel Node Biopsy Alone versus Completion Axillary Node Dissection in Node Positive Breast Cancer: Systematic Review and Meta-Analysis

    Directory of Open Access Journals (Sweden)

    Rachna Ram

    2014-01-01

    Full Text Available Introduction. There has been recent interest in validity of completion axillary node dissection after a positive sentinel node. This systematic review aims to ascertain if sentinel lymph node dissection alone was noninferior to axillary lymph node dissection for breast cancer patients who have a positive sentinel node. Method. A systematic review of the electronic databases Embase, MEDLINE, and Cochrane Register of Controlled Trials was carried out. Only randomised trials that had patients with positive sentinel node as the study sample were included in the meta-analysis using the reported hazard ratios with a fixed effect model. Results. Three randomised controlled trials and five retrospective studies were identified. The pooled effect for overall survival was HR 0.94, 95% CI [0.79, 1.19], and for disease free survival was HR 0.83, 95% CI [0.60, 1.14]. The reported rates for locoregional recurrence were similar in both groups. The surgical morbidity was found to be significantly more in patients who had underwent axillary dissection. Conclusion. Amongst patients with micrometastasis in the sentinel node, no further axillary dissection is necessary. For patients with macrometastasis in the sentinel node, it is reasonable to consider omitting axillary dissection to avoid the morbidity of the procedure.

  15. Sentinel Node Biopsy Alone versus Completion Axillary Node Dissection in Node Positive Breast Cancer: Systematic Review and Meta-Analysis

    Science.gov (United States)

    Singh, Jasprit; McCaig, Eddie

    2014-01-01

    Introduction. There has been recent interest in validity of completion axillary node dissection after a positive sentinel node. This systematic review aims to ascertain if sentinel lymph node dissection alone was noninferior to axillary lymph node dissection for breast cancer patients who have a positive sentinel node. Method. A systematic review of the electronic databases Embase, MEDLINE, and Cochrane Register of Controlled Trials was carried out. Only randomised trials that had patients with positive sentinel node as the study sample were included in the meta-analysis using the reported hazard ratios with a fixed effect model. Results. Three randomised controlled trials and five retrospective studies were identified. The pooled effect for overall survival was HR 0.94, 95% CI [0.79, 1.19], and for disease free survival was HR 0.83, 95% CI [0.60, 1.14]. The reported rates for locoregional recurrence were similar in both groups. The surgical morbidity was found to be significantly more in patients who had underwent axillary dissection. Conclusion. Amongst patients with micrometastasis in the sentinel node, no further axillary dissection is necessary. For patients with macrometastasis in the sentinel node, it is reasonable to consider omitting axillary dissection to avoid the morbidity of the procedure. PMID:25383226

  16. High prevalence of human cytomegalovirus proteins and nucleic acids in primary breast cancer and metastatic sentinel lymph nodes.

    Directory of Open Access Journals (Sweden)

    Chato Taher

    Full Text Available BACKGROUND: Breast cancer is a leading cause of death among women worldwide. Increasing evidence implies that human cytomegalovirus (HCMV infection is associated with several malignancies. We aimed to examine whether HCMV is present in breast cancer and sentinel lymph node (SLN metastases. MATERIALS AND METHODS: Formalin-fixed paraffin-embedded tissue specimens from breast cancer and paired sentinel lymph node (SLN samples were obtained from patients with (n = 35 and without SLN metastasis (n = 38. HCMV immediate early (IE and late (LA proteins were detected using a sensitive immunohistochemistry (IHC technique and HCMV DNA by real-time PCR. RESULTS: HCMV IE and LA proteins were abundantly expressed in 100% of breast cancer specimens. In SLN specimens, 94% of samples with metastases (n = 34 were positive for HCMV IE and LA proteins, mostly confined to neoplastic cells while some inflammatory cells were HCMV positive in 60% of lymph nodes without metastases (n = 35. The presence of HCMV DNA was confirmed in 12/12 (100% of breast cancer and 10/11 (91% SLN specimens from the metastatic group, but was not detected in 5/5 HCMV-negative, SLN-negative specimens. There was no statistically significant association between HCMV infection grades and progesterone receptor, estrogen receptor alpha and Elston grade status. CONCLUSIONS: The role of HCMV in the pathogenesis of breast cancer is unclear. As HCMV proteins were mainly confined to neoplastic cells in primary breast cancer and SLN samples, our observations raise the question whether HCMV contributes to the tumorigenesis of breast cancer and its metastases.

  17. Results of a sentinel lymph node biopsy for primary breast cancer

    Energy Technology Data Exchange (ETDEWEB)

    Yoshinaga, Yasuteru; Hiratsuka, Masafumi; Baba, Miki; Beppu, Richiko; Maekawa, Takafumi; Kawahara, Katsunobu; Shirakusa; Takayuki; Fujimitsu, Ritsuko [Fukuoka Univ. (Japan). School of Medicine

    2003-03-01

    Although the role of an axillary lymph node dissection for the primary breast cancer is considered to be a prognostic indicator, regarding the determination of the treatment strategy after surgery, and the best modality for regional control, this procedure is harmful rather than ineffective in cases with a histologically negative node. The sentinel lymph node (SLN) biopsy is a procedure used to assess the degree of nodal involvement before and/or during surgery. From June, 1999 to January, 2002, we performed an SLN biopsy for 47 primary breast cancer patients (T1-2N0-1M0) using either a dye or combined (dye and gamma probe guided) method with a back up conventional axillary node dissection at the Second Department of Surgery, Fukuoka University School of Medicine. The dye method was performed on 39 patients, and it resulted in the accurate identification of the SLN in 74.4% of patients, compared with 94.7% in latter series of 19 patients. In addition, the dye method demonstrated a sensitivity of 66.6%, a specificity of 100% and an accuracy of 96.6%. Eight patients received the combined method, and the SLN was identified in 100% of these patients. This combined method showed a sensitivity of 80%, a specificity of 100% and an accuracy of 87.5%. On the other hand an intraoperative examination using frozen sections resulted in a sensitivity of 50%, a specificity of 100% and an accuracy in the diagnosis of 83.3%. These data suggest that an SLN biopsy for early breast cancer (T1N0) can be performed to eliminate any unnecessary axillary node dissection in cases with negative SLN. However, the successful results of this method depend on the cooperation of the multidisciplinary team (surgeons, pathologists and nuclear radiologists) and the informed consent of all patients. (author)

  18. [Sentinel node biopsy in patients with multifocal and multicentric breast cancer: A 5-year follow-up].

    Science.gov (United States)

    Blanco Saiz, I; López Carballo, M T; Martínez Fernández, J; Carrión Maldonado, J; Cabrera Pereira, A; Moral Alvarez, S; Santamaría Girón, L; Cantero Cerquella, F; López Secades, A; Díaz González, D; Llaneza Folgueras, A; Aira Delgado, F J

    2014-01-01

    Sentinel lymph node biopsy (SLNB) as a staging procedure in multiple breast cancer is a controversial issue. We have aimed to evaluate the efficacy of sentinel node (SN) detection in patients with multifocal or multicentric breast cancer as well as the safety of its clinical application after a long follow-up. A prospective descriptive study was performed. Eighty-nine patients diagnosed of multiple breast cancer (73 multifocal; 16 multicentric) underwent SLNB. These patients were compared to those with unifocal neoplasia. Periareolar radiocolloid administration was performed in most of the patients. Evaluation was made at an average of 67.2 months of follow-up (32-126 months). Scintigraphic and surgical SN localization in patients with multiple breast cancer were 95.5% and 92.1%, respectively. A higher percentage of extra-axillary nodes was observed than in the unifocal group (11.7% vs 5.4%) as well as a significantly higher number of SN per patient (1.70 vs 1.38). The rate of SN localization in multicentric cancer was slightly lower than in multifocal cancer (87.5% vs 93.1%), and the finding of extra-axillary drainages was higher (20% vs 10%). Number of SN per patient was significantly higher in multicentric breast cancer (2.33 vs 1.57). No axillary relapses have been demonstrated in the follow-up in multiple breast cancer patients group. SLNB performed by periareolar injection is a reliable and accurate staging procedure of patients with multiple breast cancer, including those with multicentric processes. Copyright © 2013 Elsevier España, S.L. and SEMNIM. All rights reserved.

  19. Near-infrared fluorescence sentinel lymph node mapping in breast cancer: a multicenter experience.

    Science.gov (United States)

    Verbeek, Floris P R; Troyan, Susan L; Mieog, J Sven D; Liefers, Gerrit-Jan; Moffitt, Lorissa A; Rosenberg, Mireille; Hirshfield-Bartek, Judith; Gioux, Sylvain; van de Velde, Cornelis J H; Vahrmeijer, Alexander L; Frangioni, John V

    2014-01-01

    Near-infrared (NIR) fluorescence imaging using indocyanine green (ICG) has the potential to improve the sentinel lymph node (SLN) procedure by facilitating percutaneous and intraoperative identification of lymphatic channels and SLNs. Previous studies suggested that a dose of 0.62 mg (1.6 mL of 0.5 mM) ICG is optimal for SLN mapping in breast cancer. The aim of this study was to evaluate the diagnostic accuracy of NIR fluorescence for SLN mapping in breast cancer patients when used in conjunction with conventional techniques. Study subjects were 95 breast cancer patients planning to undergo SLN procedure at either the Dana-Farber/Harvard Cancer Center (Boston, MA, USA) or the Leiden University Medical Center (Leiden, the Netherlands) between July 2010 and January 2013. Subjects underwent the standard-of-care SLN procedure at each institution using (99)Technetium-colloid in all subjects and patent blue in 27 (28 %) of the subjects. NIR fluorescence-guided SLN detection was performed using the Mini-FLARE imaging system. SLN identification was successful in 94 of 95 subjects (99 %) using NIR fluorescence imaging or a combination of both NIR fluorescence imaging and radioactive guidance. In 2 of 95 subjects, radioactive guidance was necessary for initial in vivo identification of SLNs. In 1 of 95 subjects, NIR fluorescence was necessary for initial in vivo identification of SLNs. A total of 177 SLNs (mean 1.9, range 1-5) were resected: 100 % NIR fluorescent, 88 % radioactive, and 78 % (of 40 nodes) blue. In 2 of 95 subjects (2.1 %), SLNs-containing macrometastases were found only by NIR fluorescence, and in one patient this led to upstaging to N1. This study demonstrates the safe and accurate application of NIR fluorescence imaging for the identification of SLNs in breast cancer patients, but calls into question what technique should be used as the gold standard in future studies.

  20. Sentinel Lymph Node Biopsy Results in Early-Stage Breast Cancer

    Directory of Open Access Journals (Sweden)

    Ahmet Kocakuflak

    2011-06-01

    Full Text Available Aim: Sentinel lymph node biopsy (SLNB in breast cancer patients targets the evaluation of the initial lymph node (SLN which drains the primary tumor. The morbidity of unnecessary axillary dissection can be avoided by intensive preoperative assessment of SLN. Methods: Twenty-six consecutive patients who had been surgically treated for early-stage breast cancer between March 2005 and August 2007 were evaluated. Blue dye (methylene blue method was used to detect SLN. All patients underwent axillary lymph node dissection following SLNB. NCSS program was used for statistical analysis. Chi-square test was used in the comparison of binary groups. Results: Except for one, all patients were female. The mean age of the patients was 56 (29-76 years. While 13 patients underwent modified radical mastectomy (=mastectomy+axillary dissection, the remaining 13 patients underwent breast preserving surgery (lumpectomy+axillary dissection. SLN could not be found in 2 patients (7.6%.The male patient was one of these 2 patients and both of them were positive for axillary node metastases. The detection rate of SLN, specificity, negative predictive value, positive predictive value, sensitivity, false negativity, and reliability were 92.3%, 92.8%, 86%, 90.9%, 83.3%, 16.6%, and 88.4%, respectively. Conclusion: Our result support the hypothesis that SLNB with blue dye alone is a reliable technique and, surgery clinics should use it prior to axillary dissection to test their own success during the learning curve. (The Medical Bulletin of Haseki 2011; 49: 67-72

  1. [Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer. Its relation with molecular subtypes].

    Science.gov (United States)

    Ruano, R; Ramos, M; García-Talavera, J R; Ramos, T; Rosero, A S; González-Orus, J M; Sancho, M

    2014-01-01

    To evaluate the influence of the molecular subtype (MS) in the Sentinel Node Biopsy (SNB) technique after neoadjuvant chemotherapy (NAC) in women with locally advanced breast cancer (BC) and a complete axillary response (CR). A prospective study involving 70 patients with BC treated with NAC was carried out. An axillary lymph node dissection was performed in the first 48 patients (validation group: VG), and in case of micro- or macrometastases in the therapeutic application phase (therapy group:TG). Classified according to MS: 14 luminal A; 16 luminal B HER2-, 13 luminal B HER2+, 10HER2+ non-luminal, 17 triple-negative. SNB was carried out in 98.6% of the cases, with only one false negative result in the VG (FN=2%). Molecular subtype did not affect SN detection. Despite the existence of axillary CR, statistically significant differences were found in the proportion of macrometastasis (16.7% vs. 35.7%, p=0.043) on comparing the pre-NAC cN0 and cN+. Breast tumor response to NAC varied among the different MS, this being lowest in luminal A (21.5%) and highest in non-luminal HER2+ group (80%). HER2+ and triple-negative were the groups with the best axillary histological response both when there was prior clinical involvement and when there was not. Molecular subtype is a predictive factor of the degree of tumor response to NAC in breast cancer. However, it does not affect SNB detection and efficiency. SNB can also be used safely in women with prior node involvement as long as a complete clinical and radiological assessment is made of the node response to NAC. Copyright © 2014 Elsevier España, S.L.U. and SEMNIM. All rights reserved.

  2. Frozen section is superior to imprint cytology for the intra-operative assessment of sentinel lymph node metastasis in Stage I Breast cancer patients

    Directory of Open Access Journals (Sweden)

    Makita Masujiro

    2006-05-01

    Full Text Available Abstract Background A standard intra-operative procedure for assessing sentinel lymph node metastasis in breast cancer patients has not yet been established. Patients and methods One hundred and thirty-eight patients with stage I breast cancer who underwent sentinel node biopsy using both imprint cytology and frozen section were analyzed. Results Seventeen of the 138 patients had sentinel node involvement. Results of imprint cytology included nine false negative cases (sensitivity, 47.1%. In contrast, only two cases of false negatives were found on frozen section (sensitivity, 88.2%. There were two false positive cases identified by imprint cytology (specificity, 98.3%. On the other hand, frozen section had 100% specificity. Conclusion These findings suggest that frozen section is superior to imprint cytology for the intra-operative determination of sentinel lymph node metastasis in stage I breast cancer patients.

  3. Frozen section is superior to imprint cytology for the intra-operative assessment of sentinel lymph node metastasis in Stage I Breast cancer patients

    Science.gov (United States)

    Mori, Miki; Tada, Keiichiro; Ikenaga, Motoko; Miyagi, Yumi; Nishimura, Seiichiro; Takahashi, Kaoru; Makita, Masujiro; Iwase, Takuji; Kasumi, Fujio; Koizumi, Mituru

    2006-01-01

    Background A standard intra-operative procedure for assessing sentinel lymph node metastasis in breast cancer patients has not yet been established. Patients and methods One hundred and thirty-eight patients with stage I breast cancer who underwent sentinel node biopsy using both imprint cytology and frozen section were analyzed. Results Seventeen of the 138 patients had sentinel node involvement. Results of imprint cytology included nine false negative cases (sensitivity, 47.1%). In contrast, only two cases of false negatives were found on frozen section (sensitivity, 88.2%). There were two false positive cases identified by imprint cytology (specificity, 98.3%). On the other hand, frozen section had 100% specificity. Conclusion These findings suggest that frozen section is superior to imprint cytology for the intra-operative determination of sentinel lymph node metastasis in stage I breast cancer patients. PMID:16707007

  4. SNOLL. Sentinel node and occult (impalpable) lesion localization in breast cancer

    Energy Technology Data Exchange (ETDEWEB)

    Thind, C.R., E-mail: thindr@aol.com [Radiology Department, St Helens and Knowsley Teaching Hospitals NHS Trust, Prescott, Liverpool (United Kingdom); Tan, S.; Desmond, S.; Harris, O. [Radiology Department, St Helens and Knowsley Teaching Hospitals NHS Trust, Prescott, Liverpool (United Kingdom); Ramesh, H.S.J.; Chagla, L.; Ray, A.; Audisio, R. [Department of Surgery, St Helens and Knowsley Teaching Hospitals NHS Trust, Prescott, Liverpool (United Kingdom)

    2011-09-15

    Aim: To evaluate the efficacy and safety for use of dual radioisotopes for localization of occult (impalpable) breast lesions and sentinel node biopsy as a combined technique (SNOLL) using a lower dose than previous studies. Materials and methods: One hundred and twenty-seven SNOLL procedures were performed. The impalpable breast lesions were localized with an intra-lesion injection of 0.2 ml of {sup 99m}Tc MAA (1 MBq) with a particle size of 10-90 {mu}m (radio-guided occult lesion localization, or ROLL) 1 to 4 h before surgery. Sentinel node localization was performed using 0.2 mls of {sup 99}Tc nanocolloid (20 MBq) particle size no greater than 80 nm injected subdermally in the periareolar region within the index quadrant, the night before or the morning of surgery. Results: Lesion localization was consistently achieved with a lower dose than that described in other studies without the need to use scintigraphy or additional imaging with radioopaque contrast medium. One hundred percent lesion localization with a negative clearance margin of 94.8% and 100% sentinel node localization was achieved. The use of dual radioisotopes with the lower dose used for ROLL did not compromise the localization of the impalpable lesion or the sentinel nodes. Conclusion: The combined use of radioisotopes for lesion and sentinel node removal is feasible and reliable with the lower radioisotope dose suggested compared with previously published studies. This method should be recommended as a standard procedure for SNOLL.

  5. Validation of the Memorial Sloan Kettering Cancer Center nomogram for predicting non-sentinel lymph node metastasis in sentinel lymph node-positive breast-cancer patients

    Directory of Open Access Journals (Sweden)

    Bi X

    2015-02-01

    Full Text Available Xiang Bi,1,* Yongsheng Wang,2 Minmin Li,1,* Peng Chen,2 Zhengbo Zhou,2 Yanbing Liu,2 Tong Zhao,2 Zhaopeng Zhang,2 Chunjian Wang,2 Xiao Sun,2 Pengfei Qiu2 1School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences, Shandong Cancer Hospital, 2Breast Cancer Center, Shandong Cancer Hospital, Jinan, People’s Republic of China *These authors contributed equally to this study Background: The main purpose of the study reported here was to validate the clinical value of the Memorial Sloan Kettering Cancer Center (MSKCC nomogram that predicts non-sentinel lymph node (SLN metastasis in SLN-positive patients with breast cancer. Methods: Data on 1,576 patients who received sentinel lymph node biopsy (SLNB at the Shandong Cancer Hospital from December 2001 to March 2014 were collected in this study, and data on 509 patients with positive SLN were analyzed to evaluate the risk factors for non-SLN metastasis. The MSKCC nomogram was used to estimate the probability of non-SLN metastasis and was compared with actual probability after grouping into deciles. A receiver-operating characteristic (ROC curve was drawn and predictive accuracy was assessed by calculating the area under the ROC curve. Results: Tumor size, histological grade, lymphovascular invasion, multifocality, number of positive SLNs, and number of negative SLNs were correlated with non-SLN metastasis (P<0.05 by univariate analysis. However, multivariate analysis showed that tumor size (P=0.039, histological grade (P=0.043, lymphovascular invasion (P=0.001, number of positive SLNs (P=0.001, and number of negative SLNs (P=0.000 were identified as independent predictors for non-SLN metastasis. The trend of actual probability in various decile groups was comparable to the predicted probability. The area under the ROC curve was 0.722. Patients with predictive values lower than 10% (97/492, 19.7% had a frequency of non-SLN metastasis of 17.5% (17/97. Conclusion: The

  6. Staging of women with breast cancer after introduction of sentinel node guided axillary dissection

    DEFF Research Database (Denmark)

    Tvedskov, Tove Filtenborg

    2012-01-01

    was not significantly different in the two periods, whereas the proportion of patients with micrometastases increased significantly from 5.1% to 9.0%. However, the proportion of patients offered adjuvant systemic treatment due to positive nodal status as the only high-risk criterion did only increase from 7.8% to 8....../3 of patients with ITC in sentinel node for an ALND. In patients with micrometastases in sentinel node the risk of NSN metastases was significantly associated with increasing tumor size, lymphovascular invasion, negative hormone receptor status, location of tumor in the upper lateral quadrant of the breast...

  7. Evaluation of the Metasin assay for intraoperative assessment of sentinel lymph node metastases in breast cancer.

    Science.gov (United States)

    Smith, G J; Hodges, E; Markham, H; Zhang, S; Cutress, R I

    2017-02-01

    Sentinel lymph node (SLN) biopsy is the preferred surgical technique for staging the axilla in clinically node-negative breast cancer. Accurate intraoperative staging allows for the immediate performance of an axillary clearance in node-positive patients. We assessed the Metasin assay for the intraoperative analysis of SLNs in a prospective evaluation of 250 consecutive patients undergoing intraoperative SLN analysis at the Breast Unit, University Hospital, Southampton, UK. Metasin uses a quantitative reverse transcription PCR to detect two markers of metastasis: cytokeratin 19 (CK19) an epithelial marker and mammaglobin (MGB) a breast specific marker. Metasin results were compared with the results from routine paraffin block histopathology. Metasin was robust, with a failure rate of <1%, and demonstrated excellent accuracy and reproducibility. The average turnaround time for the Metasin assay was 42 min, the largest variable being the number of nodes assayed. A total of 533 SLNs were evaluated with 75 patients testing positive for MGB and/or CK19. Based on the analysis of individual SLNs, the overall concordance between Metasin and histology was 92.3% (sensitivity 88.7%, specificity 92.9%). When adjusted for tissue allocation bias, the concordance was 93.8% (sensitivity 89.8%, specificity 94.6%). In this evaluation, 57/250 patients (23%) proceeded to axillary clearance based on Metasin results and were considered spared a second operative procedure. Metasin has proven to be an accurate, reproducible and reliable laboratory test. The analysis time is acceptable for intraoperative use, and in comparison to routine histology demonstrates acceptable concordance, sensitivity and specificity. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

  8. Applied research of the combination of indocyanine green and methylene blue in mapping sentinel lymph nodes for breast cancer patients

    Institute of Scientific and Technical Information of China (English)

    Ren-Zhong Cui; Jie-Hui Yang; Cheng-Xin Pan

    2016-01-01

    Objective:To discuss the application value of combination of indocyanine green and methylene blue in sentinel lymph node biopsy for patients with breast cancer. Methods:A total of 200 cases of breast cancer patients were selected and randomly divided into test group and control group, each of 100 cases. The test group received indocyanine green and methylene blue as the lymphatic mapping tracers and the control group received methylene blue only. Intraoperative frozen section was performed, followed by conventional histopathology. Results:Thepositive rate, sensitivity, false negative rate, consistent rate and the Kappa values of the test group were 98%(98/100), 95.74%(45/47), 4.26%(2/47), 96.94%%(95/98) and 0.860, and 94%(94/100) and 86.96%(40/46), 13.04%(6/46), 93.62%(88/94) and 0.758 of control group;There were statistical significance between the differences of the positive rate, sensitivity, false negative rate, consistent rate and the Kappa values of test group and control group. Conclusion:Combination of indocyanine green and methylene blue for mapping sentinel lymph nodes in breast cancer patients has the advantages of real-time visual and accurate positioning and can reduce the false negative rate, to provide the important evidence based medicine foundation for the surgical treatment of breast cancer.

  9. Sentinel Lymph Node Detection by 3D Freehand Single-Photon Emission Computed Tomography in Early Stage Breast Cancer

    Directory of Open Access Journals (Sweden)

    Salih Sinan Gültekin

    2016-06-01

    Full Text Available We herein present our first experience obtained by 3D freehand single-photon emission computed tomography (SPECT (F-SPECT guidance for sentinel lymph node detection (SLND in two patients with early stage breast cancer. F-SPECT guidance was carried out using one-day protocol in one case and by the two-day protocol in the other one. SLND was performed successfully in both patients. Histopathologic evaluation showed that the excised nodes were tumor negative. Thus, patients underwent breast-conserving surgery alone.

  10. [Methodological issues of sentinel lymph nodes biopsy in patients with breast cancer].

    Science.gov (United States)

    Kanaev, S V; Novikov, S N; Krivorot'ko, P V; Semiglazov, V F; Zhukova, L A; Krzhivitskiĭ, P I

    2013-01-01

    Radionuclide imaging of sentinel lymph nodes (SLN) was performed in 122 breast cancer patients, which before the biopsy of lymph nodes it was performed intratumoral injection of colloidal radiopharmaceuticals (RFP): in 89 patients--nanocolloidal (NC) and in 33--colloidal with particle size from 200 to 1000 nm. After the introduction of NC the SLN image was obtained in 83 of 89 women. (93.3%). After the introduction of large colloids (200-1000 nm or more) SLN visualization in this group was achieved in 27 of 33 patients, i.e., in 81.8% of cases (p lymph nodes of the second and higher orders in axillary as well as under-and supraclavicular regions. On the contrary while using larger colloids, RFP accumulated only in SLN of axillary region in 85.1%. These differences in the topography of the absorption of various diameters radiocolloids were reliable (p = 0.01). Using the NC RFN compared with colloidal RFP of larger diameter can reliably improve SLN visualization till 98.9% however leads to a concomitant accumulation of RFP in lymph nodes of the second order in 55.8% of patients.

  11. The value of completion axillary treatment in sentinel node positive breast cancer patients undergoing a mastectomy : A Dutch randomized controlled multicentre trial (BOOG 2013-07)

    NARCIS (Netherlands)

    Roozendaal, L.M.; de Wilt, J.H.; van Dalen, T.; van der Hage, J.A.; Strobbe, L.J.; Boersma, L.J.; Linn, S.C.; Lobbes, M.B.; Poortmans, P.M.P.; Tjan-Heijnen, V. C. G.; van de Vijver, K.K.; Westenberg, A.G.; Kessels, A.G.; Smidt, M.L.; de Vries, J.

    2015-01-01

    BACKGROUND: Trials failed to demonstrate additional value of completion axillary lymph node dissection in case of limited sentinel lymph node metastases in breast cancer patients undergoing breast conserving therapy. It has been suggested that the low regional recurrence rates in these trials might

  12. The value of completion axillary treatment in sentinel node positive breast cancer patients undergoing a mastectomy : a Dutch randomized controlled multicentre trial (BOOG 2013-07)

    NARCIS (Netherlands)

    van Roozendaal, L. M.; de Wilt, J. H. W.; van Dalen, T.; van der Hage, J. A.; Strobbe, L. J. A.; Boersma, L. J.; Linn, S. C.; Lobbes, M. B. I.; Poortmans, P. M. P.; Tjan-Heijnen, V. C. G.; Van de Vijver, K. K. B. T.; de Vries, J.; Westenberg, A. H.; Kessels, A. G. H.; Smidt, M. L.

    2015-01-01

    Background: Trials failed to demonstrate additional value of completion axillary lymph node dissection in case of limited sentinel lymph node metastases in breast cancer patients undergoing breast conserving therapy. It has been suggested that the low regional recurrence rates in these trials might

  13. The value of completion axillary treatment in sentinel node positive breast cancer patients undergoing a mastectomy : A Dutch randomized controlled multicentre trial (BOOG 2013-07)

    NARCIS (Netherlands)

    Roozendaal, L.M.; de Wilt, J.H.; van Dalen, T.; van der Hage, J.A.; Strobbe, L.J.; Boersma, L.J.; Linn, S.C.; Lobbes, M.B.; Poortmans, P.M.P.; Tjan-Heijnen, V. C. G.; van de Vijver, K.K.; Westenberg, A.G.; Kessels, A.G.; Smidt, M.L.; de Vries, J.

    2015-01-01

    BACKGROUND: Trials failed to demonstrate additional value of completion axillary lymph node dissection in case of limited sentinel lymph node metastases in breast cancer patients undergoing breast conserving therapy. It has been suggested that the low regional recurrence rates in these trials might

  14. The value of completion axillary treatment in sentinel node positive breast cancer patients undergoing a mastectomy: a Dutch randomized controlled multicentre trial (BOOG 2013-07)

    NARCIS (Netherlands)

    Roozendaal, L.M. van; Wilt, J.H.W. de; Dalen, T. van; Hage, J.A. van der; Strobbe, L.J.A.; Boersma, L.J.; Linn, S.C.; Lobbes, M.B.; Poortmans, P.M.P.; Tjan-Heijnen, V.C.; Vijver, K.K. Van de; Vries, J de; Westenberg, A.H.; Kessels, A.G.; Smidt, M.L.

    2015-01-01

    BACKGROUND: Trials failed to demonstrate additional value of completion axillary lymph node dissection in case of limited sentinel lymph node metastases in breast cancer patients undergoing breast conserving therapy. It has been suggested that the low regional recurrence rates in these trials might

  15. Validation study of the modified injection technique for internal mammary sentinel lymph node biopsy in breast cancer

    Directory of Open Access Journals (Sweden)

    Cong BB

    2015-09-01

    Full Text Available Bin-Bin Cong,1,2,* Xiao-Shan Cao,1,2,* Peng-Fei Qiu,1 Yan-Bing Liu,1 Tong Zhao,1 Peng Chen,1 Chun-Jian Wang,1 Zhao-Peng Zhang,1 Xiao Sun,1 Yong-Sheng Wang1 1Breast Cancer Center, Shandong Cancer Hospital and Institute, 2School of Medicine and Life Sciences, Jinan University-Shandong Academy of Medical Sciences, Jinan, Shandong, People’s Republic of China *These authors contributed equally to this study Abstract: According to the hypothesis of internal mammary sentinel lymph node (IM-SLN lymphatic drainage pattern, a modified radiotracer injection technique (periareolar intraparenchyma, high volume, and ultrasonographic guidance was established. To verify the accuracy of the hypothesis and validate the modified radiotracer injection technique and to observe whether the lymphatic drainage of the whole breast parenchyma could reach to the same IM-SLN, different tracers were injected into different locations of the breast. The validation study results showed that the correlation and the agreement of the radiotracer and the fluorescence tracer are significant (case-base, rs =0.808, P<0.001; Kappa =0.79, P<0.001. It proved that the lymphatic drainage from different location of the breast (the primary tumor, the subareolar plexus reached the same IM-SLNs and the hypothesis of IM-SLN lymphatic drainage pattern (ie, IM-SLN receives lymphatic drainage from not only the primary tumor area, but also the entire breast parenchyma. In other words, it validated the accuracy of our modified radiotracer injection technique. Keywords: breast cancer, internal mammary, sentinel lymph node biopsy, visualization rate

  16. Role of Axillary Ultrasound, Fine Needle Aspiration Cytology and Sentinel Lymph Node Biopsy in clinically N0 Breast Cancer.

    Science.gov (United States)

    Goel, Gaurav; Janaki, P D; Smitha, N V; Anupama, Rajanbabu; Sundaram, P Shanmugha; Nataraj, Y S; Vijaykumar, D K

    2016-12-01

    This study evaluates the combined role of axillary ultrasound, fine needle aspiration cytology and sentinel lymph node biopsy in clinically N0 axilla. Between January 2014 and June 2015, 150 women with early breast cancer underwent axillary ultrasound as a first investigation for nodal status. Suspicious nodes were subjected to image guided fine needle aspiration cytology. Non-suspicious and fine needle aspiration cytology negative axillary nodes proceeded to sentinel lymph node biopsy at time of primary breast surgery. All confirmed positive (cytology and frozen) cases proceeded to axillary lymph node dissection. 52 women had positive axillary nodes at final histology. Axillary ultrasound with fine needle aspiration cytology identified 27 patients with positive axillary nodal status and had a sensitivity of 84.36 % (27/32) and specificity of 87.5 % (14/16). Intraoperative frozen analysis identified a further 13 cases with sensitivity of 56.52 % (13/23) and specificity of 97.56 % (80/82). Overall 76.92 % (40/52) patients with positive axillary metastasis were identified peri-operatively using combination of axillary ultrasound, cytology and sentinel lymph node biopsy.

  17. Contribution of SPECT/CT for sentinel node localization in patients with ipsilateral breast cancer relapse

    Energy Technology Data Exchange (ETDEWEB)

    Borrelli, Pablo [Antoni Van Leeuwenhoek Hospital, Department of Nuclear Medicine, The Netherlands Cancer Institute, Amsterdam (Netherlands); Hospital La Fe, Nuclear Medicine, Medical Imaging Clinical Area, Valencia (Spain); Donswijk, Maarten L.; Stokkel, Marcel P.; Teixeira, Suzana C. [Antoni Van Leeuwenhoek Hospital, Department of Nuclear Medicine, The Netherlands Cancer Institute, Amsterdam (Netherlands); Tinteren, Harm van [Antoni Van Leeuwenhoek Hospital, Department of Biometrics, The Netherlands Cancer Institute, Amsterdam (Netherlands); Rutgers, Emiel J.T. [Antoni Van Leeuwenhoek Hospital, Department of Surgery, The Netherlands Cancer Institute, Amsterdam (Netherlands); Valdes Olmos, Renato A. [Antoni Van Leeuwenhoek Hospital, Department of Nuclear Medicine, The Netherlands Cancer Institute, Amsterdam (Netherlands); Leiden University Medical Centre, Nuclear Medicine Section and Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden (Netherlands)

    2017-04-15

    In recent years repeat sentinel node (SN) biopsy has been proven to be feasible in local breast cancer recurrence (LBCR). However, in these patients SNs outside the ipsilateral axilla are frequently observed. This study evaluates the contribution of SPECT/CT for SN localization and surgical adjustment in LBCR patients. SN biopsy was performed in 122 LBCR patients (median age 60.5 years, range 24-87), enrolled from August 2006 to July 2015. Median disease-free time lapse was 109.5 months (range 9-365). Axillary lymph node dissection (ALND) had previously been performed in 55 patients, SN biopsy in 44, both techniques in 13 and fine-needle aspiration in 10. Primary breast cancer treatment included radiotherapy in 104 patients (85.3 %) and chemotherapy in 40 (32.8 %). Preoperative lymphatic mapping, using planar scintigraphy (PS) and SPECT/CT included report of SN location according to lymph node territory. In case of a territorial PS-SPECT/CT mismatch, surgery was adjusted according to SPECT/CT findings. SPECT/CT SN visualization rate was higher than PS (53.3 % vs. 43.4 %, p n.s.) with, in total, 19 additional SN (118 vs. 99, p n.s.). PS-SPECT/CT territory mismatch, found in 60 % (39/65) of patients with SN visualization, led to surgical adjustment in 21.3 % (26/122) of patients. The SN procedure was finally performed in 104 patients resulting in a 65.7 % surgical retrieval rate with a total of 132 removed SNs (1.86/patient). SN metastases were found in 17/71 patients (23.9 %), in 16 of them (94 %) in ipsilateral basins outside the axilla or in the contralateral axilla. Using SPECT/CT there is a trend to visualize more SNs in LBCR, providing at the same time important anatomical information to adjust intraoperative SN procedures. The addition of SPECT/CT to the standard imaging protocol may lead to better staging mainly in patients presenting drainage outside the ipsilateral axilla. (orig.)

  18. Comparison of the Efficiency for Tc-99m Tin-colloid and Tc-99m Phytate in Sentinel Node Detection in Breast Cancer Patients

    Energy Technology Data Exchange (ETDEWEB)

    Seok, Ju Won [Chung-Ang University, Seoul (Korea, Republic of); Kim, In Ju [College of Medicine, Pusan National University, Pusan (Korea, Republic of)

    2008-12-15

    Lymphoscintigraphy and sentinel node biopsy has become a standard method for detection of axillary lymph node metastasis in breast cancer patients, but the standard radiopharmaceutical was not prepared. About detection of axillary lymph node metastasis by lymphoscintigraphy and sentinel node biopsy in breast cancer patient, we compared the results of Tc-99m Tin-colloid and Tc-99m Phytate by subareolar injection. This study included 382 breast cancer patients who were performed operation during 2001-2008. Three hundred forty nine patients was injected 0.8 ml of Tc-99m Tin-colloid (37-185 MBq) by subareolar injection. Thirty three patients was injected 0.8 ml of Tc-99m Phytate (37-185 MBq). Lymphoscintigraphy was performed in supine position and sentinel node localization was performed by hand-held gamma probe in operation. Among 349 patients by Tc-99m Tin-colloid, 312 cases (89.4%) localized the sentinel node by lymphoscintigraphy, 304 cases (87.1%) localized by gamma probe. Among 33 patients by Tc-99m Phytate, 32 cases (97.0%) localized by lymphoscintigraphy, 33 cases (100%) localized by gamma probe. Detection rate by lymphoscintigraphy and gamma probe was superior for Tc-99m Phytate compared to that with Tc-99m Tin-colloid, with a statistically significant difference. (p<0.05, p<0.05) Tc-99m Phytate is a better choice for localization of sentinel node than Tc-99m Tin-colloid in breast cancer patients.

  19. Efficacy and feasibility of the immunomagnetic separation based diagnosis for detecting sentinel lymph node metastasis from breast cancer

    Directory of Open Access Journals (Sweden)

    Zhi XC

    2015-04-01

    Full Text Available Xiang-Cheng Zhi,1–3,* Min Zhang,1–3,* Ting-Ting Meng,1–3,* Xiao-Bei Zhang,1–3 Zhen-Dong Shi,1–3 Yan Liu,1–3 Jing-Jing Liu,1–3 Sheng Zhang,1–3 Jin Zhang1–3 1Third Department of Breast Cancer, People’s Republic of China Tianjin Breast Cancer Prevention, Treatment and Research Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Tianjin, People’s Republic of China; 2Key Laboratory of Breast Cancer Prevention and Therapy of the Ministry of Education, Tianjin, People’s Republic of China; 3Key Laboratory of Cancer Prevention and Therapy, Tianjin, People’s Republic of China *These authors contributed equally to this work Abstract: A purpose of this study was to establish a novel molecular diagnostic model and provide new insight into the intraoperative evaluation of the sentinel lymph node (SLN metastasis in breast cancer. A total of 124 breast cancer patients who met the criteria of sentinel lymph node biopsy (SLNB and underwent intraoperative biopsy were consecutively enrolled in this study. After the SLNs obtained from each patient were labeled, MOC-31 monoclonal antibody-mediated immunomagnetic separation (IMS and flow cytometry were used to determine the expressions of breast cancer metastasis-related markers, including Mucin 1 (MUC1, CD44v6, and HER2. Alternatively, conventional intraoperative hematoxylin and eosin (HE staining and cytokeratin immunohistochemistry (CK-IHC were performed to detect potential SLN metastasis. The sensitivity, specificity, and false-negative rate of the three intraoperative diagnostic methods were compared and analyzed. A total of 55 positive-SLNs were found in 38 breast cancer patients using IMS, yielding a sensitivity of 86.4% (38/44, specificity of 94.7% (36/38, accuracy of 93.5% (116/124, false-positive rate of 2.5% (2/80, false-negative rate of 13.6% (6/44, positive predictive value of 95.5% (42/44, and negative predictive value

  20. Sentinel lymph node biopsy after neo-adjuvant chemotherapy in patients with breast cancer: Are the current false negative rates acceptable?

    Science.gov (United States)

    Patten, D K; Zacharioudakis, K E; Chauhan, H; Cleator, S J; Hadjiminas, D J

    2015-08-01

    The advent of sentinel lymph node biopsy has revolutionised surgical management of axillary nodal disease in patients with breast cancer. Patients undergoing neo-adjuvant chemotherapy for large breast primary tumours may experience complete pathological response on a previously positive sentinel node whilst not eliminating the tumour from the other lymph nodes. Results from 2 large prospective cohort studies investigating sentinel lymph node biopsy after neo-adjuvant chemotherapy demonstrate a combined false negative rate of 12.6-14.2% and identification rate of 80-89% with the minimal acceptable false negative rate and identification rate being set at 10% and 90%, respectively. A false negative rate of 14% would have been classified as unacceptable when compared to the figures obtained by the pioneers of sentinel lymph node biopsy which was 5% or less.

  1. Characteristics and outcomes of sentinel node-positive breast cancer patients after total mastectomy without axillary-specific treatment.

    Science.gov (United States)

    Milgrom, Sarah; Cody, Hiram; Tan, Lee; Morrow, Monica; Pesce, Catherine; Setton, Jeremy; Rogers, Katherine; Arnold, Brittany; Eaton, Anne; Catalano, Jeffrey; McCormick, Beryl; Powell, Simon; Ho, Alice

    2012-11-01

    Regional failure rates are low in patients with a positive sentinel lymph node biopsy (SLNB) who undergo breast-conserving therapy without axillary lymph node dissection (ALND). The applicability of these findings to total mastectomy (TM) patients is not established. Our aims were to evaluate the characteristics and outcomes of SLNB-positive TM patients who did not receive axillary-specific treatment and to compare them to similar patients who underwent breast-conserving surgery (BCS). A total of 535 patients with early-stage breast cancer who underwent definitive breast surgery (210 TM, 325 BCS), had a positive SLNB and did not receive ALND between 1997 and 2009 were identified from an institutional database. Characteristics and outcomes were compared between the TM and BCS groups. Most patients had stage I to IIA, estrogen receptor-positive, progesterone receptor-positive, Her2-negative invasive ductal carcinoma, with minimal nodal disease. Compared to the BCS group, TM patients were younger, had larger tumors, had higher nomogram scores predicting additional axillary disease and were more likely to receive chemotherapy. Ninety-four percent of the BCS cohort and 5 % of the TM cohort received adjuvant radiotherapy. At a median follow-up of 57.8 months, the 4-year local, regional and distant failure rates were 1.7, 1.2 and 0.7 % in the TM group and 1.4, 1.0 and 3.7 % in the BCS group. The 4-year disease-free and overall survival rates were 94.8 and 97.8 % in the TM group and 90.1 and 92.6 % in the BCS group. Early-stage breast cancer patients with minimal sentinel node disease experience excellent outcomes without ALND, whether they undergo BCS or TM.

  2. Sentinel lymph node detection in breast cancer patients using surgical navigation system based on fluorescence molecular imaging technology

    Science.gov (United States)

    Chi, Chongwei; Kou, Deqiang; Ye, Jinzuo; Mao, Yamin; Qiu, Jingdan; Wang, Jiandong; Yang, Xin; Tian, Jie

    2015-03-01

    Introduction: Precision and personalization treatments are expected to be effective methods for early stage cancer studies. Breast cancer is a major threat to women's health and sentinel lymph node biopsy (SLNB) is an effective method to realize precision and personalized treatment for axillary lymph node (ALN) negative patients. In this study, we developed a surgical navigation system (SNS) based on optical molecular imaging technology for the precise detection of the sentinel lymph node (SLN) in breast cancer patients. This approach helps surgeons in precise positioning during surgery. Methods: The SNS was mainly based on the technology of optical molecular imaging. A novel optical path has been designed in our hardware system and a feature-matching algorithm has been devised to achieve rapid fluorescence and color image registration fusion. Ten in vivo studies of SLN detection in rabbits using indocyanine green (ICG) and blue dye were executed for system evaluation and 8 breast cancer patients accepted the combination method for therapy. Results: The detection rate of the combination method was 100% and an average of 2.6 SLNs was found in all patients. Our results showed that the method of using SNS to detect SLN has the potential to promote its application. Conclusion: The advantage of this system is the real-time tracing of lymph flow in a one-step procedure. The results demonstrated the feasibility of the system for providing accurate location and reliable treatment for surgeons. Our approach delivers valuable information and facilitates more detailed exploration for image-guided surgery research.

  3. Frozen section analysis of sentinel lymph nodes in patients with breast cancer does not impair the probability to detect lymph node metastases

    NARCIS (Netherlands)

    E.V.E. Madsen (Eva V. E.); J. van Dalen (Jan); P.J. van Gorp (Patrick); P.M.P. Van Oort (Poultje M. P.)

    2012-01-01

    textabstractIntra-operative frozen section analysis (FS analysis) of sentinel lymph nodes (SLNs) in patients with breast cancer can prevent a second operation for axillary lymph node dissection. In contrast, loss of tissue during FS analysis may impair the probability to detect lymph node metastases

  4. Population based study on sentinel node biopsy before or after neoadjuvant chemotherapy in clinically node negative breast cancer patients : Identification rate and influence on axillary treatment

    NARCIS (Netherlands)

    van der Heiden-van der Loo, M.; de Munck, L.; Sonke, G. S.; van Dalen, T.; van Diest, P. J.; van den Bongard, H. J. G. D.; Peeters, P. H. M.; Rutgers, E. J. T.

    The timing of the sentinel lymph node biopsy (SNB) is controversial in clinically node negative patients receiving neoadjuvant chemotherapy (NAC). We studied variation in the timing of axillary staging in breast cancer patients who received NAC and the subsequent axillary treatment in The

  5. Arm morbidity following sentinel lymph node biopsy or axillary lymph node dissection: a study from the Danish Breast Cancer Cooperative Group

    DEFF Research Database (Denmark)

    Husted, Madsen A.; Haugaard, K.; Soerensen, J.;

    2008-01-01

    BACKGROUND: Sentinel lymph node biopsy was implemented in the treatment of early breast cancer with the aim of reducing shoulder and arm morbidity. Relatively few prospective studies have been published where the morbidity was assessed by clinical examination. Very few studies have examined the i...

  6. Use of indocyanine green for detecting the sentinel lymph node in breast cancer patients: from preclinical evaluation to clinical validation.

    Directory of Open Access Journals (Sweden)

    Chongwei Chi

    Full Text Available Assessment of the sentinel lymph node (SLN in patients with early stage breast cancer is vital in selecting the appropriate surgical approach. However, the existing methods, including methylene blue and nuclides, possess low efficiency and effectiveness in mapping SLNs, and to a certain extent exert side effects during application. Indocyanine green (ICG, as a fluorescent dye, has been proved reliable usage in SLN detection by several other groups. In this paper, we introduce a novel surgical navigation system to detect SLN with ICG. This system contains two charge-coupled devices (CCD to simultaneously capture real-time color and fluorescent video images through two different bands. During surgery, surgeons only need to follow the fluorescence display. In addition, the system saves data automatically during surgery enabling surgeons to find the registration point easily according to image recognition algorithms. To test our system, 5 mice and 10 rabbits were used for the preclinical setting and 22 breast cancer patients were utilized for the clinical evaluation in our experiments. The detection rate was 100% and an average of 2.7 SLNs was found in 22 patients. Our results show that the usage of our surgical navigation system with ICG to detect SLNs in breast cancer patients is technically feasible.

  7. The value of level III clearance in patients with axillary and sentinel node positive breast cancer.

    LENUS (Irish Health Repository)

    Dillon, Mary F

    2012-02-01

    BACKGROUND: The value of level III axillary clearance is contentious, with great variance worldwide in the extent and levels of clearance performed. OBJECTIVE: To determine rates of level III positivity in patients undergoing level I-III axillary clearance, and identify which patients are at highest risk of involved level III nodes. METHODS: From a database of 2850 patients derived from symptomatic and population-based screening service, 1179 patients who underwent level I-III clearance between the years 1999-2007 were identified. The pathology, surgical details, and prior sentinel nodes biopsies of patients were recorded. RESULTS: Eleven hundred seventy nine patients had level I-III axillary clearance. Of the patients, 63% (n = 747) were node positive. Of patients with node positive disease, 23% (n = 168) were level II positive and 19% (n = 141) were level III positive. Two hundred fifty patients had positive sentinel node biopsies prior to axillary clearance. Of these, 12% (n = 30) and 9% (n = 22) were level II and level III positive, respectively. On multivariate analysis, factors predictive of level III involvement in patients with node positive disease were tumor size (P < 0.001, OR = 1.36; 95% CI: 1.2-1.5), invasive lobular disease (P < 0.001, OR = 3.6; 95% CI: 1.9-6.95), extranodal extension (P < 0.001, OR = 0.27; 95% CI: 0.18-0.4), and lymphovascular invasion (P = 0.04, OR = 0.58; 95% CI: 0.35-1). Lobular invasive disease (P = 0.049, OR = 4.1; 95% CI: 1-16.8), extranodal spread (P = 0.003, OR = 0.18; 95% CI: 0.06-0.57), and having more than one positive sentinel node (P = 0.009, OR = 4.9; 95% CI: 1.5-16.1) were predictive of level III involvement in patients with sentinel node positive disease. CONCLUSION: Level III clearance has a selective but definite role to play in patients who have node positive breast carcinoma. Pathological characteristics of the primary tumor are of particular use in identifying those who are at various risk of level III nodal

  8. New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients

    Directory of Open Access Journals (Sweden)

    Johnson Denise L

    2008-03-01

    Full Text Available Abstract Background Current practice is to perform a completion axillary lymph node dissection (ALND for breast cancer patients with tumor-involved sentinel lymph nodes (SLNs, although fewer than half will have non-sentinel node (NSLN metastasis. Our goal was to develop new models to quantify the risk of NSLN metastasis in SLN-positive patients and to compare predictive capabilities to another widely used model. Methods We constructed three models to predict NSLN status: recursive partitioning with receiver operating characteristic curves (RP-ROC, boosted Classification and Regression Trees (CART, and multivariate logistic regression (MLR informed by CART. Data were compiled from a multicenter Northern California and Oregon database of 784 patients who prospectively underwent SLN biopsy and completion ALND. We compared the predictive abilities of our best model and the Memorial Sloan-Kettering Breast Cancer Nomogram (Nomogram in our dataset and an independent dataset from Northwestern University. Results 285 patients had positive SLNs, of which 213 had known angiolymphatic invasion status and 171 had complete pathologic data including hormone receptor status. 264 (93% patients had limited SLN disease (micrometastasis, 70%, or isolated tumor cells, 23%. 101 (35% of all SLN-positive patients had tumor-involved NSLNs. Three variables (tumor size, angiolymphatic invasion, and SLN metastasis size predicted risk in all our models. RP-ROC and boosted CART stratified patients into four risk levels. MLR informed by CART was most accurate. Using two composite predictors calculated from three variables, MLR informed by CART was more accurate than the Nomogram computed using eight predictors. In our dataset, area under ROC curve (AUC was 0.83/0.85 for MLR (n = 213/n = 171 and 0.77 for Nomogram (n = 171. When applied to an independent dataset (n = 77, AUC was 0.74 for our model and 0.62 for Nomogram. The composite predictors in our model were the product of

  9. Selective sentinel node biopsy after intratumour administration of radiotracer in breast cancer patients treated with neoadjuvant chemotherapy in relation to the level of tumour response.

    Science.gov (United States)

    Díaz-Expósito, R; Martí-Bonmatí, L; Burgués, O; Casáns-Tormo, I; Bermejo-de Las Heras, B; Julve-Parreño, A; Caballero-Garate, A

    Our objective was to analyse the accuracy of the sentinel node biopsy, taking into consideration the scintigraphy detection rate after the intratumoural administration of the radiopharmaceutical in patients with breast cancer who received neoadjuvant chemotherapy. The study included 60 patients with a diagnosis of invasive breast carcinoma, stage T1-T3, who received treatment with neoadjuvant chemotherapy, and were subsequently subjected to breast surgery and sentinel node biopsy after intra-tumour administration of the radiopharmaceutical. Scintigraphic detection of some sentinel node was achieved in 55/60 patients (91.6%). When those cases that received a second injection of the radiopharmaceutical, performed peri-areolarly due to a lack of tracer migration, were excluded, the detection rate dropped to 70% (42/60). When the detection of sentinel node, or its absence, was compared in those 42 patients, no differences were found with age, laterality-location of the lesion, size pre- and post-neoadjuvant chemotherapy, histological grade, or immunohistochemical profile. There were significant differences when comparing the groups according to the degree of pathological tumour response, both with the Miller-Payne system (non-detection 44.4%-detection 16.7%, p = 0.003) as well as the residual cancer burden (72.2%-28.6%, p<0.01). The scintigraphic detection of the sentinel node after intratumoural administration of the radiopharmaceutical in patients with breast cancer who received neoadjuvant chemotherapy was below the optimal value, and sometimes a further, peri-areolar, injection was necessary, probably in relation to an alteration in the lymphatic drainage pathways. There was a significant inverse relationship between the detection of the sentinel node and level of pathological tumour response. Copyright © 2016 Elsevier España, S.L.U. y SEMNIM. All rights reserved.

  10. Hot spots of sentinel node biopsy in breast cancer%乳腺癌前哨淋巴结活组织检查的研究

    Institute of Scientific and Technical Information of China (English)

    王永胜

    2009-01-01

    乳腺癌前哨淋巴结(SLN)活检代表着乳腺癌外科治疗的发展水平,但其广泛开展可能超越了已有的证据支持.目前乳腺癌SLN活检研究的热点包括SLN微转移的预后意义、SLN阳性患者非SLN(nSLN)转移预测及SLN术中分子诊断等,结合2008年圣·安东尼奥乳腺癌会议的最新研究结果对其进行述评.%Sentinel lymph node biopsy represents the state of the art of breast surgery, but its widely application might surpass the support of available evidences. The hot spots of sentinel lymph node biopsy in breast cancer include the prognosis of micrometastases in sentinel nodes, the prediction of non-sentinel nodes metastases in positive sentinel nodes patients, and the intraoperative molecular diagnosis of sentinel nodes.These are discussed accompanying with the updated results from the 31st SABCS held in December, 2008.

  11. Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

    Science.gov (United States)

    Lyman, Gary H; Somerfield, Mark R; Bosserman, Linda D; Perkins, Cheryl L; Weaver, Donald L; Giuliano, Armando E

    2016-12-12

    Purpose To provide current recommendations on the use of sentinel node biopsy (SNB) for patients with early-stage breast cancer. Methods PubMed and the Cochrane Library were searched for randomized controlled trials, systematic reviews, meta-analyses, and clinical practice guidelines from 2012 through July 2016. An Update Panel reviewed the identified abstracts. Results Of the eight publications identified and reviewed, none prompted a change in the 2014 recommendations, which are reaffirmed by the updated literature review. Conclusion Women without sentinel lymph node (SLN) metastases should not receive axillary lymph node dissection (ALND). Women with one to two metastatic SLNs who are planning to undergo breast-conserving surgery with whole-breast radiotherapy should not undergo ALND (in most cases). Women with SLN metastases who will undergo mastectomy should be offered ALND. These three recommendations are based on randomized controlled trials. Women with operable breast cancer and multicentric tumors, with ductal carcinoma in situ, who will undergo mastectomy, who previously underwent breast and/or axillary surgery, or who received preoperative/neoadjuvant systemic therapy may be offered SNB. Women who have large or locally advanced invasive breast cancer (tumor size T3/T4), inflammatory breast cancer, or ductal carcinoma in situ (when breast-conserving surgery is planned) or are pregnant should not undergo SNB.

  12. RT-PCR for mammaglobin genes, MGB1 and MGB2, identifies breast cancer micrometastases in sentinel lymph nodes.

    Science.gov (United States)

    Ouellette, Rodney J; Richard, Dominique; Maïcas, Emmanuel

    2004-05-01

    In the present study, we examined the expression of the mammaglobin genes, MGB1 and MGB2, in the sentinel lymph nodes (SLNs) of patients with breast cancer and compared our results with the histologic status of the same SLNs. Compared with immunohistochemical staining for cytokeratin 8, which detected metastases in 17 of 42 patients, reverse transcription-polymerase chain reaction (RT-PCR) for MGB1 or MGB2 genes was positive in 22 patients. The concordance between the expression of any mammaglobin and histologic status was 79% (33/42), with a sensitivity of 88% and specificity of 72%. The detection of patients with metastases was more sensitive when testing for both MGB1 and MGB2 (P MGB2 (P < .0005) or MGB1 (P < .05) alone. The increased detection rate relative to histologic examination suggests that using RT-PCR for the mammaglobin genes might identify patients at higher risk compared with patients with negative RT-PCR results.

  13. The use of 99mTc-Al2O3 for detection of sentinel lymph nodes in breast cancer

    Science.gov (United States)

    Sinilkin, I.; Chernov, V.; Medvedeva, A.; Zeltchan, R.; Slonimskaya, E.; Doroshenko, A.; Varlamova, N.; Skuridin, V.

    2016-08-01

    Purpose: to study the feasibility of using the new radiopharmaceutical based on the technetium-99m-labeled gamma-alumina for identification of sentinel lymph nodes (SLNs) in breast cancer patients. The study included two groups of breast cancer patients who underwent single photon emission computed tomography (SPECT) and intraoperaive gamma probe identification of sentinel lymph nodes (SLNs). To identify SLNs, the day before surgery Group I patients (n = 34) were injected with radioactive 99mTc-Al2O3, and Group II patients (n = 30) received 99mTc-labeled phytate colloid. A total of 37 SLNs were detected in Group I patients. The number of identified SLNs per patient ranged from 1 to 2 (the average number of identified SLNs was 1.08). Axillary lymph nodes were the most common site of SLN localization. 18 hours after 99mTc-Al2O3 injection, the percentage of its accumulation in the SLN was 7-11% (of the counts in the injection site) by SPECT and 17-31% by gamma probe detection. In Group II SLNs were detected in 27 patients. 18 hours after injection of the phytate colloid the percentage of its accumulation in the SLN was 1.5-2% out of the counts in the injection site by SPECT and 4-7% by gamma probe. The new radiopharmaceutical based on the 99mTc-Al2O3 demonstrates high accumulation in SLNs without redistribution through the entire lymphatic basin. The sensitivity and specificity of 99mTc-Al2O3 were 100% for both SPECT and intraoperative gamma probe identification.

  14. Optimized lymph node staging in breast cancer in the era of sentinel node biopsy

    NARCIS (Netherlands)

    Madsen, E.V.E.

    2012-01-01

    SLNB has revolutionized staging and treatment in breast cancer patients, several issues provoked renewed attention. If small lymph node metastases are relevant, the pathologist should detect them. The current Dutch pathology guideline is not sensitive enough to detect them. To obtain a 95% detection

  15. The use of {sup 99m}Tc-phytate for sentinel node mapping in melanoma, breast cancer and vulvar cancer: a study of 100 cases

    Energy Technology Data Exchange (ETDEWEB)

    Tavares, M.G.M.; Sapienza, M.T.; Endo, I.S.; Soares, J. Jr.; Lewin, S.; Marone, M.M.S. [UDDO - Nuclear Medicine Dept., Sao Paulo, SP (Brazil); Galeb, N.A. Jr.; Belfort, F.A.; Costa, R.R.; Osorio, C.A.B.T.; Goes, J.C.S. [Brazilian Inst. of Cancer Control (IBCC), Sao Paulo (Brazil)

    2001-11-01

    Sentinel node mapping reduces surgical morbidity and allows the use of more accurate tumour staging techniques. Radionuclide studies are preferentially performed using small colloids, which have limited availability in our country. The possibility of using phytate for sentinel node mapping was raised because of the similarity between its biodistribution and that of nanocolloids in the reticulo-endothelial system. In this paper we evaluated the use of {sup 99m}Tc-phytate for sentinel node mapping, correlating the histopathological results with the status of the rest of the lymph node chain in different malignant tumours. A total of 100 patients were studied. group 1 consisted of 62 patients with breast cancer, group 2 of 20 patients with melanoma and group 3 of 18 patients with vulvar carcinoma. Lymph node scintigraphy was carried out after injecting {sup 99m}Tc-phytate subdermally, and the sentinel node projection was marked on the skin. After 18-24 h, intraoperative sentinel node localisation was performed using a gamma probe (combined with visual localisation using patent blue dye) in 75 patients, and lymph node dissection was then carried out. Radionuclide scintigraphy identified the sentinel node in 98% of all studies. Intraoperative detection using the gamma probe was equally efficient: group 1=93% (38/41), group 2=95% (18/19) and group 3=100% (15/15). The sentinel node was involved in 41%, 31% and 20% of cases in groups 1, 2 and 3, respectively. Among the patients with positive nodes, the sentinel node was the only one affected in 53% of group 1, 50% of group 2 and 67% of group 3 cases. The method's negative predictive value was 91% in group 1 and 100% in the other groups. One false-negative study occurred in a patient who had a multifocal tumour and an intraparenchymatous lymph node; another occurred in a patient with a macroscopically affected node found during surgery. There were no side-effects related to the {sup 99m}Tc-phytate. It is concluded that

  16. The Axillary Nodal Harvest in Breast Cancer Surgery Is Unchanged by Sentinel Node Biopsy or the Timing of Surgery

    Directory of Open Access Journals (Sweden)

    B. E. Byrne

    2012-01-01

    Full Text Available Introduction. Patients with a positive sentinel lymph node biopsy may undergo delayed completion axillary dissection. Where intraoperative analysis is available, immediate completion axillary dissection can be performed. Alternatively, patients may undergo primary axillary dissection for breast cancer, historically or when preoperative assessment suggests axillary metastases. This study aims to determine if there is a difference in the total number of lymph nodes or the number of metastatic nodes harvested between the 3 possible approaches. Methods. Three consecutive comparable groups of 50 consecutive patients who underwent axillary dissection in each of the above contexts were identified from the Portsmouth Breast Unit Database. Patient demographics, clinicopathological variables, and surgical treatment were recorded. The total pathological nodal count and the number of metastatic nodes were compared between the groups. Results. There were no differences in clinico-pathological features between the three groups for all features studied with the exception of breast surgical procedure (P<0.001. There were no differences in total nodal harvest (P=0.822 or in the number of positive nodes harvested (P=0.157 between the three groups. Conclusion. The three approaches to axillary clearance yield equivalent nodal harvests, suggesting oncological equivalence and robustness of surgical technique.

  17. Staging the Axilla with selective sentinel node biopsy in patients with previous excision of non-palpable and palpable breast cancer

    Energy Technology Data Exchange (ETDEWEB)

    Ruano, R.; Garcia-Talavera, J.R.; Arriba, A. de [University Hospital of Salamanca, Nuclear Medicine, Salamanca (Spain); Ramos, M.; Gonzalez-Orus, J.; Iglesias, M. [University Hospital of Salamanca, General Surgery, Salamanca (Spain); Serrano, E.; Macias, M.C. [University Hospital of Salamanca, Pathology, Salamanca (Spain)

    2008-07-15

    To present our experience in the therapeutic approach of the sentinel node biopsy (SNB) in patients with previous excision of the breast cancer, divided in non-palpable and palpable lesions, in comparison with time treatment and stagement of breast cancer. In the period 2001-2006, 138 patients with prior diagnostic excisional biopsy (96 non-palpable and 42 palpable breast cancer) and 328 without previous surgery (32 non-palpable; 296 palpable cancer) were treated. The combined technique ({sup 99m}Tc-colloidal rhenium and isosulfan blue dye) was the approach for sentinel lymph node (SLN) detection. Axillary lymph node dissection (ALND) was completed only when the SLN was positive for metastasis or not located. Detection rate, if there was prior surgery, was 95% for non-palpable and 98% for palpable cancer, and 99% for one-time treatment group. Metastasis rate in the SLN was 15% in non-palpable cancer (14/91), significantly smaller than in palpable breast cancer (39% if prior surgery and 37% in one-time surgery). According to tumoral size, ALND metastasis rate was similar for T1 and T2 tumors (43-44%). In the follow-up of the groups with prior diagnostic biopsy or surgery of the breast cancer we have not found any false negative in the axilla. The detection of the SLN is also feasible in patients with previous surgery of breast cancer. Because SLN metastasis rates are significantly smaller in non-palpable lesions, the effort in screening programs for early detection of breast cancer and also in improving histopathological confirmation of malignancy with ultrasound or stereotactic guided core biopsies must continue. (orig.)

  18. The value of breast MRI in high‐risk patients with newly diagnosed breast cancer to exclude invasive disease in the contralateral prophylactic mastectomy: Is there a role to choose wisely patients for sentinel node biopsy?

    OpenAIRE

    Freitas, Vivianne; Crystal, Pavel; Kulkarni, Supriya R.; Ghai, Sandeep; Bukhanov, Karina; Escallon, Jaime; Scaranelo, Anabel M.

    2016-01-01

    Abstract The aim of this study was to evaluate the presence of clinically and mammographically occult disease using breast MRI in a cohort of cancer patients undergoing contralateral prophylactic mastectomy (CPM) and the utmost indication of axillary assessment (sentinel node biopsy (SLNB)) for this side. A retrospective review of patients with unilateral invasive breast cancer or ductal carcinoma in situ (DCIS) from institutional MRI registry data (2004–2010) was conducted. Characteristics o...

  19. Potential advantage of preoperative three-dimensional mapping of sentinel nodes in breast cancer by a hybrid single photon emission CT (SPECT)/CT system

    OpenAIRE

    Ibusuki, Mutsuko; Yamamoto, Yutaka; Kawasoe, Teru; Shiraishi, Shinya; Tomiguchi, Seiji; Yamashita, Yasuyuki; Honda, Yumi; Iyama, Kenichi; Iwase, Hirotaka; イブスキ, ムツコ; ヤマモト, ユタカ; カワソエ, テル; シライシ, シンヤ; トミグチ, セイジ; ヤマシタ, ヤスユキ

    2010-01-01

    Objective: This study aims to assess the role of three dimensional single-photon emissioncomputed tomography (3D-SPECT/CT) in sentinel node (SN) identification, and toanalyze the impact of such information on estimating metastases to SNs.Background: Nodal status is a key factor for breast cancer. SN biopsy has beenestablished as the alternative to routine axillary dissection these days. We investigatedboth the anatomical location of SNs demonstrated by our 3D-SPECT/CT system and thecorrelatio...

  20. Axillary Irradiation as an Imperative Alternative to Axillary Dissection in Clinically Lymph Node-Negative but Sentinel Node-Positive Breast Cancer Patients?

    OpenAIRE

    Nitsche, Mirko; Hermann, Robert

    2011-01-01

    At the moment, positive sentinel lymph node dissection (SLND) of the axilla is followed by axillary lymph node dissection (ALND) as standard of care. Recent data proves that omitting ALND after positive SLND in clinically lymph node-negative early stage breast cancer patients is feasible with low recurrence rates. The well known effect of radiotherapy to destroy occult tumor cells highly contributes to these results as a large extent of level I and II lymph nodes are unavoidably included in s...

  1. Study of internal mammary sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy

    Directory of Open Access Journals (Sweden)

    Cao XS

    2015-10-01

    Full Text Available Xiao-Shan Cao,1,2 Bin-Bin Cong,1,2 Xiao Sun,1 Peng-Fei Qiu,1 Yong-Sheng Wang1 1Breast Cancer Center, Shandong Cancer Hospital and Institute, Jinan, Shandong, People’s Republic of China; 2School of Medicine and Life Sciences, Jinan University-Shandong Academy of Medical Sciences, Jinan, Shandong, People’s Republic of ChinaInternal mammary lymph node (IMLN metastasis has a similar prognostic importance as axillary lymph nodal involvement in breast cancer patients.1 Patients with both axillary- and internal mammary-positive nodes have a very poor prognosis.2 Reliable data for internal mammary nodal metastases are reported to be present in 18%–33% (mean 23.4% of patients who have not been treated with neoadjuvant chemotherapy (NAC mostly concomitant with axillary metastases, and metastases exclusively situated in the internal mammary chain occur in 2%–11% of patients,3 but limited data are available in the context of NAC.

  2. The clinical significance of axillary sentinel lymph node biopsy in different clinical stages breast cancer patients after neoadjuvant chemotherapy

    Institute of Scientific and Technical Information of China (English)

    Juan Xu; Xinhong Wu; Yaojun Feng; Feng Yuan; Wei Fan

    2013-01-01

    Objective:We aimed to study the success and false negative rate of sentinel lymph node biopsy (SLNB) in dif-ferent clinical stages breast cancer patients being carried out with neoadjuvant chemotherapy (NAC), and the clinical signifi-cance of SLNB, we conducting this trial. Methods:One hunderd and thirty-seven cases were enrol ed in this clinical research from March 2003 to March 2007. Al of the patients’ sentinel lymph nodes were detected with 99mTc-Dx and methylene blue. There were 61 patients with stage T1-2N0M0 carried SLNB without NAC (group A), 76 cases were carried out NAC 3-4 cycles before SLNB, including 39 T2-4N0-1M0 cases (group B) and 27 T2-4N2-3M0 cases (group C). The success and false negative rate of SLNB were analysed with chi-square test. Results:In group A, the successful and false negative rate of SLNB were 92.31%(36/39), 8.57%(3/35), and in group B and C were 92.31%(36/39), 8.57%(3/35) and 74.07%(20/27), 18.52%(5/27), respectively. The successful rate of group C decreased and false negative rate increased significantly compared with group A and B (P0.05). Conclusion:The SLNB can accurately predict lymph node status of axil ary lymph node in N0-1 stage patients with NAC, but in N2-3 stage patients the success rate decreased and false rate increased negative significantly.

  3. Selective sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer: results of the GEICAM 2005-07 study.

    Science.gov (United States)

    Piñero-Madrona, Antonio; Escudero-Barea, María J; Fernández-Robayna, Francisco; Alberro-Adúriz, José A; García-Fernández, Antonio; Vicente-García, Francisco; Dueñas-Rodriguez, Basilio; Lorenzo-Campos, Miguel; Caparrós, Xavier; Cansado-Martínez, María P; Ramos-Boyero, Manuel; Rojo-Blanco, Roberto; Serra-Genís, Constantí

    2015-01-01

    A controversial aspect of breast cancer management is the use of sentinel lymph node biopsy (SLNB) in patients requiring neoadjuvant chemotherapy (NCT). This paper discusses the detection rate (DT) and false negatives (FN) of SLNB after NCT to investigate the influence of initial nodal disease and the protocols applied. Prospective observational multicenter study in women with breast cancer, treated with NCT and SLNB post-NCT with subsequent lymphadenectomy. DT and FN rates were calculated, both overall and depending on the initial nodal status or the use of diagnostic protocols pre-SLNB. No differences in DT between initial node-negative cases and positive cases were found (89.8 vs. 84.4%, P=.437). Significant differences were found (94.1 vs. 56.5%, P=0,002) in the negative predictive value, which was lower when there was initial lymph node positivity, and a higher rate of FN, not significant (18.2 vs. 43.5%, P=.252) in the same cases. The axillary study before SLNB and after the NCT, significantly decreased the rate of FN in patients with initial involvement (55.6 vs 12.5, P=0,009). NCT means less DT and a higher rate of FN in subsequent SLNB, especially if there is initial nodal involvement. The use of protocols in axillary evaluation after administering the NCT and before BSGC, decreases the FN rate in these patients. Copyright © 2013 AEC. Publicado por Elsevier España, S.L.U. All rights reserved.

  4. Evolution of radionuclide imaging of sentinel node lymphscintigraphy in breast cancer%乳腺癌前哨淋巴结核素显像新进展

    Institute of Scientific and Technical Information of China (English)

    马乐; 张万春; 李晓敏

    2016-01-01

    乳腺癌是全球女性发病率最高的恶性肿瘤,为保证患者的生存率、减少术后并发症,20世纪90年代用“腋窝前哨淋巴结活检术取代腋窝淋巴结清扫”的观点被提出并逐渐发展成为乳腺癌患者保乳术的常规方法.除腋窝前哨淋巴结外,内乳前哨淋巴结的重要性同样不容忽视,但是否将其作为前哨淋巴结活检的对象仍存在争议.面对目前形势,核医学工作者做了大量研究,在保证腋窝前哨淋巴结高显示率的同时尽可能提高内乳前哨淋巴结的显示率.笔者对近十年来国内外研究者在乳腺癌前哨淋巴结核素显像中的核素示踪剂、注射技术、显像仪器等方面的最新进展进行综述.%Breast cancer is the most common cancer that affects women worldwide.Axillary sentinel lymph node biopsy was introduced in the 1900s and has become a routine in breast-conserving surgery to ensure survival of patients and reduce complications related to the disease.The importance of the internal mammary sentinel lymph node,in addition to the axillary sentinel lymph node,cannot be ignored.A controversial issue is whether to accept the internal mammary sentinel lymph node as object of sentinel node biopsy.Nuclear medicine researchers have extensively investigated the response of sentinel node lymphoscintigraphy to clinical requirements,thereby improving the detection rate of both axillary and internal mammary sentinel lymph nodes.This review presents the evolution of sentinel node lymphoscintigraphy in terms of nuclide tracer,injection technology,and imaging devices over an almost 10-year period locally and internationally.

  5. Which prediction models best identify additional axillary disease after a positive sentinel node biopsy for breast cancer?

    Science.gov (United States)

    Berrang, Tanya S; Lesperance, Mary; Truong, Pauline T; Walter, Caroline; Hayashi, Allen H; Olivotto, Ivo A

    2012-06-01

    To determine which web-based model best identifies women at low risk of further axillary disease after a positive sentinel lymph node (SLN+) biopsy. 673 women with T1-2cN0M0 SNB+ breast cancer who underwent completion axillary dissection (AxD) were identified. A subgroup not eligible to avoid AxD as part of the Z0011 study was defined (Z0011 exclusion group). Predicted risk of further axillary disease was generated using seven web-based models. "Low risk" was defined as a ≤10% risk of further axillary disease. False negative ("low risk" prediction but AxD+) rates (FNRs), area under the receiver operating characteristic curve (AUC), and Brier score were determined for each model. 6 of 7 models identified "low risk" patients but FNRs ranged from 14 to 30%. The Stanford and Memorial Sloan-Kettering (MSKCC) models had the best FNRs. FNRs were lower with SLN micrometastasis (7-15%) and higher in the Z0011 exclusion group (21-41%). All models under-predicted further nodal disease in low risk patients and over-predicted in higher-risk patients. The Stanford and MSKCC models were able to identify women with SLN micrometastasis with a ≤10% FNR. Models were not able to accurately identify low risk women from a cohort that would have been excluded from Z0011.

  6. Medico-economic impact of MSKCC non-sentinel node prediction nomogram for ER-positive HER2-negative breast cancers

    Science.gov (United States)

    Guillot, Eugénie; Feron, Jean-Guillaume; Fourchotte, Virginie; Alran, Séverine; Pierga, Jean-Yves; Cottu, Paul; Lerebours, Florence; Stevens, Denise; Vincent-Salomon, Anne; Sigal-Zafrani, Brigitte; Campana, François; Rouzier, Roman; Reyal, Fabien

    2017-01-01

    Background Avoiding axillary lymph node dissection (ALND) for invasive breast cancers with isolated tumor cells or micrometastatic sentinel node biopsy (SNB) could decrease morbidity with minimal clinical significance. Purpose The aim of this study is to simulate the medico-economic impact of the routine use of the MSKCC non-sentinel node (NSN) prediction nomogram for ER+ HER2- breast cancer patients. Methods We studied 1036 ER+ HER2- breast cancer patients with a metastatic SNB. All had a complementary ALND. For each patient, we calculated the probability of the NSN positivity using the MSKCC nomogram. After validation of this nomogram in the population, we described how the patients’ characteristics spread as the threshold value changed. Then, we performed an economic simulation study to estimate the total cost of caring for patients treated according to the MSKCC predictive nomogram results. Results A 0.3 threshold discriminate the type of sentinel node (SN) metastases: 98.8% of patients with pN0(i+) and 91.6% of patients with pN1(mic) had a MSKCC score under 0.3 (false negative rate = 6.4%). If we use the 0.3 threshold for economic simulation, 43% of ALND could be avoided, reducing the costs of caring by 1 051 980 EUROS among the 1036 patients. Conclusion We demonstrated the cost-effectiveness of using the MSKCC NSN prediction nomogram by avoiding ALND for the pN0(i+) or pN1(mic) ER+ HER2- breast cancer patients with a MSKCC score of less than or equal to 0.3. PMID:28241044

  7. Low risk of recurrence in breast cancer with negative sentinel node

    DEFF Research Database (Denmark)

    Hildebrandt, Malene Grubbe; Bartram, Peter; Bak, Martin;

    2011-01-01

    The sentinel lymph node (SLN) procedure has emerged as a safe staging method with a low morbidity. The objective of the present study was to examine the recurrence rates including especially the axillary recurrence rate in SLN-negative patients after a long follow-up period....

  8. Sentinel node localization in breast cancer patients using intradermal dye injection

    DEFF Research Database (Denmark)

    Ilum, Lars; Bak, Martin; Olsen, K E

    2000-01-01

    -sectioning and immunohistochemical staining for cytokeratin. In one case a benign epithelial inclusion was found. The sentinel node was false negative in 9.1% of cases. The consensus from the literature is that the best results are achieved using a combination of dye and isotopic techniques....

  9. Meta‐analysis of sentinel lymph node biopsy in breast cancer using the magnetic technique

    NARCIS (Netherlands)

    Zada, A.; Peek, M.C.L.; Ahmed, M.; Anninga, B.; Baker, R.; Kusakabe, M.; Sekino, M.; Klaase, J.M.; Haken, ten B.; Douek, M.

    2016-01-01

    Background The standard for sentinel lymph node biopsy (SLNB), the dual technique (radiolabelled tracer and blue dye), has several drawbacks. A novel magnetic technique without these drawbacks has been evaluated in a number of clinical trials. It uses a magnetic tracer and a handheld magnetometer to

  10. Axillary sentinel node identification in breast cancer patients: degree of radioactivity present at biopsy is critical

    DEFF Research Database (Denmark)

    Nielsen, Kristina R; Oturai, Peter S; Friis, Esbern;

    2011-01-01

    The radioactivity present in the patient (Act(rem) ) at sentinel node (SN) biopsy will depend on injected activity amount as well as on the time interval from tracer injection to biopsy, which both show great variations in the literature. The purpose of this study was to analyse the influence...

  11. Comparative study between ultrasound-guided fine needle aspiration cytology of axillary lymph nodes and sentinel lymph node histopathology in early-stage breast cancer

    Science.gov (United States)

    Cardoso-Coelho, Lívio Portela; Borges, Rafael Soares; Alencar, Airlane Pereira; Cardoso-Campos-Verdes, Larysse Maira; da Silva-Sampaio, João Paulo; Borges, Umbelina Soares; Gebrim, Luiz Henrique; da Silva, Benedito Borges

    2017-01-01

    The replacement of sentinel lymph node biopsy (SNB) by ultrasound-guided fine-needle aspiration (US-guided FNA) cytology of axillary lymph nodes is controversial, despite the simplicity and reduced cost of the latter. In the present study, US-guided FNA was performed in 27 patients with early-stage breast cancer for comparison with SNB. Data were analyzed by calculation of sample proportions. Tumor subtypes included invasive ductal carcinoma (85%), invasive lobular carcinoma (7%), and tubular and metaplastic carcinoma (4%). FNA had a sensitivity of 45%, specificity of 100%, positive predictive value of 100% and a negative predictive value of 73%. Axillary lymph node cytology obtained by US guided-FNA in patients with breast cancer had a specificity similar to that of sentinel lymph node histopathology in the presence of axillary node metastases. However, when lymph node cytology is negative, it does not exclude the existence of metastatic implants, due to its low sensitivity in comparison to sentinel lymph node histopathology. PMID:28521436

  12. [Diagnostic validity of the intraoperative analysis in frozen section of the sentinel lymph node in the surgical management of breast cancer].

    Science.gov (United States)

    Bañuelos-Andrío, Luis; Rodríguez-Caravaca, Gil; Argüelles-Pintos, Miguel; Mitjavilla-Casanovas, Mercedes

    2014-01-01

    The method for intraoperative sentinel lymph node (SLN) evaluation has still not been established in breast cancer staging. This study has evaluated the diagnostic validity and impact of intraoperative analysis using the frozen section (FS) of SLN. We performed a descriptive study of the diagnostic validity of the FS of the SLN in patients with breast cancer and selective sentinel node biopsy (SSNB) from October-2006 to October-2012. The diagnostic validity indexes were evaluated using sensitivity, specificity, positive and negative predictive values and global value. Gold standard was considered as the final histopathological results of the biopsies. A total of 370 patients were studied. Sensitivity and specificity for detection of metastasis by FS in the SLN were 67% and 100%, respectively. Global diagnostic validity was 95%. There was a correlation between detection of metastasis and tumor size (pcancer. FS reduces the need for second interventions, at least for most patients who have breast cancer with identifiable positive SLN and unequivocal evidence of positive lymph node disease. Copyright © 2013 Elsevier España, S.L. and SEMNIM. All rights reserved.

  13. Ganglio centinela en cáncer de mama: Estudio histológico de 67 casos Sentinel node in breast cancer: Histological study of 67 cases

    Directory of Open Access Journals (Sweden)

    A. Córdoba

    2004-08-01

    Full Text Available Fundamento. La extirpación del ganglio centinela es una técnica quirúrgica muy extendida cuyo objetivo es evitar el vaciamiento axilar en pacientes con cáncer de mama en estadios iniciales. La determinación de la infiltración tumoral puede ser evidente en caso de macrometástasis (>2mm, o difícil de detectar en las micrometástasis (2mm, 5 fueron micrometástasis Background. The extirpation of the sentinel node is a widespread surgical technique whose aim is to avoid axillary resection in patients with breast cancer at early stages. Determination of tumoral infiltration can be evident in the case of macrometastasis (>2mm, or difficult to detect in micrometastasis (2mm, 5 were micrometastases <2mm and 3 were isolated cellular groups (between 0.2 and 2mm. In 6 cases (43%, the metastases only became evident with queratine staining in serialized cuts. Axillary resection was carried out in 44 cases. Conclusions. The histological study of the sentinel nodes makes it possible to evaluate the status of tumoral infiltration of the axillary ganglions and to greatly reduce axillary lymphadenectomies. The conventional study of the sentinel node (with a single section is insufficient for the diagnosis of tumoral infiltration. In our series, histological study using a protocol of serialized sections has enabled us to detect some 43% of metastases in the sentinel node that were not evident in the initial section.

  14. Sentinel lymph nodes in cancer of the oral cavity

    DEFF Research Database (Denmark)

    Thomsen, Jørn Bo; Christensen, Rikke Kølby; Sørensen, Jens Ahm;

    2007-01-01

    BACKGROUND: Extended histopathologic work-up has increased the detection of micrometastasis in sentinel lymph nodes in malignant melanoma and breast cancer. The aim of this study was to examine if (A) step-sectioning of the central 1000 microM at 250 microM levels with immunostaining were accurate...... when compared with (B) step-sectioning and immunostaining of the entire sentinel lymph node at 250 microM levels. METHODS: Forty patients with T1/T2 cN0 oral cancer were enrolled. Three patients were excluded. In one patient no sentinel lymph node was identified. The remaining two had unidentified...... sentinel lymph nodes due to lymphoscintigraphic and surgical sampling error. The central 1000 microM of 147 sentinel lymph nodes were step-sectioned in 250-microm intervals and stained with hematoxylin and eosin and CK-KL1. All lymph nodes were recorded as negative or positive for macrometastases...

  15. Axillary Irradiation as an Imperative Alternative to Axillary Dissection in Clinically Lymph Node-Negative but Sentinel Node-Positive Breast Cancer Patients?

    Science.gov (United States)

    Nitsche, Mirko; Hermann, Robert

    2011-10-01

    At the moment, positive sentinel lymph node dissection (SLND) of the axilla is followed by axillary lymph node dissection (ALND) as standard of care. Recent data proves that omitting ALND after positive SLND in clinically lymph node-negative early stage breast cancer patients is feasible with low recurrence rates. The well known effect of radiotherapy to destroy occult tumor cells highly contributes to these results as a large extent of level I and II lymph nodes are unavoidably included in standard tangential radiation treatment fields. Reviewing the up to date published data on axillary lymph node treatment with radiotherapy, we hypothesize that full dosage coverage of level I and II of the axilla in early stage breast cancer will improve outcome and should be further evaluated.

  16. [Selective biopsy of the sentinel lymph node in breast cancer: without axillary recurrences after a mean follow-up of 4.5 years].

    Science.gov (United States)

    Bañuelos Andrío, Luis; Rodríguez Caravaca, Gil; Argüelles Pintos, Miguel; Mitjavilla Casanova, Mercedes

    2014-01-01

    To analyze the rate of axillary recurrences (AR) in patients with early breast cancer who had not undergone an axillary node dissection (ALND) because of a negative sentinel lymph node biopsy (SLNB). The study includes 173 patients operated on for breast cancer and selective node biopsy. In 32 patients the SLNB was positive and undergone subsequent ALND. We followed up 141 patients with negative SLNB without LDN, with a median follow up of 55 months (range 74-36). The detection rate of SLN was of 99.42%. After a median follow-up of 4.5 years, there were no axillary recurrences. Two patients developed local recurrence, other two patients developed distant metastases and four patients developed a metachronous tumor. Four patients died, none of them because of breast cancer. The results obtained support the SLNB as an accurate technique in the axillary stratification of patients with breast cancer, offering in the cases of negative SLNB a safe axillary control after 4.5 year follow-up. Copyright © 2013 Elsevier España, S.L.U. and SEMNIM. All rights reserved.

  17. Evaluating TIMP-1, Ki67, and HER2 as markers for non-sentinel node metastases in breast cancer patients with micrometastases to the sentinel node

    DEFF Research Database (Denmark)

    Tvedskov, Tove Filtenborg; Bartels, Annette; Jensen, Maj-Britt;

    2011-01-01

    between 2001 and 2007 at the Department of Breast Surgery, Herlev Hospital. The study was designed as a matched case-control study with 25 cases with micrometastases to SN and, in addition, metastatic spread to NSN and 50 matched controls with micrometastases to SN, but without NSN metastases. Patient...... and tumor characteristics were retrieved from the Danish Breast Cancer Cooperative Group database. Immunohistochemical analyses of TIMP-1 and Ki67 and measurements of HER2 on formalin-fixed paraffin-embedded tumor tissue were performed. No significant differences in the immunoreactivity of TIMP-1 and Ki67...

  18. Accuracy and Significance of Polymerase Chain Reaction Detection of Sentinel Node Metastases in Breast Cancer Patients

    Science.gov (United States)

    2000-10-01

    Special Conference, Traverse City, Ml, October 11-15, 2000. RESEARCH INTERESTS: PCR detection of micrometastatic disease Cancer immunology The...Department of Physiology, ECU, "Galactose a 1,3 galactosyltransferase for cancer gene therapy: Harmonic convergence of transplantation and cancer ... immunology ", April 28,1998. American Society of Transplant Surgeons, Chicago IL "Short Term Antilymphocyte Serum, Rapamycin and Donor Bone Marrow

  19. Sentinel Lymph Node Detection in Contralateral Axilla at Initial Presentation of a Breast Cancer Patient: Case Report

    Directory of Open Access Journals (Sweden)

    Gülin Uçmak Vural

    2010-06-01

    Full Text Available The main basin for breast lymphatic drainage is ipsilateral axilla. However, extra-axillary drainage may be seen in some patients. The most common extra-axillary site is internal mammary chain, while contralateral axillary drainage is an extremely rare situation in previously untreated patients. We describe a case of untreated right breast retroareolar carcinoma with contralateral axillary drainage detected on preoperative lymphoscintigraphy. Contralateral axillary dissection was performed based on the result of frozen section examination of the sentinel lymph node (SLN which turned out to burden micrometastasis. Postoperative histopathological examination revealed invasive ductal carcinoma metastasis in 17 out of 22 lymph nodes from the ipsilateral axillary dissection, whereas 14 lymph nodes from contralateral axillary dissection other than the SLN were nonmetastatic. In our opinion, determination of contralateral axillary metastasis in primary staging process had a major contribution to the management of the patient

  20. Phase-Transition Nanodroplets for Real-Time Photoacoustic/Ultrasound Dual-Modality Imaging and Photothermal Therapy of Sentinel Lymph Node in Breast Cancer

    Science.gov (United States)

    Yang, Lu; Cheng, Juan; Chen, Yuli; Yu, Shengjie; Liu, Fengqiu; Sun, Yang; Chen, Yu; Ran, Haitao

    2017-01-01

    Pathological status of lymph nodes (LNs) plays a critical role in staging and treatment for the patients with breast cancer. Sentinel lymph node biopsy has become the standard method in determining pathological status of axillary LNs. Therefore, the determination of sentinel lymph nodes (SLNs) and therapy of metastatic LNs are highly desirable in clinic. Herein, an unprecedented carbon nanoparticles (CNs)-incorporated liquid-gas phase-transition nanodroplets (CNPs) with strong near-infrared (NIR) absorption, good biocompatibility, excellent photoacoustic (PA) and ultrasound (US) contrast, and high photothermal-conversion efficiency are reported in this study. Upon laser irradiation, liquid-gas phase transition of the CNPs has been demonstrated to provide excellent contrasts for PA/US dual-modality imaging both in vitro and in vivo. Additionally, the CNPs are capable of staining lymph nodes, which can contribute significantly to the identification of LNs with naked eyes. With increased laser energy, the CNPs exhibit the high performance in killing the breast cancer cells both in vitro and in vivo, due to the photothermal effect induced from the CNs within CNPs. These results suggest that the developed multifunctional phase-transition nanodroplets have high potential to act as the theranostic agents in both SLNs detection and therapy of metastatic LNs. PMID:28338071

  1. Total tumor load assessed by one-step nucleic acid amplification assay as an intraoperative predictor for non-sentinel lymph node metastasis in breast cancer.

    Science.gov (United States)

    Nabais, Celso; Figueiredo, Joana; Lopes, Paulina; Martins, Manuela; Araújo, António

    2017-04-01

    This study aimed to determine the relationship between CK19 mRNA copy number in sentinel lymph nodes (SLN) assessed by one-step nucleic acid amplification (OSNA) technique, and non-sentinel lymph nodes (NSLN) metastization in invasive breast cancer. A model using total tumor load (TTL) obtained by OSNA technique was also constructed to evaluate its predictability. We conducted an observational retrospective study including 598 patients with clinically T1-T3 and node negative invasive breast cancer. Of the 88 patients with positive SLN, 58 patients fulfill the inclusion criteria. In the analyzed group 25.86% had at least one positive NSLN in axillary lymph node dissection. Univariate analysis showed that tumor size, TTL and number of SLN macrometastases were predictive factors for NSLN metastases. In multivariate analysis just the TTL was predictive for positive NSLN (OR 2.67; 95% CI 1.06-6.70; P = 0.036). The ROC curve for the model using TTL alone was obtained and an AUC of 0.805 (95% CI 0.69-0.92) was achieved. For TTL >1.9 × 10(5) copies/μL we got 73.3% sensitivity, 74.4% specificity and 88.9% negative predictive value to predict NSLN metastases. When using OSNA technique to evaluate SLN, NSLN metastases can be predicted intraoperatively. This prediction tool could help in decision for axillary lymph node dissection. Copyright © 2016 Elsevier Ltd. All rights reserved.

  2. Is there a requirement for axillary lymph node dissection following identification of micro-metastasis or isolated tumour cells at sentinel node biopsy for breast cancer?

    LENUS (Irish Health Repository)

    Joyce, D P

    2012-02-29

    INTRODUCTION: Recent decades have seen a significant shift towards conservative management of the axilla. Increasingly, immunohistochemical analysis of sentinel nodes leads to the detection of small tumour deposits, the significance of which remains uncertain. The aims of this study are to examine patients whose sentinel lymph nodes are positive for macro-metastasis, micro-metastasis or isolated tumour cells (ITCs) and to determine the rate of further nodal disease after axillary lymph node dissection (ALND). METHODS: A retrospective analysis of all patients undergoing a sentinel lymph node biopsy (SLNB) between January 2007 and December 2010 in a tertiary referral breast unit was performed. Patients who underwent an axillary lymph node dissection for macro-metastasis, micro-metastasis or ITCs were identified. Demographics, histological data and the rate of further axillary disease were examined. RESULTS: In total, 664 breast cancer patients attended the symptomatic breast unit during the study period, 360 of whom underwent a SLNB. Seventy patients had a SLNB positive for macro-metastasis. All of these patients underwent ALND. A positive SLNB with either micro-metastasis or ITCs was identified in 58 patients. Only 41 of the 58 patients went on to have an ALND, due primarily to variations in surgeons\\' preferences. Nineteen patients with micro-metastasis underwent an ALND. Four patients had further axillary disease (21%). Twenty-two patients had ITCs identified, of whom only one had further disease (4.5%). No statistically significant difference was found between the two groups in terms of tumour size, grade, lymphovascular invasion or oestrogen receptor status. CONCLUSION: ALND should be considered in patients with micro-metastasis at SLNB. It should rarely be employed in the setting of SLNB positive for ITCs.

  3. Sentinel lymph node biopsy using dye alone method is reliable and accurate even after neo-adjuvant chemotherapy in locally advanced breast cancer - a prospective study

    Directory of Open Access Journals (Sweden)

    Mishra Ashwani

    2011-02-01

    Full Text Available Abstract Background Sentinel lymph node biopsy (SLNB is now considered a standard of care in early breast cancers with N0 axillae; however, its role in locally advanced breast cancer (LABC after neo-adjuvant chemotherapy (NACT is still being debated. The present study assessed the feasibility, efficacy and accuracy of sentinel lymph node biopsy (SLNB using "dye alone" (methylene blue method in patients with LABC following NACT. Materials and methods Thirty, biopsy proven cases of LABC that had received three cycles of neo-adjuvant chemotherapy (cyclophosphamide, adriamycin, 5-fluorouracil were subjected to SLNB (using methylene blue dye followed by complete axillary lymph node dissection (levels I-III. The sentinel node(s was/were and the axilla were individually assessed histologically. The SLN accuracy parameters were calculated employing standard definitions. The SLN identification rate in the present study was 100%. The sensitivity of SLNB was 86.6% while the accuracy was 93.3%, which were comparable with other studies done using dual lymphatic mapping method. The SLN was found at level I in all cases and no untoward reaction to methylene blue dye was observed. Conclusions This study confirms that SLNB using methylene blue dye as a sole mapping agent is reasonably safe and almost as accurate as dual agent mapping method. It is likely that in the near future, SLNB may become the standard of care and provide a less morbid alternative to routine axillary lymph node dissection even in patients with LABC that have received NACT.

  4. Internal Mammary Sentinel Lymph Nodes in Breast Cancer - Effects on Disease Prognosis and Therapeutic Protocols - A Case Report

    Directory of Open Access Journals (Sweden)

    Sinisa Stojanoski

    2015-03-01

    CONCLUSION: Detection of internal mammary lymph node metastases improves N (nodal grading of breast cancer by selecting a high risk subgroup of patients that require adjuvant hormone therapy, chemotherapy and/or radiotherapy.

  5. Assessment the diagnostic accuracy of sentinel lymph nodes lymphoscintigraphy using Technetium-99m phytate in breast cancer

    Directory of Open Access Journals (Sweden)

    M Eftekhari

    2009-08-01

    Full Text Available "nBackground: Technetium-99m phytate (99mTc-ph is a readily available radiopharmaceutical and has been suggested as a suitable agent for sentinel lymph node (SLN detection. In this study, the diagnostic accuracy and false-negative rate of radionuclide SLN mapping using 99mTc-ph were investigated. "nMethods: Forty three women (mean age 52.3 years, range 31-74 years, who all had been diagnosed with breast cancer were enrolled in the study. All patients had no palpable axillary lymph nodes and had not undergone exploratory tumor resection or any drug treatment, previously. 99mTc-ph was injected peri-tumorally at four sites. Following SLN scintigraphic imaging, the patients were operated. Intraoperatively SLN were detected by a scintillation probe and a blue dye technique. Modified radical mastectomies with radical axillary dissection were performed with excision of the lymph nodes, to evaluate the accuracy of the SLN technique. "nResults: Intraoperative scinti-mapping identified SLN in 40 of the 43 patients (detection rate: 93%. Scintigraphically, none of the patients had internal mammary drainage or contralateral axillary involvement. The blue dye detection rate in 23 patients under study was 87% and all lymph nodes detected by the blue dye technique were also detected as "hot" spots in the lymphoscintigraphy. Using pathology as the gold standard, the sensitivity and negative predictive value of scintigraphic lymphatic mapping in detection of SLN by 99mTc-ph were 90% and 90.9%, respectively. The same values for blue dye lymphatic mapping were 84.6% and 77.7%, respectively. "nConclusion: 99mTc-ph used for SLN mapping is readily available, has low cost and gives better results than the blue dye technique. Long-term follow-up is required to assess accurately the incidence of failure in patients with negative SLN and the overall diagnostic accuracy and efficacy of the SLN mapping using 99mTc-ph as the radioactive tracer.

  6. Positive versus negative sentinel nodes in early breast cancer patients: axillary or loco-regional relapse and survival. A study spanning 2000-2012.

    Science.gov (United States)

    García Fernández, A; Chabrera, C; García Font, M; Fraile, M; Lain, J M; Barco, I; González, C; Gónzalez, S; Reñe, A; Veloso, E; Cassadó, J; Pessarrodona, A; Giménez, N

    2013-10-01

    Sentinel Node Biopsy (SNB) is a minimally invasive alternative to elective axillary lymph node dissection (ALND) for nodal staging in early breast cancer. The present study was conducted to evaluate prognostic implications of a negative sentinel node (SN) versus a positive SN (followed by completion ALND) in a closely followed-up sample of early breast cancer patients. We studied 889 consecutive breast cancer patients operated for 908 primaries. Patients received adjuvant therapy with chemotherapy, hormone therapy and eventually trastuzumab. Radiation therapy was based on tangential radiation fields that usually included axillary level I. Median follow-up was 47 months. Axillary recurrence was seen in 1.2% (2/162) of positive SN patients, and 0.8% (5/625) of negative SN patients (p = n.s.). There was an overall 3.2% loco-regional failure rate (29/908). Incidence of distant recurrence was 3.3% (23/693) for negative SN patients, and 4.6% (9/196) for positive SN patients (p = n.s.). Overall mortality rate was 4% (8/198) for positive SN patients, while the corresponding specific mortality rate was 2.5% (5/198). For patients with negative SNs, overall mortality was 4.9% (34/693), and the specific mortality was 1.4% (19/693) (p = n.s.). We did not find significant differences in axillary/loco-regional relapse, distant metastases, disease-free interval or mortality between SN negative and SN positive patients, with a follow-up over 4 years. Copyright © 2013 Elsevier Ltd. All rights reserved.

  7. Can methylene blue dye be used as an alternative to patent blue dye to find the sentinel lymph node in breast cancer surgery?

    Directory of Open Access Journals (Sweden)

    Asieh Sadat Fattahi

    2014-01-01

    Full Text Available Background: Sentinel lymph node biopsy (SLNB is standard care to evaluate axillary involvement in early breast cancer. It has fewer complications than complete lymph node dissection; however, using blue dye in SLNB is controversial. We have evaluated the detection rate and local complications associated with methylene blue dye (MBD used in SLNB in early breast cancer patients and compared these results to patent blue dye (PBD. Materials and Methods : In a cohort prospective study, 312 patients with early breast cancer without axillary lymph node involvement were divided into two groups according to dye type. All of the patients received radiotracer and one type of blue dye. We filled out a checklist for the patients that contained demographic data, size of tumor, stage, detection of sentinel lymph node, and complications and then analyzed the data. Results: Demographic and histopathologic characteristics were not significantly different in both groups. Mean (standard deviation [SD] tumor size in all patients was 2.4 (0.8 cm. Detection rate in the MBD group was 77.5% with dye alone and 94.2% with dye and radioisotope; and in the PBD group it was 80.1% and 92.9% respectively (P > 0.05. We had blue discoloration of the skin in 23.7% in the PBD and 14.1% in the MBD group (P < 0.05 local inflammation was detected in one patient in the PBD and five in the MBD group (P < 0.05. Skin necrosis and systemic complications were not observed. Conclusion: Methylene blue has an acceptable detection rate, which may be a good alternative in SLNB. Complication such as blue discoloration of the skin was also lower with MBD.

  8. Evaluation of Early Breast Cancer Sentinel Lymph Node Biopsy%早期乳腺癌前哨淋巴结活检术的应用评价

    Institute of Scientific and Technical Information of China (English)

    黄两喜; 林艇; 蔡道广

    2014-01-01

    Objective To explore the significance and value of sentinel lymph node biopsy applied in patients with early breast cancer. Methods 60 cases of patients with early breast cancer treated in our hospital from March, 2009 to January, 2013 were se-lected. All the patients were node-negative, and given axillary sentinel lymph node biopsy without axillary dissection, 1% concen-tration of methylene blue solution could be used for specific operation. Results 60 patients were followed up for 3 years after surgery, it was found that the patients had no upper extremity numbness, swelling and upper limb movement disorders and other complications, all patients showed no evidence of enlarged axillary lymph nodes and local recurrence. Conclusion For patients with early breast cancer, axillary sentinel lymph node biopsy can reduce the incidence of complications and replace axillary dis-section, which is recommended to be applied and promoted clinically.%目的:探讨对早期乳腺癌患者应用前哨淋巴结活检术的意义及价值。方法该研究选取在该院接受治疗的60例早期乳腺癌患者,所选患者均为淋巴结阴性,不予以腋窝清扫,对所有患者使用腋窝前哨淋巴结活检术,具体可应用浓度为1%的亚甲蓝溶液进行操作。结果对60例患者进行随访3年,术后发现患者无上肢麻木感、上肢肿胀以及运动障碍等并发症,全部患者检查未见腋窝肿大淋巴结,更无局部复发情况。结论对早期乳腺癌患者使用腋窝前哨淋巴结活检术,可以减少并发症,能够替代腋窝清扫术,在临床可建议应用与推广。

  9. [Selective biopsy of the sentinel lymph node in patients with breast cancer and previous excisional biopsy: is there a change in the reliability of the technique according to time from surgery?].

    Science.gov (United States)

    Sabaté-Llobera, A; Notta, P C; Benítez-Segura, A; López-Ojeda, A; Pernas-Simon, S; Boya-Román, M P; Bajén, M T

    2015-01-01

    To assess the influence of time on the reliability of sentinel lymph node biopsy (SLNB) in breast cancer patients with previous excisional biopsy (EB), analyzing both the sentinel lymph node detection and the lymph node recurrence rate. Thirty-six patients with cT1/T2 N0 breast cancer and previous EB of the lesion underwent a lymphoscintigraphy after subdermal periareolar administration of radiocolloid, the day before SLNB. Patients were classified into two groups, one including 12 patients with up to 29 days elapsed between EB and SLNB (group A), and another with the remaining 24 in which time between both procedures was of 30 days or more (group B). Scintigraphic and surgical detection of the sentinel lymph node, histological status of the sentinel lymph node and of the axillary lymph node dissection, if performed, and lymphatic recurrences during follow-up, were analyzed. Sentinel lymph node visualization at the lymphoscintigraphy and surgical detection were 100% in both groups. Histologically, three patients showed macrometastasis in the sentinel lymph node, one from group A and two from group B. None of the patients, not even those with malignancy of the sentinel lymph node, relapsed after a medium follow-up of 49.5 months (24-75). Time elapsed between EB and SLNB does not influence the reliability of this latter technique as long as a superficial injection of the radiopharmaceutical is performed, proving a very high detection rate of the sentinel lymph node without evidence of lymphatic relapse during follow-up. Copyright © 2014 Elsevier España, S.L.U. and SEMNIM. All rights reserved.

  10. A modified sentinel node and occult lesion localization (SNOLL) technique in non-palpable breast cancer: a pilot study

    OpenAIRE

    Follacchio, Giulia Anna; Monteleone, Francesco; Anibaldi, Paolo; De Vincentis, Giuseppe; Iacobelli, Silvia; Merola, Raffaele; D’Orazi, Valerio; Monti, Massimo; Pasta, Vittorio

    2015-01-01

    Background The spread of mammographic screening programs has allowed an increasing amount of early breast cancer diagnosis. A modern approach to non-palpable breast lesions requires an accurate intraoperative localization, in order to achieve a complete surgical resection. In addiction, the assessment of lymph node status is mandatory as it represents a major prognostic factor in these patients. The aim of this study is to evaluate the reliability of a modified technical approach using a sing...

  11. Comparison of efficacy of Tc-99m HIG and Tc-99m nanocolloid on sentinel lymph node mapping in patients with breast cancer.

    Science.gov (United States)

    Yalçin, Hulya; Gençoglu, Esra Arzu; Yagmurdur, Mahmut; Aras, Murat; Ozen, Aynur; Aktas, Ayse

    2010-10-01

    This study compared the effectiveness of Tc-99m human polyclonal immunoglobulin (HIG) and Tc-99m nanocolloid at detecting sentinel lymph nodes (SLNs) with lymphoscintigraphy and an intraoperative gamma-probe (IGP) in patients with early breast cancer. The study group consisted of 50 women; 25 patients each were given Tc-99m HIG or Tc-99m nanocolloid for lymphoscintigraphy. Then, intraoperative SLN localization with IGP was performed. The results of IGP, lymphoscintigraphy, blue dye injected just before surgery, and pathology were compared. In the Tc-99m HIG group, one patient had tumours in both breasts. In two patients, we could not detect SLNs with lymphoscintigraphy, although they were detected with IGP and blue dye. We found SLNs for all tumours with IGP. With the intraoperative blue dye, SLNs were identified for 25 tumours; for one tumour, no SLN was detected with blue dye. In the histopathological examination, 13 tumours showed metastasis in the SLN and in 11 of these 13, there were also metastases in the axilla. One patient had a skip metastasis. In the Tc-99m nanocolloid group, SLNs were identified in 24 patients with lymphoscintigraphy. IGP found SLNs in 24 patients. The blue dye detected SLNs in all patients. On histopathological examination, 10 patients had metastasis in the SLN and there were also metastases in the axilla in all of these patients. Tc-99m HIG can be used in SLN detection with preoperative lymphoscintigraphy and IGP in early-stage breast cancer patients.

  12. The first experience of using of 99mTc-Al2O3 for detection of sentinel lymph nodes in breast cancer

    Science.gov (United States)

    Doroshenko, A.; Chernov, V.; Medvedeva, A.; Zeltchan, R.; Slonimskaya, E.; Varlamova, N.; Skuridin, V.; Dergilev, A.; Sinilkin, I.

    2016-06-01

    Purpose: to study the feasibility of using the new radiopharmaceutical based on the technetium-99m-labeled gamma-alumina for identification of sentinel lymph nodes (SLNs) in breast cancer patients. Materials and methods. The study included two groups of breast cancer patients who underwent single photon emission computed tomography (SPECT) and intraoperaive gamma probe identification of sentinel lymph nodes (SLNs). To identify SLNs, the day before surgery Group I patients (n=34) were injected with radioactive 99mTc-Al203, and Group II patients (n=30) received 99mTc-labeled phytate colloid. Results. A total of 37 SLNs were detected in Group I patients. The number of identified SLNs per patient ranged from 1 to 2 (the average number of identified SLNs was 1.08). Axillary lymph nodes were the most common site of SLN localization. At 18 hours after 99mTc-Al203 injection, the percentage of its accumulation in the SLN was 7-11% (of the counts in the injection site) by SPECT and 17-31% by gamma probe detection. In Group II patients, SLNs were detected in 27 patients. At 18 hours after injection of the phytate colloid, the percentage of its accumulation in the SLN was 1.5-2% out of the counts in the injection site by SPECT and 4-7% by gamma probe. Conclusion. The new radiopharmaceutical based on the 99mTc - Al203 demonstrates high accumulation in SLNs without redistribution through the entire lymphatic basin. Sensitivity and specificity of 99mTc - Al203 were 100% for both SPECT and intraoperative gamma probe identification.

  13. The use of {sup 99m}Tc-Al{sub 2}O{sub 3} for detection of sentinel lymph nodes in breast cancer

    Energy Technology Data Exchange (ETDEWEB)

    Sinilkin, I., E-mail: sinilkinig@oncology.tomsk.ru; Chernov, V.; Medvedeva, A.; Zeltchan, R. [Tomsk Cancer Research Institute, Tomsk, 634050 (Russian Federation); Tomsk Polytechnic University, Tomsk, 634050 (Russian Federation); Slonimskaya, E.; Doroshenko, A. [Tomsk Cancer Research Institute, Tomsk, 634050 (Russian Federation); Varlamova, N.; Skuridin, V. [Tomsk Polytechnic University, Tomsk, 634050 (Russian Federation)

    2016-08-02

    Purpose: to study the feasibility of using the new radiopharmaceutical based on the technetium-99m-labeled gamma-alumina for identification of sentinel lymph nodes (SLNs) in breast cancer patients. The study included two groups of breast cancer patients who underwent single photon emission computed tomography (SPECT) and intraoperaive gamma probe identification of sentinel lymph nodes (SLNs). To identify SLNs, the day before surgery Group I patients (n = 34) were injected with radioactive {sup 99m}Tc-Al{sub 2}O{sub 3}, and Group II patients (n = 30) received {sup 99m}Tc-labeled phytate colloid. A total of 37 SLNs were detected in Group I patients. The number of identified SLNs per patient ranged from 1 to 2 (the average number of identified SLNs was 1.08). Axillary lymph nodes were the most common site of SLN localization. 18 hours after {sup 99m}Tc-Al{sub 2}O{sub 3} injection, the percentage of its accumulation in the SLN was 7–11% (of the counts in the injection site) by SPECT and 17–31% by gamma probe detection. In Group II SLNs were detected in 27 patients. 18 hours after injection of the phytate colloid the percentage of its accumulation in the SLN was 1.5–2% out of the counts in the injection site by SPECT and 4–7% by gamma probe. The new radiopharmaceutical based on the {sup 99m}Tc-Al{sub 2}O{sub 3} demonstrates high accumulation in SLNs without redistribution through the entire lymphatic basin. The sensitivity and specificity of {sup 99m}Tc-Al{sub 2}O{sub 3} were 100% for both SPECT and intraoperative gamma probe identification.

  14. [Evaluation of the efficacy of sentinel node detection in breast cancer: chronological course and influence of the incorporation of an intra-operative portable gamma camera].

    Science.gov (United States)

    Goñi Gironés, E; Vicente García, F; Serra Arbeloa, P; Estébanez Estébanez, C; Calvo Benito, A; Rodrigo Rincón, I; Camarero Salazar, A; Martínez Lozano, M E

    2013-01-01

    To define the sentinel node identification rate in breast cancer, the chronological evolution of this parameter and the influence of the introduction of a portable gamma camera. A retrospective study was conducted using a prospective database of 754 patients who had undergone a sentinel lymph node biopsy between January 2003 and December 2011. The technique was mixed in the starting period and subsequently was performed with radiotracer intra-peritumorally administered the day before of the surgery. Until October 2009, excision of the sentinel node was guided by a probe. After that date, a portable gamma camera was introduced for intrasurgical detection. The SN was biopsied in 725 out of the 754 patients studied. The resulting technique global effectiveness was 96.2%. In accordance with the year of the surgical intervention, the identification percentage was 93.5% in 2003, 88.7% in 2004, 94.3% in 2005, 95.7% in 2006, 93.3% in 2007, 98.8% in 2008, 97.1% in 2009 and 99.1% in 2010 and 2011. There was a significant difference in the proportion of identification before and after the incorporation of the portable gamma camera of 4.6% (95% CI of the difference 2-7.2%, P = 0.0037). The percentage of global identification exceeds the recommended level following the current guidelines. Chronologically, the improvement for this parameter during the study period has been observed. These data suggest that the incorporation of a portable gamma camera had an important role. Copyright © 2013 Elsevier España, S.L. and SEMNIM. All rights reserved.

  15. Application of Sentinel Lymph Node Biopsy in Breast Cancer Operation%前哨淋巴结活检在乳腺癌手术中的应用

    Institute of Scientific and Technical Information of China (English)

    王勇; 黄鑫; 唐恬

    2014-01-01

    Objective:To study the application of sentinel lymph node biopsy in breast cancer operation.Method:The clinical data of 28 cases of breast cancer patients in our hospital from June 2011 to June 2014 were retrospectively analyzed,in the preoperative 2-4 h in tumor or tumor bed below the injection of 0.4 mL/37MBq radioactive substances 99mTc_DX,R detector was used tolocate and remove the sentinel lymph node,then breast tumor excision andaxillary lymph node cleaning. The first routine HE testing on SLN and ALN,andimmunohistochemistry(1HC)test and reverse transcription polymerase chain reaction(RT-PCR)detection of cytokeratin 19(CKl9)mRNA expression in thedetection of lymph node micrometastasis.Result:The detection rate was 100%,a total of 43 pieces of sentinel lymph node detection. 18 patients had 1,5 cases of 2,5 cases of 3. 67 axillary lymph nodes were detected. After HE staining detection found that 4 patients with metastatic.Using printing slice cytology of sentinel lymph node in patients with masculine,through inspection and found positive in 5 cases,23 cases of negative.Conclusion:Breast cancer SLNB is feasible,the transfer of SLNS could predict ALN detected,it played an important role in protect milk,and is conducive to determine whether patients with axillary lymph node cleaning,use to be promoted.%目的:研究前哨淋巴结活检(SLNB)在乳腺癌手术中的应用。方法:回顾性分析本院2011年6月-2014年6月间收治的28例行乳腺癌手术患者的临床资料,于术前2~4 h在肿瘤下方或瘤床内注射0.4 mL/37MBq放射性物质99mTc_DX,术中用r探测仪定位并切除前哨淋巴结(SLN),再行乳腺肿瘤切除及腋窝淋巴结(ALN)清扫。首先对SLN及ALN进行常规HE检测,再行免疫组织化学(1HC)检测及逆转录多聚酶链反应(RT-PCR)检测细胞角蛋白19(CKl9)mRNA的表达以检测淋巴结的微转移。结果:本次研究的检出率为100%,共检出43

  16. Population based study on sentinel node biopsy before or after neoadjuvant chemotherapy in clinically node negative breast cancer patients: Identification rate and influence on axillary treatment.

    Science.gov (United States)

    van der Heiden-van der Loo, M; de Munck, L; Sonke, G S; van Dalen, T; van Diest, P J; van den Bongard, H J G D; Peeters, P H M; Rutgers, E J T

    2015-05-01

    The timing of the sentinel lymph node biopsy (SNB) is controversial in clinically node negative patients receiving neoadjuvant chemotherapy (NAC). We studied variation in the timing of axillary staging in breast cancer patients who received NAC and the subsequent axillary treatment in The Netherlands. Patients diagnosed with clinically node negative primary breast cancer between 1st January 2010 and 30th June 2013 who received NAC and SNB were selected from the Netherlands Cancer Registry. Data on patient and tumour characteristics, axillary staging and treatment were analysed. Two groups were defined: (1) patients with SNB before NAC (N=980) and (2) patients with SNB after NAC (N=203). Eighty-three percent of patients underwent SNB before NAC, with large regional variation (35-99%). The SN identification rate differed for SNBs conducted before and after NAC (98% versus 95%; p=0.032). A lower proportion of patients had a negative SNB when assessed before NAC compared to after (54% versus 67%; p=0.001). The proportion of patients receiving any axillary treatment was higher for those with SNB before NAC than after (45% versus 33%; p=0.006). In conclusion, variation exists in the timing of SNB in clinical practice in The Netherlands for clinically node negative breast cancer patients receiving NAC. The post-NAC SN procedure is, despite some lower SN identification rate, associated with a significantly less frequent axillary treatment and thus with less expected morbidity. The effect on recurrence rate is not yet clear. Patients in this registry will be followed prospectively for long-term outcome. Copyright © 2015 Elsevier Ltd. All rights reserved.

  17. What Is Breast Cancer?

    Science.gov (United States)

    ... Research? Breast Cancer About Breast Cancer What Is Breast Cancer? Breast cancer starts when cells in the breast ... spread, see our section on Cancer Basics . Where breast cancer starts Breast cancers can start from different parts ...

  18. Sentinel Lymph Node Mapping In Gastric Cancer Surgery: Current Status

    Directory of Open Access Journals (Sweden)

    Bara Tivadar

    2016-12-01

    Full Text Available Lymphonodular metastases remain an important predictive and prognostic factor in gastric cancer development. The precise determination of the lymphonodular invasion stage can be made only by extended intraoperative lymphadenectomy and histopathological examination. But the main controversy is the usefulness of extended lymph dissection in early gastric cancer. This increases the duration of the surgery and the complications rate, and it is unnecessary without lymphonodular invasion. The identification of the sentinel lymph nodes has been successfully applied for some time in the precise detection of lymph nodes status in breast cancer, malignant melanoma and the use for gastric cancer patients has been a controversial issue. The good prognosis in early gastric cancer had been a surgery challenge, which led to the establishment of minimally invasive individualized treatment and acceptance of sentinel lymph node mapping. The dual-tracer method, submucosally administered endoscopically is also recommended in sentinel lymph node biopsy by laparoscopic approach. There are new sophisticated technologies for detecting sentinel lymph node such as: infrared ray endoscopy, florescence imaging and near-infrared technology, carbon nanoparticles, which will open new perspectives in sentinel lymph nodes mapping.

  19. Development and piloting of a decision aid for women considering participation in the Sentinel Node Biopsy versus Axillary Clearance 2 breast cancer trial.

    Science.gov (United States)

    Juraskova, Ilona; Butow, Phyllis; Fisher, Alana; Bonner, Carissa; Anderson, Caroline; Bu, Stella; Scarlet, Jenni; Stockler, Martin R; Wetzig, Neil; Ung, Owen; Campbell, Ian

    2015-08-01

    This study aimed to (1) develop a decision aid for women considering participation in the Sentinel Node Biopsy versus Axillary Clearance 2 (SNAC-2) breast cancer surgical trial and (2) obtain evidence on its acceptability, feasibility, and potential efficacy in routine trial clinical practice via a two-stage pilot. The decision aid was developed according to International Patient Decision Aid Standards. Study 1: an initial pilot involved 25 members of the consumer advocacy group, Breast Cancer Network Australia. Study 2: the main pilot involved 20 women eligible to participate in the SNAC-2 trial in New Zealand. In both pilots, a questionnaire assessed: information and involvement preferences, decisional conflict, SNAC-2 trial-related understanding and attitudes, psychological distress, and general decision aid feedback. A follow-up telephone interview elicited more detailed feedback on the decision aid design and content. In both pilots, participants indicated good subjective and objective understanding of SNAC-2 trial and reported low decisional conflict and anxiety. The decision aid was found helpful when deciding about trial participation and provided additional, useful information to the standard trial information sheet. The development and two-stage piloting process for this decision aid resulted in a resource that women found very acceptable and helpful in assisting decision-making about SNAC-2 trial participation. The process and findings provide a guide for developing other trial decision aids. © The Author(s) 2015.

  20. The value of breast MRI in high-risk patients with newly diagnosed breast cancer to exclude invasive disease in the contralateral prophylactic mastectomy: Is there a role to choose wisely patients for sentinel node biopsy?

    Science.gov (United States)

    Freitas, Vivianne; Crystal, Pavel; Kulkarni, Supriya R; Ghai, Sandeep; Bukhanov, Karina; Escallon, Jaime; Scaranelo, Anabel M

    2016-06-01

    The aim of this study was to evaluate the presence of clinically and mammographically occult disease using breast MRI in a cohort of cancer patients undergoing contralateral prophylactic mastectomy (CPM) and the utmost indication of axillary assessment (sentinel node biopsy (SLNB)) for this side. A retrospective review of patients with unilateral invasive breast cancer or ductal carcinoma in situ (DCIS) from institutional MRI registry data (2004-2010) was conducted. Characteristics of patients undergoing CPM with breast MRI obtained less than 6 month before surgery were evaluated. A total of 2322 consecutive patients diagnosed with DCIS or stage I to III infiltrating breast cancer underwent preoperative breast MRI. Of these, 1376 patients (59.2%) had contralateral clinical breast exam and mammography without abnormalities; and 116 patients (4.9%) underwent CPM (28 excluded patients had breast MRI more than 6 months before CPM). The mean age of the 88 patients was 49 years (range 28-76 years). Two (2.3%) DCIS identified on surgical pathology specimen were not depicted by MRI and the 5 mm T1N0 invasive cancer (1.1%) was identified on MRI. Preoperative MRI showed 95% accuracy to demonstrate absence of occult disease with negative predicted value (NPV) of 98% (95% CI: 91.64-99.64%). Occult disease was present in 3.4% of CPM. MRI accurately identified the case of invasive cancer in this cohort. The high negative predictive value suggests that MRI can be used to select patients without consideration of SLNB for the contralateral side.

  1. The Effect of the Excisional Biopsy in the Detection of the Sentinel Lymph Node By Lymphoscintigraphy and Intraoperative Gamma Probe in Breast Cancer

    Directory of Open Access Journals (Sweden)

    Pelin Arıcan

    2011-12-01

    Full Text Available Objective: Sentinel lymph node (SLN scintigraphy is used widespread in breast cancer, but the effect of the radionuclide agent, injec¬tion technique, the method of biopsy, tumor localization, breast size remain controversial. We examined the effects of the excisional biopsy in the rate of the SLN identification with lymphoscintigraphy (LS and intraoperative gamma probe (IGP. Material and Methods: One hundred patients (age range: 28-79 yr with breast cancer were included in the study. They consist¬ed of two groups: Group 1; there were 58 patients without excisional biopsy Group 2; there were 42 patients with excisional biopsy LS: 2 hours before the operation, 37 MBq/ ml Tc 99m colloidal rhenium sulphide was injected at the periaerolar region intradermally Anterior and lateral static images were acquired. IGP: The hot spot of greatest radioactivity were marked on the skin during the surgery with IGP and removed. Excised SLNs were examined with frozen section. After that histopathological and immunohistochemical examinations were performed. Results: SLNs were found in all patients in group 1 (100%, in 39 patients of group 2 (93% with LS. SLNs were excised in 57 of the 58 patients of group 1 (98%, in 38 of the 42 patients of group 2 (90% with IGF? Metastases were found in SLNs in 27 patients (28%. Axillary dissection was performed in these patients. Conclusion: According to results of our study the excisional biopsy was not the only factor but also other factors such as breast mass, calcified or metastatic lymph node may be affected the success rate of the SLN. (MIRT2011;20:100-103

  2. Sentinel lymph node biopsy for breast cancer using methylene blue dye manifests a short learning curve among experienced surgeons: a prospective tabular cumulative sum (CUSUM analysis

    Directory of Open Access Journals (Sweden)

    Valentine Christopher SP

    2009-01-01

    Full Text Available Abstract Background The benefits of sentinel lymph node biopsy (SLNB for breast cancer patients with histologically negative axillary nodes, in whom axillary lymph node dissection (ALND is thereby avoided, are now established. Low false negative rate, certainly with blue dye technique, mostly reflects the established high inherent accuracy of SLNB and low axillary nodal metastatic load (subject to patient selection. SLN identification rate is influenced by volume, injection site and choice of mapping agent, axillary nodal metastatic load, SLN location and skill at axillary dissection. Being more subject to technical failure, SLN identification seems to be a more reasonable variable for learning curve assessment than false negative rate. Methylene blue is as good an SLN mapping agent as Isosulfan blue and is much cheaper. Addition of radio-colloid mapping to blue dye does not achieve a sufficiently higher identification rate to justify the cost. Methylene blue is therefore the agent of choice for SLN mapping in developing countries. The American Society of Breast Surgeons recommends that, for competence, surgeons should perform 20 SLNB but admits that the learning curve with a standardized technique may be "much shorter". One appropriate remedy for this dilemma is to plot individual learning curves. Methods Using methylene blue dye, experienced breast surgeons performed SLNB in selected patients with breast cancer (primary tumor Results The CUSUM plot crossed the SPRT limit line after 8 consecutive, positively identified SLN, signaling achievement of an acceptable level of competence. Conclusion Tabular CUSUM charting, based on a justified choice of parameters, indicates that the learning curve for SLNB using methylene blue dye is completed after 8 consecutive, positively identified SLN. CUSUM charting may be used to plot individual learning curves for trainee surgeons by applying a proxy parameter for failure in the presence of a mentor (such as

  3. Sentinel lymph node biopsy for breast cancer using methylene blue dye manifests a short learning curve among experienced surgeons: a prospective tabular cumulative sum (CUSUM) analysis.

    Science.gov (United States)

    East, Jeffrey M; Valentine, Christopher S P; Kanchev, Emil; Blake, Garfield O

    2009-01-27

    The benefits of sentinel lymph node biopsy (SLNB) for breast cancer patients with histologically negative axillary nodes, in whom axillary lymph node dissection (ALND) is thereby avoided, are now established. Low false negative rate, certainly with blue dye technique, mostly reflects the established high inherent accuracy of SLNB and low axillary nodal metastatic load (subject to patient selection). SLN identification rate is influenced by volume, injection site and choice of mapping agent, axillary nodal metastatic load, SLN location and skill at axillary dissection. Being more subject to technical failure, SLN identification seems to be a more reasonable variable for learning curve assessment than false negative rate. Methylene blue is as good an SLN mapping agent as Isosulfan blue and is much cheaper. Addition of radio-colloid mapping to blue dye does not achieve a sufficiently higher identification rate to justify the cost. Methylene blue is therefore the agent of choice for SLN mapping in developing countries. The American Society of Breast Surgeons recommends that, for competence, surgeons should perform 20 SLNB but admits that the learning curve with a standardized technique may be "much shorter". One appropriate remedy for this dilemma is to plot individual learning curves. Using methylene blue dye, experienced breast surgeons performed SLNB in selected patients with breast cancer (primary tumor chart with sequential probability ratio test (SPRT) limits based on a target identification rate of 85%. The CUSUM plot crossed the SPRT limit line after 8 consecutive, positively identified SLN, signaling achievement of an acceptable level of competence. Tabular CUSUM charting, based on a justified choice of parameters, indicates that the learning curve for SLNB using methylene blue dye is completed after 8 consecutive, positively identified SLN. CUSUM charting may be used to plot individual learning curves for trainee surgeons by applying a proxy parameter for

  4. Feasibility and accuracy of sentinel lymph node biopsy in clinically node-positive breast cancer after neoadjuvant chemotherapy: a meta-analysis.

    Directory of Open Access Journals (Sweden)

    Jian-Fei Fu

    Full Text Available Sentinel lymph node biopsy (SLNB has replaced conventional axillary lymph node dissection (ALND in axillary node-negative breast cancer patients. However, the use of SLNB remains controversial in patients after neoadjuvant chemotherapy (NAC. The aim of this review is to evaluate the feasibility and accuracy of SLNB after NAC in clinically node-positive patients. Systematic searches were performed in the PubMed, Embase, and Cochrane Library databases from 1993 to December 2013 for studies on node-positive breast cancer patients who underwent SLNB after NAC followed by ALND. Of 436 identified studies, 15 were included in this review, with a total of 2,471 patients. The pooled identification rate (IR of SLNB was 89% [95% confidence interval (CI 85-93%], and the false negative rate (FNR of SLNB was 14% (95% CI 10-17%. The heterogeneity of FNR was analyzed by meta-regression, and the results revealed that immunohistochemistry (IHC staining may represent an independent factor (P = 0.04. FNR was lower in the IHC combined with hematoxylin and eosin (H&E staining subgroup than in the H&E staining alone subgroup, with values of 8.7% versus 16.0%, respectively (P = 0.001. Thus, SLNB was feasible after NAC in node-positive breast cancer patients. In addition, the IR of SLNB was respectable, although the FNR of SLNB was poor and requires further improvement. These findings indicate that IHC may improve the accuracy of SLNB.

  5. Application of methylene blue in sentinel lymph node biopsy in breast conservative therapy of breast cancer%亚甲蓝在保乳术前哨淋巴结活检中的应用

    Institute of Scientific and Technical Information of China (English)

    谢舜峰; 孙淑明; 卢晓峰; 吴丽娥

    2011-01-01

    目的 探讨亚甲蓝染色在乳腺癌保乳术前哨淋巴结活检(SLNB)中的应用价值.方法 55例临床Ⅰ~Ⅱ期乳腺癌患者,行亚甲蓝染色定位前哨淋巴结(SLN),SLNB并腋窝淋巴结清扫(ALND),对全部的SLN和腋窝淋巴结行病理检查并分析结果.结果 55例中成功检出SLN 52例,检出率95%,SLNB的灵敏度为100%(20/20),准确率为93%(52/55),假阴性率为5%(1/20),假阳性率为0.结论 亚甲蓝染色是乳腺癌前哨淋巴结活检的可靠方法,SLNB是一种简便、安全的检测技术,可用于了解腋窝淋巴结的状况.%Objective To explore the clinical value of methylene blue in sentinel lymph node biopsy ( SLNB) in breast conservative therapy of breast cancer. Methods 55 patients performed sentinel lymph node biopsy( SLNB)in were analyzed,with breast conservative therapy of breast cancer in clinical stage Ⅰ-Ⅱ. The mapping procedures and SLNB were performed using subareolar injection of Methylene blue dye,followed by the axillary lymph node dissection(ALND). All of the SLN and ALN were evaluated pathologically after the operations. Results Among 55 cases ,52 cases were checked out sentinel lymph node and the positive rate was 95% (52/55). The axillary status was 100% accurately predicted by SLNs;Sensitivity in this group was 93% (52/55) ;False negative rate was 5% (1/20);False positive rate was 0. Conclusion Methylene blue dye is a reliable method for sentinel lymph node biopsy. SLNB is a simple and safe technic, which helps to reveal the state of the axillary lymph nodes.

  6. A prospective randomized trial comparing patent blue and methylene blue for the detection of the sentinel lymph node in breast cancer patients.

    Science.gov (United States)

    Paulinelli, Régis Resende; Freitas-Junior, Ruffo; Rahal, Rosemar Macedo de Souza; Oliveira, Luis Fernando de Pádua; Vilela, Maria Helena Tavares; Moreira, Marise Amaral Rebouças; Alves, Katyane Larissa; Peleja, Marina Berquó; Resende, Tatiane Coelho Capel de

    2017-02-01

    Methylene blue is more widely available and less expensive than patent blue, with an apparently lower risk of anaphylaxis. The two dyes were compared regarding detection of the sentinel lymph node (SLN). A prospective, randomized trial involved 142 patients with invasive breast carcinoma. Sixty-nine (49.3%) assigned to patent blue (group A) and 71 (50.70%) to methylene blue (group B). Thirty-five patients (25.0%) were clinical stage III or IV; 55 (38.7%) had axillary lymph nodes affected; and 69 (49.3%) underwent neoadjuvant chemotherapy. Two patients were excluded because the dye type was not recorded. Patients and tumor characteristics were similar in both groups. SLNs were identified in 47 women (68.1%) in group A and 43 (60.6%) in group B (p=0.35). SLNs were affected in 22 cases (51.2%) in group A and 21 (48.8%) in group B (p=0.62). The SLN was the only node affected in 12 cases (54.5%) in group A and six (33.3%) in group B (p=0.18). The time and degree of difficulty involved in identifying the SLN were similar in both groups. There were no complications or allergies. Methylene blue performed as well as patent blue in identifying the SLN in breast cancer patients.

  7. Is axillary lymph node dissection necessary after sentinel lymph node biopsy in patients with mastectomy and pathological N1 breast cancer?

    Science.gov (United States)

    Fu, Yun; Chung, Debra; Cao, Minh-An; Apple, Sophia; Chang, Helena

    2014-12-01

    The American College of Surgeons Oncology Group (ACOSOG) Z0011 trial reported that axillary lymph node dissection (ALND) did not change the recurrence and overall survival (OS) rates in patients with lumpectomy and one to two positive nodes detected by sentinel lymph node biopsy (SLNB). The aim of this study was to determine whether patients with mastectomy and pathological N1 disease found by SLNB could forego ALND. This is a retrospective study of 214 patients diagnosed with primary invasive breast cancer who were treated by mastectomy and lymph node staging surgery (SLNB or ALND) at the Revlon/UCLA Breast Center between January 2002 and December 2010. Patients with pathological N1 disease were separated by their first nodal surgery into SLNB (subgroups: observation, radiation, and additional ALND with or without radiation) and ALND groups (subgroups: ALND with or without radiation). After a median follow-up of 43.6 months, the OS and systemic relapse-free survival (RFS) rate of the radiation group and additional ALND group were significantly better than the observation group (p = 0.031 and 0.046, respectively). Human epidermal growth factor receptor 2 (HER2) expression was found to predict OS and patients' age, histological grade and HER2 expression predicted systemic recurrence. Compared with the SLNB group, pain (p = 0.021) and lymphedema (p = 0.043) occurred more frequently in the ALND group. Radiation was as effective as ALND in patients with mastectomy and N1 disease for OS and RFS rates, yet radiation after SLNB had fewer side effects than ALND. SLNB followed by radiation could replace ALND in patients with mastectomy and pathological N1 breast cancer identified by SLNB.

  8. A 10-year follow-up of treatment outcomes in patients with early stage breast cancer and clinically negative axillary nodes treated with tangential breast irradiation following sentinel lymph node dissection or axillary clearance.

    Science.gov (United States)

    Wernicke, A Gabriella; Goodman, Robert L; Turner, Bruce C; Komarnicky, Lydia T; Curran, Walter J; Christos, Paul J; Khan, Imraan; Vandris, Katherine; Parashar, Bhupesh; Nori, Dattatreyudu; Chao, K S Clifford

    2011-02-01

    We compare long-term outcomes in patients with node negative early stage breast cancer treated with breast radiotherapy (RT) without the axillary RT field after sentinel lymph node dissection (SLND) or axillary lymph node dissection (ALND). We hypothesize that though tangential RT was delivered to the breast tissue, it at least partially sterilized occult axillary nodal metastases thus providing low nodal failure rates. Between 1995 and 2001, 265 patients with AJCC stages I-II breast cancer were treated with lumpectomy and either SLND (cohort SLND) or SLND and ALND (cohort ALND). Median follow-up was 9.9 years (range 8.3-15.3 years). RT was administered to the whole breast to the median dose of 48.2 Gy (range 46.0-50.4 Gy) plus boost without axillary RT. Chi-square tests were employed in comparing outcomes of two groups for axillary and supraclavicular failure rates, ipsilateral in-breast tumor recurrence (IBTR), distant metastases (DM), and chronic complications. Progression-free survival (PFS) was compared using log-rank test. There were 136/265 (51%) and 129/265 (49%) patients in the SLND and ALND cohorts, respectively. The median number of axillary lymph nodes assessed was 2 (range 1-5) in cohort SLND and 18 (range 7-36) in cohort ALND (P breast RT and SLND alone, experience low AFR or SFR. Our findings, while awaiting mature long-term data from NSABP B-32, support that in patients with negative axillary nodal status such treatment provides excellent long-term cure rates while avoiding morbidities associated with ALND or addition of axillary RT field.

  9. What's wrong with sentinel node mapping in colon cancer?

    Institute of Scientific and Technical Information of China (English)

    2007-01-01

    Despite near-universal embrace of the concept and clinical relevance of lymphatic mapping for sentinel node identification and analysis for cancers of the breast and integument, the same technique has struggled to a find a role in gastrointestinal cancers in general and,perhaps, in colon cancer in particular. Despite many studies demonstrating its feasibility in malignancies of the large bowel, concern is continually aroused by the variable and often unacceptably low sensitivity rates.Additionally, many confess uncertainty as to what benefit it could ever confer to patients even if it were proven sufficiently accurate given that standard surgical resection incorporates mesenteric resection anyway.However, the huge impact sentinel node mapping has had on clinical practice in certain cancers means that each of these aspects merit careful reconsideration, from very first principles.

  10. Potential advantage of preoperative three-dimensional mapping of sentinel nodes in breast cancer by a hybrid single photon emission CT (SPECT)/CT system.

    Science.gov (United States)

    Ibusuki, Mutsuko; Yamamoto, Yutaka; Kawasoe, Teru; Shiraishi, Shinya; Tomiguchi, Seiji; Yamashita, Yasuyuki; Honda, Yumi; Iyama, Kenichi; Iwase, Hirotaka

    2010-06-01

    This study aims to assess the role of three-dimensional single-photon emission computed tomography (3D-SPECT/CT) in sentinel node (SN) identification, and to analyze the impact of such information on estimating metastases to SNs. Nodal status is a key factor for breast cancer. SN biopsy has been established as the alternative to routine axillary dissection these days. We investigated both the anatomical location of SNs demonstrated by our 3D-SPECT/CT system and the correlation to SN positivity. Two hundred and twenty-three clinically node-negative patients underwent SN biopsy. All of the axillary structures, including SNs, were visualized by a SPECT/CT combined system after subcutaneous injection of (99m)Tc-phytate. By plotting the visualized SNs, the most frequent SN location 'Pedestal area (PA)' was designated. SPECT/CT detected (99m)Tc uptake in 217 cases (97.3%). 3D-SPECT/CT images visualized the accurate location of SNs in each case. In patients whose SNs were histopathologically negative (SN-), 228 (98.3%) SNs were found in the PA, and 4 (1.7%) were in other zones. In those with histopathologically positive SNs (SN+), 65 (78.3%) SNs were in the PA and 18 (21.7%) were outside it. The difference in SN distribution (i.e., in or out of the PA) between SN+ and SN- patients was statistically significant (pSNs in patients with breast cancer. Atypical distribution of SNs out of the PA may suggest SN positivity, reflecting failure of the lymphatic drainage systems.

  11. Investigation of {sup 18}F-FDG PET in the selection of patients with breast cancer as candidates for sentinel node biopsy after neoadjuvant therapy

    Energy Technology Data Exchange (ETDEWEB)

    Gilardi, Laura; De Cicco, Concetta; Paganelli, Giovanni [European Institute of Oncology, Division of Nuclear Medicine, Milan (Italy); Colleoni, Marco; Cardillo, Anna; Montagna, Emilia; Dellapasqua, Silvia [European Institute of Oncology, Research Unit in Medical Senology, Department of Medicine, Milan (Italy); Galimberti, Viviana [European Institute of Oncology, Division of Senology, Milan (Italy); Bagnardi, Vincenzo [European Institute of Oncology, Division of Epidemiology and Biostatistics, Milan (Italy)

    2010-10-15

    The main objective of this study was to determine the role of [{sup 18}F]-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) in the selection of patients with breast cancer as candidates for sentinel node biopsy (SNB) after neoadjuvant therapy. Forty-four patients with primary breast cancer clinically classified as cT2, cT3 or cT4{sub a-c} cN0-N2 or cN3 M0 and with a baseline FDG PET scan positive both in the site of primary tumour and axillary lymph nodes underwent neoadjuvant therapy and then a second FDG PET scan. In the case of axillary FDG PET uptake, patients underwent axillary lymph node dissection (ALND). If the second FDG PET scan was negative for axillary involvement, SNB was performed in order to evaluate axillary lymph node status. Only in the case of SN positivity did total ALND follow. Specificity and positive predictive value of FDG PET for detection of axillary lymph node metastases after neoadjuvant therapy were as high as 83% (95% confidence interval: 51-97%) and 85% (95% confidence interval: 54-97%), respectively, whereas sensitivity, negative predictive value and diagnostic accuracy were inadequate for a correct staging (34, 32 and 48%, respectively). The poor sensitivity of FDG PET in detecting axillary lymph node metastases makes SNB mandatory in cases of a negative scan. The relatively high positive predictive value seems to suggest a role of FDG PET in selecting patients who, after neoadjuvant therapy, are candidates for ALND, avoiding SNB. However, this issue requires confirmation in a larger series of patients. (orig.)

  12. Identification of sentinel lymph node in breast cancer by lymphoscintigraphy and surgical gamma probe with peritumoral injection of scintimammographic agent ''{sup 99m}Tc MIBI''

    Energy Technology Data Exchange (ETDEWEB)

    Aras, G.; Arican, P.; Cam, R.; Kuecuek, N.OE.; Ibis, E.; Tuezuener, A.; Soylu, A [Ankara Univ. (Turkey). Medical Faculty

    2002-04-01

    The purpose of this study was to evaluate the efficacy of lymphoscintigraphy and the surgical gamma probe (SGP) with peritumoral injection of {sup 99m}Tc MIBI in sentinel lymph node (SLN) detection in breast cancer regardless of whether metastatic or not. Thirty patients with T1/T2 breast cancer had peritumoral injections of {sup 99m}Tc MIBI (74 MBq/0.2 ml at 4 different locations) at 2, 6 and 24 hours before surgery. Anterior, anterolateral, and lateral spot images were taken at 10, 30, 45, 60 and 120 minutes. Counts were collected from the injection site, affected breast tissue, internal mammaries, axillary and supraclavicular regions, and the contralateral side. Peritumoral blue dye was also injected at surgery. The first lymph nodes with counts twice the background tissue and/or with blue dye uptake were surgically isolated, and histopathological evaluations were made. Modified radical mastectomy was performed on all patients. Twenty-three out of thirty patients had lymph nodes in scintigrams and the sentinel lymph nodes were identified with SGP in 25/30 patients. Lymphoscintigraphy and subsequent SGP detection with peritumoral injection of {sup 99m}Tc MIBI can be used for identifying SLN in breast cancer. (author)

  13. Comparison of intraoperative frozen section analysis of sentinel node with preoperative positron emission tomography in the diagnosis of axillary lymph node status in breast cancer patients

    Energy Technology Data Exchange (ETDEWEB)

    Yang, Jung-Hyun; Nam, Seok-Jin; Lee, Hae-Kyung; Kim, Byung-Tae [Sungkyunkwan Univ., Seoul (Korea, Republic of); Lee, Tae-Seung; Jung, Sung-Hoo

    2001-01-01

    Although axillary lymph node status is an important prognostic factor and axillary dissection is regarded as the gold standard for staging, it requires radical surgery which is accompanied by considerable postoperative problems such as lymphedema. This study was carried out to evaluate the diagnostic accuracy of preoperative positron emission tomography (PET) and intraoperative frozen biopsy of sentinel lymphadenectomy (SLND) in detecting axillary lymph node metastasis. We studied 18 patients who had preoperative PET and SLND for breast cancer in the Department of Surgery at Samsung Medical Center. They all had preoperative PET with a radiolabeled glucose analogue ([{sup 18}F]FDG) to visualize primary tumors and metastatic nodes. Isosulphan blue dye was used for intraoperative SLND. Frozen and permanent biopsies were then compared after full axillary dissection. In 18 cases, six had positive metastatic nodes in the permanent biopsy of full axillary dissection but were negative in three cases by preoperative PET. There was one false negative result by frozen biopsy of SLND which was later shown to be positive by permanent biopsy. The sensitivity and specificity of SLND and PET for detecting axillary node metastasis were 83, 100% and 50, 100%, respectively. Although both methods are good for axillary nodal status, the intraoperative frozen biopsy result of SLND was superior to preoperative PET in our preliminary study. (author)

  14. Breast Cancer Overview

    Science.gov (United States)

    ... Cancer > Breast Cancer > Breast Cancer: Overview Request Permissions Breast Cancer: Overview Approved by the Cancer.Net Editorial Board , ... bean-shaped organs that help fight infection. About breast cancer Cancer begins when healthy cells in the breast ...

  15. Models predicting non-sentinel node involvement also predict for regional recurrence in breast cancer patients without axillary treatment

    NARCIS (Netherlands)

    Pepels, M.J.; Vestjens, J.H.; Boer, M. de; Bult, P.; Dijck, J.A.A.M. van; Menke-Pluijmers, M.; Diest, P.J. van; Borm, G.; Tjan-Heijnen, V.C.

    2013-01-01

    BACKGROUND: Non-SN prediction models are frequently used in clinical decision making to identify patients that may not need axillary treatment, but these models still need to be validated by follow-up data. Our purpose was the validation of non-sentinel node (SN) prediction models in predicting

  16. Breast Cancer

    Science.gov (United States)

    Breast cancer affects one in eight women during their lives. No one knows why some women get breast cancer, but there are many risk factors. Risks that ... who have family members with breast or ovarian cancer may wish to be tested for the genes. ...

  17. Application of sentinel lymph node (SLN) biopsy in breast cancer patients%前哨淋巴结活检在乳腺癌中的应用

    Institute of Scientific and Technical Information of China (English)

    Tao Zhang; Baoning Zhang; Hong Wang; Baoping Chen; Xiliang Wei; Ying Fu; Lin Liu; Hongying Yang; Shengzu Chen

    2007-01-01

    Objective: To discuss if the sentinel lymph node (SLN) biopsy is able to reflect the status of the axillary lymph node and the application of this technic in clinic. Methods: Using 99mTc-signed dextran, SLN-biopsy (SLNB) was carried out in182 cases with breast cancer during May 1999 to September 2006. During the operation, y-detector was used for orientation.After the SLNB, a modified radical mastectomy or breast conserving surgery were carried out to the patients, then a particular separate pathological examination of the SLN was made. Results: 178 cases of SLNB were carried out successfully, and the success rate was 97.8%, the out-checked SLN of each case ranged from 1 to 4, with an average of 2.5. All SLN was located at the first level of axilla, sensitivity of the SLN B was 93.4%, specificity was 100%, false negative rate was 6.6%, false positive rate was 0, accuracy was 97.8%, positive predictive value was 100.0%, negative predictive value was 96.7%, and Youden's index was 0.934. Immunohistochemical examination was carried out in 59 cases of SLN, and 14 cases showed the existences of micro-metastasis, however, metastasis had not been found in non-SLN of these cases. Conclusion: SLN is able to reflect the metastasis of the axillary lymph node, and this can suggest the necessity of the axillary dissection in clinic. The SLNB using the isotope-tracer technic is simple and accurate.

  18. Research progress sentinel lymph node micrometastasis in breast cancer%乳腺癌前哨淋巴结微转移研究进展

    Institute of Scientific and Technical Information of China (English)

    陈政; 王晨; 左文述; 杨莉

    2012-01-01

    目的:综述乳腺癌前哨淋巴结(SLN)微转移研究进展和临床应用价值.方法:以“乳腺癌、前哨淋巴结、微转移”为关键词,检索PubMed、万方医学网和中国知网数据库2003-2012年发表的相关文献,共检索到中文文献40条,英文文献226条.纳入标准:1)乳腺癌SLN微转移的病例对照和前瞻性研究;2)SLN微转移检测万法的研究;3)SLN微转移的研究现况.根据纳入标准,共纳入分析30条文献.结果:腋淋巴结阴性的早期乳腺癌,前哨淋巴结活检(SLNB)可以替代腋淋巴结清除术(ALND)判断腋淋巴结状态.连续切片(SS)方法、IHC技术和分子分析技术均可以增加微转移的检出率.SLN微转移可能代表了渐进性的病情进展和非前哨淋巴结转移的高风险性.结论:SLN微转移的临床意义存在争论,随着SLNB技术的成熟,可以提高阳性淋巴结的检出率,进一步提高SLN的预测能力.%OBJECTIVE; To summarize research progress of sentinel lymph node (SLN) micrometastasis in breast cancer and clinical application value. METHODS: Literatures, published from 2003 -2012) were searched.in Medline and PubMed databases, with breast cancer, SLN and micrometastasis as key words. Totally 40 Chinese literatures and 226 English literatures were got. Inclusion criteria;Case control study and prospective study of SLN micrometastasis in breast cancer (Study about research assay of SLN micrometaslasis; Research status of SLN micrometastasis. According to the criteria 30 literatures were involved. RESULTS; In early breast cancer with negative axillary nodes, the SLN biopsy(SL-NB) can be used to replace axillary lymph node dissectionCALND) to determine the status of axillary nodes. The SLN micrometastasis can be detected with serial section.IHC technique,and-molecule technique.besides the conventional pathology assay. CONCLUSION. For SLN micrometastasis in patients with breast cancer prognosis should not be considered to be the same. SLN

  19. ALND for Women with Breast Cancer Micrometastases

    Science.gov (United States)

    A summary of results from a randomized clinical trial that compared axillary lymph node dissection versus no axillary lymph node dissection in women with breast cancer and only micrometastases in their sentinel lymph nodes.

  20. Surgery for Breast Cancer

    Science.gov (United States)

    ... Pregnancy Breast Cancer Breast Cancer Treatment Surgery for Breast Cancer Surgery is a common treatment for breast cancer, ... Relieve symptoms of advanced cancer Surgery to remove breast cancer There are two main types of surgery to ...

  1. Application Value of Methylene Blue Tracer in Sentinel Lymph Node Biopsy in Breast Cancer%亚甲蓝示踪法在乳腺癌前哨淋巴结活检中的应用价值分析

    Institute of Scientific and Technical Information of China (English)

    丁贵坡

    2016-01-01

    Objective To investigate the value of methylene blue in sentinel lymph node biopsy for breast cancer.Methods 125 cases of breast cancer in our hospital were selected as the research object,injected 1%methylene blue injection into the tumor or breast tissue,and then taken sentinel lymph node biopsy and axillary lymph node dissection,analyzed the rate of sentinel lymph node detection,accuracy,sensitivity and false negative.Results The operation of all cases were successful,and there were no adverse reactions and complications after operation.The detection rate of sentinel lymph nodes was 93.6%,the accuracy rate was 92%,the sensitivity was 87.3%,and the false negative rate was 14.5%.Conclusion Methylene blue has important value in sentinel lymph node biopsy for breast cancer.%目的探讨亚甲蓝示踪法在乳腺癌前哨淋巴结活检中的应用价值。方法选取我院确诊收治的125例乳腺癌患者作为研究对象,选择1%亚甲蓝注射液作为示踪剂,注射于肿瘤周围或乳腺组织内,然后行前哨淋巴结活检术和腋窝淋巴结清扫术,分析前哨淋巴结检出率、准确率、敏感度及假阴性率。结果本组125例患者手术均取得成功,术后未出现不良反应和并发症。前哨淋巴结检出率为93.6%,准确率为92.0%,敏感度为87.3%,假阴性率为14.5%。结论亚甲蓝示踪法在乳腺癌前哨淋巴结活检中具有重要的价值。

  2. Association of occult metastases in sentinel lymph nodes and bone marrow with survival of women with early-stage invasive breast cancer

    Science.gov (United States)

    Giuliano, Armando E.; Hawes, Debra; Ballman, Karla V.; Whitworth, Pat W.; Blumencranz, Peter W.; Reintgen, Douglas S.; Morrow, Monica; Leitch, A. Marilyn; Hunt, Kelly K.; McCall, Linda M.; Abati, Andrea; Cote, Richard

    2017-01-01

    Context Immunochemical staining of sentinel lymph nodes (SLNs) and bone marrow identifies breast cancer metastases not seen with routine pathologic or clinical examination. Objective To determine the association between survival and metastases detected by immunochemical staining of SLNs and bone marrow from patients with early-stage breast cancer. Design, Setting, and Patients From May 1999 to May 2003, 126 sites in the American College of Surgeons Oncology Group Z0010 trial enrolled women with clinical T1–T2, N0, M0 invasive breast carcinoma in a prospective observational study. Interventions All patients underwent breast-conserving surgery and SLN dissection; bone marrow aspiration at the time of operation was initially optional and subsequently mandatory (March 2001). SLN specimens (hematoxylin-eosin negative) and bone marrow specimens were sent to a central laboratory for immunochemical staining; treating clinicians were blinded to results. Main Outcome Measures Overall survival (primary end point) and disease-free survival (a secondary end point). Results Of 5119 (98.3%) SLN specimens, 3904 (76.3%) were tumor-negative by hematoxylin-eosin staining. Of 3326 SLN specimens examined by immunohistochemistry, 349 (10.5%) were tumor-positive. Of 3413 bone marrow specimens examined by immunocytochemistry, 104 (3.0%) were positive. At a median follow-up of 6.3 years (through April 2010), 435 patients had died and 376 had disease recurrence. Immunohistochemical evidence of SLN metastases was not significantly associated with overall survival (5-year rates: 95.7% (95% CI, 95.0%–96.5%) for immunohistochemical positive and 95.1% (95% CI, 92.7%–97.5% for immunohistochemical negative disease, P=0.64), unadjusted hazard ratio [HR], 0.90; 95% confidence interval [CI], 0.59–1.39; P=.64). Bone marrow metastases were associated with decreased overall survival (5-year rates: 95.0% (95% CI, 94.3%–95.8%) and 90.1% (95% CI, 84.5%–96.1%), respectively (P=.01) (unadjusted

  3. The FLARE™ Intraoperative Near-Infrared Fluorescence Imaging System: A First-in-Human Clinical Trial in Breast Cancer Sentinel Lymph Node Mapping

    Science.gov (United States)

    Troyan, Susan L.; Kianzad, Vida; Gibbs-Strauss, Summer L.; Gioux, Sylvain; Matsui, Aya; Oketokoun, Rafiou; Ngo, Long; Khamene, Ali; Azar, Fred; Frangioni, John V.

    2009-01-01

    Background Invisible NIR fluorescent light can provide high sensitivity, high-resolution, and real-time image-guidance during oncologic surgery, but imaging systems that are presently available do not display this invisible light in the context of surgical anatomy. The FLARE™ imaging system overcomes this major obstacle. Methods Color video was acquired simultaneously, and in real-time, along with two independent channels of NIR fluorescence. Grayscale NIR fluorescence images were converted to visible “pseudo-colors” and overlaid onto the color video image. Yorkshire pigs weighing 35 kg (n = 5) were used for final pre-clinical validation of the imaging system. A 6-patient pilot study was conducted in women undergoing sentinel lymph node (SLN) mapping for breast cancer. Subjects received 99mTc-sulfur colloid lymphoscintigraphy. In addition, 12.5 µg of indocyanine green (ICG) diluted in human serum albumin (HSA) was used as an NIR fluorescent lymphatic tracer. Results The FLARE™ system permitted facile positioning in the operating room. NIR light did not change the look of the surgical field. Simultaneous pan-lymphatic and SLN mapping was demonstrated in swine using clinically available NIR fluorophores and the dual NIR capabilities of the system. In the pilot clinical trial, a total of 9 SLNs were identified by 99mTc-lymphoscintigraphy and 9 SLNs were identified by NIR fluorescence, although results differed in two patients. No adverse events were encountered. Conclusions We describe the successful clinical translation of a new NIR fluorescence imaging system for image-guided oncologic surgery. PMID:19582506

  4. Impact of axillary nodal metastases on lymphatic mapping and sentinel lymph node identification rate in patients with early stage breast cancer

    Energy Technology Data Exchange (ETDEWEB)

    Pelosi, Ettore [Ospedale S. Giovanni Battista, S.C.D.U. Medicina Nucleare 2, Turin (Italy); Universita Torino, Dottorato di Ricerca Radioimmunolocalizzazione dei Tumori Umani, Turin (Italy); Ala, Ada; Bussone, Riccardo [Ospedale S. Giovanni Battista, Reparto di Chirurgia Oncologica 10, Turin (Italy); Bello, Marilena; Douroukas, Anastasios; Varetto, Teresio [Ospedale S. Giovanni Battista, S.C.D.U. Medicina Nucleare 2, Turin (Italy); Migliaretti, Giuseppe [Universita di Torino, Dipartimento di Sanita Pubblica e Microbiologia, Turin (Italy); Berardengo, Ester [Ospedale S. Giovanni Battista, Servizio di Anatomia Patologica 4, Turin (Italy); Bisi, Gianni [Ospedale S. Giovanni Battista, S.C.D.U. Medicina Nucleare 2, Turin (Italy); Universita di Torino, Dipartimento di Medicina Interna, SCDU Medicina Nucleare 2, Turin (Italy)

    2005-08-01

    The aim of this study was to define the impact of the presence of axillary nodal metastases on lymphatic mapping and sentinel lymph node (SLN) identification rate in patients with early breast cancer. Two hundred and forty-six lymphatic mapping procedures were performed with both labelled nanocolloid and blue dye, followed by SLN biopsy and/or complete axillary dissection. The following parameters were recorded: patient's age, tumour laterality and location, tumour size, tumour histology, tumour stage, tumour grade, lymphovascular invasion, radiotracer injection site (subdermal-peritumoural/peri-areolar), SLN visualisation at lymphoscintigraphy, SLN metastases (presence/absence, size) and other axillary metastases (presence/absence, number). Discriminant analysis was used to analyse the data. SLNs were identified by labelled nanocolloid alone in 94.7% of tumours, by blue dye alone in 93.5% and by the combined technique in 99.2%. Discriminant analysis showed the gamma probe SLN identification rate to be significantly limited by the presence of axillary nodal metastases. In particular, the size of SLN metastases and the number of other axillary metastases were the most important variables in reducing the gamma probe SLN identification rate (p=0.004 and p=0.002, respectively). On the other hand, high tumour grade was the only parameter limiting the blue dye SLN identification rate. The accuracy of lymphatic mapping with labelled nanocolloid is limited by the presence of axillary nodal metastases, and particularly by the degree of SLN tumoural invasion and the presence and number of other axillary nodal metastases. Neither of these elements seems to interfere with the blue dye identification rate. The combination of the two tracers maximises the SLN identification rate. (orig.)

  5. Visualisation of sentinel lymph node with indium-based near infrared emitting Quantum Dots in a murine metastatic breast cancer model.

    Directory of Open Access Journals (Sweden)

    Marion Helle

    Full Text Available Due to its non-invasiveness, high temporal resolution and lower cost, fluorescence imaging is an interesting alternative to the current method (blue dye and radiocolloid of sentinel lymph node (SLN mapping in breast cancer. Near-infrared (NIR emitting cadmium-based Quantum Dots (QDs could be used for this purpose; however, their wide application is limited because of the toxicity of heavy metals composing the core. Our recent work demonstrated that indium-based QDs exhibit a weak acute local toxicity in vivo compared to their cadmium-based counterparts. In the present study we confirmed the weak toxicity of CuInS(2/ZnS QDs in different in vitro models. Further in vivo studies in healthy mice showed that In-based QDs could be visualised in SLN in a few minutes after administration with a progressive increase in fluorescence until 8 h. The quantity of indium was assessed in selected organs and tissues by inductively coupled plasma - mass spectroscopy (ICP-MS as a function of post-injection time. QD levels decrease rapidly at the injection point in the first hours after administration with a parallel increase in the lymph nodes and to a lesser extent in the liver and spleen. In addition, we observed that 3.5% of the injected indium dose was excreted in faeces in the first 4 days, with only trace quantities in the urine. Metastatic spread to the lymph nodes may hamper its visualisation. Therefore, we further performed non-invasive fluorescence measurement of QDs in SLN in tumour-bearing mice. Metastatic status was assessed by immunohistology and molecular techniques and revealed the utmost metastatic invasion of 36% of SLN. Fluorescence signal was the same irrespective of SLN status. Thus, near-infrared emitting cadmium-free QDs could be an excellent SLN tracer.

  6. A tattoo pigmented node and breast cancer.

    Science.gov (United States)

    Soran, A; Kanbour-Shakir, A; Bas, O; Bonaventura, M

    2014-01-01

    Over the last decade, the axillary SLNB has replaced routine ALND for clinical staging in early breast cancer. Studies describe a potential pitfall in the identification of a true sentinel node during surgery due to lymph node pigmentation secondary to migration of tattoo dye. These pigmented “pseudo-sentinel” nodes, if located superficially in the axilla, may mimic the blue sentinel node on visual inspection, therefore missing the true sentinel node and potentially understaging the patient. Here, we present a case report of a breast cancer patient with a tattoo and discuss the importance of tattoo pigment in the LN (Fig. 1, Ref. 8).

  7. Intraoperative injection of technetium-{sup 99m}-dextran 500 for the identification of sentinel lymph node in breast cancer; Injecao intraoperatiria de dextran-500-{sup 99m}-tecnecio para identificacao do linfonodo sentinela em cancer de mama

    Energy Technology Data Exchange (ETDEWEB)

    Delazeri, Gerson Jacob, E-mail: gersonjacob@gmail.co [Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS (Brazil). Programa de Pos-Graduacao em Medicina e Ciencias Medicas; Xavier, Nilton Leite [Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS (Brazil). Fac. de Medicina. Dept. de Ginecologia e Obstetricia; Menke, Carlos Henrique; Bittelbrunn, Ana Cristina [Hospital de Clinicas (HCPA), Porto Alegre, RS (Brazil). Servico de Mastologia; Spiro, Bernardo Leao [Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS (Brazil). Fac. de Medicina. Dept. de Radiologia; Mosmann, Marcos Pretto [Hospital de Clinicas (HCPA), Porto Alegre, RS (Brazil). Servico de Medicina Nuclear; Graudenz, Marcia Silveira [Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS (Brazil). Dept. de Patologia

    2010-07-01

    Purpose: to determine the efficacy of intraoperative injection of Dextran-500-{sup 99m}-technetium (Tc) for the identification of the sentinel lymph node (SLN) in breast cancer and analyze time to label the SLN in the axillary region. Methods: a prospective study between April 2008 and June 2009, which included 74 sentinel lymph node biopsies (SLNB) in patients with breast cancer in stages T1N0 and T2N0. After induction of anesthesia, 0.5 to 1.5 mCi of Dextran-500-{sup 99m}-Tc filtered 0.22 {mu}m in a volume of 5 mL was injected intraoperative using the subareolar technique for SLNB. After labeling with the radioisotope, 2 mL of patent blue was injected. The time elapsed between injection and the axillary hot spot, the in vivo and ex vivo counts of the hottest nodes, the background count, and the number of SLN identified were documented. Data were analyzed using descriptive statistics with SPSS program, version 18. Results: we identified the SLN in 100% of cases. The rate of SLN identification with the probe was 98% (73/74 cases). In one case (1.35%) the SLN was labeled only with the blue dye. The mean dose of radioisotope injected was 0.97{+-}0.22 mCi. The average time to label the SLN was 10.7 minutes ({+-}5.7 min). We identified on average of 1.66 SLN labeled with the radioisotope. Conclusion: the procedure for SLN identification with an intraoperative injection of the radioisotope is oncologically safe and comfortable for the patient, providing agility to the surgical team. (author)

  8. Sentinel-lymph node procedure in breast, uterine cervix, prostate, vulva and penile cancers: Practical methodology; La pratique de la technique du ganglion sentinelle dans diverses indications: sein, col uterin, prostate, vulve et verge. Methodologie pratique

    Energy Technology Data Exchange (ETDEWEB)

    Brenot-Rossi, I. [Centre de Lutte Contre le Cancer, Institut Paoli-Calmettes, Service de Medecine Nucleaire, 13 - Marseille (France)

    2008-08-15

    The nodal status is the strongest prognostic factor in early stage cancers. The sentinel-lymph node (S.L.N.) is defined as the first draining lymph node of an organ; the lymph node status is determined by the histological results of S.L.N.. The lymphadenectomy, with high morbidity, is realised only in case of metastatic S.L.N.. The S.L.N. identification, in most of cases, is performed using the combination of blue dye and radiocolloid {sup 99m}Tc injections. The purpose of this article is to give some practical details about the S.L.N. isotopic procedure in breast cancer, vulva and penile cancer, uterine cervix and prostate cancer. (author)

  9. What doctors and patients think about false-negative sentinel lymph nodes in vulvar cancer

    NARCIS (Netherlands)

    de Hullu, J.A.; Ansink, A.C.; Tijmstra, T.; van der Zee, A. G. J.

    2001-01-01

    The sentinel lymph node procedure is a relatively new, minimally-invasive method for the assessment of nodal status in malignancies such as breast cancer, cutaneous melanoma and vulvar cancer. Although highly accurate, this new method is inevitably associated with a certain false-negative rate, poss

  10. The molecular subtype classification is a determinant of sentinel node positivity in early breast carcinoma.

    Directory of Open Access Journals (Sweden)

    Fabien Reyal

    Full Text Available INTRODUCTION: Several authors have underscored a strong relation between the molecular subtypes and the axillary status of breast cancer patients. The aim of our work was to decipher the interaction between this classification and the probability of a positive sentinel node biopsy. MATERIALS AND METHODS: Our dataset consisted of a total number of 2654 early-stage breast cancer patients. Patients treated at first by conservative breast surgery plus sentinel node biopsies were selected. A multivariate logistic regression model was trained and validated. Interaction covariate between ER and HER2 markers was a forced input of this model. The performance of the multivariate model in the training and the two validation sets was analyzed in terms of discrimination and calibration. Probability of axillary metastasis was detailed for each molecular subtype. RESULTS: The interaction covariate between ER and HER2 status was a stronger predictor (p = 0.0031 of positive sentinel node biopsy than the ER status by itself (p = 0.016. A multivariate model to determine the probability of sentinel node positivity was defined with the following variables; tumour size, lympho-vascular invasion, molecular subtypes and age at diagnosis. This model showed similar results in terms of discrimination (AUC = 0.72/0.73/0.72 and calibration (HL p = 0.28/0.05/0.11 in the training and validation sets. The interaction between molecular subtypes, tumour size and sentinel nodes status was approximated. DISCUSSION: We showed that biologically-driven analyses are able to build new models with higher performance in terms of breast cancer axillary status prediction. The molecular subtype classification strongly interacts with the axillary and distant metastasis process.

  11. Breast cancer screening

    Science.gov (United States)

    Mammogram - breast cancer screening; Breast exam - breast cancer screening; MRI - breast cancer screening ... performed to screen women to detect early breast cancer when it is more likely to be cured. ...

  12. Prone decubitus dual incidence dynamic lymphoscintigraphy for sentinel lymph node localization in breast cancer; Lymphoscintigraphie dynamique en decubitus ventral et double incidence pour la localisation du ganglion sentinelle des cancers du sein

    Energy Technology Data Exchange (ETDEWEB)

    Gremillet, E.; Soler, C.; Champailler, A.; Griot, A.; Berger, E.; Griot, J.P.; Villard, P.; Bouteille, C. [Centre Hospitalier Prive de la Loire, 42 - Saint-Etienne (France)

    2000-09-01

    The sentinel lymph mode (SLN) technique in breast cancer is aimed to avoid useless axillary lymph node dissection (ALND). We present here our experience in a series of 42 patients. After some protocol evolutions imposed by the first results, 37 patients were similarly studied: 4 to 6 peritumoral injections (0,75 ml sulfur colloid labeled with {sup 99m}Tc) were immediately followed by local gentle massage for 5 min, and then by dynamic imaging (anterior and lateral simultaneously) in prone decubitus with pending breast. Then the SLN was skin-land-marked in surgical position (dorsal decubitus) in two incidences (typically anterior and lateral); SLN localisation on ventral decubitus images directed additional actions as necessary: pulling the breast, oblique incidence. Upon surgery, after primary lesion malignancy confirmation, the SLN was electively dissected and then the usual ALND was performed. If we exclude from analysis the 4 cases of previous lumpectomy (among which we had one total lack of tracer migration and one prediction error), the final diagnostic results were perfect: lympho-scintigraphic and per-operative SLN detection were 100%, predictive error was 0%. This result seems to be mainly due to prone decubitus imaging which moves away peritumoral activity from axilla and thus makes easier final land-marking in dorsal decubitus. (author)

  13. 乳腺癌前哨淋巴结活检术学习曲线研究%Reserach of learing curve of sentinel lymph node biopsy in breast cancer

    Institute of Scientific and Technical Information of China (English)

    陈秀春; 赵英智; 郝凯峰; 张明芳; 仲广生

    2013-01-01

    Objective To evaluate the learning curve and the efficacy of sentinel lymph node biopsy (SLNB) by the breast surgeon in the existing medical conditions.Methods Forty cases of breast tumor without axillary lymph node (ALN) by palpation were enrolled in this study.And using the methylene blue as the tracer agent,All patients were treated by segment resection plus axillary lymph node dissection (ALND).Biopsies of sentinel lymph nodes and axitlary lymph nodes were taken in all patients.Results The SLN were detected in 38 patients,11 cases has metasis and 27 cases has no metasis,the accurate rate of SLNB was 95 %,1 case was negative detected by the rapid pathology but positive by the routine pathology,its false negative rate was 9.09% (1/11).There was no significant difference between the effect of detection of metastasis by sentinel lymph node or axillary lymph node biopsy.Conclusion The SLN of the breast cancer can accurately reflect the status of the patients with armpit lymph node,SLNB replacing ALND will be a standard handler for the early stage breast cancer without ALN by palpation.%目的 探讨乳腺外科医生前哨淋巴结活检术(SLNB)的学习曲线,分析影响学习曲线的因素,以便SLNB在临床上广泛开展.方法 以40例临床体检腋窝淋巴结(ALN)阴性,可手术乳腺癌患者作为研究对象,所有患者均单独采用美蓝染色剂作为前哨淋巴结(sentinel lymphnode,SLN)示踪剂,常规行SLNB活检和ALND(腋淋巴结清扫术).结果 本组共有38例患者找到SLN,成功率为95.0%,其中病理报告SLN癌性转移者11例,无转移27例,1例SLN冰冻阴性,常规病理阳性,假阴性率为9.1% (1/11).SLNB与ALND转移检测比较效果相一致,准确率高,统计无差异性.结论 应用美蓝进行SLNB能替代ALND成为临床腋淋巴结阴性早期乳腺癌患者的标准处理模式.

  14. Sentinel node techniques in cancer of the vulva.

    Science.gov (United States)

    de Hullu, Joanne A; van der Zee, Ate G J

    2003-02-01

    The sentinel lymph node procedure, with the combined technique (preoperative lymphoscintigraphy with (99m)Technetium-labeled Nanocolloid and Patente Blue V ), is a promising staging technique for patients with vulvar cancer. The clinical implementation of the sentinel lymph node procedure and the role of additional histopathologic techniques of the sentinel lymph nodes are under investigation.

  15. [Therapeutic advances in breast cancer].

    Science.gov (United States)

    Pestalozzi, B C

    2006-04-01

    The treatment of breast cancer has made significant improvements during the past ten years. For early breast cancer with a clinically negative axilla sentinel node biopsy has become the preferred approach. For endocrine therapy of postmenopausal patients the selective aromatase inhibitors have become standard in metastatic as well as in early breast cancer. Trastuzumab (Herceptin) plays an important role in the treatment of HER2-positive breast cancer in the metastatic and since 2005 also in the adjuvant setting. When chemotherapy is used to treat metastatic breast cancer drug combinations are superior to monotherapy only in terms of response rates. By contrast, in the adjuvant setting combination drug therapy is the standard. New methods of tissue analysis including expression patterns of mRNA and proteins are promising research strategies to further advance the field.

  16. Linfonodo sentinela: um novo conceito no tratamento cirúrgico do câncer de mama Sentinel lymph-node: a new concept in surgical treatment of breast cancer

    Directory of Open Access Journals (Sweden)

    Cícero de Andrade Urban

    2001-06-01

    Full Text Available O linfonodo sentinela é o primeiro linfonodo que recebe a drenagem linfática proveniente do câncer de mama. A sua detecção tem a finalidade de predizer o estado da axila e evitar o esvaziamento axilar nos pacientes sem comprometimento metastático. Os autores realizaram uma ampla revisão da literatura, envolvendo os aspectos cirúrgicos, de Medicina Nuclear e de Anatomia Patológica do linfonodo sentinela. Muitos estudos demonstraram a eficácia do linfonodo sentinela em predizer o comprometimento axilar. Entretanto, existem várias técnicas empregadas para a identificação desse linfonodo, sem haver ainda um consenso em relação ao método mais adequado e reproduzível. A associação do corante vital com o probe, até o presente, é a que tem apresentado os melhores resultados. Também não existe uma padronização do exame patológico intra-operatório do linfonodo sentinela e os índices de falso-negativos encontrados são bastante variáveis. A biópsia do linfonodo sentinela pode oferecer uma alternativa segura à dissecção axilar e com menos efeitos colaterais nos pacientes com axila clinicamente negativa. Entretanto alguns pontos conflitantes devem ser resolvidos antes que o método passe a ser utilizado na prática com o câncer de mama. O objetivo desse trabalho foi discutir os principais aspectos envolvidos no desenvolvimento e na aplicação dessa técnica.The sentinel lymph node is the first in line to receive lymphatic flow from a primary site in breast cancer. The purpose of this study is to review the most recently results in the literature with this technique. This is a comprehensive review in surgical, nuclear medicine, and pathological aspects of sentinel lymph node in breast cancer. Several reports have demonstrated the accurate prediction of axillary nodal status with sentinel lymph node technique. However, a wide range of different methods and materials has been employed for lymphatic mapping. The association of

  17. Breast Cancer Treatment

    Science.gov (United States)

    ... Breast & Gynecologic Cancers Breast Cancer Screening Research Breast Cancer Treatment (PDQ®)–Patient Version General Information About Breast Cancer ... clinical trials before, during, or after starting their cancer treatment. Some clinical trials only include patients who have ...

  18. Breast Cancer Research Update

    Science.gov (United States)

    ... JavaScript on. Feature: Breast Cancer Breast Cancer Research Update Winter 2017 Table of Contents National Cancer Institute ... Addressing Breast Cancer's Unequal Burden / Breast Cancer Research Update Winter 2017 Issue: Volume 11 Number 4 Page ...

  19. Other Considerations for Pregnancy and Breast Cancer

    Science.gov (United States)

    ... Cancer Patient Breast Cancer Patient Breast Cancer Treatment Male Breast Cancer Treatment Breast Cancer Treatment & Pregnancy Breast Cancer Prevention Breast Cancer Screening Health Professional Breast Cancer Treatment Male ... Treatment Breast Cancer Treatment & Pregnancy Breast Cancer Prevention ...

  20. Breast cancer

    CERN Multimedia

    2002-01-01

    "Cancer specialists will soon be able to compare mammograms with computerized images of breast cancer from across Europe, in a bid to improve diagnosis and treatment....The new project, known as MammoGrid, brings together computer and medical imaging experts, cancer specialists, radiologists and epidemiologists from Bristol, Oxford, Cambridge, France and Italy" (1 page).

  1. 亚甲蓝染色法乳腺癌前哨淋巴结活检术100例分析%Methylene blue staining method in the sentinel lymph node biopsy in 100 cases of early breast cancer

    Institute of Scientific and Technical Information of China (English)

    于昌盛; 陈剑平; 王亚兵

    2014-01-01

    目的 探讨分析前哨淋巴结活检术在乳腺癌手术中的应用价值及存在的问题.方法 回顾分析皖南医学院弋矶山医院甲乳外科2012年1月-2013年12月确诊为早期乳腺癌并使用亚甲蓝染色法行前哨淋巴结活检的100例女性患者的病例资料,对前哨淋巴结及腋窝淋巴结的病理结果进行对比分析.结果 100例患者中,92例可见SLN,成功率92%,共检出前哨淋巴结217个,每例1~6枚,平均2.4枚,92例均行ALND.其中,SLN阴性ALN阴性的58例,SLN阴性ALN阳性的4例,SLN阳性ALN阳性的30例,所有患者没有出现过敏反应.SLNB的假阳性率为0,假阴性率为11.8%,灵敏度88.3%,特异度100%,诊断符合率为95.7%.结论 SLNB在早期乳腺癌手术中较传统的ALND有明显的优势,对于SLN阴性的病例可不行ALND.%Objective To analysis the application value and the existing problems of sentinel lymph node biopsy in breast cancer surgery.Methods Pathological findings were retrospectively analysised in 100 female cases of breast cancer,who were diagnosed with early breast cancer and used blue dye in sentinel lymph node biopsy.Results Among 100 cases,92 cases were found SLNS,that the detected rate was 92%.Detected 217 sentinel lymph node,every case has 1 to 6 node,with the average of 2.4.Nintg-two cases were performed ALND.Among them,the SLNS negative detected 58 cases of ALN feminine,SLNS negative ALN detected positive 4 cases,30 cases of SLNS positive ALN positive detected.All of the patients did not appear allergic reaction.SLNB false positive rate of O,the false negative rate was 11.8%,sensitivity 88.3%,specific degree of 100%,the diagnostic coincidence rate was 95.7%.Conclusions Compared with the conventional axillary lymph node dissection,the sentinel lymph node biopsy has obvious advantages in early breast cancer surgery.For the cases of sentinel lymph node negative,there was no necessary to do the axillary lymph node dissection.

  2. 染料法乳腺癌前哨淋巴结活检的多因素分析%Multivariate analysis of sentinel lymph node biopsy in breast cancer using blue dye methods

    Institute of Scientific and Technical Information of China (English)

    龚益平; 孙青海; 邵军; 程洪涛; 夏和顺; 熊斌

    2009-01-01

    Objective: Blue dye was one of the methods for sentinel lymph node biopsy in breast cancer, but the success rate was affected by multiple factors. This study was to determine the related factors contributing to the success of sentinel lymph node biopsy in breast cancer using blue dye method. Method:From Jan. 2007 to Aug.2008, sentinel lymph node biopsy was performed by periareolarly injecting 1% methylene blue in 141 breast cancer patients followed by axillary clearance. Pathological diagnosis was performed for all of the lymph nodes by conventional HE staining. Unconditional logistic regression was applied to make both univariate and multiva-riate analysis. Results:Sentinel lymph node was successfully detected in 126 patients. But the biopsy was failed in the 15 patients. The success rate was 89.4% and the false negative rate was 6.82%. Univariate analysis showed that success rate of biopsy was in association with patients' age, body mass index (BMI), tumor size, preoperative axillary node's status, pathological grade as well as ≥4 positive axillary lymph nodes involved. Multivariate analysis indicated that the patients'age (OR=4.587, P=0.024), BMI (OR=4.882, P=0.011) as well as 4 or more of the axillary nodes involved (OR=3.143, P=0.013) were independent predicting factors for the success of sentinel lymph node biopsy. Conclusions:Methylene blue dyeing is a reliable method for sentinel lymph node biopsy. The rate of success is associated with patients' age, BMI as well as the number of metastases in axillary lymph nodes.%目的:染料法是乳腺癌前哨淋巴结活检的方法之一,其成功率受多种因素影响.本研究旨在探讨影响染料法乳腺癌前哨淋巴结活检成功率的相关因素.方法:2007年1月-2008年8月乳腺癌患者141例,于乳晕周围注射1%亚甲蓝,实施前哨淋巴结活检,随后行腋窝淋巴结清扫,常规HE染色进行病理诊断.采用非条件logistic回归进行单因素和多因素分析.结果:126

  3. [Treatment of elderly patients with breast cancer

    DEFF Research Database (Denmark)

    Paaschburg, B.; Pedersen, A.; Tuxen, M.K.;

    2008-01-01

    The latest investigations have been searched in order to present new guidelines for the treatment of elderly patients with primary breast cancer. It is concluded that breast-conserving surgery should be offered as well as the sentinel node technique. Axillary lymph node dissection is not necessary...

  4. 乳腺癌前哨淋巴结不同检测方法效果研究%Research on the Effects of Different Test Methods for Sentinel Lymph Node(SLN) of Breast Cancer

    Institute of Scientific and Technical Information of China (English)

    董义臣

    2014-01-01

    目的:研究染色法、同位素法、联合法3种不同检测方法对乳腺癌前哨淋巴结检测的影响。方法:选取2007年9月~2013年11月在我院就诊的早期女性乳腺癌患者为研究对象,将患者随机分为3组,蓝染料组、核素组、联合组。比较各组乳腺癌前哨淋巴结活检的成功率、准确率及假阴性率。结果:与单纯使用染料的方法相比,联合法的假阴性率显著性降低,差异有统计学意义。与单用染料组及核素组相比,联合法发现的SLN数较多,但无统计学差异。结论:联合应用染料及同位素示踪较单一方法更能提高前哨淋巴结检测的成功率,降低假阴性率。%Objective: To observe the effects of staining, isotopes and combined tests on Sentinel Lymph Node(SLN) of breast cancer.Methods: Picking women patients in our hospital with early breast cancer as study objects and randomly dividing them into 3 groups as blue dye, nuclide and combined ones to compare the success rates, accuracy rates and false negative rates of each group’s sentinel lymph node biopsy of breast cancer. Result: Compared with that of single dye usage, the combined test group showed a signiifcantly lower false negative rate; Compared with those of single dye usage and nuclide, the combined test group found more SLN number, yet without statistical differences.Conclusion: A combined application of dyes and isotopic tracing shows a better success rate of sentinel lymph node test and a lower false negative rate than single test.

  5. Application of contrast-enhanced ultrasound in showing sentinel lymphatic channels and sentinel lymph nodes of breast cancer%超声造影技术在评估乳腺癌前哨淋巴通道及前哨淋巴结多样性中的应用

    Institute of Scientific and Technical Information of China (English)

    王莹; 巩海燕; 杜丽雯; 李春莲; 栗翠英

    2016-01-01

    目的:探讨超声造影技术在显示乳腺癌前哨淋巴通道(SLC)及前哨淋巴结(SLN)多样性中的应用价值。方法女性乳腺癌患者26例,术前均接受乳晕及深层腺体内注射超声造影剂行超声造影探查SLC和SLN。术中于乳晕及深层腺体内注射亚甲蓝,术后解剖蓝染的SLC和SLN ,并进一步将超声造影探及的SLN及蓝染的SLN送病理检查。结果用超声造影技术,26例患者探及至少1条SLC及1个SLN。探及到3种类型的SLC ,分别为浅层前哨淋巴通道(SSLC)、穿支前哨淋巴通道(PSLC )和深层前哨淋巴通道(DSLC )。探及到5种淋巴引流模式(LDP ),分别为 SSLC、PSLC、SSLC+PSLC、SSLC+DSLC和SSLC+ PSLC+DSLC。超声造影探及的LDP与手术LDP相一致的患者为24例(92.31%)。6例患者探及到分叉的SLC ;3例患者探及到中断的SLC ,且相对应的SLN没有强化;术后病理证实该3例患者腋窝淋巴结均有癌转移。结论超声造影在术前评估乳腺癌SLC和SLN多样性中具有一定的可行性,并且对进一步SLN活检具有指导意义。%Objective To assess the application of contrast-enhanced ultrasonography in showing the variation of sentinel lymphatic channels (SLC) and sentinel lymph nodes(SLN) of breast cancer .Methods The SLC and SLN of 26 women with breast cancer were examined with intradermal and peritumoral injection of contrast microbubbles for ultrasonography before operation .The methylene blue was injected subareolarly and peritumorally during surgery .The SLC and SLN coloured with blue dye were anatomized after operation .The SLN detected by contrast-enhanced ultrasonography and coloured with blue dye were all sent for pathology examination .Results With contrast-enhanced ultrasonography ,at least one SLC and one SLN were detected in all 26 cases .Three types of SLC were detected ,which included superficial sentinel lymphatic channel (SSLC) ,penetrating

  6. 99 Tcm -硫胶体前哨淋巴结检测联合超声在早期乳腺癌前哨淋巴结转移诊断中的临床价值%The clinical significance of 99 Tcm - sulfur colloid for sentinel lymph node examination combined with ultrasound in diagnosis of metasta-sis in sentinel lymph nodes from early breast cancer

    Institute of Scientific and Technical Information of China (English)

    左莉莉; 谷云芝; 王文娟; 甄萍; 孙霞; 尹长恒; 宋德余; 姜玉荣

    2016-01-01

    Objective To explore the clinical significance of diagnostic 99Tcm- sulfur colloid examination for sentinel lymph nodes in combination with color Doppler ultrasound examination for metastasis in sentinel lymph nodes in patients with early breast cancer. Methods A to-tal of 78 patients suspected with early breast cancer had 99 Tcm - sulfur colloid examination and Doppler ultrasounography for sentinel lymph nodes, and they were confirmed by pathological diagnosis. The detection rate of metastasis in sentinel lymph nodes by combination of these 2 kinds of de-tection,and the specificity,sensitivity and accuracy of the joint detection for diagnosing metastasis in sentinel lymph nodes of early breast cancer had been observed. Results The detection rate of 99 Tcm - sulfur colloid examination for metastasis in sentinel lymph nodes was 97. 44%,the detection rate of ultrasonic examination for sentinel lymph nodes was 51. 28%,the degree of diagnostic specificity of ultrasound joint 99 Tcm -sulfur colloid examination for metastasis in sentinel lymph nodes of early breast cancer was 91. 67%,with sensitivity of 91. 67% and accuracy of 92. 31%respectively. Conclusion The detection rate of 99 Tcm - sulfur colloid examination for check of metastasis in sentinel lymph nodes for early breast cancer is higher,and it in combination with ultrasound for the diagnosis of metastasis in sentinel lymph nodes has advantages of high accuracy.%目的探讨99 Tcm -硫胶体前哨淋巴结联合彩色多普勒超声检查在早期乳腺癌前哨淋巴结转移诊断中的临床价值。方法选取疑似早期乳腺癌的患者78例,均进行99 Tcm -硫胶体前哨淋巴结与多普勒超声检查,并经手术病理诊断确诊。观察两种方法单独检测前哨淋巴结的检出率,以及联合检测诊断早期乳腺癌前哨淋巴结转移的特异度、灵敏度和准确性。结果99 Tcm -硫胶体前哨淋巴结检测对前哨淋巴结的检出率为97.44%,超声检查对前

  7. Status of the non-sentinel lymph node metastasis in breast cancer patients with small number of positive sentinel lymph node%乳腺癌低负荷前哨淋巴结阳性对非前哨淋巴结转移的预测分析

    Institute of Scientific and Technical Information of China (English)

    王文彦; 王昕; 王杰; 高纪东; 宣立学

    2016-01-01

    目的:探讨前哨淋巴结(sentinel lymph node,SLN)阳性≤2个乳腺癌非前哨淋巴结(non-sen-tinel lymph node,NSLN)状态及其影响因素。方法回顾性分析88例SLN阳性≤2个的乳腺癌病例资料,分析NSLN状态相关影响因素。结果88例病例资料纳入分析,8例NSLN出现转移(9.09%),方差分析显示肿瘤分期(P=0.046)、组织学分级(P=0.014)、ER状态(P=0.009)在NSLN阳性和阴性2组中分布存在差异, Logistic 多因素分析显示组织学分级是 NSLN 状态的独立影响因素(P=0.016,OR=1.150,95% CI=0.598~7.740)。SLN微转移18例(20.45%),宏转移70例(79.54%),SLN假阴性率10.23%。中位随访时间11个月,无复发、转移、死亡病例。结论低负荷SLN阳性的乳腺癌患者,NSLN转移率较低,NSLN转移受肿瘤分期、组织学分级、ER表达情况等因素影响。%Objective To explore the risk factors and metastasis of non-sentinel lymph node (NSLN) in breast cancer patients with sentinel lymph node metastasis≤2. Methods 88 cases of breast cancer with sentinel lymph node metastasis≤2 were retrospectively analyzed. Factors influencing the status of NSLN were studied. Results 8 cases (9.09%) had NSLN metastasis. Variance analysis showed that tumor stage(P=0.014), histolog-ical grade(P=0.014) and ER statuts(P=0.009) were correlated with NSLN metastasis. Logistic analysis showed that only histological grade was the independent predictor for NSLN metastasis (P=0.016,OR=1.150,95%CI=0.598~7.740).18 cases had micro-metastasis of sentinel lymph node and 70 cases had macro-metastasis of sentinel lymph node. The ratio of false negative SLN was 10.23%. The mean follow-up time was 11 months. There was no case of recurrence, metastasis or death. Conclusions The metastasis rate of NSLN is relatively low in breast cancer patients with small number of positive SLNs. NSLN metastasis is related to tumor stage, histological grade, and ER

  8. Sentinel Node in Oral Cancer

    DEFF Research Database (Denmark)

    Tartaglione, Girolamo; Stoeckli, Sandro J; de Bree, Remco;

    2016-01-01

    PURPOSE: Nuclear imaging plays a crucial role in lymphatic mapping of oral cancer. This evaluation represents a subanalysis of the original multicenter SENT trial data set, involving 434 patients with T1-T2, N0, and M0 oral squamous cell carcinoma. The impact of acquisition techniques, tracer...

  9. Determined with Methylene Blue Sentinel Lymph Node Metastasis of Breast Cancer Clinical Applications%用亚甲蓝判定乳腺癌前哨淋巴结转移的临床应用

    Institute of Scientific and Technical Information of China (English)

    蒋新宇; 林其声; 黎犇犇

    2014-01-01

    ObjectiveTo evaluate the performance and feasibility of sentinel lymph node (SLN) in breast cancer using methylene blue as a tracer.MethodsIn our Hospital, from June 2011 100 patients with cTis~3N0~2M0 underwent SLNB, which is followed by standard axillary dissection. Methylene blue was used to detect the SLN during surgery.ResultsThe sentinel node is successfully identiifed in 91% (91/100) of the patients. The number of sentinel nodes was 201, average 2.20, the sensitivity in the study was 91.00% (91/100), accuracy was 96.70% (88/91), false negative rate 5.66% (3/53), positive predictive value of 100%. ConclusionsThis method using methylene blue as a tracer can accurately ifnd the sentinel lymph node, and can predict axillary lymph node metastasis.%目的:以亚甲蓝为示踪剂探测乳腺癌前哨淋巴结( sentinel lymph node,SLN),评价前哨淋巴结预测腋窝淋巴结转移的准确性。方法研究对象为自2011年6月份起我院普外科收治的100例cTis~3N0~2M0的乳腺癌患者。使用亚甲蓝为示踪剂,进行前哨淋巴结活检,之后行腋窝清扫。结果91例患者中成功地发现了SLN,SLN的数量为201个,平均每例2.20个。SLNB的灵敏度91.00%(91/100),准确率96.70%(88/91),假阴性率5.66%(3/53),阳性预测值为100%。结论使用亚甲蓝作为示踪剂能准确找到前哨淋巴结,并能较好的预测腋窝淋巴结转移情况。

  10. Understanding a Breast Cancer Diagnosis

    Science.gov (United States)

    ... Cancer A-Z Breast Cancer Understanding a Breast Cancer Diagnosis If you’ve been diagnosed with breast cancer, ... Prevention Early Detection and Diagnosis Understanding a Breast Cancer Diagnosis Treatment Breast Reconstruction Surgery Living as a Breast ...

  11. Evaluation of nomograms in early breast cancer

    OpenAIRE

    2015-01-01

    Background and aims: Since the introduction of the sentinel node biopsy in the treatment of early breast cancer, the axillary lymph node dissection became the norm in case of sentinel node métastatic. Although it is associated with an important risk of nervous complications of the upper limb and lymphoedema. The use of scores or abacuses, allowed the deletion of axillary lymph node dissection on patients with good pronostic. Scores and abacuses were developed to estimate the risk of invasion ...

  12. 蓝染料法乳腺癌前哨淋巴结活检的应用价值%Clinical value of sentinel lymph node biopsy in breast cancer with blue dye

    Institute of Scientific and Technical Information of China (English)

    康华峰; 王西京; 刘小旭; 代志军; 薛锋杰; 薛兴欢

    2005-01-01

    目的研究蓝染料法在乳腺癌前哨淋巴结(sentinel lymph node,SLN)活检的应用价值.方法95例期乳腺癌患者,采用亚甲蓝为示踪剂行SLN定位活检,继行腋窝淋巴结清扫,对SLN和非SLN淋巴结分别病理检查.结果SLN检出成功率为97.89%(93/95);准确性为97.85%(91/93);灵敏性为91.67%(22/24);假阴性率为8.33%(2/24);特异性为100%(71/71).结论蓝染料乳晕区皮下注射SLN定位活检方法的成功率高,能较准确地预测腋窝淋巴结状态.%[Objective] To study the value of blue dye method of sentinel lymph nodes (SLN) biopsy in breast cancer and its clinical significance. [Methods] 95 cases of T1~2 breast cancer patients with clinical node-negative underwent intraoperative lymphatic mapping using blue dye, then a complete axillary node dissection were performed, SLN and non-SLN lymph node underwent pathological investigation respectively. [Results] SLN was successfully identified in 97.85% (93/95) patients, accuracy rate was 97.85% (91/93), sensitivity rate was 91.67% (22/24), false negative rate was 8.33%(2/24) and specificity rate was 100%(71/71). [Conclusions] Intraoperative lymphatic mapping using blue dye can accurately identify SLN, and SLN biopsy can accurately predict the condition of axillary nodes.

  13. Lymph Drainage Studied by Lymphoscintigraphy in the Arms after Sentinel Node Biopsy Compared with Axillary Lymph Node Dissection Following Conservative Breast Cancer Surgery

    Energy Technology Data Exchange (ETDEWEB)

    Celebioglu, F.; Perbeck, L.; Frisell, J.; Groendal, E.; Svensson, L.; Danielsson, R. [Dept. of Molecular Medicine and Surgery, Karolinska Inst., Karolinska Univ Hospital Solna, Stockholm (Sweden)

    2007-07-15

    Purpose: To investigate lymphatic drainage as measured by lymphoscintigraphy in the arms of patients undergoing either sentinel lymph node biopsy (SNB) or axillary lymph node dissection (ALND). Material and Methods: From January 2001 to December 2002, 30 patients with unilateral invasive breast carcinoma underwent breast-conserving surgery with SNB and 30 patients with ALND. All patients received radiotherapy to the breast. Lymphoscintigraphy was performed, and skin circulation, skin temperature, and arm volume were measured 2-3 years after radiotherapy. Results: None of the 30 patients who underwent SNB showed any clinical manifestation of lymphedema. Of the 30 patients undergoing ALND, six (20%) had clinical lymphedema, with an arm volume that was >10% larger on the operated than on the non-operated side (P<0.01). Scintigraphically, visual analysis revealed lymphatic dysfunction in three patients, manifested as forearm dermal back flow. Two of these patients also had an increased arm volume. Quantitative analysis showed no differences between the groups, apart from a smaller amount of isotope in the axilla in the ALND group. There was no difference in skin circulation or skin temperature. Conclusion: Our study shows that lymph drainage in the operated arm compared with the non-operated arm was less affected by SNB than by ALND, and that morbidity associated with SNB was lower than with ALND. However, the results do not confirm our hypothesis that lymphoscintigraphy can reveal differences in lymph circulation that are not evident clinically in the form of manifest lymphedema. The most sensitive clinical method of assessing lymph drainage seems to be measurement of arm volume.

  14. A grid matrix-based Raman spectroscopic method to characterize different cell milieu in biopsied axillary sentinel lymph nodes of breast cancer patients.

    Science.gov (United States)

    Som, Dipasree; Tak, Megha; Setia, Mohit; Patil, Asawari; Sengupta, Amit; Chilakapati, C Murali Krishna; Srivastava, Anurag; Parmar, Vani; Nair, Nita; Sarin, Rajiv; Badwe, R

    2016-01-01

    Raman spectroscopy which is based upon inelastic scattering of photons has a potential to emerge as a noninvasive bedside in vivo or ex vivo molecular diagnostic tool. There is a need to improve the sensitivity and predictability of Raman spectroscopy. We developed a grid matrix-based tissue mapping protocol to acquire cellular-specific spectra that also involved digital microscopy for localizing malignant and lymphocytic cells in sentinel lymph node biopsy sample. Biosignals acquired from specific cellular milieu were subjected to an advanced supervised analytical method, i.e., cross-correlation and peak-to-peak ratio in addition to PCA and PC-LDA. We observed decreased spectral intensity as well as shift in the spectral peaks of amides and lipid bands in the completely metastatic (cancer cells) lymph nodes with high cellular density. Spectral library of normal lymphocytes and metastatic cancer cells created using the cellular specific mapping technique can be utilized to create an automated smart diagnostic tool for bench side screening of sampled lymph nodes. Spectral library of normal lymphocytes and metastatic cancer cells created using the cellular specific mapping technique can be utilized to develop an automated smart diagnostic tool for bench side screening of sampled lymph nodes supported by ongoing global research in developing better technology and signal and big data processing algorithms.

  15. Breast Cancer -- Male

    Science.gov (United States)

    ... Home > Types of Cancer > Breast Cancer in Men Breast Cancer in Men This is Cancer.Net’s Guide to Breast Cancer in Men. Use the menu below to choose ... social workers, and patient advocates. Cancer.Net Guide Breast Cancer in Men Introduction Statistics Risk Factors and Prevention ...

  16. 前哨淋巴结活检术在乳腺癌手术治疗中的应用%Clinical application of sentinel lymph node biopsy in breast cancer operation

    Institute of Scientific and Technical Information of China (English)

    山世岩; 屈翔; 张慧明; 高超英

    2014-01-01

    Objective To evaluate the feasibility of sentinel lymph node biopsy(SLNB) by using subareolar injection of methylene blue in breast cancer and predict axillary lymph node staging. Methods A retrospective study was conducted to analyze 60 cases of breast cancer's sentinel lymph node biopsy on the consent of patients in Beijing Fengtai hospital from July 2009 to July 2012. All 60 cases were using methylene blue dye areola injections in subareolar. Axillary lymph node dissection(ALND) in all cases. Results Of 60 cases, 57 patients' sentinel lymph nodes were detected successfully in all 60 cases.Only 3 cases were not detected and 3 periods negative; the detection rate was 95.0%(57/60); the accuracy rate was 94.7%(54/57); the sensitivity was 89.3%(25/28); the false negative rate was 10.7%(3/28). Age, location of tumor, histological type and estrogen receptor status were not associated with intraoperative detection rate of SLN(P>0.05). Conclusion Sentinel lymph node biopsy can accurately predict the axillary lymph nodes of breast cancer.%目的 探讨乳晕下亚甲蓝法前哨淋巴结活检术(SLNB)用于乳腺癌手术治疗的可行性及其对腋窝淋巴结分期的预测情况.方法 回顾性分析2009年7月至2012年7月北京丰台医院普外科所实施的60例行SLNB患者的病历资料.60例患者均于患侧乳晕皮下注射1%亚甲蓝2 ml(分4象限注射,每点注射0.5 ml),并行腋窝淋巴结清扫.结果 60例乳腺癌术中行SLNB病例中57例发现紧急的SLNB,检出率为95.0%.病理检查者发现28例腋窝淋巴结有转移,32例无转移.前哨淋巴结与腋窝淋巴结完全符合者54例,保受阴性者3例.SLNB的准确率为94.7%(54/57),灵敏度为89.3%(25/28),假阴性率为10.7%(3/28).前哨淋巴结检出率与年龄、肿瘤位置、病理类型、雌激素受体无关(P>0.05).结论 乳晕下亚甲蓝法SLNB能准确地预测乳腺癌腋窝淋巴结的转移状态.

  17. Clinical research of sentinel lymph node biopsy in patients with early breast cancers%早期乳腺癌前哨淋巴结活检的临床研究

    Institute of Scientific and Technical Information of China (English)

    祝琴; 孙治君

    2014-01-01

    Objective To perform the sentinel lymph node biopsy (SLNB) in the patients with early breast cancer by the strict screening conditions and to analyze the accuracy of the sentinel lymph node for predicting the axillary lymph node status .Methods SLNB combined with methylene blue dye and isotope was performed in 266 cases of early breast cancer treated in this department with full treatment courses .Then the axillary lymph node dissection(ALND) was routinely conducted .With the pathological ex-amination as the standard ,the related factors affecting SLNB were analyzed .Results The detection rate of SLN ,accuracy rate ,sen-sitivity and the false negative rate were 100% ,98 .5% ,95 .56% and 4 .44% respectively ;the accuracy of SLN was significantly cor-related with the tumor size ,pathological type and axillary lymph node status(P<0 .01);the false negative rate of SLN was related with the tumor location(P<0 .05) .Conclusion The combination of methylene blue dye and isotope used in SLNB is feasible in the patients with early breast cancer ,SLN could accurately predict the axillary lymph node metastasis status .%目的:通过严格的筛查条件对早期乳腺癌行前哨淋巴结活检(SLNB),分析前哨淋巴结(SLN)对腋窝淋巴结状态预测的准确性。方法联合核素和亚甲蓝对266例全程在该科治疗的早期乳腺癌行SLNB ,然后行常规腋窝淋巴结清扫,以病理检查为标准了解影响SLNB的相关因素。结果 SLN检出率100%,准确率98.50%,假阴性率4.44%,灵敏度95.56%;SLN的准确率与肿块大小、病理类型及腋窝淋巴结情况有相关性(P<0.01);SLN的假阴性率和肿块的位置相关(P<0.05)。结论核素联合亚甲蓝在早期乳腺癌患者中行SLNB是可行的,SLNB可准确预测腋窝淋巴结的转移状态。

  18. Application of Lymphoscintigraphy and Blue Dye Method in Sentinel Lymph Node Location of Breast Cancer%淋巴显像和蓝染法在乳腺癌前哨淋巴结定位中的应用

    Institute of Scientific and Technical Information of China (English)

    黄秒; 肖国有; 姚忠强; 张雪辉; 李党生; 邓李燕

    2011-01-01

    Objective To evaluate the clinical application of lymphoscintigraphy and blue dye method in sentinel lymph node(SLN) location of breast cancer. Methods One hundred and ninety-one breast cancer patients underwent 99mTc-DX lymphoscintigraphy and blue dye method to locate sentinel lymph node, and then underwent sentinel lymph node biopsy (SLNB). Results The detectable rate of SLN for lymphoscintigraphy was 86. 9% (166/191), the rate for blue dye method was 83. 8% (160/191), and the rate for lymphoscintigraphy combined with blue dye method was 96. 3% (184/191). The positive rate of combined detectable method was significantly higher than that of lymphoscintigraphy or blue dye method (P<0. 05). There was no significant difference of detectable rate between lymphoscintigraphy and blue dye method. The detectable rate was unrelated to patient's age, medical history, biopsy, tumor location,clinical stage, pathology and immunohistochemical result(P>0. 05). Conclusion Lymphoscintigraphy or blue dye method or combined method could be used to locate SLN, furthermore the combined method was the best one to identify SLNB.%目的 探讨淋巴显像和蓝染法在乳腺癌前哨淋巴结(sentinel lymph node,SLN)定位中的应用.方法 对191例乳腺癌患者应用99mTc-右旋糖苷(99mTc-DX)淋巴显像及美蓝蓝染法进行SLN识别与定位,并行前哨淋巴结活检术(sentinel lymph node biopsy,SLNB).结果 淋巴显像方法探测SLN的检出率为86.9%(166/191),蓝染法为83.8%(160/191),淋巴显像联合蓝染法为96.3%(184/191);联合法检出率比淋巴显像、蓝染法的检出率高(P0.05);术前淋巴显像是否成功检出SLN与患者年龄、病史长短、显像前是否活检过、原发肿瘤部位、临床分期、病理类型、免疫组织化学染色结果均无关(P>0.05).结论 淋巴显像和蓝染法均能较准确的识别与定位乳腺癌SLN,淋巴显像联合蓝染法可以提高SLN的检出率,可用于指导SLNB.

  19. 吲哚菁绿在乳腺癌前哨淋巴结活检中的应用%Application of indocyanine green in sentinel lymph node biopsy for breast cancer

    Institute of Scientific and Technical Information of China (English)

    唐巍; 张显岚; 曾繁余

    2016-01-01

    目的:探讨吲哚菁绿(ICG)在乳腺癌前哨淋巴结活检(SLNB)中的应用价值。方法对我院2013年1月至2015年12月160例乳腺癌患者进行检测分析,随机分为亚甲蓝组、亚甲蓝联合吲哚菁绿组,分别为65例和95例。比较2组患者的检出成功率、准确率和假阴性率。结果亚甲蓝联合吲哚菁绿组的检出成功率和准确性明显高于亚甲蓝组,差异具有统计学意义(P <0.05);亚甲蓝联合吲哚菁绿组的假阴性率明显低于亚甲蓝组,差异具有统计学意义(P <0.05);亚甲蓝联合吲哚菁绿组检出的前哨淋巴结(2.9±0.9)枚/例,明显多于亚甲蓝组(1.9±0.5)枚/例,差异具有统计学意义(P <0.05);亚甲蓝联合吲哚菁绿组的手术用时明显短于亚甲蓝组。结论吲哚菁绿应用于乳腺癌前哨淋巴结检测可降低其假阴性率,提高乳腺癌的诊断水平。%Objective To explore the application value of indocyanine green (ICG)in sentinel lymph node biopsy(SLNB)for breast cancer.Methods A total of 160 patients with breast cancer in our hospital from January 2013 to December 2015 were analyzed,who were randomly divided into methylene blue group(n =65)and methylene blue plus ICG group(n =95).The success rate of detection,accuracy and false negative rate between two groups were compared.Results The success rate of detection and accuracy in methylene blue plus ICG group was significantly higher than thoase in methylene blue group,with statistically significant difference(P <0.05).The false negative rate of methylene blue plus ICG group was significantly lower than that of methylene blue group,with statistically significant difference (P <0.05).The number of sentinel lymph node in methylene blue plus ICG group was (2.9 ±0.9)/case which was more than (1.9 ± 0.5)/case in methylene blue group ,with statistically significant difference(P <0.05).The length of opertion of methylene

  20. Surgical sentinel lymph node biopsy in early breast cancer. Could it be avoided by performing a preoperative staging procedure? A pilot study.

    Science.gov (United States)

    Testori, Alberto; Meroni, Stefano; Moscovici, Oana Codrina; Magnoni, Paola; Malerba, Paolo; Chiti, Arturo; Rahal, Daoud; Travaglini, Roberto; Cariboni, Umberto; Alloisio, Marco; Orefice, Sergio

    2012-09-01

    The aim of this pilot trial was to study the feasibility of sentinel node percutaneous preoperative gamma probe-guided biopsy as a valid preoperative method of assessment of nodal status compared to surgical sentinel lymph node biopsy. This prospective study enrolled 10 consecutive patients without evidence of axillary lymph node metastases at preoperative imaging. All patients underwent sentinel node occult lesion localization (SNOLL) using radiotracer intradermic injection that detected a "hot spot" corresponding to the sentinel node in all cases. Gamma probe over the skin detection with subsequent ultrasonographically guided needle biopsy of the sentinel node were performed. The percutaneous needle core histopathological diagnosis was compared to the results of the surgical biopsy. Preoperative sentinel node identification was successful in all patients. The combination of preoperative gamma probe sentinel node detection and ultrasound-guided biopsy could represent a valid alternative to intraoperative sentinel node biopsy in clinically and ultrasonographically negative axillary nodes, resulting in shorter duration of surgery and lower intraoperative risks.

  1. Male Breast Cancer

    Science.gov (United States)

    ... breast cancer include exposure to radiation, a family history of breast cancer, and having high estrogen levels, which can happen with diseases like cirrhosis or Klinefelter's syndrome. Treatment for male breast cancer is usually ...

  2. Sentinel node approach in prostate cancer.

    Science.gov (United States)

    Vidal-Sicart, S; Valdés Olmos, R A

    2015-01-01

    In general terms, one of the main objectives of sentinel lymph node (SLN) biopsy is to identify the 20-25% of patients with occult regional metastatic involvement. This technique reduces the associated morbidity from lymphadenectomy, as well as increasing the identification rate of occult lymphatic metastases by offering the pathologist those lymph nodes with the highest probability of containing metastatic cells. Pre-surgical lymphoscintigraphy is considered a "road map" to guide the surgeon towards the sentinel nodes and to ascertain unpredictable lymphatic drainages. In prostate cancer this aspect is essential due to the multidirectional character of the lymphatic drainage in the pelvis. In this context the inclusion of SPECT/CT should be mandatory in order to improve the SLN detection rate, to clarify the location when SLNs are difficult to interpret on planar images, to achieve a better definition of them in locations close to injection site, and to provide anatomical landmarks to be recognized during operation to locate SLNs. Conventional and laparoscopic hand-held gamma probes allow the SLN technique to be applied in any kind of surgery. The introduction and combination of new tracers and devices refines this technique, and the use of intraoperative images. These aspects become of vital importance due to the recent incorporation of robot-assisted procedures for SLN biopsy. In spite of these advances various aspects of SLN biopsy in prostate cancer patients still need to be discussed, and therefore their clinical application is not widely used. Copyright © 2015 Elsevier España, S.L.U. and SEMNIM. All rights reserved.

  3. Breast Cancer Surgery

    Science.gov (United States)

    FACTS FOR LIFE Breast Cancer Surgery The goal of breast cancer surgery is to remove the whole tumor from the breast. Some lymph nodes ... might still be in the body. Types of breast cancer surgery There are two types of breast cancer ...

  4. Breast cancer in pregnancy.

    Science.gov (United States)

    Krishna, Iris; Lindsay, Michael

    2013-09-01

    Pregnancy-associated breast cancer is defined as breast cancer diagnosed during pregnancy or in the first postpartum year. Breast cancer is one of the more common malignancies to occur during pregnancy and, as more women delay childbearing, the incidence of breast cancer in pregnancy is expected to increase. This article provides an overview of diagnosis, staging, and treatment of pregnancy-associated breast cancer. Recommendations for management of breast cancer in pregnancy are discussed.

  5. Application of Ultrasonography in the Qualitative Diagnosis of Sentinel Node in Early Breast Cancer%超声在早期乳腺癌前哨淋巴结定性诊断中的应用

    Institute of Scientific and Technical Information of China (English)

    李辉(综述); 陈芸(审校)

    2015-01-01

    乳腺癌引流区淋巴结转移与否为疾病的 TNM 分期、手术方式的选择、术后辅助治疗及判断预后提供重要依据,淋巴结转移越广泛,预后越差。随着超声医学技术的发展,超声造影等新技术的应用为疾病定性诊断提供了新的诊断思路。超声在早期乳腺癌前哨淋巴结( SN)定性诊断中的临床应用价值越来越得到重视,确认原发癌有无 SN转移对治疗方案的选择及判断预后有重要意义。该文就乳腺癌SN的定义、意义及超声检查技术在早期乳腺癌SN定性诊断中的应用予以综述。%Determining whether the draining sentinel node ( SN) ,metastasis in breast cancer provides an important basis for the assessment of TNM stage,the choice of surgical approach,the adjuvant therapy of post-operative and the estimation of prognosis.Accordingly,it indicates a mournful result when abundant lymph nodes are infected.more extensive SN metastasis,the worse the prognosis.With the development of technology of ultrasound in medicine ,contrast-enhanced ultrasonography have provided a new diagnostic approach in the qualitative diagnosis of disease .The technology of ultrasonography is more and more get attention in early breast cancer SN qualitative diagnosis clinically .It has important significance to confirm whether the exist-ence of primary cancer's SN metastases on the choice of treatment and prognosis .Here,we will summarize the definition and the significance of SN in breast cancer ,but also the application of ultrasound technology in the early diagnosis of SN in breast cancer.

  6. 乳腺癌哨兵淋巴结核素显像的的影响因素%Influence Factors of Radionuclide Imaging of Breast Cancer Sentinel Lymph Node

    Institute of Scientific and Technical Information of China (English)

    陈志军; 吴真; 谭丽玲; 孙正魁; 周爱清; 刘洁; 王文俊; 沈军瑾; 许波; 粟宇

    2015-01-01

    目的:探讨分析影响乳腺癌哨兵淋巴结核素显像结果的各种因素。方法选择不同部位Ⅰ~Ⅱa期乳腺恶性肿瘤129例,其中瘤体局部切除手术患者17例,分析注射部位、显像剂、显像时间等不同因素对哨兵淋巴结显像结果的影响。结果99mTc-DX和99mTc-SC哨兵显像的阳性率差异无统计学意义(P>0.5)。但两者哨兵淋巴结显像时间差异有统计学意义(P<0.005)。行乳腺肿瘤局部切除术的患者哨兵淋巴结显像的阳性率低于未行手术的患者,但差异无统计学意义(P>0.05)。不同的注射部位哨兵淋巴显像的阳性率各不相同,差异有统计学意义(P<0.01)。不同位置的肿瘤哨兵淋巴显像阳性率各不相同,但差异无统计学意义(P>0.25)。不同位置内乳淋巴阳性率各不相同,差异有统计学意义( P<0.005)。结论影响乳腺哨兵淋巴显像的因素较多,不同部位注射哨兵淋巴显像率各不相同,以乳晕区注射最高;99m Tc-DX较99m Tc-SC早;局部切除术对哨兵淋巴显像率无明显影响;不同部位肿瘤哨兵淋巴显像率各不相同,都表现为腋前区最高,中央区及内侧象限内乳淋巴显像率明显高于外侧象限。%Objective To investigate the influence factors of radionuclide imaging of breast cancer sentinel lymph nodes.Methods 129 cases of patients with Ⅰ~Ⅱa stage breast malignant tumor were selected ,including 17 cases of patients underwent partial resection of the tumor .The injection site ,imaging agent ,developing time ,such as the influence of different fac-tors on the imaging results of the sentinel lymph node were analyzed .Results There had no statistically significant difference in positive rate of 99mTc-DX and 99mTc-SC sentinel imaging (P>0.5).But sentinel imaging time had statistically significant differ-ence (P0.05).The positive rate of sentinel imaging by differ-ent injection

  7. Lessons from a clinicopathological study of breast cancer

    Directory of Open Access Journals (Sweden)

    S. G. D. Gangadaran

    2016-12-01

    Conclusions: Epidemiological profile of breast cancer in south India confirms to national trends. BCS and sentinel node biopsy are considered standard of care in breast cancer care however seems unavailable in government funded hospitals in south India. [Int J Res Med Sci 2016; 4(12.000: 5325-5328

  8. A longitudinal comparison of arm morbidity in stage I-II breast cancer patients treated with sentinel lymph node biopsy, sentinel lymph node biopsy followed by completion lymph node dissection, or axillary lymph node dissection

    NARCIS (Netherlands)

    Kootstra, Jan J.; Hoekstra-Weebers, Josette E.; Rietman, Johan S.; Vries, de Jakob; Baas, Peter C.; Geertzen, Jan H.B.; Hoekstra, Harald J.

    2010-01-01

    Background: Long-term shoulder and arm function following sentinel lymph node biopsy (SLNB) may surpass that following complete axillary lymph node dissection (CLND) or axillary lymph node dissection (ALND). We objectively examined the morbidity and compared outcomes after SLNB, SLNB + CLND, and ALN

  9. Metástase oculta em linfonodo sentinela no câncer de mama em estádios iniciais Occult metastasis in sentinel lymph node in early-stage breast cancer

    Directory of Open Access Journals (Sweden)

    José Roberto Morales Piato

    2008-09-01

    Full Text Available OBJETIVO: a identificação e biópsia do linfonodo sentinela (LS no câncer de mama em estádio inicial vêm substituindo a dissecção axilar total. Neste estudo, será apresentada a técnica de processamento do LS, visando o diagnóstico de metástase oculta com base no exame histológico e imuno-histoquímico. MÉTODOS: entre os anos de 2002 e 2005, 266 linfonodos sentinelas foram dissecados em 170 pacientes com câncer de mama em estádio inicial. Foram incluídos apenas os linfonodos considerados negativos durante análise intra-operatória por citologia. Os linfonodos foram seccionados tranversalmente em quatro ou cinco fatias e incluídos em parafina. Em cada bloco de parafina, dois cortes histológicos com 4 µm de espessura foram montados em lâminas para microscopia de luz e corados pela técnica da hematoxilina-eosina e imunoperoxidase (citoqueratina AE1/AE3. RESULTADOS: a avaliação histológica convencional identificou metástase no LS de 22 pacientes (12,9%. Em seis destas (3,5%, o acometimento foi do tipo micrometástase. Já a metástase oculta diagnosticada exclusivamente pela imuno-histoquímica ocorreu em 16 pacientes (9,4%. Em 11 destas (6,5% foram detectadas células tumorais isoladas e em cinco (2,9%, micrometástases. CONCLUSÕES: a associação do exame histológico de parafina e imuno-histoquímica aumenta a capacidade de identificar metástase oculta no LS de pacientes com câncer de mama em estádios iniciais.PURPOSE: sentinel lymph node biopsy in early-stage breast cancer patients has been substituting the total axillary lymph node is presented dissection. The technique of processing the sentinel lymph node and the aim of this study was to investigate the efficacy of occult metastasis identification based on the standard histological and immunohistochemical examination. METHODS: between 2002 and 2005, 266 sentinel lymph nodes were harvested from axillary biopsy of 170 patients with early stage breast cancer. All

  10. Sentinel lymph node biopsy in breast cancer--experience with the combined use of dye and radioactive tracer at Aarhus University Hospital

    DEFF Research Database (Denmark)

    Lauridsen, Mette Cathrine; Garne, Jens Peter; Sørensen, Flemming Brandt;

    2004-01-01

    -needle aspiration biopsy (FNAB) were not included. For identifying the SLNs, a combination of Tc-99m-labelled human albumin (Solco-ALBU-RES) and blue dye (Patent Blue V) was used. No lymphoscintigraphy was performed. The SLN was successfully identified in 122 out of 124 (98%) patients and 66 (54%) patients were...... found to have metastatic involvement of the axillary lymph nodes. In 52 (79%) of these patients, the SLNs were the only nodes involved, 28 (54%) had micrometastasis only. The false-negative rate was 1.5%. This method has proven valid in the staging of the axilla in patients with breast cancer...

  11. Metaplastic breast cancer with chondroid differentiation.

    Science.gov (United States)

    Myint, Zin W; Raparla, Sandeep; Kamugisha, Lois K

    2015-01-01

    Metaplastic carcinoma of the breast is an extremely rare subtype of breast cancer with an incidence of nuclear staining. Ki-67 index was 52% with strong nuclear staining. The overall ELSTON grade of invasive carcinoma was grade 3. The patient received adjuvant chemotherapy with AC-T (adriamycin, cytoxan, and taxol) and is currently undergoing surveillance for recurrent disease. Metaplastic breast cancer is an extremely rare subtype of breast carcinoma. Initial management of localized disease consists of wide excision with clear surgical margins followed by radiation or mastectomy and sentinel lymph node biopsy. Although standard breast chemotherapy regimens such as AC-T are routinely used in metaplastic breast cancer in both adjuvant and metastatic settings, outcomes are significantly inferior to other breast subtypes. Further studies are required to explore targeted treatment to achieve better outcomes in this patient population.

  12. Sentinel lymph node biopsy with methylene blue after neoadjuvant chemotherapy for breast cancer%染料法前哨淋巴结活检在乳腺癌新辅助化疗后的临床意义

    Institute of Scientific and Technical Information of China (English)

    郑文博; 叶熹罡; 潘凌霄

    2011-01-01

    Objective: To evaluate the feasibility, efficacy and accuracy of sentinel lymph node biopsy (SLNB) with methylene blue after neoadjuvant chemotherapy (NAC) in patients with breast cancer. Methods:A total of 41 breast cancer patients ( stage II or HI ) admitted to Department of Breast Surgery, First Affiliated Hospital of Guangzhou Medical College,between May 2007 and April 2011,received two to four cycles of NAC. They then underwent SLNB ( using methylene blue) , followed by either modified radical mastectomy or breast-sparing conservative surgery with complete axillary lymph node dissection (levels I - Ⅱ /Ⅲ). Results: 39 cases were found to have sentinel lymph nodes ( SLNs) among level I axillary lymph nodes, with a mean of 1.5 ± 0.2 SLNs and 17 ±5 axillary lymph nodes resected in each case. The SLN detection rate,accuracy, sensitivity and false-negative rate were 95. 1% ,92.3% ,88.0% and 12.0% respectively,which were not correlated with the size of primary tumor, level of regional lymph nodes,TNM staging,age,or body mass index before NAC(P>0.05). This study confirms that SLNB with methylene blue after NAC is safe, feasible and accurate for evaluating axillary lymph nodes in certain patients with breast cancer.%目的:探讨乳腺癌新辅助化疗后行染料法前哨淋巴结活检的可行性、有效性及准确性.方法:对2007年5月至2011年4月期间41例广州医学院第一附属医院乳腺外科确诊为乳腺癌的患者(Ⅱ期或Ⅲ期)予2~4个疗程新辅助化疗后,行患侧亚甲蓝示踪前哨淋巴结活检+乳腺癌改良根治术或联合腋窝淋巴结(Ⅰ-Ⅱ/Ⅲ级)清扫的乳腺癌保乳术.结果:在Ⅰ级腋窝淋巴结中检出前哨淋巴结39例,每例平均前哨淋巴结及腋窝淋巴结的检出数目分别为1.5±0.2枚和17±5枚.前哨淋巴结的检出率、准确率、灵敏度,假阴性率分别为95.1%、92.3%、88.0%、12.0%,以上各指标与新辅助化疗前患者的原发肿瘤大小、区域淋

  13. Sentinel lymph nodes in cancer of the oral cavity

    DEFF Research Database (Denmark)

    Thomsen, Jørn Bo; Sørensen, Jens Ahm; Krogdahl, Annelise

    2005-01-01

    BACKGROUND: Sentinel lymph node biopsy, step sectioning and immunohistochemistry have changed detection of tumour deposits. Isolated tumour cells (ITC) are detected more frequently than earlier because of a changed level of detection. METHODS: A total of 108 sentinel lymph nodes from 30 patients...... with T1/T2 cN0 oral cancer were re-classified histologically to find possible ITC and to describe technical pitfalls. RESULTS: Primarily we found metastatic spread in 12 of 108 sentinel lymph nodes: five macrometastasis and seven micrometastasis. After re-classification, we found seven lymph nodes...

  14. Breast Cancer Disparities

    Science.gov (United States)

    ... 2.65 MB] Read the MMWR Science Clips Breast Cancer Black Women Have Higher Death Rates from Breast ... of Page U.S. State Info Number of Additional Breast Cancer Deaths Among Black Women, By State SOURCE: National ...

  15. Preliminary study on sentinel lymph node detection by contrast-enhanced ultrasound in patients with breast cancer%乳腺癌前哨淋巴结超声造影的初步研究

    Institute of Scientific and Technical Information of China (English)

    李娅; 常才; 张迅; 乐坚; 范亦武; 周世崇

    2014-01-01

    目的:研究超声造影技术是否可用于探测乳腺癌前哨淋巴结,是否比传统同位素联合亚甲蓝示踪探测技术有优势。方法对36例乳腺癌患者先后进行超声造影、同位素联合亚甲蓝示踪法两项检查探测乳腺癌患者腋下前哨淋巴结,对比病理结果,进行分析。结果超声造影技术发现前哨淋巴结的准确率为88.89%,同位素联合亚甲蓝示踪法发现前哨淋巴结的准确率为97.22%。结论超声造影可发现乳腺癌腋下前哨淋巴结,但其准确率略低于同位素联合亚甲蓝示踪法,临床价值还需进一步研究。%Objective To study the application feasibility of contrast-enhanced ultrasound (CEUS) in sentinel lymph node (SLN) detection in patients with breast cancer, and to compare it with traditional methylene blue dye combined with radioisotope as tracer. Methods Thirty-six patients with breast cancer received axillary SLN detection by CEUS and methylene blue dye combined with radioisotope before surgery. The results were compared and analyzed. Results The accuracies of CEUS and methylene blue dye combined with radioisotope were 88.89% and 97.22%, respectively. Conclusion CEUS can detect SLNs, but not better than methylene blue dye in combined with radioisotope. The value of CEUS needs more research.

  16. Breast cancer in men

    Science.gov (United States)

    ... in situ - male; Intraductal carcinoma - male; Inflammatory breast cancer - male; Paget disease of the nipple - male; Breast cancer - male ... The cause of breast cancer in men is not clear. But there are risk factors that make breast cancer more likely in men: Exposure to ...

  17. Clinical application on methylene blue dye in sentinel lymph node biopsy for the patients with breast cancer%亚甲蓝染色法前哨淋巴结活检在乳腺癌手术中的应用分析(附66例报告)

    Institute of Scientific and Technical Information of China (English)

    罗国庆; 胡宁东; 夏旭; 刘秋华; 郭远峰; 郑辉; 周晶晶

    2014-01-01

    Objective To explore the appropriate dose,waiting time after injection of methylene blue dye and identification of sentinel lymph node location in sentinel lymph node biopsy for the patients with breast cancer by means of methylene blue dye. Method Sixty-six patients with breast cancer underwent sentinel lymph node biopsy after injection of methylene blue dye to identificate the location of sentinel lymph node.The injection site of methylene blue dye was selected in the subcutaneous tissue of the tumor surface that located in outer upper quadrant, it would be selected in areola or in outer upper quadrant when tumor located in other places. Sentinel lymph node was excised according to rule of nine. Results Of 66 patients with breast cancer 17 underwent breast conservating surgery, 49 underwent modify radical mastectomy. Sentinel lymph node was successfully found in every patient. A total of 210 sentinel lymph nodes were excised with an average of 3.2 (range 1~8).The successful rate was 100%. Conclusion The subcutaneous diffuse injection of 2ml methylene blue dye and waiting time is 5 minutes in sentinel lymph node biopsy for the patients with breast cancer.The successful rate of sentinel lymph node biopsy will be higher according to rule of nine.%目的:总结亚甲蓝染色法前哨淋巴结活检在乳腺癌手术中应用时亚甲蓝注射的适宜剂量、注射后的等待时间及前哨淋巴结的定位及追踪经验。方法66例乳腺癌病人,以1%亚甲蓝注射剂为示踪剂,肿瘤位于外上象限者,则注射于肿瘤表面皮下,若肿瘤位于其他部位,则注射于乳晕或者外上象限皮下。九分法定位切取前哨淋巴结。结果66例患者施行保乳手术17例,改良根治术49例,均成功检出前哨淋巴结,共检出前哨淋巴结210枚,平均每例3.2枚(1~8枚),成功率为100%。结论选择亚甲蓝剂量为2ml,根据肿瘤位置选择注射位置,皮下弥漫浸润注射,注射后按摩5

  18. Imaging male breast cancer

    Energy Technology Data Exchange (ETDEWEB)

    Doyle, S., E-mail: sdoyle2@nhs.net [Primrose Breast Care Unit, Derriford Hospital, Plymouth (United Kingdom); Steel, J.; Porter, G. [Primrose Breast Care Unit, Derriford Hospital, Plymouth (United Kingdom)

    2011-11-15

    Male breast cancer is rare, with some pathological and radiological differences from female breast cancer. There is less familiarity with the imaging appearances of male breast cancer, due to its rarity and the more variable use of preoperative imaging. This review will illustrate the commonest imaging appearances of male breast cancer, with emphasis on differences from female breast cancer and potential pitfalls in diagnosis, based on a 10 year experience in our institution.

  19. 50例早期乳腺癌前哨淋巴结活检的临床分析%The analysis of 50 sentinel lymph node biopsy of patients with clinical primary breast cancer

    Institute of Scientific and Technical Information of China (English)

    何志刚; 尹宏

    2012-01-01

      目的:通过前哨淋巴结活检术(SLNB)预测腋窝淋巴结状态,以达到取代腋窝淋巴结清扫(ALND),减轻ALND术后并发症.方法:回顾性分析50例临床早期乳腺癌患者的蓝染法SLNB病例资料.结果:50例蓝染法SLNB的成功率94%、准确率97.9%、灵敏度92.3%.1例假阴性出现,假阴性率7.7%.结论:蓝染法SLNB安全、有效、简便易行,SLNB阴性的患者,可以替代ALND.%  objective:To evaluate the sensitivity and specificity of Sentinel Lymph Node Biopsy(SLNB)in predicting the status of axillary lymph node.Methods:The clinical data of 50 patients with clinical primary breast cancer who received SLNB with blue dying were analyzed retrospectively.Results:In this series,the identification rate of SLNs was 94%.the false negative rate was 7.7%.Conclusion:Subareolar injection of methylene blue is effective,safe,and convenient for the treatment of patients with negative SLNB.It is a good alternative for ALND.

  20. 乳腺癌腔镜下腋窝前哨淋巴结活检术的可行性研究%Feasibility study of the axillary sentinel lymph node biopsy of breast cancer under endoscopy

    Institute of Scientific and Technical Information of China (English)

    刘峰

    2014-01-01

    Objective To investigate the clinical feasibility of the axillary sentinel lymph node biopsy under endos-copy for breast cancer. Methods From January 2010 to October 2012,45 patients with early breast cancer in people’s hospital of Rizhao were chose. The patients were performed with ESLNB at first,and the obtained sentinel lymph nodes were sended for intraoperative rapid pathologic and postoperative pathologic examination,and then the axillary lymph nodes were obtained by axillary lymph node dissection(ALND),the obtained axillary lymph nodes were sended for postoperative pathologic examination. The sensitivity,accuracy,false negative rate and false positive rate of ESLNB was evaluated. The assessment results of axillary lymph node metastasis situation by ESLNB and ALND were compared. Results Forty-three sentinel lymph nodes were successfully detected,the success rate was 95. 6% . The sensitivity of ESLNB intraoperative fast pathologic examination was 90. 1% ,and the accuracy rate was 88. 4% ;the false negative rate was 9. 1% ,and false posi-tive rate was 6. 06% ;The sensitivity of ESLNB postoperative pathologic examination was 93. 9% ,and the accuracy rate was 90. 1% ;the false negative rate was 6. 06% ,and the false positive rate was 6. 06% . There was no significant differ-ence in the evaluation results of axillary lymph node metastasis status between ESLNB intraoperative rapid / postoperative pathologic examination and ALND postoperative pathologic examination(P ﹥ 0. 05). Conclusions The axillary sentinel lymph node biopsy of breast cancer by endoscopic surgery through methylene blue staining is feasible and safe. It opens a new route for narrowing the operation scope of breast cancer.%目的:探讨乳腺癌腔镜下腋窝前哨淋巴结活检术(ESLNB)的临床可行性。方法选取2010年1月至2013年10月日照市人民医院外科收治住院的45例早期乳腺癌患者。首先行 ESLNB,所获前哨淋巴结送术中快速病理和术后病

  1. Sentinel lymph node biopsy in oral cancer

    DEFF Research Database (Denmark)

    Thomsen, Jørn Bo; Sørensen, Jens Ahm; Grupe, Peter;

    2005-01-01

    PURPOSE: To validate lymphatic mapping combined with sentinel lymph node biopsy as a staging procedure, and to evaluate the possible clinical implications of added oblique lymphoscintigraphy and/or tomography and test the intra- and interobserver reproducibility of lymphoscintigraphy. MATERIAL...... AND METHODS: Forty patients (17 F and 23 M, aged 32-90) with 24 T1 and 16 T2 squamous cell carcinoma of the oral cavity. Planar lymphoscintigraphy, emission and transmission tomography were performed. Detection and excision of the sentinel nodes were guided by a gamma probe. The sentinel nodes were step......-sectioning and stained with hematoxylin and eosin and cytokeratin (CK 1). Histology and follow-up were used as "gold standard". Tumor location, number of sentinel lymph nodes, metastasis, and recurrences were registered. Two observers evaluated the lymphoscintigraphic images to assess the inter-rater agreement. RESULTS...

  2. [The lymphotropic marking and biopsy of sentinel lymph nodes in T1 tumors--a new approach to the staging of axillary lymphatic metastasis in breast cancer].

    Science.gov (United States)

    Deliĭski, T; Baĭchev, G; Popovska, S; Penkova, R

    1997-01-01

    It is the purpose of the study to assay the possibility of demonstrating axillary lymph status through marking and biopsy of sentinel lymph nodes. Preoperative lymphotropic marking of sentinel lymph nodes is performed in 48 female patients presenting mammary gland carcinoma, measuring up to two centimeters. Drimaren 0.5 ml (in 18 cases), Mitoxantrone (17 cases) or Patent Blue (13 cases) each are perineoplastically injected in two points. Intraoperatively, in 34 patients blue stained lymph nodes (from Patent Blue and Mitoxantrone mainly) are identified, and compared with the results of axillary dissection. Metastases in sentinel nodes are documented in seven instances. In the remainder (30) which are histologically negative, lymph node metastasis II level is discovered in one case (false negative = 3.3 per cent). As shown by the initial observations perioperative marking of lymph nodes with Patent Blue and Mitoxantrone contribute to demonstrate sentinel nodes, and by biopsy study of the latter it is possible to judge about the pattern of lymph metastasizing of mammary gland carcinoma.

  3. Sentinel Lymph Node Identification in Endometrial Cancer

    Institute of Scientific and Technical Information of China (English)

    Bin Li; Lingying Wu; Xiaoguang Li; Haizhen Lu; Ping Bai; Shumin Li; Wenhua Zhang; Juzhen Gao

    2009-01-01

    OBJECTIVE To evaluate the feasibility of intra-operative detection of sentinel lymph nodes (SLN) in the patient with endometrial cancer (EC).METHODS Thirty-one patients with Stage Ⅰ and Ⅱ endometrial cancer, who underwent a hysterectomy and a lymphadenectomy,were enrolled in the study. At laparotomy, methylene blue dye tracer was injected into the subserosal myometrium of corpus uteri at multiple sites, and dye uptake into the lymphatic channels was observed. The blue nodes which were identified as SLNs were traced and excised. The other nodes were then removed. All of the excised nodes were submitted for pathological hematoxylin and eosin (H&E) staining examination.RESULTS Failure of dye uptake occurred in 4 of the 31 cases (12.9%) because of spillage, and no lymphatic coloration was observed there. Lymphatic staining was clearly observable as blue dye diffused to the lymphatic channels of the uterine surface and the infundibulopelvic ligaments in 27 (87.1%) cases. Concurrent coloration in the pelvic lymphatic vessels was also observed in 22of the 27 patients. The SLNs were identified in 23 of the 27 (85.2%)cases with a lymphatic staining, with a total number of 90 SLNs,and a mean of 3.9 in each case (range, 1-10). Besides one SLN (1.1%)in the para-aortic area, the other 89 (98.9%) were in the nodes of the pelvis. The most dense locations of SLNs included obturator in 38 (42.2%) and interiliac in 19 (21.1%) cases. In our group, pelvic lymphadenectomy was conducted in 27 (87.1%) patients and pelvic nodal sampling in 4 (12.9%). Of the 31 cases, a concurrent abdominal para-aortic lymph node sampling was conducted in 7. A total of 926 nodes were harvested, with an average of 39.8 in each case (range, 14-55). Nodal metastases occurred in 3 patients (9.7%), 2 of them with SLN involvement and the other without SLN involvement. Adverse reactions or injury related to the study was not found.CONCLUSION Application of methylene blue dye is feasible in an intra

  4. Clinical study on sentinel lymph node in breast cancer patients through injection of methylene blue%亚甲蓝示踪乳腺癌前哨淋巴结的临床研究

    Institute of Scientific and Technical Information of China (English)

    李庄; 吴学东; 李乐生; 李俊; 李爱民; 杨利杰

    2008-01-01

    Objective To identify the sentinel lymph node in breast cancer patients by injection of methylene blue andanalyse the relations between the sentinel lymph node(SLN)and axillary lymph node(ALN).Method 45 breast cancer patients were injected with methylene blue to find SLN during operation.The SLN dyed by methylene blue and Cancer specimens were removed and submitted to pathological examination at the same time.All patients suffering from breast cancer showed by pathological examination were treated by the traditional radical or modified radical mastectomy.The sensitivity in prediction of ALN metastasis by SLN biopsy was showed through postoperative pathological analysis and would provide data for the development in operation of breast cancer.Results In 45 cases,SLN dyed by methylene blue was identified in 36.Malignant turnout invasion was revealed in 21 of 36 cases,and cancer metastasis was also observed by postoperative axillary lymph node pathology in the 21 patients.13 of 36 cases showed no cancer invasion and ALN metastasis by pathological examination.2 of 36 patients who showed uninvaded SLN were demonstrated to have ALN metastasis.Therefore,the prediction of ALN metastasis by SLN biopsy showed a sensitivity of 94.5%(34/36)and a false negative rate of 5.5%(2/36).SLN was not identified at the time of operation in 9 patients,and postoperative axillary lymph node pathology also showed no cancer metastasis in all of them.Conclusion SLN in breast cancer patients can be identified by injection of methylene blue,and the sensitivity in prediction of ALN metastasis by SLN biopsy is 94.5%.If the 9 patients in whom SLN are not identified are regarded as the corresponding cases,the sensitivity may be up to 95.6%(43/45).The false negative rate of the study is 4.4%(2/45).%目的 应用亚甲蓝注射示踪乳腺癌患者前哨淋巴结(SLN),分析前哨淋巴结(SLN)与腋窝淋巴结(ALN)的关系.方法 对45例早期乳腺癌患者采用活体染料亚甲蓝作为SLN示

  5. Breast cancer awareness

    OpenAIRE

    2012-01-01

    The incidence of breast cancer is rising among women in many European countries, affecting up to 1 in 16 women and has become the most common cause of cancer in European women. In Malta breast cancer is the commonest oncological cause of death in females. In fact 5.2% of all deaths in females in 2010 was from breast cancer.

  6. Touch imprint cytology with cytokeratin immunostaining versus Papanicolau staining for intraoperative evaluation of sentinel lymph node metastasis in clinically node-negative breast cancer.

    Science.gov (United States)

    Fujishima, M; Watatani, M; Inui, H; Hashimoto, Y; Yamamoto, N; Hojo, T; Hirai, K; Yamato, M; Shiozaki, H

    2009-04-01

    This study investigated whether intraoperative assessment of SLN status in patients with clinically node-negative breast cancer was improved using touch imprint immunohistochemistry. Each SLN was cut into slices 2mm thick and evaluated intraoperatively by touch imprint cytology with Papanicolaou staining until the end of 2005, or by a combination of Papanicolaou staining and immunostaining with an anti-cytokeratin antibody from early 2006. When intraoperative cytology of SLN in 85 patients who were clinically node-negative was evaluated with Papanicolaou staining, 81 patients were diagnosed as negative and four were positive. Intraoperative cytology with Papanicolaou staining had a sensitivity of 30%, specificity of 99%, false-negative rate of 70%, false-positive rate of 1.3%, and accuracy of 90.6%. When intraoperative cytology was done with immunohistochemistry plus Papanicolaou staining for SLN evaluation, 92 patients were diagnosed as negative and 17 patients were positive. Intraoperative cytology with immunohistochemistry had a sensitivity of 79%, specificity of 98%, false-negative rate of 21%, false-positive rate of 2.2%, and accuracy of 94.5%. Compared with intraoperative cytology using Papanicolaou staining alone, the combination of immunohistochemistry and Papanicolaou staining achieved a significant increase in sensitivity and a significant decrease in the false-negative rate. Intraoperative SLN evaluation by imprint cytology with immunohistochemistry achieves a more accurate diagnosis of metastasis than imprint cytology alone. This combined method is considered useful for deciding whether to perform axillary lymph node dissection.

  7. Prognostic value of isolated tumor cells and micrometastases of lymph nodes in early-stage breast cancer: a French sentinel node multicenter cohort study.

    Science.gov (United States)

    Houvenaeghel, Gilles; Classe, Jean-Marc; Garbay, Jean-Rémy; Giard, Sylvia; Cohen, Monique; Faure, Christelle; Hélène, Charytensky; Belichard, Catherine; Uzan, Serge; Hudry, Delphine; Azuar, Pierre; Villet, Richard; Penault Llorca, Frédérique; Tunon de Lara, Christine; Goncalves, Anthony; Esterni, Benjamin

    2014-10-01

    To define the prognostic value of isolated tumor cells (ITC), micrometastases (pN1mi) and macrometastases in early stage breast cancer (ESBC). We conducted a retrospective multicenter cohort study at 13 French sites. All the eligible patients who underwent SLNB from January 1999 to December 2008 were identified, and appropriate data were extracted from medical records and analyzed. Among 8001 patients, including 70% node-negative (n = 5588), 4% ITC (n = 305), 10% pN1mi (n = 794) and 16% macrometastases (n = 1314) with a median follow-up of 61.3 months, overall survival (OS) and recurrence-free survival (RFS) rates at 84 months were not statistically different in ITC or pN1mi compared to tumor-free nodes. Axillary recurrence (AR) was significantly more frequent in ITC (1.7%) and pN1mi (1.5%) compared to negative nodes (0.6%). Survival and AR rates of single macrometastases were not different from those of ITC or pN1mi. In case of 2 macrometastases or more, survival rates decreased and recurrence rates increased significantly. Micrometastases and ITC do not have a negative prognostic value. Single macrometastases might have an intermediate prognostic value while 2 macrometastases or more are associated with poorer prognosis.

  8. Sentinel lymph node biopsy in bladder cancer: Systematic review and technology update

    OpenAIRE

    Liss, Michael A.; Noguchi, Jonathan; Lee, Hak J.; Vera, David R.; Kader, A. Karim

    2015-01-01

    A sentinel lymph node (SLN) is the first lymph node to drain a solid tumor and likely the first place metastasis will travel. SLN biopsy has been well established as a staging tool for melanoma and breast cancer to guide lymph node dissection (LND); its utility in bladder cancer is debated. We performed a systematic search of PubMed for both human and animal studies that looked at SLN detection in cases of urothelial carcinoma of the bladder. We identified a total of nine studies that assesse...

  9. Application and Clinical Observation on Sentinel Lymph Node Biopsy of Breast Cancer by Cavity Mirror%腔镜下乳腺癌前哨淋巴结活体组织检查的应用及临床效果观察

    Institute of Scientific and Technical Information of China (English)

    孙爱军; 黄选东; 宋勇罡

    2013-01-01

    目的::探讨在腔镜下乳腺癌前哨淋巴结活体组织检查(活检)的临床价值及临床效果。方法:对2007年1月~2012年12月在我院行乳腺癌前哨淋巴结活检的400病例,112例为腔镜下活检288例为开放活检,采用亚甲蓝法和放射性核素+亚甲蓝联合法对前哨淋巴结进行探测。结果:腔镜下活检组亚甲蓝法检出率为87.86%,亚甲蓝法和放射性核素联合法检出率为95.76%;开放活检组亚甲蓝法检出率为85.03%,亚甲蓝法和放射性核素联合法检出率为95.53%;开放活检组检出前哨淋巴结数量亚甲蓝法平均1.95枚/例,联合法平均1.89枚/例,;腔镜组则分别为1.93枚/例和1.81枚/例。上述两组间各指标的差异均无统计学意义(P>0.05)。腔镜组术后患皮下积液概率高于开放组。结论:腔镜下乳腺癌前哨淋巴结活检与传统乳腺癌前哨淋巴结活检安全性与临床效果相似,但腔镜下乳腺癌前哨淋巴结活检能较好地满足患者的美观要求,腔镜下乳腺癌前哨淋巴结活检在临床上值得推广。%Objective:To investigate the cavity in sentinel lymph node biopsy in breast cancer clinical effect.Methods:In our line of the sentinel lymph node biopsy,400 cases of breast cancer,112 cases for biopsy under the cavity mirror,288 cases of open biopsy,with methylene blue method and radionuclide+methylene blue method to detect the sentinel lymph node.Results:Under the cavity mirror biopsy group of methylene blue method detection rate was 87.86%,the methylene blue method and joint method of radioactive nuclide detection rate is 95.76%;Open group of methylene blue method detection rate was 85.03%,the methylene blue method and joint method of radioactive nuclide detection rate is 95.53%;Open group of sentinel lymph node detection quantity methylene blue method,on average,1.95/cases,combined method,an average of 1.89/case;Cavity mirror group were 1.93 and 1.81/rings/cases.There were no

  10. International multicenter tool to predict the risk of four or more tumor-positive axillary lymph nodes in breast cancer patients with sentinel node macrometastases

    DEFF Research Database (Denmark)

    Meretoja, Tuomo J; Audisio, R A; Heikkilä, P S

    2013-01-01

    to develop a novel international multicenter predictive tool to estimate a patient-specific risk of having four or more tumor-positive axillary lymph nodes (ALN) in patients with macrometastatic sentinel node(s) (SN). A series of 675 patients with macrometastatic SN and completion ALND from five European...... centers were analyzed by logistic regression analysis. A multivariate predictive model was created and validated internally by 367 additional patients and then externally by 760 additional patients from eight different centers. All statistical tests were two-sided. Prevalence of four or more tumor...

  11. Learning about Breast Cancer

    Science.gov (United States)

    ... for the genetic terms used on this page Learning About Breast Cancer What do we know about ... for a small fraction of breast cancers. In Learning About the BRCAX Study , researchers discuss a recent ...

  12. Breast cancer staging

    Science.gov (United States)

    ... this page: //medlineplus.gov/ency/patientinstructions/000911.htm Breast cancer staging To use the sharing features on this ... Once your health care team knows you have breast cancer , they will do more tests to stage it. ...

  13. Influence of excisional biopsy on detection rate of sentinel lymph node biopsy through methylene blue in breast cancer%术中切除活检对亚甲蓝行乳腺癌前哨淋巴结活检术检出率的影响

    Institute of Scientific and Technical Information of China (English)

    王翀; 朱应昌; 梁伟潮; 陈启生; 熊海波; 梁雄; 陈烈欢

    2014-01-01

    目的 探讨肿物切除活检术后对亚甲蓝染色行乳腺癌前哨淋巴结活检的检出率有无影响.方法 回顾性分析2009年7月-2014年7月南方医科大学附属南海医院接受前哨淋巴结活检的T1-2N0M0期乳腺癌患者共76例,其中直接行前哨淋巴结活检者37例,将乳腺肿物局部切除后再行前哨淋巴结活检者39例.比较两组患者前哨淋巴结的检出率差异有无统计学意义.结果 76例患者共有70例成功检出前哨淋巴结,检出率为92.1%.其中切除活检组成功活检34例,检出率为87.2%,穿刺活检组成功活检36例,检出率为97.3%,但两组结果经统计其差异并无统计学意义(P>0.05).结论 术中切除活检对亚甲蓝行乳腺癌前哨淋巴结活检术的检出率似乎并无显著影响.%Objective To study the influence of excisional biopsy on detection rate of sentinel lymph node biopsy through methylene blue in breast cancer.Methods A review of 76 patients with clinical stage T1-2N0M0 breast cancer who had a successful sentinel lymph node biopsy at the Affiliated Nanhai Hospital of Southern Medical University between July 2009 to July 2014 was analyzed.There were 37 patients received sentinel lymph node biopsy directly.And 39 patients received sentinel lymph node biopsy after a excisional biopsy to primary lesion.We compare the difference of detection rate of sentinel lymph node between the two groups.Results Seventy cases had been found sentinel lymph node successfully in a total of 76 patients and the detection rate is 92.1%.There were 34 cases had sentinel lymph node biopsy in successfully in group of excisional biopsy and the detection rate is 87.2%.There were 36 cases had sentinel lymph node biopsy in successfully in group of needle core biopsy and the detection rate is 97.3%.This difference,however,was not statistically significant between the two groups (P > 0.05).Conclusions The influence of excisional biopsy on detection rate of sentinel

  14. Application of Methylene blue in sentinel node biopsy of breast cancer%亚甲蓝法在乳腺癌前哨淋巴结活检中的应用

    Institute of Scientific and Technical Information of China (English)

    闫平钊; 杨小花; 崔宾; 王建华

    2013-01-01

    目的:探讨亚甲篮作为示踪法进行前哨淋巴结活检在乳腺癌治疗中的应用价值.方法:对已确诊的172例临床腋窝淋巴结阴性的乳腺癌患者术中亚甲蓝乳晕周围皮下注射后行腋窝前哨淋巴结切除,送冰冻病理检查,再行乳腺癌改良根治术,并常规腋窝淋巴结清扫,术后病理石蜡切片检查前哨淋巴结及手术切除标本.结果:167例(97.1%)成功实施SLNB,5例(2.9%)术中未能发现SLN,立即改行腋窝淋巴结清扫术(ALND).行SLNB的167例中,术中冰冻报告SLN癌转移21例,即行ALND;146例冰冻检查SLN未见癌转移.5例术后HE染色检查发现SLN存在1枚微转移淋巴结,4例接受ALND,1例拒绝行腋窝淋巴结清扫.142例SLNB代替ALND者中位随访时间18个月(3~64个月),均未发现腋窝淋巴结转移.结论:亚甲蓝法SLNB安全、有效、简便易行,SLNB阴性患者,可以替代ALND.%Objective: To explore the clinical value of methylene blue in sentind node biopsy (SLNB) in breast cancer. Methods: A xilla sentinel node resection was performed in 172 patients with breast cancer after subcu taneous injection with methylene blue, these sentinel nodes were checked by cryo pathologic examination, and by litho biopsy examination after the operation. Then, modified radical mastectomy was done in these patients. Results: The SLNB was completed successfully in 167 of the patients(97. 1 %) ;in the other5 cases(2. 9%) ,no SLN was de tected,and thus ALND was carried out. In the 167 cases who received SLNB,SLN metastasis wag found in 21 cases, which then underwent ALND as well. After the operation, HE staining showed lymph nodes micrometastasis in 5 pa tients;4 of them therefore received ALND(the other patient refused any further operation). Totally 142 patients had the SLNB instead of ALND, these patients were followed up for 18 months (ranged from 3 to 64months), during which no axillary metastasis was detected. Conclusion: Subareolar injection of methylene

  15. Breast Cancer Early Detection and Diagnosis

    Science.gov (United States)

    ... En Español Category Cancer A-Z Breast Cancer Breast Cancer Early Detection and Diagnosis Breast cancer is sometimes ... cancer screening is so important. Learn more. Can Breast Cancer Be Found Early? Breast cancer is sometimes found ...

  16. Breast Cancer and Infertility

    OpenAIRE

    2015-01-01

    Breast cancer is the most common malignancy among women and may accompany infertility. The relationship between infertility treatment and breast cancer has not yet been proven. However, estrogen exposure is well known to cause breast cancer. Recent advances in treatment options have provided young patients with breast cancer a chance of being mother [Archives Medical Review Journal 2015; 24(3.000): 317-323

  17. Breast Cancer (For Kids)

    Science.gov (United States)

    ... With Breast Cancer Breast Cancer Prevention en español Cáncer de mama You may have heard about special events, like walks or races, to raise money for breast cancer research. Or maybe you've seen people wear ...

  18. SENTINEL LYMPH NODE CONCEPT IN DIFFERENTIATED THYROID CANCER

    Directory of Open Access Journals (Sweden)

    Markovic Ivan

    2014-12-01

    Full Text Available Introduction: Differentiated thyroid carcinoma (DTC account up to 90% of all thyroid malignacies, and represents the most common malignant tumors of endocrine system. The incidence of papillary thyroid carcinoma (PTC, especially small tumors is rapidly increasing during past three decades. At the time of diagnosis, the incidence of lymph node metastases (LNM ranges from 80 to 90%. During the last 15 years, LNM were recognized as bad prognostic factor for both local-regional relapse (LRR and cancer specific survival. There is general agreement that neck dissections are indicated in cases of clinically apparent LNM. The subject of the current controversy is the surgical treatment of occult LNM that remain unrecognized on preoperative diagnosis (cN0. The extent of operations of the lymph nodes ranges from “wait and see” so-called “Western school” principle substantiated the role of applying ablative I131therapy and frequency peroperative complications (recurrent laryngeal nerve injury and hypoparathyroidism, especially for less experienced teams to mutual prophylactic dissection of the central and lateral compartments so-called “Japanese school” due to the limited use of radioactive iodine therapy and significantly lower operating morbidity if dissetion was done during primary operation. Despite high prevalence of occult LNM, existing controversies regarding diagnosis, longterm prognostic impact and extent of lymph node surgery, motivated some authors to apply consept of sentinel lymph node biopsy (SLNb in DTC, taking into account excellent results of SLN concept in breast cancer and skin melanoma. This review presents the summarized results of relevant studies and three meta-analysis of accuracy and applicability of SLN concept in patients with differentiated thyroid carcinoma.

  19. Sentinel lymph node concept in differentiated thyroid cancer

    Directory of Open Access Journals (Sweden)

    Markovic Ivan

    2014-12-01

    Full Text Available Introduction: Differentiated thyroid carcinoma (DTC account up to 90% of all thyroid malignacies, and represents the most common malignant tumors of endocrine system. The incidence of papillary thyroid carcinoma (PTC, especially small tumors is rapidly increasing during past three decades. At the time of diagnosis, the incidence of lymph node metastases (LNM ranges from 80 to 90%. During the last 15 years, LNM were recognized as bad prognostic factor for both local-regional relapse (LRR and cancer specific survival. There is general agreement that neck dissections are indicated in cases of clinically apparent LNM. The subject of the current controversy is the surgical treatment of occult LNM that remain unrecognized on preoperative diagnosis (cN0. The extent of operations of the lymph nodes ranges from 'wait and see' so-called 'Western school' principle substantiated the role of applying ablative I131 therapy and frequency peroperative complications (recurrent laryngeal nerve injury and hypoparathyroidism, especially for less experienced teams to mutual prophylactic dissection of the central and lateral compartments so-called 'Japanese school' due to the limited use of radioactive iodine therapy and significantly lower operating morbidity if dissetion was done during primary operation. Despite high prevalence of occult LNM, existing controversies regarding diagnosis, longterm prognostic impact and extent of lymph node surgery, motivated some authors to apply concept of sentinel lymph node biopsy (SLNb in DTC, taking into account excellent results of SLN concept in breast cancer and skin melanoma. This review presents the summarized results of relevant studies and three meta-analysis of accuracy and applicability of SLN concept in patients with differentiated thyroid carcinoma.

  20. Breast Cancer Rates by State

    Science.gov (United States)

    ... Associated Lung Ovarian Prostate Skin Uterine Cancer Home Breast Cancer Rates by State Language: English Español (Spanish) Recommend ... from breast cancer each year. Rates of Getting Breast Cancer by State The number of people who get ...

  1. 6 Common Cancers - Breast Cancer

    Science.gov (United States)

    ... have revolutionized breast cancer treatment: tamoxifen (Nolvadex) and trastuzumab (Herceptin). Bernard Fisher, M.D., of the University of ... breast tumors. Dr. Slamon and his colleagues developed trastuzumab (Herceptin). Trastuzumab, a monoclonal antibody, was the first ...

  2. Do We Know What Causes Breast Cancer?

    Science.gov (United States)

    ... Research? Breast Cancer About Breast Cancer How Does Breast Cancer Form? Changes or mutations in DNA can cause ... requests, please contact permissionrequest@cancer.org . More In Breast Cancer About Breast Cancer Risk and Prevention Early Detection ...

  3. Histologic changes associated with false-negative sentinel lymph nodes after preoperative chemotherapy in patients with confirmed lymph node-positive breast cancer before treatment.

    Science.gov (United States)

    Brown, Alexandra S; Hunt, Kelly K; Shen, Jeannie; Huo, Lei; Babiera, Gildy V; Ross, Merrick I; Meric-Bernstam, Funda; Feig, Barry W; Kuerer, Henry M; Boughey, Judy C; Ching, Christine D; Gilcrease, Michael Z

    2010-06-15

    A wide range of false-negative rates has been reported for sentinel lymph node (SLN) biopsy after preoperative chemotherapy. The purpose of this study was to determine whether histologic findings in negative SLNs after preoperative chemotherapy are helpful in assessing the accuracy of SLN biopsy in patients with confirmed lymph node-positive disease before treatment. Eighty-six patients with confirmed lymph node-positive disease at presentation underwent successful SLN biopsy and axillary dissection after preoperative chemotherapy at a single institution between 1994 and 2007. Available hematoxylin and eosin-stained sections from patients with negative SLNs were reviewed, and associations between histologic findings in the negative SLNs and SLN status (true negative vs false negative) were evaluated. Forty-seven (55%) patients had at least 1 positive SLN, and 39 (45%) patients had negative SLNs. The false-negative rate was 22%, and the negative predictive value was 67%. The negative SLNs from 17 of 34 patients with available slides had focal areas of fibrosis, some with associated foamy parenchymal histiocytes, fat necrosis, or calcification. These histologic findings occurred in 15 (65%) of 23 patients with true-negative SLNs and in only 2 (18%) of 11 patients with false-negative SLNs (P = .03, Fisher exact test, 2-tailed). The lack of these histologic changes had a sensitivity and specificity for identifying a false-negative SLN of 82% and 65%, respectively. Absence of treatment effect in SLNs after chemotherapy in patients with lymph node-positive disease at initial presentation has good sensitivity but low specificity for identifying a false-negative SLN.

  4. Sentinel lymph node identification in breast cancer using periareolar and subdermal injection of the radiopharmaceutical in four points; Identificacao do linfonodo sentinela no cancer de mama com injecao subdermica periareolar em quatro pontos do radiofarmaco

    Energy Technology Data Exchange (ETDEWEB)

    Coelho-Oliveira, Afranio; Rocha, Augusto Cesar Peixoto [Hospital Universitario Clementino Fraga Filho, Rio de Janeiro, RJ (Brazil). Servico de Ginecologia]. E-mail: afranioliveira@hotmail.com; Gutfilen, Bianca; Pessoa, Maria Carolina Pinheiro; Fonseca, Lea Mirian Barbosa da [Universidade Federal, Rio de Janeiro, RJ (Brazil). Faculdade de Medicina. Dept. de Radiologia e Medicina Nuclear

    2004-08-01

    The aim of this study was to identify the sentinel node by periareolar injection of the radiopharmaceutical in four points, regardless of tumor topography. The sentinel node biopsy reduces morbidity in axillary staging. Fifty-seven sentinel node biopsies were prospectively performed in two groups: group A (25 patients) and group B (32 patients). The peritumoral injection technique was used in group A and the new injection technique in four points was used in group B. The sentinel node biopsies were studied by imprint cytology and hematoxylin and eosin staining followed by axillary lymph node dissection in all patients of group A and only in the positive cases of group B. In group A, 88% (22/25) of the sentinel nodes were identified. There was no false negative case; the sensibility and specificity were of 100%. In group B, 96% (31/32) of sentinel nodes were identified and the status of the axillary lymph nodes showed a predictive positive value of 100%. The number of sentinel nodes varied from 1 to 7, mode of 1 and median of 2.7. The hotspot area was 10 to 100 times the background radiation. The periareolar injection in four points seems to be a good lymphatic mapping method for identification of the sentinel node. We suggest the standardization of this site for injections to identify the sentinel node, although further studies to confirm these findings are necessary. (author)

  5. Breast Cancer in Men

    Science.gov (United States)

    ... Older age • B RCA2 gene mutation • F amily history of breast cancer • Gynecomastia (enlargement of the breast tissue) • Klinefelter’s syndrome (a genetic condition related to high levels ...

  6. Advances and surgical decision‐making for breast reconstruction

    National Research Council Canada - National Science Library

    Kronowitz, Steven J; Kuerer, Henry M

    2006-01-01

    ...‐making for breast reconstruction after mastectomy include the breast cancer stage, status of axillary sentinel lymph node, smoking status, body habitus, preexisting scars, prior radiation therapy...

  7. Breast Cancer Immunotherapy

    Institute of Scientific and Technical Information of China (English)

    JuhuaZhou; YinZhong

    2004-01-01

    Breast cancer is a leading cause of cancer-related deaths in women worldwide. Although tumorectomy, radiotherapy, chemotherapy and hormone replacement therapy have been used for the treatment of breast cancer, there is no effective therapy for patients with invasive and metastatic breast cancer. Immunotherapy may be proved effective in treating patients with advanced breast cancer. Breast cancer immunotherapy includes antibody based immunotherapy, cancer vaccine immunotherapy, adoptive T cell transfer immunotherapy and T cell receptor gene transfer immunotherapy. Antibody based immunotherapy such as the monoclonal antibody against HER-2/neu (trastuzumab) is successfully used in the treatment of breast cancer patients with over-expressed HER-2/neu, however, HER-2/neu is over-expressed only in 25-30% of breast cancer patients. Cancer vaccine immunotherapy is a promising method to treat cancer patients. Cancer vaccines can be used to induce specific anti-tumor immunity in breast cancer patients, but cannot induce objective tumor regression. Adoptive T cell transfer immunotherapy is an effective method in the treatment of melanoma patients. Recent advances in anti-tumor T cell generation ex vivo and limited clinical trial data have made the feasibility of adoptive T cell transfer immunotherapy in the treatment of breast cancer patients. T cell receptor gene transfer can redirect the specificity of T cells. Chimeric receptor, scFv(anti-HER-2/neu)/zeta receptor, was successfully used to redirect cytotoxic T lymphocyte hybridoma cells to obtain anti-HER-2/neu positive tumor cells, suggesting the feasibility of treatment of breast cancer patients with T cell receptor gene transfer immunotherapy. Clinical trials will approve that immunotherapy is an effective method to cure breast cancer disease in the near future. Cellular & Molecular Immunology.

  8. Breast Cancer Immunotherapy

    Institute of Scientific and Technical Information of China (English)

    Juhua Zhou; Yin Zhong

    2004-01-01

    Breast cancer is a leading cause of cancer-related deaths in women worldwide. Although tumorectomy,radiotherapy, chemotherapy and hormone replacement therapy have been used for the treatment of breast cancer, there is no effective therapy for patients with invasive and metastatic breast cancer. Immunotherapy may be proved effective in treating patients with advanced breast cancer. Breast cancer immunotherapy includes antibody based immunotherapy, cancer vaccine immunotherapy, adoptive T cell transfer immunotherapy and T cell receptor gene transfer immunotherapy. Antibody based immunotherapy such as the monoclonal antibody against HER-2/neu (trastuzumab) is successfully used in the treatment of breast cancer patients with over-expressed HER-2/neu, however, HER-2/neu is over-expressed only in 25-30% of breast cancer patients. Cancer vaccine immunotherapy is a promising method to treat cancer patients. Cancer vaccines can be used to induce specific anti-tumor immunity in breast cancer patients, but cannot induce objective tumor regression. Adoptive T cell transfer immunotherapy is an effective method in the treatment of melanoma patients. Recent advances in anti-tumor T cell generation ex vivo and limited clinical trial data have made the feasibility of adoptive T cell transfer immunotherapy in the treatment of breast cancer patients. T cell receptor gene transfer can redirect the specificity of T cells. Chimeric receptor, scFv(anti-HER-2/neu)/zeta receptor, was successfully used to redirect cytotoxic T lymphocyte hybridoma cells to obtain anti-HER-2/neu positive tumor cells, suggesting the feasibility of treatment of breast cancer patients with T cell receptor gene transfer immunotherapy. Clinical trials will approve that immunotherapy is an effective method to cure breast cancer disease in the near future.

  9. Effect of patient age, breast density, and topical anesthetic cream on perceived pain with sentinel lymph node scintigraphy.

    Science.gov (United States)

    Chandler, Kimberly J; Hunt, Christopher H; Morreale, Robert; Johnson, Geoffrey B; Peller, Patrick J

    2012-03-01

    Although an extremely useful technique for sentinel lymph node (SLN) identification in breast cancer, injections of (99m)Tc-sulfur colloid can be quite painful. The purpose of this study was to determine whether there is a correlation between perceived pain of injection and age, breast density, or timing of topical anesthetic cream administration. A retrospective review was conducted of women with breast cancer who received injections for sentinel lymphoscintigraphy from 2008 to 2010. After receiving 4 unilateral, intradermal, periareolar injections, women ranked their pain using a comparative scale (0 = no pain; 10 = unbearable pain). There were 3 categories based on length of time that topical anesthetic cream (2.5% lidocaine and 2.5% prilocaine) was applied before injection (1 h prior, 20 min prior, or no cream). In addition, other demographic information and breast density on mammography were analyzed for correlation with the comparative pain scale. Among the 82 women (mean age, 58 y; range, 32-87 y), a wide spectrum on the comparative pain scale was recorded (mean, 4.0; SD, 2.6), with 35% attesting to significant pain, rated 5 or greater. The demographic information and breast density per the Breast Imaging Reporting and Data System were retrospectively reviewed (density: fatty, 14.6%; scattered fibroglandular, 36.6%; heterogeneous, 39.0%; extremely dense, 9.8%). Using bivariate linear regression, no correlation between the comparative pain scale and age (R(2) = 0.0029, P = 0.63) or breast density (R(2) = 0.00049, P = 0.84) was identified. Most patients had topical anesthetic cream applied 20 min before injection (n = 47, or 57.3%) with 24 (29.3%) having topical anesthetic cream applied 1 h beforehand. Eleven women (13.4%) had no topical anesthetic cream applied because of patient preference or concern about allergy. Again, no correlation was found between comparative pain scale and time of application or use of topical anesthetic cream (Kruskal-Wallis: χ(2

  10. Ganglio centinela en cáncer de mama: biopsia selectiva comparada con linfadenectomía axilar. Seguimiento a largo plazo Sentinel ganglion in breast cancer: selective biopsy compared with axillary lymphadectomy

    Directory of Open Access Journals (Sweden)

    E. Goñi

    2009-12-01

    Full Text Available Fundamento. La biopsia selectiva del ganglio centinela (BSGC ha reemplazado a la linfadenectomía axilar (LA, como procedimiento de elección, en el estadiaje del cáncer de mama en estadios iniciales y axila clínicamente negativa. El objetivo de este trabajo es comparar la supervivencia global y libre de eventos de aquellas pacientes a las que se realizó, en el periodo de validación de la técnica, BSGC seguida de LA respecto a las que se practicó BSGC y LA si el ganglio centinela (GC presentaba metástasis. Material y métodos. Se han incluido 148 pacientes, 81 pertenecientes al periodo de validación y 67 al grupo de aplicación clínica. El radiocoloide se administró intra-peritumoralmente, obteniéndose imágenes hasta la visualización del GC, posteriormente en la intervención quirúrgica se procedió a su identificación y extirpación. Resultados. En el grupo de validación, la eficacia de la técnica ha sido del 92,5%, la sensibilidad del 95,6% y la tasa de falsos negativos del 4%. De las 81 pacientes, 75 se encuentran libres de enfermedad (92,6%. De las 67 pacientes pertenecientes al grupo de aplicación clínica, 63 (94% viven libres de enfermedad. Ninguna paciente ha presentado recurrencia ganglionar axilar. Conclusiones. En la validación de la técnica hemos obtenido unos valores que se hallan dentro de las exigencias de calidad generalmente aceptadas. Con una media de seguimiento de 6 años no hemos observado recurrencia axilar en ninguno de los dos grupos. No existe diferencia estadísticamente significativa en la supervivencia global y libre de eventos entre ambos grupos.Background. Selective biopsy of the sentinel ganglion (SBSG has replaced axillary lymphadectomy (AL as the procedure of choice in staging breast cancer in its initial stages and in clinically negative axilla. The aim of this study is to compare global event-free survival of those patients subjected to SBSG followed by AL, during the period of validation of

  11. Breast Cancer and Bone Loss

    Science.gov (United States)

    ... Menopause Map Featured Resource Find an Endocrinologist Search Breast Cancer and Bone Loss July 2010 Download PDFs English ... G. Komen Foundation What is the link between breast cancer and bone loss? Certain treatments for breast cancer ...

  12. Sentinel lymph node biopsy in patients with locally advanced breast cancer after neoadjuvant chemotherapy Biopsia do linfonodo sentinela em câncer na mama localmente avançado pós-quimioterapia neoadjuvante

    Directory of Open Access Journals (Sweden)

    Paulo Henrique Walter Aguiar

    2012-12-01

    Full Text Available PURPOSE: To check the rate of sentinel lymph node (SLN identification in patients with locally advanced breast cancer who underwent neoadjuvant chemotherapy comparing intraoperative contact cytology (imprint and embedded in paraffin and validation of methods. METHODS: A cross-sectional validation of diagnostic test involving 34 patients from the outpatient clinic of the Maternity School Assis Chateaubriand. The patients had locally advanced breast cancer and were treated with neoadjuvant chemotherapy. Those with clinically negative axilla underwent SLN biopsy, studied by imprint and histopathology in paraffin. All patients underwent axillary dissection and its histopathological study. RESULTS: The SLN identification rate was 85.3% (29/34. The sensitivity of imprint associated with paraffin on detection of metastasis compared to histopathology of the axillary content was 84.62% and specificity of 100% with false-negative rate of 12.01% and an accuracy of 92.77%. CONCLUSION: The search for metastases in the SLN by imprint and histopathological analysis in paraffin compared to the gold standard (axillary dissection had a low sensitivity with high rate of false negatives in our sample.OBJETIVO: Verificar a taxa de identificação do linfonodo sentinela (LS em pacientes portadoras de câncer na mama localmente avançado e que foram submetidos à quimioterapia neoadjuvante comparando a citologia de contato intraoperatória (imprint e a inclusão em parafina e validação dos procedimentos. MÉTODOS: Estudo transversal de validação de teste diagnóstico envolvendo 34 pacientes oriundas do Ambulatório da Maternidade-Escola Assis Chateaubriand. As pacientes eram portadoras de câncer na mama localmente avançado e foram tratadas com quimioterapia neoadjuvante. Àquelas com axila clinicamente negativa foram submetidas à biopsia do LS, esse estudado por impint e histopatologia em parafina. Todas as pacientes foram submetidas a esvaziamento axilar e seu

  13. Express and interpretation on American society of clinical oncology guideline update for Sentinel lymph node biopsy in early-stage breast cancer%美国临床肿瘤学会《早期乳腺癌病人前哨淋巴结活检指南》更新介绍与解读

    Institute of Scientific and Technical Information of China (English)

    吴克瑾

    2015-01-01

    2014 April, American Society of Clinical Oncology (ASCO) issued new clinical practice guideline on sentinel lymph node biopsy for patients with early-stage breast cancer in Journal of Clinical Oncology (JCO). This guideline update reflects some changes since the 2005 guideline. Based on randomized clinical trials (RCTs), there are three recommendations: (1) Women without sentinel lymph node (SLN) metastases should not accept axillary lymph node dissection (ALND). (2) In most cases, Women with 1-2 metastatic SLNs going to undergo breast-conserving surgery (BCS) with whole-breast radiotherapy should not adopt ALND. (3) Women with SLN metastases planning to receive mastectomy should be provided ALND. Based on cohort studies and/or informal consensus, there are two prime recommendations. (1) Sentinel node biopsy (SNB) may be offered to those women with operable breast cancer and multicentric tumors, with ductal carcinoma in situ (DCIS) planning to undergo mastectomy, who previously got breast and/or axillary surgery or who accepted preoperative/neoadjuvant systemic therapy. (2) SNB should not be offered to those women with large or locally advanced invasive breast cancer (tumor size T3/T4), inflammatory breast cancer, or DCIS will undergo BCS, or are pregnant.%2014年4月,临床肿瘤学杂志(Journal of Clinical Oncology,JCO)上发表了美国临床肿瘤学会(American Society of Clinical Oncology,ASCO)关于早期乳腺癌病人应用前哨淋巴结活检(sentinel node biopsy,SNB)的若干新推荐。这是继2005年该学会首次推荐《早期乳腺癌病人前哨淋巴结活检指南》后的第一次更新。基于随机临床试验(RCT)证据,该项指南提出3条推荐:(1)无前哨淋巴结(sentinel lymph node,SLN)转移的女性病人不必接受腋窝淋巴结清扫术(axillary lymph node dissection, ALND);(2)大多数伴有1~2个SLN转移,且计划接受保乳术及术后全乳放疗者无需行ALND;(3

  14. Advances in sentinel node dissection in prostate cancer from a technical perspective.

    Science.gov (United States)

    Acar, Cenk; Kleinjan, Gijs H; van den Berg, Nynke S; Wit, Esther Mk; van Leeuwen, Fijs Wb; van der Poel, Henk G

    2015-10-01

    The most important feature of sentinel node biopsy for prostate cancer procedure is that staging can be improved. Sentinel nodes might be found outside the extended pelvic lymph node dissection template what renders the sentinel node additive of extended pelvic lymph node dissection. At the same time, staging within the template can be further refined. We reviewed the literature regarding the sentinel node biopsy procedure for prostate cancer. PubMed and Embase were searched for all English-language publications from January 1999 to September 2014 by using the keywords as "prostate cancer" and "sentinel lymph node" plus "biopsy" "dissection" and/or "procedure." The present review discusses step-by-step sentinel node biopsy for prostate cancer. Topics of discussion are: (i) preoperative sentinel node mapping (tracers and imaging); (ii) intraoperative sentinel node identification (surgical procedure and outcome); and (iii) novelties to improve sentinel node identification (pre- and intraoperative approaches). Conventional sentinel node mapping is carried out after the injection of a (99m) Tc-based tracer and subsequent preoperative imaging; for example, lymphoscintigraphy and single-photon emission computed tomography/computed tomography. This approach allowed the detection of sentinel nodes outside the extended lymph node dissection template in 3.6-36% of men with intermediate- and high-risk prostate cancer. Hereby, an overall false negative rate of sentinel nodes was reported between 0% and 24.4%. To further refine the intraoperative sampling procedure, novel imaging methods such as fluorescence imaging have been introduced. Prospective randomized comparison studies are required to confirm the added benefit of sentinel template directed nodal dissection. A proper and obtainable end-point of such a study could be the number of removed positive nodes for carrying out nodal dissection with or without sentinel template directed dissection. Similarly, the clinical

  15. Meta-analysis of sentinel lymph node biopsy at the time of prophylactic mastectomy of the breast

    Science.gov (United States)

    Zhou, Wen-Bin; Liu, Xiao-An; Dai, Jun-Cheng; Wang, Shui

    2011-01-01

    Background Prophylactic mastectomy is performed to decrease the risk of breast cancer in women at high risk for the disease. The benefit of sentinel lymph node biopsy (SLNB) at the time of prophylactic mastectomy is controversial, and we performed a meta-analysis of the reported data to assess that benefit. Methods We searched MEDLINE, EMBASE and the Cochrane Library databases from January 1993 to December 2009 for studies on patients who underwent SLNB at the time of prophylactic mastectomy. Two reviewers independently evaluated all the identified papers, and only retrospective studies were included. We used a mixed-effect model to combine data. Results We included 6 studies in this review, comprising a total study population of 1251 patients who underwent 1343 prophylactic mastectomies. Of these 1343 pooled prophylactic mastectomies, the rate of occult invasive cancer (21 cases) was 1.7% (95% confidence interval [CI] 1.1%–2.5%), and the rate of positive SLNs (23 cases) was 1.9% (95% CI 1.2%–2.6%). In all, 36 cases (2.8%, 95% CI 2.0%–3.8%) led to a significant change in surgical management as a result of SLNB at the time of prophylactic mastectomy. In 17 cases, patients with negative SLNs were found to have invasive cancer at the time of prophylactic mastectomy and avoided axillary lymph node dissection (ALND). In 19 cases, patients with positive SLNBs were found not to have invasive cancer at the time of prophylactic mastectomy and needed a subsequent ALND. Of the 23 cases with positive SLNs, about half the patients had locally advanced disease in the contralateral breast. Conclusion Sentinel lymph node biopsy is not suitable for all patients undergoing prophylactic mastectomy, but it may be suitable for patients with contralateral, locally advanced breast cancer. PMID:21651834

  16. Cancer in radar technicians exposed to radiofrequency/microwave radiation: sentinel episodes.

    Science.gov (United States)

    Richter, E; Berman, T; Ben-Michael, E; Laster, R; Westin, J B

    2000-01-01

    Controversy exists concerning the health risks from exposures to radiofrequency/microwave irradiation (RF/MW). The authors report exposure-effect relationships in sentinel patients and their co-workers, who were technicians with high levels of exposure to RF/MW radiation. Information about exposures of patients with sentinel tumors was obtained from interviews, medical records, and technical sources. One patient was a member of a cohort of 25 workers with six tumors. The authors estimated relative risks for cancer in this group and latency periods for a larger group of self-reported individuals. Index patients with melanoma of the eye, testicular cancer, nasopharyngioma, non-Hodgkin's lymphoma, and breast cancer were in the 20-37-year age group. Information about work conditions suggested prolonged exposures to high levels of RF/MW radiation that produced risks for the entire body. Clusters involved many different types of tumors. Latency periods were extremely brief in index patients and a larger self-reported group. The findings suggest that young persons exposed to high levels of RF/MW radiation for long periods in settings where preventive measures were lax were at increased risk for cancer. Very short latency periods suggest high risks from high-level exposures. Calculations derived from a linear model of dose-response suggest the need to prevent exposures in the range of 10-100 microw/cm(2).

  17. 乳腺癌患者前哨淋巴结活检术后生活质量研究%Quality of Life after Sentinel Lymph Node Biopsy in Patients with Breast Cancer

    Institute of Scientific and Technical Information of China (English)

    王春英; 季玮; 孙晓; 陈鹏; 王永胜

    2011-01-01

    Objective To evaluate the quality of life after sentinel lymph node biopsy (SLNB) in patients with breast cancer. Methods From January 2004 to December 2006, 591 patients with breast cancer who were suitable for SLNB were divided into SLNB group (n=339) and axillary lymph node dissection (ALND) group (n = 252). All patients didn't have the upper extremity joints disease, the vascular nerve disease. And the cervical spondylosis previously. Results ①In patients with SLNB, the circumferences of upper arm in one, two, and three weeks after operation were similar to those before operation (P = 0. 232, P = 0. 318, and P = 0. 415, respectively). While, in patients with ALND, the circumferences of upper arm in one or two weeks after operation were significantly bigger than those before operation (P=0. 011, P=0. 041, respectively) , and the circumference in three weeks after operation was similar to that before operation (P = 0. 290). ②In patients with SLNB, the outreach angles of shoulder joint in one and two weeks after operation were significantly smaller than those before operation (P = 0. 031, P = 0. 043, respectively), and the angle in three weeks after operation was similar to that before operation (P=0. 196). However, in patients with ALND, the angles in one, two or three weeks after operation were significantly smaller than those before operation (all P<0. 001). ③The retention time of drainage tube in patients with ALND who received breast conserving surgery or mastectomy was significantly longer than that in patients with SLNB who received mastectomy (all P<0. 001). ④The infection rate and the sensory disjunction rate in patients with ALND were significantly higher than those in patients with SLNB (P=0. 002, P<0. 001, respectively). Conclusions For patients with lymph node negative breast cancer, SLNB could decrease postoperative complications, and improve the quality of life. It could also save money by reducing hospital stay.%目的 对比分析乳腺

  18. Breast cancer statistics, 2011.

    Science.gov (United States)

    DeSantis, Carol; Siegel, Rebecca; Bandi, Priti; Jemal, Ahmedin

    2011-01-01

    In this article, the American Cancer Society provides an overview of female breast cancer statistics in the United States, including trends in incidence, mortality, survival, and screening. Approximately 230,480 new cases of invasive breast cancer and 39,520 breast cancer deaths are expected to occur among US women in 2011. Breast cancer incidence rates were stable among all racial/ethnic groups from 2004 to 2008. Breast cancer death rates have been declining since the early 1990s for all women except American Indians/Alaska Natives, among whom rates have remained stable. Disparities in breast cancer death rates are evident by state, socioeconomic status, and race/ethnicity. While significant declines in mortality rates were observed for 36 states and the District of Columbia over the past 10 years, rates for 14 states remained level. Analyses by county-level poverty rates showed that the decrease in mortality rates began later and was slower among women residing in poor areas. As a result, the highest breast cancer death rates shifted from the affluent areas to the poor areas in the early 1990s. Screening rates continue to be lower in poor women compared with non-poor women, despite much progress in increasing mammography utilization. In 2008, 51.4% of poor women had undergone a screening mammogram in the past 2 years compared with 72.8% of non-poor women. Encouraging patients aged 40 years and older to have annual mammography and a clinical breast examination is the single most important step that clinicians can take to reduce suffering and death from breast cancer. Clinicians should also ensure that patients at high risk of breast cancer are identified and offered appropriate screening and follow-up. Continued progress in the control of breast cancer will require sustained and increased efforts to provide high-quality screening, diagnosis, and treatment to all segments of the population.

  19. [Prospect and guideline update of sentinel lymph node biopsy for patients with early-stage breast carcinoma].

    Science.gov (United States)

    Zhou, Mei-qi; Chen, Hai-long; Hu, Yue; Deng, Yong-chuan; Zheng, Shu

    2014-07-01

    Axillary lymph nodes are the most common and initial site of metastasis of breast carcinoma. Precise axillary staging of breast carcinoma before initial treatment is crucial as it allows efficient identification for local and systemic treatment options, and provides prognostic information. Sentinel lymph node biopsy (SLNB) is an accurate minimally invasive technology for axillary staging. Although top evidence of high-quality clinical trials showed that SLNB could safely and effectively replace axillary lymph node dissection (ALND) for axillary negative patients with decrease in complications and improvement in quality of life, there are specific indications and contraindications for SLNB. Clinicians should balance the compliance of guideline and native clinical practice, especially for the circumstance of multifocal/multicentric lesion, breast biopsy history, and neoadjuvant chemotherapy. With the accumulation of clinical practice and new results of clinical trials, axillary therapy has changed from unique surgery to patient-tailored multi-disciplinary intervention, although ALND should be recommended traditionally if SLNB is positive. Intensive and accurate preoperative axillary staging is gradually valued by clinicians. Development of imaging modality especially ultrasonography and ultrasound-guided biopsy can identify some extra lymph node positive patients directly to ALND with avoidance of unnecessary SLNB. Thus, the positive rate of SLNB will decline significantly. It seems possible that axillary management will step into a noninvasive era abandoning SLNB in some patients with small breast cancer. In this article we review the prospect and guideline update of SLNB for patients with early-stage breast cancer.

  20. Supine MRI for regional breast radiotherapy: imaging axillary lymph nodes before and after sentinel-node biopsy

    Science.gov (United States)

    van Heijst, Tristan C. F.; Eschbach-Zandbergen, Debora; Hoekstra, Nienke; van Asselen, Bram; Lagendijk, Jan J. W.; Verkooijen, Helena M.; Pijnappel, Ruud M.; de Waard, Stephanie N.; Witkamp, Arjen J.; van Dalen, Thijs; Desirée van den Bongard, H. J. G.; Philippens, Marielle E. P.

    2017-08-01

    Regional radiotherapy (RT) is increasingly used in breast cancer treatment. Conventionally, computed tomography (CT) is performed for RT planning. Lymph node (LN) target levels are delineated according to anatomical boundaries. Magnetic resonance imaging (MRI) could enable individual LN delineation. The purpose was to evaluate the applicability of MRI for LN detection in supine treatment position, before and after sentinel-node biopsy (SNB). Twenty-three female breast cancer patients (cTis-3N0M0) underwent 1.5 T MRI, before and after SNB, in addition to CT. Endurance for MRI was monitored. Axillary levels were delineated. LNs were identified and delineated on MRI from before and after SNB, and on CT, and compared by Wilcoxon signed-rank tests. LN locations and LN-based volumes were related to axillary delineations and associated volumes. Although postoperative effects were visible, LN numbers on postoperative MRI (median 26 LNs) were highly reproducible compared to preoperative MRI when adding excised sentinel nodes, and higher than on CT (median 11, p  <  0.001). LN-based volumes were considerably smaller than respective axillary levels. Supine MRI of LNs is feasible and reproducible before and after SNB. This may lead to more accurate RT target definition compared to CT, with potentially lower toxicity. With the MRI techniques described here, initiation of novel MRI-guided RT strategies aiming at individual LNs could be possible.

  1. PET scan for breast cancer

    Science.gov (United States)

    ... radioactive substance (called a tracer) to look for breast cancer. This tracer can help identify areas of cancer ... only after a woman has been diagnosed with breast cancer. It is done to see if the cancer ...

  2. Breast cancer

    Science.gov (United States)

    ... women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med . 2014;160:271-281. PMID: 24366376 www.ncbi. ... Cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med . [Epub ahead of print 12 January 2016] doi: ...

  3. Sentinel lymph node mapping in early stage of endometrial and cervical cancers

    Directory of Open Access Journals (Sweden)

    Tajossadat Allameh

    2015-01-01

    Full Text Available Background: The sentinel lymph node (SLN is defined as the first chain node in the lymphatic basin that receives primary lymphatic flow. If the SLN is negative for metastatic disease, then other nodes are expected to be disease-free. SLN techniques have been extensively applied in the staging and treatment of many tumors, including melanoma, breast and vulvar cancers. This study aims to evaluate our technique in SLN mapping in early stage endometrial and cervical cancers. Materials and Methods: We scheduled a cross-sectional pilot study for patients undergoing staging surgery for endometrial and cervical cancer from November 2012 to February 2014 in Beheshti and Sadoughi Hospitals. Our SLN mapping technique included 1 h preoperative or intraoperative injection of 4 ml of 1% methylene blue dye in the tumor site. At the time of surgery, blue lymph nodes were removed and labeled as SLNs. Then systematic lymph node dissection was completed, and all of the nodes were sent for pathologic examination concerning metastatic involvement. All of the sentinel nodes were first stained with hematoxylin and eosin and examined. Those negative in this study were then stained with immunohistochemistry using anti-keratin antibody. Descriptive statistics, sensitivity, negative predictive values (NPV, false negative (FN and detection rates were calculated. Results: Twenty-three patients including 62% endometrial and 38% cervical cancers enrolled in the study. Median of SLN count in the endometrial and cervical cancers was 3 and 2, respectively. Among endometrial and cervical cancers, detection rate of metastatic disease was 80% and 87.5%, respectively. The FN rate for this technique was 0 and the sensitivity and NPV are 100% for both endometrial and cervical cancers. Conclusion: Considering the lower risk of metastases in early stage of both endometrial and cervical cancers, SLN technique allows for confident and accurate staging of cancer.

  4. Risks of Breast Cancer Screening

    Science.gov (United States)

    ... of dying from breast cancer. MRI (magnetic resonance imaging) in women with a high risk of breast ... a mammogram , the breast is placed between 2 plates that are pressed together. Pressing the breast helps ...

  5. BREAST CANCER AND EXERCISE

    Science.gov (United States)

    2008-03-19

    Prevent Osteoporosis and Osteoporotic Fractures; Improve Quality of Life; Improve Weight Control, and Muscular and Cardiovascular Fitness; Help the Patients to Return to Working Life; Reduce the Risk of Breast Cancer Recurrence; Prevent Other Diseases and Reduce All-Cause Mortality in Patients With Primary Breast Cancer.

  6. Synchronous bilateral breast cancer in a male

    Science.gov (United States)

    Rubio Hernández, María Caridad; Díaz Prado, Yenia Ivet; Pérez, Suanly Rodríguez; Díaz, Ronald Rodríguez; Aleaga, Zaili Gutiérrez

    2013-01-01

    Male breast cancer, which represents only 1% of all breast cancers, is occasionally associated with a family history of breast cancer. Sporadic male breast cancers presenting with another primary breast cancer are extremely rare. In this article, we report on a 70-year-old male patient with bilateral multifocal and synchronous breast cancer and without a family history of breast cancer. PMID:24319497

  7. General Information about Breast Cancer

    Science.gov (United States)

    ... Screening Research Breast Cancer Treatment (PDQ®)–Patient Version General Information About Breast Cancer Go to Health Professional ... are linked by thin tubes called ducts. Enlarge Anatomy of the female breast. The nipple and areola ...

  8. CDC Vital Signs: Breast Cancer

    Science.gov (United States)

    ... 2.65 MB] Read the MMWR Science Clips Breast Cancer Black Women Have Higher Death Rates from Breast ... of Page U.S. State Info Number of Additional Breast Cancer Deaths Among Black Women, By State SOURCE: National ...

  9. Promising results using sentinel node biopsy as a substitute for radical lymphadenectomy in endometrial cancer staging

    DEFF Research Database (Denmark)

    Mosgaard, Berit Jul; Skovlund, Vibeke Ravn; Hendel, Helle Westergren

    2013-01-01

    The objective of this study was to evaluate the efficacy of the sentinel node (SN) procedure in endometrial cancer patients.......The objective of this study was to evaluate the efficacy of the sentinel node (SN) procedure in endometrial cancer patients....

  10. Endoscopic Sentinel Lymph Node Biopsy in Breast Cancer: Clinical Application and Effect Analysis%腔镜下乳腺癌前哨淋巴结活检临床应用及效果分析

    Institute of Scientific and Technical Information of China (English)

    张毅; 杨新华; 范淋军; 唐鹏; 王姝姝; 姜军

    2012-01-01

    Objective To investigate the feasibility and operation effect of endoscopic sentinel lymph node biopsy (SLNB) in breast cancer. Methods The data of 410 breast cancer patients who underwent SLNB (including 107 patients with endoscopy and 303 with open operation) were analyzed in our hospital from January 2009 to March 2012. SLNB was performed by using methylene blue staining or the combination of methylene blue and 99Tcm-sulfur colloid tracing. Results The successful rate of SLN detection with methylene blue and 99Tcm-sulfur colloid tracing was 94. 56% (139/147) in open operation group and 94. 25% (82/87) in endoscopy group. The successful rate of SLN detection with methylene blue was 88.46% (138/156) in open operation group and 85. 00% (17/20) in endoscopy group. The mean of detected SLN number with combined method or methylene blue was 1. 90/1. 98 in open operation group and 1. 91/1. 82 in endoscopy group respectively. SLN-positive rate was 22. 30% (31/139) and 25. 36% (35/138) in open operation group, and 19. 51% (16/82) and 23. 53% (4/17) in endoscopy group, respectively. The rate of subcutaneous effusion in endoscopy group was higher than that in open operation group (P-0. 001) , but other postoperative complications presented no significant difference. Conclusions Endoscopic SLNB can obtain the similar safety and the clinical efficacy with traditional SLNB, but superior cosmetic effect. So it is worthy of clinical application in breast cancer.%目的 探讨在腔镜下进行乳腺癌前哨淋巴结活检(SLNB)的可行性及手术效果.方法 分析笔者所在医院2009年1月至2012年3月期间行乳腺癌SLNB病例,其中腔镜下活检107例,开放活检303例,采用放射性核素+亚甲蓝联合法与单用亚甲蓝法进行前哨淋巴结(SLN)探测.结果 开放组SLN检出率联合法为94.56%(139/147),亚甲蓝法为88.46%(138/156);腔镜组联合法为94.25% (82/87),亚甲蓝法为85.00% (17/20).检出前哨淋巴结

  11. Breast Cancer and Bone Loss

    Science.gov (United States)

    ... Balance › Breast Cancer and Bone Loss Fact Sheet Breast Cancer and Bone Loss July, 2010 Download PDFs English ... JoAnn Pinkerton, MD What is the link between breast cancer and bone loss? Certain treatments for breast cancer ...

  12. Intracystic papillary breast cancer: a clinical update

    Science.gov (United States)

    Reefy, Sara Al; Kameshki, Rashid; Sada, Dhabya Al; Elewah, Abdullah Al; Awadhi, Arwa Al; Awadhi, Kamil Al

    2013-01-01

    Introduction: Intracystic (encysted) papillary cancer (IPC) is a rare entity of breast cancer accounting for approximately (1–2%) of all breast tumours [1], usually presenting in postmenopausal women and having an elusive natural history. The prediction of the biological behaviour of this rare form of breast cancer and the clinical outcome showed its overall favourable prognosis; however, its consideration as a form of ductal carcinoma in situ with non-invasive nature is to be reconsidered as it has been shown to present histologically with invasion of basement membrane and even metastasis [2]. The objective of this review is to shed some light on this rare, diagnostically challenging form of breast cancer, including its radiological, histological, and molecular characteristics and its pathological classification. The final goal is to optimize the clinical management including the role of sentinel lymph node biopsy (SLNB), general management with adjuvant radiotherapy (RT), mammary ductoscopy, and hormonal treatment. Methods: A literature review, facilitated by Medline, PubMed, and the Cochrane database, was carried out using the terms ‘Intracystic (encysted) papillary breast cancer’. Results: Intracystic papillary breast cancer (IPC) is best managed in the context of a multidisciplinary team. Surgical excision of the lump with margins in excess of 2 mm is considered satisfactory. Sentinel lymph node biopsy (SLNB) is recommended as data have shown the possibility of the presence of invasive cancer in the final histology. RT following IPC alone is of uncertain significance as this form of cancer is usually low grade and rarely recurs. However, if it is associated with DCIS or invasive cancer and found in young women, radiotherapy may be prudent to reduce local recurrence. Large tumours, centrally located or in cases where breast conserving surgery is unable to achieve a favourable aesthetic result, a skin sparing mastectomy with the opportunity for immediate

  13. Breast reconstruction after breast cancer.

    Science.gov (United States)

    Serletti, Joseph M; Fosnot, Joshua; Nelson, Jonas A; Disa, Joseph J; Bucky, Louis P

    2011-06-01

    After reading this article, the participant should be able to: 1. Describe the mental, emotional, and physical benefits of reconstruction in breast cancer patients. 2. Compare the most common techniques of reconstruction in patients and detail benefits and risks associated with each. 3. Outline different methods of reconstruction and identify the method considered best for the patient based on timing of the procedures, body type, adjuvant therapies, and other coexisting conditions. 4. Distinguish between some of the different flaps that can be considered for autologous reconstruction. Breast cancer is unfortunately a common disease affecting millions of women, often at a relatively young age. Reconstruction following mastectomy offers women an opportunity to mollify some of the emotional and aesthetic effects of this devastating disease. Although varying techniques of alloplastic and autologous techniques are available, all strive to achieve the same goal: the satisfactory reformation of a breast mound that appears as natural as possible without clothing and at the very least is normal in appearance under clothing. This article summarizes the various approaches to breast reconstruction and offers a balanced view of the risks and benefits of each, all of which in the end offer the opportunity for excellent and predictable results with a high degree of patient satisfaction.

  14. Immunolymphoscintigraphy for Metastatic Sentinel Nodes

    DEFF Research Database (Denmark)

    Chakera, A.H.; Nielsen, B.S.; Madsen, J.;

    2011-01-01

    Aim. To develop a method and obtain proof-of-principle for immunolymphoscintigraphy for identification of metastatic sentinel nodes. Methods. We selected one of four tumour-specific antibodies against human breast cancer and investigated (1), in immune- deficient (nude) mice with xenograft human...... in healthy rabbits. Results and Conclusion. Our paper suggests the theoretical possibility of a model of dual isotope immuno-lymphoscintigraphy for noninvasive, preoperative, malignant sentinel node imaging....

  15. Subareolar injection of methylene blue versus intradermal injection for sentinel lymph node mapping and biopsy in breast cancer%乳腺癌前哨淋巴结活检乳晕下、皮内染料注射法对比

    Institute of Scientific and Technical Information of China (English)

    秦长岭; 李汉贤; 赵晓春; 欧阳军; 曾郁

    2008-01-01

    目的 比较美蓝乳晕下(SA)注射法与皮内(ID)注射法行乳腺癌前哨淋巴结活检(SLNB)的检出率、灵敏度.方法 将62例T1、T2期乳腺癌患者按注射部位不同以1:1随机分为SA组和ID组.硬膜外麻醉后,取1%美蓝(MB)5 ml注入乳晕四周皮下或肿瘤上方对应皮肤周围,注射后10 min取腋窝切口,切开腋筋膜解剖腋窝,循蓝染淋巴管寻找蓝染淋巴结(即SLN),行SLNB,然后实施腋窝淋巴结清扫(ALND).所有标本送病检.结果 SA组SLNB检出率为87.1%(27/31),灵敏度为85.7%(6/7),准确率为96.3%(26/27),假阴性率为14.3%(1/7).ID组SLNB检出率为93.5%(29/31),灵敏度为87.5%(7/8),准确度为96.6%(28/29),假阴性率为12.5%(1/8).两组间差异无统计学意义(P>0.05).结论 采用ID法行乳腺癌SLNB的准确率和灵敏度与SA法相当,但尚需要大样本随机研究做进一步证实.%Objective To compare the accuracy and success rate of two techniques,intradermal injection of methylene blue versus subareolar injection in sentinel lymph node localization in the management of early breast cancer. Methods Sixty -two patients with clinical stage T1-T2, No breast cancer who were eligible for the study were randomized in a 1 : 1 manner to one of two injection routes for methylene blue (MB) : ID,SA. Immediately after the induction of epidural anesthesia, patients were injected with 5 ml of 1% MB in the SA location or the skin overlying the tumor. Then 10 minutes later, the blue SLNs were identified by searching for the blue lymphatic vessel and the blue lymph node via a small axillary incision, followed by sentinel lymph node biopsy and axillary dissection. All removed nodes were sent for pathological examination, with the sentinel node tagged separately from other nodes. Results The sentinel lymph node was identified in 27/31 (87.1% ) SA and 29/31 (93.5%) ID ( overall P = 0. 668 ). SLNB accuracy, sensitivity, false - negative rate were 96. 3% (26/27),85.7% (6/7), 14. 3% (1/7) ,87

  16. DETECTION OF SENTINEL LYMPH NODE IN EARLY CERVICAL CANCER

    Institute of Scientific and Technical Information of China (English)

    刘琳; 李斌; 章文华

    2004-01-01

    Objective: To assess the value of sentinel lymph node (SLN) localization by lymphoscintigraphy and gamma probe detection in early cervical cancer. Methods: A total of 27 patients with operable invasive early cervical cancer and clinically proved negative pelvic lymph nodes were included in this study. The 99Tcm-dextran of 74 MBq (2 mCi) was injected around the cervix at 2( and 10(. Lymphoscintigraphy and gamma probe detection were used to find the SLN. Results: The SLN was identified in 27 patients. The sensitivity and specificity of the SLN detection to predict the metastasis of the pelvic lymph node were 100% and 100% respectively. Conclusion: Identification of the SLN using radionuclide is feasible and possible in women with early cervical cancer.

  17. Comparison of sentinel lymph node detection by methylene blue and carbon nanoparticle suspension injection in early breast cancer%纳米炭混悬注射液与亚甲蓝注射液在早中期乳腺癌前哨淋巴结活检中的应用

    Institute of Scientific and Technical Information of China (English)

    葛洁; 颜博; 曹旭晨

    2011-01-01

    Objective To compare the efficacy of methylene blue versus carbon nanopartIcles suspension injection as a tracer for sentinel lymph node detection in breast cancer and the factors associated with the definition of sentinel lymph node biopsy. Methods One hundred and sixteen patients with early breast cancer underwent intraoperative sentinel lymph node biopsy, among them 51 patients accepted injection of methylene blue dye, while 65 patients received carbon nanopartIcles suspension injection. The mapping procedures and SLNB were performed using subareolar or peritumoral injection of methylene blue or carbon nanopartIcles suspension injection at the site of the primary breast cancer, followed by the axil lary lymph node dissection (ALND). All the SLN and ALN were evaluated pathologically post-operatively.Results In the MB group, the false-negative, sensitivity, accuracy, specificity rate of SLNB detection were 88.2%, 13.3%, 86.7%, 84. 3%, and 100%, respectively. In the CNP group, the false-negative,sensitivity, accuracy, specificity rate of SLNB detection were 98.5%, 8.7%, 91.3%, 95.4%, and 100%,respectively. The false-negative, sensitivity, specificity rate in the CNP group were trended to be higher than those in the MB group, but the difference of the accuracy and detection rates are significant ( P < 0.05 ).Conclusions Compared with methylene blue solution, the carbon nanoparticle injection shows a better stability and operability for the sentinel lymph node detection in breast cancers.%目的 探讨纳米炭混悬注射液在乳腺癌前哨淋巴结(SLN)活检中的应用价值和优势.方法 随机将无腋窝淋巴结(ALN)转移的T1N0M0~T2N0M0乳腺癌患者116例分为两组,分别给予亚甲蓝注射液和纳米炭混悬注射液示踪.其中亚甲蓝组51例,纳米炭组65例.在摘取SLN后进行乳腺癌保乳根治术或乳腺癌仿根治术,对全部ALN进行清扫,比较两组患者中SLN的检出率、假阴性率、特异性

  18. The important value of 99Tcm-SC combining methylene blue in sentinel lymph node biopsy of breast cancer%99Tcm硫胶体联合美蓝在乳腺癌前哨淋巴结活检中的临床应用价值

    Institute of Scientific and Technical Information of China (English)

    崔志超; 王宇; 赵亚婷; 胡继卫; 马杰; 张景华; 胡万宁

    2012-01-01

    Objective To study the feasibility and accuracy of sentinel lymph node biopsy(SLNB)in early breast cancer.Methods In 76 cases of T1 or T2 breast cancer,sentinel lymph nodes identified by 99Tcm-sulfur colloid (99Tcm-SC )combining methylene blue were excised for biopsy. Sentinel lymph node was examined pathologically to observe the conformance rate and to study value of the combination approach of SLNB of early breast cancer.Results Sentinel lymph node was identified in 76 cases.In 7 cases axillary lymph node dissection was performed because the SLNB was positive.The sensitivity rate of 99Tcm-SC and methylene blue method was 85.7%(6/7)and 71.4% (5/7 ).The accuracy rate of 99Tcm-SC and methylene blue method was 98.7 % (75/76)and 97.4% (74/76).The false negative rate of 99Tcm-SC and methylene blue method was 14.3% (1/7)and 28.6%(2/7).The sensitivity rate and the accuracy rate of combination method was 100% (7/7,76/76).The false positive rate was zero(0/7).Conclusion 99Tcm-SC combining methylene blue can decrease the false negative rate of SLNB in early breast cancer.%目的 探讨99Tcm硫胶体(99Tcm-sulfur colloid,99Tcm-SC)联合美蓝在早期乳腺癌前哨淋巴结活检(SLNB)中的可行性、准确性及临床应用价值.方法 采用99Tcm-SC联合美蓝对76例T1~ 2N0M0乳腺癌患者进行SLNB,将切除的前哨淋巴结行病理检查了解其符合率,探讨联合法在早期乳腺癌SLNB中的临床应用价值.结果 成功确定患者前哨淋巴结76例,7例前哨淋巴结病理检测阳性并行腋窝淋巴结清扫,99Tcm-SC灵敏度为85.7% (6/7),准确性为98.7%( 75/76),假阴性率为14.3%( 1/7),美蓝法灵敏度为71.4% (5/7),准确性为97.4% (74/76),假阴性率为28.6% (2/7).联合法灵敏度、准确性为100.0%(7/7,76/76),假阳性率为0(0/7).结论 99Tcm-SC联合美蓝可明显降低早期乳腺癌SLNB的假阴性率.

  19. Breast Cancer in Young Women

    Science.gov (United States)

    ... NPCR 2017 CDC National Cancer Conference Stay Informed Breast Cancer in Young Women Recommend on Facebook Tweet Share Compartir Syndicate this page Marleah's family history of breast cancer was her motivation for pursuing a career where ...

  20. Application of Radiocolloid Combined with Methylene Blue in Sentinel Lymph Node Biopsy for Patients with Early Breast Cancer%核素标记法联合亚甲蓝在早期乳腺癌前哨淋巴结活检中的应用价值

    Institute of Scientific and Technical Information of China (English)

    卢振铎; 刘真真; 杨辉; 焦得闯; 乔江华; 李文亮; 崔树德

    2012-01-01

    [Purpose] To investigate the value of radiocolloid combined with methylene blue dye in sentinel lymph node biopsy (SLNB) for patients with early breast cancer. [Methods] SLNB followed by axillary lymph node dissection (ALND) were carried out in 65 breast cancer patients,and SLN was detected by To-sulfur colliod and methylene blue. [Results] The success rate,accuracy rate and false negative rate of SLNB were 100.00% ,98.46% and 6.25% Respectively. [Conclusions ] Combination of radiocolliod and methylene blue tracer are practical in detecting sentinel lymph node,and it can effectively predict the metastases of axillary lymph node.%[目的]探讨核素标记法联合亚甲蓝在早期乳腺癌前哨淋巴结活检中的临床应用价值.[方法]对65例临床确诊的早期乳腺癌患者联合应用mTc-硫胶体和亚甲蓝标记法进行前哨淋巴结活检,并行腋淋巴结清扫术.[结果]前哨淋巴结活检成功率为100.00%,准确率98.46%,假阴性率6.25%.[结论]核素标记和亚甲蓝联合定位法在前哨淋巴结活检中具有明确的实用性,能有效预测早期乳腺癌腋窝淋巴结转移状况.

  1. Breast Cancer In Women

    Science.gov (United States)

    This infographic shows the Breast Cancer Subtypes in Women. It’s important for guiding treatment and predicting survival. Know the Science: HR = Hormone receptor. HR+ means tumor cells have receptors for the hormones estrogen or progesterone, which can promote the growth of HR+ tumors. Hormone therapies like tamoxifen can be used to treat HR+ tumors. HER2 = Human epidermal growth Factor receptor, HER2+ means tumor cells overexpress (make high levels of) a protein, called HE2/neu, which has been shown to be associated with certain aggressive types of breast cancer. Trastuzumab and some other therapies can target cells that overexpress HER2. HR+/HER2, aka “LuminalA”. 73% of all breast cancer cases: best prognosis, most common subtype for every race, age, and poverty level. HR-/HER2, aka “Triple Negative”: 13% of all breast cancer cases, Worst prognosis, Non-Hispanic blacks have the highest rate of this subtype at every age and poverty level. HR+/HER2+, aka “Luminal B”, 10% of all breast cancer cases, little geographic variation by state. HR-/HER2+, aka”HER2-enriched”, 5% of all breast cancer cases, lowest rates for all races and ethnicities. www.cancer.gov Source: Special section of the Annual Report to the Nation on the Status of Cancer, 1975-2011.

  2. Hormone receptors in breast cancer

    NARCIS (Netherlands)

    Suijkerbuijk, K. P M; van der Wall, E.; van Diest, P. J.

    2016-01-01

    Steroid hormone receptors are critical for the growth and development of breast tissue as well as of breast cancer. The importance of the role estrogens in breast cancer has been delineated for more than 100 years. The analysis of its expression has been used not only to classify breast cancers but

  3. Video-assisted breast surgery can sample the second and third sentinel nodes to omit axillary node dissection for sentinel-node-positive patients.

    Science.gov (United States)

    Yamashita, K; Shimizu, K

    2009-07-01

    The preservation of the axillary node (AN) has become standard therapy for early breast cancer patients with a metastasis-positive sentinel node (SN). However, about half of the patients with metastasis in the SN have no metastasis in the other AN. Late-phase three-dimensional computed tomographic lymphography (3D-CT LG) of the breast can show the axillary lymphatic architecture from the SN into the venous angle. These nodes are classified into five groups. For the sake of aesthetics, video-assisted breast surgery (VABS) was used to sample the second and third nodes shown by 3D-CT LG. For marking the SN on the skin, 3D-CT LG was performed the day before the surgery. Iopamiron 300 (2 ml) was injected subcutaneously. A 16-channel multidetector-row helical CT image was reconstructed to produce a 3D image of the lymph ducts and nodes. A biopsy of the SN was performed by the dye-staining method using Visiport-aided endoscopy for VABS. Stained nodes were located by following the dye in the lymph ducts on a video monitor. For SN-metastasis-positive patients, standard AN dissection was performed under video assistance. Since July 2002, the authors have performed SN biopsy for 186 patients as well as 3D-CT LG and VABS SN biopsy for 146 patients. Five chained-node groups were shown. Even in the multiple SN case, the lymph ducts were converging into the second node. The second and third nodes beyond the SN were detected and sampled in 82 patients (56.2%) by VABS assisted with 3D-CT LG. Sentinel node metastasis (n = 40) involved SN metastasis alone in 21 cases (52.5%) and SN, second-node, and third-node metastasis in eight cases. A reviewed lymphoid path by 3D-CT LG confirmed that metastasis occurred in order of lymph flow. The use of 3D-CT LG-guided VABS SN biopsy of the second and third nodes will predict SN metastasis alone and help to obviate the need for dissection of more nodes.

  4. [Synchronous male bladder cancer and breast cancer - a case report].

    Science.gov (United States)

    Yabe, Nobushige; Murai, Shinji; Kunugi, Chikara; Nakadai, Jyunpei; Oto, Ippei; Yoshikawa, Takahisa; Kitasato, Kenjiro; Shimizu, Hirotomo; Nakamura, Akihiko; Masuda, Aya; Miyazaki, Yasumasa; Ohashi, Masakazu; Jinno, Hiromitsu; Kitagawa, Yuko

    2014-11-01

    A 74-year-old man complained of blood in his urine over a 1-week period beginning in early October 2013, and was examined in the urology department of our hospital. A thorough examination revealed bladder cancer, and surgery was planned after two cycles of preoperative gemcitabine plus cisplatin chemotherapy. A chest computed tomography (CT) performed to evaluate the response to chemotherapy revealed a mass in the right breast. The patient had previously complained about the same site, and mammography and ultrasonography had suggested the possibility of a malignant mammary gland tumor. The results of aspiration cytology were Class V, and based on that finding, a diagnosis of cancer of the right breast was made. In February 2014, we performed a mastectomy, while preserving the pectoral muscles, along with sentinel node biopsy, total cystectomy, urethrectomy, pelvic lymph node dissection, and ureteroileal anastomosis. The histopathological diagnosis of the right breast tumor was invasive ductal carcinoma[scirrhous carcinoma, ly (+), v (-), g (+), f (+), s (+), nuclear grade 1=atypia 2+mitosis 1, EIC (-), ICT (-), NCAT (-)]. A micrometastatic tumor measuring approximately 1mm was observed in the sentinel lymph node. The breast disease was classified as pT1N1mi(sn)M0, Stage IIA, and the tumor was ER (+), PgR (+), HER2/neu (2+), and FISH (-). The bladder cancer was diagnosed as urothelial carcinoma, non-papillary, invasive G2>G3, pT2a; no pelvic lymph node metastases were detected, and it was classified as pT2aN0M0, Stage II. Synchronous male breast cancer and bladder cancer is a very rare condition, and we report the case with a review of the literature.

  5. Small but significant socioeconomic inequalities in axillary staging and treatment of breast cancer in the Netherlands

    NARCIS (Netherlands)

    M.J. Aarts (Mieke); V.C. Hamelinck (V.); E. Bastiaannet (Esther); J.W.W. Coebergh (Jan Willem); G.-J. Liefers (Gerrit-Jan); A.C. Voogd (Adri); M.J.C. van der Sangen (Maurice); M.W.J. Louwman (Marieke)

    2012-01-01

    textabstractBackground: The use of sentinel node biopsy (SNB), lymph node dissection, breast-conserving surgery, radiotherapy, chemotherapy and hormonal treatment for breast cancer was evaluated in relation to socioeconomic status (SES) in the Netherlands, where access to care was assumed to be equa

  6. Living Beyond Breast Cancer

    Science.gov (United States)

    ... Styles Common Yoga Poses Special Situations Yoga and Lymphedema Risk Yoga and Metastatic Breast Cancer Side Effects ... Insomnia and Fatigue Treatment for Insomnia and Fatigue Lymphedema Lymphedema Risk Treating Lymphedema Menopausal Symptoms Mouth Sores ...

  7. Recurrent Breast Cancer

    Science.gov (United States)

    ... that can help you cope with distress include: Art therapy Dance or movement therapy Exercise Meditation Music ... mayoclinic.org/diseases-conditions/recurrent-breast-cancer/basics/definition/CON-20032432 . Mayo Clinic Footer Legal Conditions and ...

  8. Inflammatory Breast Cancer

    Science.gov (United States)

    ... Other Funding Find NCI funding for small business innovation, technology transfer, and contracts Training Cancer Training at ... means they developed from cells that line the milk ducts of the breast and then spread beyond ...

  9. Preeclampsia and breast cancer

    DEFF Research Database (Denmark)

    Pacheco, Nadja Livia Pekkola; Andersen, Anne-Marie Nybo; Kamper-Jørgensen, Mads

    2015-01-01

    BACKGROUND: In parous women preeclampsia has been associated with reduced risk of developing breast cancer. Characteristics of births following preeclamptic pregnancies may help understand mechanisms involved in the breast cancer risk reduction inferred by preeclampsia. METHODS: We conducted...... a register-based cohort study of all Danish women giving birth during 1978-2010 (n = 778,701). The association between preeclampsia and breast cancer was evaluated overall and according to birth characteristics by means of incidence rate ratios (IRR) estimated in Poisson regression models. RESULTS: Compared......, and in women giving birth to boys. These findings, however, did not reach statistical significance. Finally, risk reduction was slightly greater following milder forms of preeclampsia. CONCLUSION: Our data is compatible with an approximately 20% reduction in risk of developing breast cancer following...

  10. Contralateral breast cancer

    African Journals Online (AJOL)

    Department of Surgery, Ahmadu Bello University Teaching Hospital, Kaduna, Nigeria ... This second breast cancer remains, however largely sub-clinical. .... therapeutic mastectomy and prophylactic ... basis against the operation's physical and.

  11. Understanding Lymphatic Drainage Pathways of the Ovaries to Predict Sites for Sentinel Nodes in Ovarian Cancer

    NARCIS (Netherlands)

    Kleppe, M.; Kraima, A.C.; Kruitwagen, R.F.P.M.; Van Gorp, T.; Smit, N.N.; Van Munsteren, J.C.; De Ruiter, M.C.

    2015-01-01

    Objective: In ovarian cancer, detection of sentinel nodes is an upcoming procedure. Perioperative determination of the patient’s sentinel node(s) might prevent a radical lymphadenectomy and associated morbidity. It is essential to understand the lymphatic drainage pathways of the ovaries, which are

  12. Hormones and Breast Cancer.

    Science.gov (United States)

    1997-10-01

    criteria were: having ever been treated with chemotherapy, or been diagnosed with systemic lupus erythematosus or liver cirrhosis; having smoked the previous...history of breast cancer) was not associated with increased risk of breast cancer. Moreover, OC use before age 25 or first pregnancy was not...radioimmunoassay of unconjugated estriol in Endocrinol Metab 65:792-795 (1987). pregnancy plasma. Steroids 24:225-238 (1974). 47. Longcope C, Gorbach S

  13. Targeting Breast Cancer Metastasis

    OpenAIRE

    2015-01-01

    Metastasis is the leading cause of breast cancer-associated deaths. Despite the significant improvement in current therapies in extending patient life, 30–40% of patients may eventually suffer from distant relapse and succumb to the disease. Consequently, a deeper understanding of the metastasis biology is key to developing better treatment strategies and achieving long-lasting therapeutic efficacies against breast cancer. This review covers recent breakthroughs in the discovery of various me...

  14. The Premenopausal Breast Cancer Collaboration

    DEFF Research Database (Denmark)

    Nichols, Hazel B; Schoemaker, Minouk J; Wright, Lauren B

    2017-01-01

    Breast cancer is a leading cancer diagnosis among premenopausal women around the world. Unlike rates in postmenopausal women, incidence rates of advanced breast cancer have increased in recent decades for premenopausal women. Progress in identifying contributors to breast cancer risk among premen...

  15. 经皮注射淋巴结超声造影在乳腺癌患者前哨淋巴结中的诊断价值%The daignostic value of contrast-enhanced ultras ound with percutaneous injection of contrast agents for the sentinel lymph nodes in breast cancer patients

    Institute of Scientific and Technical Information of China (English)

    王泽爱; 樊云清; 王兴田

    2016-01-01

    Objective To compare the diagnostic values of conventional ultrasound and contrast -enhanced ultra-sound with percutaneous injection of contrast agents in the lymph nodes for the sentinel lymph nodes in breast cancer pa -tients.Methods A total of79 breast cancer patients who were admitted into our hospital from February 2013 to April 2015were enrolled into the current study .They were percutaneously injected with lyophilized powders for ultrasound ex -amination of the sentinel lymph nodes ,with methylene blue as a contrast agent .Meanwhile , they were subjected to con-ventional ultrasound .Results Among 42 patients performing contrast -enhanced ultrasound were 29 patients with the sentinel lymph nodes ( 38 lymph nodes ) , including 19 sentinel lymph nodes ( where 15 nodes were pathological diag-nosed), and 19 non-metastatic lymph nodes (where 17 nodes were pathological diagnosed ), achieving 83.3%sensitiv-ity, 92.3%specificity and 93.1% accuracy.Meanwhile, 21 lymph nodes were found in 37 patients after conventional ultrasound , including 13 sentinel lymph nodes ( where 10 nodes were pathological diagnosed ) , and 8 non-metastatic lymph nodes(where 6 nodes were pathological diagnosed ), achieving 37.5%sensitivity, 42.9%specificity and 53.8%accuracy.Compared with conventional ultrasound , contrast-enhanced ultrasound could produce significant improvement in sensitivity, specificity and accuracy for diagnosis of the sentinel lymph nodes in breast cancer patients ( P<0.05 ). Conclusion Contrast-enhanced ultrasound with percutaneous injection of contrast agents in the lymph nodes can well determine the sentinel lymph nodes in breast cancer patients , with superior clinical values to conventional ultrasound .%目的:探讨经皮注射淋巴结超声造影与常规超声对乳腺癌前哨淋巴结显像及转移的诊断价值。方法对79例乳腺癌患者进行研究,以手术过程中的亚甲蓝染色作为对比,应用经皮注射冻干粉剂对这些患者

  16. Stereotactic Image-Guided Navigation During Breast Reconstruction in Patients With Breast Cancer

    Science.gov (United States)

    2017-04-12

    Ductal Breast Carcinoma in Situ; Lobular Breast Carcinoma in Situ; Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer

  17. Predictors for contralateral prophylactic mastectomy in breast cancer patients.

    Science.gov (United States)

    Fu, Yun; Zhuang, Zhigang; Dewing, Michelle; Apple, Sophia; Chang, Helena

    2015-01-01

    In recent years, radical breast cancer surgery has been largely replaced by breast conservation treatment, due to early diagnosis and more effective adjuvant treatment. While breast conservation is mostly preferred, the trend of bilateral mastectomy has risen in the United States. The aim of this study is to determine factors influencing patients' choice for having contralateral prophylactic mastectomy (CPM). This is a retrospective study of 373 patients diagnosed with primary invasive breast cancer who were treated by bilateral or unilateral mastectomy (BM or UM) at the Revlon/UCLA Breast Center between Jan. 2002 and Dec. 2010. In the BM group, only those with unilateral breast cancer who chose CPM were included in the analysis. When compared with the UM group, the following factors were found to be associated with BM: younger age, pre-menopausal, a family history of breast/ovarian cancer, BRCA mutation, more breast biopsies, history of breast augmentation, having MRI study within 6 months before the surgery, more likely to have reconstruction and sentinel lymph node biopsy (SLNB) and fewer had neoadjuvant/adjuvant chemotherapy/radiation. When patients with bilateral breast cancer were excluded, multivariate logistic regression analysis indicated younger patients with negative nodes, SLNB as the only nodal surgery and positive family history were significant factors predicting CPM and immediate reconstruction using tissue expanders or implants. Younger age, lower TN stage, requiring only SLNB and high risk family history predict contralateral prophylactic mastectomy. Tissue expander/implant-based reconstructions were more frequently chosen by patients with BM.

  18. Viruses and Breast Cancer

    Energy Technology Data Exchange (ETDEWEB)

    Lawson, James S., E-mail: james.lawson@unsw.edu.au; Heng, Benjamin [School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney (Australia)

    2010-04-30

    Viruses are the accepted cause of many important cancers including cancers of the cervix and anogenital area, the liver, some lymphomas, head and neck cancers and indirectly human immunodeficiency virus associated cancers. For over 50 years, there have been serious attempts to identify viruses which may have a role in breast cancer. Despite these efforts, the establishment of conclusive evidence for such a role has been elusive. However, the development of extremely sophisticated new experimental techniques has allowed the recent development of evidence that human papilloma virus, Epstein-Barr virus, mouse mammary tumor virus and bovine leukemia virus may each have a role in the causation of human breast cancers. This is potentially good news as effective vaccines are already available to prevent infections from carcinogenic strains of human papilloma virus, which causes cancer of the uterine cervix.

  19. Increasing Breast Cancer Surveillance Among African American Breast Cancer Survivors

    Science.gov (United States)

    2010-01-01

    Family history of breast cancer  specifically mother or sister diagnosed with breast cancer  Not the same as genetic risk for breast cancer...treatment. Table 5 presents sociodemographic variables for the first 20 SIS participants. The majority of participants were African American, unmarried

  20. Breast Cancer Basics and You

    Science.gov (United States)

    ... in both men and women, although male breast cancer is rare. The Breasts Inside a woman's breast are 15 to 20 sections called lobes. Each lobe contains many smaller sections called lobules. These are groups of tiny glands that make breast milk. Breast milk flows through thin tubes called ducts ...

  1. Current innovations in sentinel lymph node mapping for the staging and treatment of resectable lung cancer.

    Science.gov (United States)

    Hachey, Krista J; Colson, Yolonda L

    2014-01-01

    Despite surgical resectability, early-stage lung cancer remains a challenge to cure. Survival outcomes are hindered by variable performance of adequate lymphadenectomy and the limitations of current pathologic nodal staging. Sentinel lymph node (SLN) mapping, a mainstay in the management of breast cancer and melanoma, permits targeted nodal sampling for efficient and accurate staging that can influence both intraoperative and adjuvant treatment decisions. Unfortunately, standard SLN identification techniques with blue dye and radiocolloid tracers have not been shown to be reproducible in lung cancer. In more recent years, intraoperative near-infrared image-guided lung SLN mapping has emerged as promising technology for the identification of the tumor-associated lymph nodes most likely to contain metastatic disease. Additionally, the clinical relevance of SLN mapping for lung cancer remains pressing, as the ability to identify micrometastatic disease in SLNs could facilitate trials to assess chemotherapeutic response and the clinical effect of occult nodal disease. This review outlines the status of lung cancer lymphatic mapping and techniques in development that may help close the gap between translational research in this field and routine clinical practice.

  2. Genetics Home Reference: breast cancer

    Science.gov (United States)

    ... Facebook Share on Twitter Your Guide to Understanding Genetic Conditions Search MENU Toggle navigation Home Page Search ... Conditions Genes Chromosomes & mtDNA Resources Help Me Understand Genetics Home Health Conditions breast cancer breast cancer Enable ...

  3. Inflammatory breast cancer: an overview

    NARCIS (Netherlands)

    Uden, D.J. van; Laarhoven, H.W.M. van; Westenberg, A.H.; Wilt, J.H. de; Blanken-Peeters, C.F.

    2015-01-01

    Inflammatory breast cancer (IBC) is the most aggressive entity of breast cancer. Management involves coordination of multidisciplinary management and usually includes neoadjuvant chemotherapy, ablative surgery if a tumor-free resection margin is expected and locoregional radiotherapy. This multimoda

  4. Preventing Breast Cancer: Making Progress

    Science.gov (United States)

    ... Navigation Bar Home Current Issue Past Issues Preventing Breast Cancer: Making Progress Past Issues / Fall 2006 Table of ... 000 women will have been diagnosed with invasive breast cancer, and nearly 41,000 women will die from ...

  5. STUDY ON THE METASTASIS OF AXILLARY LYMPH NODE POSITIVE EARLY BREAST CANCER SENTINEL LYMPH NODES%前哨淋巴结阳性早期乳腺癌其腋窝淋巴结转移状况的研究

    Institute of Scientific and Technical Information of China (English)

    陈卓荣; 罗智辉; 沈三弟

    2014-01-01

    目的:探讨早期乳腺癌前哨淋巴结( sentinel lymphnode ,SLN)阴性患者、1枚阳性SLN患者与2枚以上阳性SLN患者的非前哨淋巴结( non-sentinel lymphnode,NSLN)转移状况。方法:对90例T1-2N0M0乳腺癌患者应用美蓝为示踪剂行前哨淋巴结活检术( sentinel lymphnode biopsy,SLNB),进再行常规腋窝淋巴结清扫术( axillary lymph node dissection,ALND),根据检查结果将患者分成SLN(-)组、SLN(+)=1组及SLN(+)≥2组,并对各组的NSLN阳性率进行比较。结果:32例SLN (-)组检出NSLN阳性1例,阳性率3.1%,39例SLN(+)=1组检出NSLN阳性4例,阳性率为10.3%,19例SLN(+)≥2组检出NSLN阳性9例,阳性率为47.4%,SLNB检查假阴性1例,准确率为96.9%;SLN(+)=1组的NSLN阳性率略高于SLN阴性组,但差异无统计学意义P>0.05;SLN(+)≥2组患者的NSLN阳性率显著高于SLN(-)组及SLN(+)=1组,差异均具有统计学意义P<0.05。结论:研究结果提示1枚SLN阳性患者可仅行SLNB免行ALND,但≥2枚SLN阳性患者则需常规行ALND。%Objective:To explore the early sentinel lymph node in breast cancer ( sentinel, lymphnode, SLN) non sentinel lymph node negative patients, 1 positive in SLN patients with more than 2 pieces of SLN patients with positive nodes ( non-sentinel lymph-node, NSLN) metastasis.Methods:90 T1-2N0M0 patients with breast cancer using methylene blue as tracer for sentinel lymph node biopsy ( sentinel lymphnode biopsy, SLNB ) , and enter the routine axillary lymphadenectomy ( axillary lymph node dissection, ALND) , according to the test results of the patients were divided into SLN ( -) group, =1 group and SLN ( +) SLN ( +) ≥2 groups, and each group of NSLN positive rates were compared.Results:32 cases of SLN (-) group was 1 cases with positive NSLN, the positive rate was 3.1%, 39 cases of SLN (+) =1 was detected in 4

  6. Sentinel node biopsy (image)

    Science.gov (United States)

    Sentinel node biopsy is a technique which helps determine if a cancer has spread (metastasized), or is contained locally. When a ... is closest to the cancer site. Sentinel node biopsy is used to stage many kinds of cancer, ...

  7. Sentinel lymph node mapping with indocyanine green in vaginal cancer.

    Science.gov (United States)

    Lee, In Ok; Lee, Jung Yun; Kim, Sunghoon; Kim, Sang Wun; Kim, Young Tae; Nam, Eun Ji

    2017-07-01

    Sentinel lymph node (SLN) mapping is being adapted to gynecologic cancer. Higher SLN mapping rates were reported with indocyanine green (ICG) compared to other dyes. The aim of this film is to share our experience of SLN mapping with ICG in vaginal cancer. A 40 year-old woman was diagnosed with squamous cell vaginal cancer. About 1.5 cm-sized tumor was located on the posterior vaginal fornix. Preoperatively she was assumed to be stage I vaginal cancer. Beginning of surgery, we performed SLN mapping by ICG injection into 3- and 9-o'clock positions of the vaginal tumor. Concentrated in 1.25 mg/mL, 1 mL of ICG solution was injected into deep stroma and another 1 mL submucosally in both sides. Bilateral SLN identification and lymphadenectomy were done. Afterward, laparoscopic Type C1 Querleu-Morrow radical hysterectomy with vaginectomy was done. A fluorescence endoscope produced by KARL STORZ (Tuttlingen, Germany) was used for ICG detection. To our knowledge, this is the first film report performing SLN mapping with ICG in vaginal cancer. The mapping was successful and we were able to recognize SLN of vaginal cancer. SLNs were located in the bilateral obturator fossa. According to the pathologic diagnosis, the mass size was 15 mm and invasion depth was 1 mm. Subvaginal tissue involvement and pelvic wall extension were absent. Resection margin of the vagina was free from carcinoma. No lymph node metastasis was reported including the bilateral SLNs. For vaginal cancer, SLN mapping can be applied by injecting ICG into the bilateral sides of the vaginal tumor.

  8. Mulig forbedret behandling af kolorektal cancer med sentinel lymph node-diagnostik

    DEFF Research Database (Denmark)

    Burgdorf, Stefan K; Eriksen, Jens Ravn; Gögenür, Ismail

    2014-01-01

    Possibly improved treatment of colorectal cancer by sentinel lymph node mapping Prognosis for colorectal cancer is dependent on radical surgical intervention. Chemotherapy in patients with advanced disease has improved the survival. A considerable proportion of the patients going through radical...... surgery will subsequently relapse. Adjuvant chemotherapy is reserved for patients with lymph node metastases, why undetected malignant lymph nodes will result in understaging and exclusion from the possible benefit of adjuvant chemotherapy. With sentinel lymph node mapping it may be possible to detect...

  9. Affluence and Breast Cancer.

    Science.gov (United States)

    Lehrer, Steven; Green, Sheryl; Rosenzweig, Kenneth E

    2016-09-01

    High income, high socioeconomic status, and affluence increase breast cancer incidence. Socioeconomic status in USA breast cancer studies has been assessed by block-group socioeconomic measures. A block group is a portion of a census tract with boundaries that segregate, as far as possible, socioeconomic groups. In this study, we used US Census income data instead of block groups to gauge socioeconomic status of breast cancer patients in relationship with incidence, prognostic markers, and survival. US state breast cancer incidence and mortality data are from the U.S. Cancer Statistics Working Group, United States Cancer Statistics: 1999-2011. Three-Year-Average Median Household Income by State, 2010 to 2012, is from the U.S. Census Bureau, Current Population Survey, 2011 to 2013 Annual Social and Economic Supplements. County incomes are from the 2005-2009 American Community Survey of the U.S. Census Bureau. The American Community Survey is an ongoing statistical survey that samples a small percentage of the population yearly. Its purpose is to provide communities the information they need to plan investments and services. Breast cancer county incidence and survival data are from the National Cancer Institute's Surveillance, Epidemiology and End Results Program (SEER) data base. We analyzed SEER data from 198 counties in California, Connecticut, Georgia, Hawaii, Iowa, New Mexico, Utah, and Washington. SEER uses the Collaborative Stage (CS) Data Collection System. We have retained the SEER CS variables. There was a significant relationship of income with breast cancer incidence in 50 USA states and the District of Columbia in White women (r = 0.623, p breast cancer. Income was not correlated with 5-year survival of Black race (p = 0.364) or other races (p = 0.624). The multivariate general linear model with income as covariate, 5-year survival by race as a dependent variable, showed a significant effect of income and White race on 5-year survival (p breast cancer

  10. 新辅助化疗对乳腺癌前哨淋巴结活检的影响及临床意义%Effect and Clinical Value of Neoadjuvant Chemotherapy on Sentinel Lymph Node Biopsy in Patients with Breast Cancer

    Institute of Scientific and Technical Information of China (English)

    杨波; 刘斌; 蒲永东; 刘卫平; 王颐; 吕刚; 吴有军

    2011-01-01

    目的:通过比较接受新辅助化疗(Neoadjuvant chemotherapy,NAC) 和未接受新辅助化疗两组乳腺癌患者前哨淋巴结(sentinel lymph node biopsy,SLN) 活检的结果,探讨新辅助化疗后乳腺癌前哨淋巴结活检的可行性以及相关临床及病理因素对前哨淋巴结活检的影响.方法:选取2004 年2月-2010 年10 月期间经我科治疗的乳腺癌患者共96 例作为研究对象,其中行新辅助化疗组(A 组)54 例,以PFE 方案(每疗程紫杉醇210mg 、氟尿嘧啶2.5g 、吡柔比星60mg) 行2-4 疗程化疗,然后再行前哨淋巴结活检.未行新辅助化疗组(B 组)42 例,直接行前哨淋巴结活检.两组患者术前经乳腺原发肿瘤(或活检残腔)周围或乳晕区皮下组织分3点注射1% 亚甲蓝,术中肉眼寻找蓝染的前哨淋巴结并切除,然后常规清扫腋窝Ⅰ、Ⅱ组淋巴结.术后对前哨淋巴结活检和腋窝淋巴结清扫的病理结果进行比较分析.结果:A 组前哨淋巴结检出率明显低于B组(81.48%vs95.24%,P0.05);A 组中,肿瘤(或残腔)位置注射美兰者的检出率略低于乳晕注射者(75.86%vs88.00%,P=0.427);SLNB 的检出率及假阴性率与患者年龄及雌激素受体表达情况无关,相应数据两组之间差异均无统计学意义(P 值均≈1.00).结论:NAC 能够降低SLNB 的检出率,但NAC 后的患者的SLN 情况仍能代表腋窝淋巴结状况,新辅助化疗后仍可对患者进行SLNB,新辅助化疗后肿瘤(或残腔)处注射的SLNB 检出率略低于乳晕注射处.%Objective To investigate the feasibility and clinical value of the sentinel lymph node biopsy in breast cancer treaded with neoadjuvant chemotherapy and the influence factor of relevant clinical and pathological features. Methods:In this retrospective study,from Feb. 2004 to Oct. 2009,96 patients with breast cancer from our department were included. In group A, 54 patients treated with sentinel lymph node biopsy after received 2-4 cycles neoadjuvant

  11. 亚甲蓝法与超声造影法检测乳腺癌前哨淋巴结的对比研究%Comparison of methylene blue dye injection and contrast enhanced ultrasonography in detection of sentinel lymph nodes in breast cancer

    Institute of Scientific and Technical Information of China (English)

    付明刚; 刘莎; 郭丽英

    2015-01-01

    Objective To study the feasibility of contrast enhanced ultrasonography (CEUS)in detecting sentinel lymph node (SLN)in patients with breast cancer during operation and its clinical significance. Methods 21 patients who underwent radical resection of a primary breast cancer were enrolled.During op-eration,1% methylene blue was injected around the tumor,and SLN mapping was performed.Then the SonoVue was injected at the same sites,then CEUS was performed to observe changes of SLN in real time, and marked them.The SLN detection rate and accuracy of CEUS were compared to those of conventional dye guided method.Results SLN were successfully imaged by SonoVue,the detection rate of CEUS for SLN was 80.95%,and the accuracy was 93.55%.The detection rate of dye guided method for SLN was 85.71%,and the accuracy was 93.75%,there was no statistically significant difference between CEUS and dye guided method (P >0.05).Conclusion Peritumoral injection is a good method for evaluating and pre-dicting sentinel lymph nodes in breast cancer.When injected SonoVue in peritumoral,the good mapping of SLN in patients with breast cancer can be obtained,and it will play an important role in clinical application to map SLN in patients with breast cancer.%目的:探讨超声造影法在乳腺癌术中检测前哨淋巴结(SLN)的可行性及临床应用价值。方法选择21例乳腺癌根治术患者,术中于肿瘤周围注射1%亚甲蓝,寻找被蓝染的 SLN;于相同注射部位注射超声造影剂声诺维(SonoVue),动态观察并标记显像 SLN。对比超声造影法和亚甲蓝法对 SLN 的检出率和准确率。结果注射 SonoVue 后能够获得清晰的传人淋巴管和 SLN 图像。超声造影法对乳腺癌患者 SLN 的检出率为85.71%,准确率为89.29%;亚甲蓝法对其检出率为80.95%,准确率为93.33%,2种方法检出率和准确率比较差异均无统计学意义(P >0.05)。结论超

  12. Breast cancer and autism.

    Science.gov (United States)

    Radcliff, Lisa

    2013-03-01

    Case Study Amy is a 44-year-old woman with severe autism. She lives with her sister Susan, who is her caregiver and guardian. Amy is ambulatory and able to dress and feed herself. She is a healthy individual with no other significant comorbidities. She walks daily and enjoys her sister's company. Amy's life expectancy is greater than 10 years. However, she is difficult to care for medically, as she will not allow a physical examination and strikes out when strangers try to touch her. She is nonverbal and unable to participate in decision-making. INITIAL DIAGNOSIS Amy has a history of breast cancer diagnosed 2 years ago, originally presenting as a stage I lesion (T2N0) that was palpated by her caregiver while bathing. She underwent right simple mastectomy with sentinel lymph node resection. Susan recalls that the mastectomy was a very challenging ordeal, as Amy kept pulling out IV lines, drains, and dressings. Susan felt that Amy withdrew from her after the procedure as she most likely associated Susan with the cause of the pain, making her role as caregiver more difficult. Pathology confirmed an invasive ductal carcinoma, moderately differentiated, 2.4 cm, estrogen/progesterone receptor negative, HER2/neu negative, with negative surgical margins. Two right axillary sentinel lymph nodes were negative for disease. The standard of care for a patient with these tumor features is surgery plus adjuvant chemotherapy (National Comprehensive Cancer Network [NCCN], 2012). According to the Adjuvant Online! database (2012), Amy's risk for relapse was approximately 40% without adjuvant treatment; her risk for mortality was approximately 29%. After meeting with a medical oncologist, Amy did not receive adjuvant chemotherapy. According to Susan, she was not offered the choice, and the decision was not explained to them. She was simply told that it was not necessary. Aside from pathology, previous records were unavailable for review. Medical assessment of Amy's level of autism

  13. Abortion, Miscarriage, and Breast Cancer Risk

    Science.gov (United States)

    ... of Breast & Gynecologic Cancers Breast Cancer Screening Research Abortion, Miscarriage, and Breast Cancer Risk: 2003 Workshop In ... cancer risk, including studies of induced and spontaneous abortions. They concluded that having an abortion or miscarriage ...

  14. Early detection of breast cancer.

    Science.gov (United States)

    Nettles-Carlson, B

    1989-01-01

    Timely, comprehensive screening for breast cancer is a major, though often overlooked, component of primary health care for women. This article reviews the scientific rationale for screening and outlines the current recommendations of the American Cancer Society and the U.S. Preventive Services Task Force regarding the use of mammography, clinical breast examination (CBE), and breast self-examination (BSE). Nursing interventions to decrease barriers to effective screening are discussed, and an expanded role of nurses in breast cancer screening is proposed.

  15. Breast cancer epidemiology.

    Science.gov (United States)

    Kelsey, J L; Berkowitz, G S

    1988-10-15

    The various risk factors for breast cancer have been recognized for many years. A table lists these established breast cancer risk factors together with the approximate magnitude of the increase in risk associated with them. Breast cancer incidence rates increase with age throughout the life span in Western countries, although the rate of increase is greater up to age 50 years than after 50 years. Breast cancer is more common among women in upper rather than lower social classes, among women who never have been married, among women living in urban areas, among women living in the northern US than in the southern US, and among whites than blacks, at least among those over age 50. Women in North American and Northern European countries have the highest risk for breast cancer, women in Southern European and Latin American countries are at intermediate risk, and women in Africa and Asian countries have the lowest risk. Yet, rapid rates of increase in incident rates have been noted in recent years in many Asian, Central European, and some South American countries. The later the age at which a woman has her 1st full-term pregnancy, the higher her risk for breast cancer; the earlier the age at menarche and the later the age at menopause the higher the risk; and among women who have a premenopausal oophorectomy, the earlier the age at which this occurs the lower the risk. Among postmenopausal women, obesity is associated with an increase in risk. Lactation is negatively associated with subsequent breast cancer risk. Some current research is considering potential risk factors that have not been well studied in the past, including alcohol consumption, cigarette smoking, caffeine consumption, exposure to diethylstilbestrol (DES), emotional stress, exposure to electric power, and lack of physical activity. Other areas of current research reviewed here include radiation, mammographic parenchymal patterns, a high-fat diet, use of oral contraceptives (OCs), use of estrogen

  16. Lymphatic drainage from the treated versus untreated prostate: feasibility of sentinel node biopsy in recurrent cancer

    Energy Technology Data Exchange (ETDEWEB)

    Vermeeren, Lenka; Valdes Olmos, Renato A. [Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Department of Nuclear Medicine, Amsterdam (Netherlands); Meinhardt, Willem; Poel, Henk G. van der [Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Department of Urology, Amsterdam (Netherlands)

    2010-11-15

    The goal of this study was to establish the feasibility of sentinel node biopsy in patients with recurrent prostate cancer after initial local treatment and to compare lymphatic drainage patterns of the treated versus untreated prostate. In ten patients with a proven local recurrence after initial local treatment (four external beam radiation, four brachytherapy and two high-intensity focused ultrasound), the radiotracer ({sup 99m}Tc-nanocolloid, GE Healthcare) was injected into the prostate. Planar images after 15 min and 2 h were followed by SPECT/CT (Symbia T, Siemens) to visualize lymphatic drainage. Laparoscopic sentinel lymphadenectomy was assisted by a gamma probe (Europrobe, EuroMedical Instruments) and a portable gamma camera (Sentinella, S102, Oncovision). Sentinel node identification and lymphatic drainage patterns were compared to a consecutive series of 70 untreated prostate carcinoma patients from our institute. Lymphatic drainage was visualized in all treated patients, with a median of 3.5 sentinel nodes per patient. Most sentinel nodes were localized in the pelvic area, although the percentage of patients with a sentinel node outside the pelvic para-iliac region (para-aortic, presacral, inguinal or near the ventral abdominal wall) was high compared to the untreated patients (80 versus 34%, p = 0.01). In patients with recurrent prostate cancer, 95% of the sentinel nodes could be harvested and half of the patients had at least one positive sentinel node on pathological examination. Lymphatic mapping of the treated prostate appears feasible, although sentinel nodes are more frequently found in an aberrant location. Larger trials are needed to assess the sensitivity and therapeutic value of lymphatic mapping in recurrent prostate cancer. (orig.)

  17. Breast Cancer in Art Painting

    OpenAIRE

    2011-01-01

    Breast cancer is an emotive cancer. It is a disease that affects a visible sexual organ and it is the commonest single cause of death of women between 40 and 60 years of age. Nevertheless, this type of cancer was infrequently depicted in art paintings. In this article the themes from the breast cancer in famous art paintings are discussed.

  18. Breast cancer screening with digital breast tomosynthesis.

    Science.gov (United States)

    Skaane, Per

    2017-01-01

    To give an overview of studies comparing full-field digital mammography (FFDM) and digital breast tomosynthesis (DBT) in breast cancer screening. The implementation of tomosynthesis in breast imaging is rapidly increasing world-wide. Experimental clinical studies of relevance for DBT screening have shown that tomosynthesis might have a great potential in breast cancer screening, although most of these retrospective reading studies are based on small populations, so that final conclusions are difficult to draw from individual reports. Several retrospective studies and three prospective trials on tomosynthesis in breast cancer screening have been published so far, confirming the great potential of DBT in mammography screening. The main results of these screening studies are presented. The retrospective screening studies from USA have all shown a significant decrease in the recall rate using DBT as adjunct to mammography. Most of these studies have also shown an increase in the cancer detection rate, and the non-significant results in some studies might be explained by a lack of statistical power. All the three prospective European trials have shown a significant increase in the cancer detection rate. The retrospective and the prospective screening studies comparing FFDM and DBT have all demonstrated that tomosynthesis has a great potential for improving breast cancer screening. DBT should be regarded as a better mammogram that could improve or overcome limitations of the conventional mammography, and tomosynthesis might be considered as the new technique in the next future of breast cancer screening.

  19. Evaluation of the tracing effect of carbon nanoparticles and methylene blue combined with 99 Tcm-sulfur colloid in endoscopic sentinel lymph node biopsy for breast cancer%纳米炭和亚甲蓝联合核素示踪法在腔镜乳腺癌前哨淋巴结活组织检查中的对照研究

    Institute of Scientific and Technical Information of China (English)

    张永松; 梁全琨; 钟玲; 张毅; 陈莉; 范林军; 姜军

    2015-01-01

    Objective To explore the application effect of 99 Tcm-sulfur colloid combined with carbon nanoparticles or methylene blue in endoscopic sentinel lymph node biopsy ( ESLNB) in breast cancer patients. Methods From March 2014 to December 2014, a total of 80 breast cancer patients were randomly divided into two equal groups ( n=40 ) . Both groups underwent ESLNB. One group received carbon nanoparticles plus 99Tcm-sulfur colloid tracing sentinel lymph node (SLB) (nanocarbon group) and the other group received methylene blue plus 99Tcm-sulfur colloid tracing SLB (methylene blue group). After operation, the detection rate of SLB, positive rate and postoperative complications were compared between two groups. Measurement data were expressed as x¯±s and processed by independent sample t test. The count data were compared by χ2 test or Fisher exact test. Results The detection rate of sentinel lymph nodes was 100% ( 40/40 ) in nanocarbon group and 97. 5% ( 39/40 ) in methylene blue group respectively. The mean number of detected sentinel lymph nodes per patient was 3. 4 ± 1. 5 in nanocarbon group and 3. 2 ± 1. 5 in methylene blue group respectively, indicating no significant difference between two groups (t=0. 984,P=0. 326). The positive rate of sentinel lymph nodes was 32. 5% (13/40) in nanocarbon group and 25. 6% (10/39, one did not detect the SLN) in methylene blue group respectively, indicating no significant difference between two groups (χ2 =0. 450,P=0. 502). Totally 116 non-sentinel lymph nodes were detected in nanocarbon group, mean (3. 2 ± 1. 1) per patient (range:2-5), including 57 black-stained lymph nodes (49. 1%). In methylene blue group, 97 non-sentinel lymph nodes were detected, mean (2. 8 ± 1. 1) per patient (range 1-5), including 26 blue-stained lymph nodes ( 26. 8%) . The number of detected non-sentinel lymph nodes per patient and stain rate showed significant differences between two groups(t=2. 632, P=0. 009,χ2=11. 079,P=0. 001). There was no

  20. Prostate cancer is not breast cancer

    Directory of Open Access Journals (Sweden)

    Ajit Venniyoor

    2016-01-01

    Full Text Available Cancers of the prostate and breast are hormone dependent cancers. There is a tendency to equate them and apply same algorithms for treatment. It is pointed out that metastatic prostate cancer with bone-only disease is a potentially fatal condition with a much poorer prognosis than metastatic breast cancer and needs a more aggressive approach.

  1. [Sentinel lymph node biopsy in endometrial cancer--a part of modern operative treatment].

    Science.gov (United States)

    Jordanov, A; Gorchev, G; Tomov, S; Hinkova, N

    2014-01-01

    After brest cancer the endometrial cancer is the most common gynaecological malignancy. The lymphno destatus is with great prognostic value. There is no agreement for the therapeutic valuae and the contents of the lymph node desectionin early stages. That is why the sentinel lymph node biopsy is a part of modern operative treatment of endometrial cancer.

  2. 美兰在72例乳腺癌前哨淋巴结活检术中的临床应用分析%Clinical Value of Methylene Blue in Sentinel Lymph Node Biopsy for Breast Cancer:Report of 72 Cases

    Institute of Scientific and Technical Information of China (English)

    钟慕仪; 叶艳娜; 吴丽华; 张蓉; 张爱玲

    2013-01-01

      目的:探讨美兰染色在乳腺癌前哨淋巴结活检术中的临床应用及准确性分析.方法:选择笔者所在医院2007-2012年72例乳腺癌患者,体查均未扪及腋窝肿大淋巴结,在确诊后于乳晕周或病灶周取4个点皮下注射美兰,定位前哨淋巴结,行前哨淋巴结活检并清扫腋窝淋巴结.结果:72例患者中检出前哨淋巴结70例(检出率97.2%),前哨淋巴结阳性31例(44.2%),其中,其余腋窝淋巴结阳性为15例,阴性16例;前哨淋巴结阴性39例(55.7%),其中其余腋窝淋巴结为阳性的3例,阴性的36例.结论:美兰染色在乳腺癌前哨淋巴结中的应用具有敏感性和准确性,可以预测腋窝淋巴结的转移状态.%Objective:To evaluate the efficacy of sentinel lymph node biopsy(SLNB)by using methylene blue in the management of breast cancer. Method:From 2007-2012,totally 72 patients with breast cancer in our hospital,physical examination of no palpable lymph nodes,received subareolar or under the skin injection of methylene blue for SLNB,and then axillary lymph node dissection.Result:The SLNB was completed successfully in 70 of the patients(97.2%),in the 70 cases who received SLNB,SLN metastasis was found in 31 cases,;and not found in 39 cases.Conclusion:The metastasis to the axillary lymph nodes can be found earlier by sentinel lymph node biopsy.

  3. Hereditary breast cancer

    DEFF Research Database (Denmark)

    Larsen, Martin J; Thomassen, Mads; Gerdes, Anne-Marie

    2014-01-01

    Pathogenic mutations in BRCA1 or BRCA2 are only detected in 25% of families with a strong history of breast cancer, though hereditary factors are expected to be involved in the remaining families with no recognized mutation. Molecular characterization is expected to provide new insight into the t......Pathogenic mutations in BRCA1 or BRCA2 are only detected in 25% of families with a strong history of breast cancer, though hereditary factors are expected to be involved in the remaining families with no recognized mutation. Molecular characterization is expected to provide new insight...... into the tumor biology to guide the search of new high-risk alleles and provide better classification of the growing number of BRCA1/2 variants of unknown significance (VUS). In this review, we provide an overview of hereditary breast cancer, its genetic background, and clinical implications, before focusing...... on the pathologically and molecular features associated with the disease. Recent transcriptome and genome profiling studies of tumor series from BRCA1/2 mutation carriers as well as familial non-BRCA1/2 will be discussed. Special attention is paid to its association with molecular breast cancer subtypes as well...

  4. Breast Cancer - Early Diagnosis

    Centers for Disease Control (CDC) Podcasts

    2011-04-28

    This podcast answers a listener's question about how to tell if she has breast cancer.  Created: 4/28/2011 by National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP).   Date Released: 4/28/2011.

  5. Breast Cancer Research Program

    Science.gov (United States)

    2010-09-01

    tion of tumor cells with red indicating the highest density of tumor cells at the primary tumor (4th mammary fat pad ) and purple/blue showing the...Idea Award Elaine Hardman and Philippe Georgel “ Maternal Consumption of Omega 3 Fatty Acids to Reduce Breast Cancer Risk in Offspring” FY09

  6. Progestins and breast cancer.

    Science.gov (United States)

    Pasqualini, Jorge R

    2007-10-01

    Progestins exert their progestational activity by binding to the progesterone receptor (form A, the most active and form B, the less active) and may also interact with other steroid receptors (androgen, glucocorticoid, mineralocorticoid, estrogen). They can have important effects in other tissues besides the endometrium, including the breast, liver, bone and brain. The biological responses of progestins cover a very large domain: lipids, carbohydrates, proteins, water and electrolyte regulation, hemostasis, fibrinolysis, and cardiovascular and immunological systems. At present, more than 200 progestin compounds have been synthesized, but the biological response could be different from one to another depending on their structure, metabolism, receptor affinity, experimental conditions, target tissue or cell line, as well as the biological response considered. There is substantial evidence that mammary cancer tissue contains all the enzymes responsible for the local biosynthesis of estradiol (E(2)) from circulating precursors. Two principal pathways are implicated in the final steps of E(2) formation in breast cancer tissue: the 'aromatase pathway', which transforms androgens into estrogens, and the 'sulfatase pathway', which converts estrone sulfate (E(1)S) into estrone (E(1)) via estrone sulfatase. The final step is the conversion of weak E(1) to the potent biologically active E(2) via reductive 17beta-hydroxysteroid dehydrogenase type 1 activity. It is also well established that steroid sulfotransferases, which convert estrogens into their sulfates, are present in breast cancer tissues. It has been demonstrated that various progestins (e.g. nomegestrol acetate, medrogestone, promegestone) as well as tibolone and their metabolites can block the enzymes involved in E(2) bioformation (sulfatase, 17beta-hydroxysteroid dehydrogenase) in breast cancer cells. These substances can also stimulate the sulfotransferase activity which converts estrogens into the biologically

  7. [INDOCYANINE GREEN (ICG) IN THE DETECTION OF SENTINEL LYMPH NODES IN ENDOMETRIAL AND CERVIX CANCER].

    Science.gov (United States)

    Berlev, I V; Ulrikh, E A; Ibragimov, Z N; Guseinov, K D; Gorodnova, T V; Korolkova, E N; Trifanov, Yu N; Nekrasova, E A; Saparov, A B; Khadzhimba, A V; Mikaya, N A; Urmancheeva, A F

    2015-01-01

    We analyzed the international and our own experience of using different dyes in the identification of sentinel lymph nodes in oncogynecological practice. We evaluated the possibility of using indocyanine green (ICG) in the detection of sentinel lymph nodes in patients with endometrial and cervical cancer. The first results of the use of ICG at the Oncogynecology Department of the N.N.Petrov Research Institute of Oncology are presented.

  8. Acurácia do Linfonodo Sentinela em Pacientes com Câncer Inicial da Mama Tratadas com Quimioterapia Neoadjuvante Sentinel Lymph Node Accuracy in Early Breast Cancer Treated with Neoadjuvant Chemotherapy

    Directory of Open Access Journals (Sweden)

    José Roberto Morales Piato

    2002-03-01

    Full Text Available Objetivo: avaliar a capacidade preditiva do estudo do linfonodo sentinela (LS em relação ao estado linfonodal axilar em pacientes com carcinoma invasor inicial de mama submetidas ou não a quimioterapia neoadjuvante. Métodos: foi realizado estudo prospectivo de 112 pacientes, que foram divididas em dois grupos. O primeiro grupo foi constituído por 70 pacientes que não receberam quimioterapia prévia (Grupo I e o segundo foi formado por 42 pacientes que foram submetidas a quimioterapia neoadjuvante, com três ciclos do esquema AC (adriamicina + ciclofosfamida (Grupo II. A resposta à quimioterapia foi parcial >50% em 21 pacientes, sendo que em três foi completa, e parcial Purpose: to evaluate the predictive capacity of the sentinel lymph node (SLN in relation to the axillary lymph node status in patients with initial invasive breast carcinoma submitted or not to neoadjuvant chemotherapy. Method: a prospective study was performed in 112 patients divided into two groups. The first group comprised 70 patients who had not received previous chemotherapy (Group I and the second consisted of 42 patients who were submitted to neoadjuvant chemotherapy in three cycles of AC (adriamycin + cyclophosphamide (Group II. Regarding chemotherapy, we observed partial response >50% in 21 patients, being complete in three of them, and <50% in 19 patients; in two patients progression of the disease occurred. A peritumoral injection of 99mTc dextran was applied with the help of stereotaxy in 29 patients with nonpalpable tumors, 16 of Group I and 13 of Group II. The radioactive accumulation shown by scintigraphy guided the biopsy of the axillary SLN with the help of a probe. The anatomopathologic study of SLN was based initially on a single section. When the LSN was free, it was submitted to serial sections at 50 mum intervals, stained with HE. Results: SLN was identified in 108 patients. No identification has been obtained in four patients, all with nonpalpable

  9. Mindfulness Meditation or Survivorship Education in Improving Behavioral Symptoms in Younger Stage 0-III Breast Cancer Survivors (Pathways to Wellness)

    Science.gov (United States)

    2017-03-21

    Cancer Survivor; Early-Stage Breast Carcinoma; Stage 0 Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer

  10. Opioids and breast cancer recurrence

    DEFF Research Database (Denmark)

    Cronin-Fenton, Deirdre P; Heide-Jørgensen, Uffe; Ahern, Thomas P

    2015-01-01

    BACKGROUND: Opioids may alter immune function, thereby potentially affecting cancer recurrence. The authors investigated the association between postdiagnosis opioid use and breast cancer recurrence. METHODS: Patients with incident, early stage breast cancer who were diagnosed during 1996 through...... 2008 in Denmark were identified from the Danish Breast Cancer Cooperative Group Registry. Opioid prescriptions were ascertained from the Danish National Prescription Registry. Follow-up began on the date of primary surgery for breast cancer and continued until breast cancer recurrence, death......, emigration, 10 years, or July 31, 2013, whichever occurred first. Cox regression models were used to compute hazard ratios and 95% confidence intervals associating breast cancer recurrence with opioid prescription use overall and by opioid type and strength, immunosuppressive effect, chronic use (≥6 months...

  11. Heterogeneity in breast cancer.

    Science.gov (United States)

    Polyak, Kornelia

    2011-10-01

    Breast cancer is a heterogeneous disease. There is a high degree of diversity between and within tumors as well as among cancer-bearing individuals, and all of these factors together determine the risk of disease progression and therapeutic resistance. Advances in technologies such as whole-genome sequencing and functional viability screens now allow us to analyze tumors at unprecedented depths. However, translating this increasing knowledge into clinical practice remains a challenge in part due to tumor evolution driven by the diversity of cancer cell populations and their microenvironment. The articles in this Review series discuss recent advances in our understanding of breast tumor heterogeneity, therapies tailored based on this knowledge, and future ways of assessing and treating heterogeneous tumors.

  12. [Occult multicentric breast cancer].

    Science.gov (United States)

    Vtorushin, S V; Zab'ialova, M V; Glushchenko, S A; Perel'muter, V M; Slonimskaia, E M

    2009-01-01

    The study included 92 patients with invasive ductal breast cancer (T2-4N0-2M0-1). In 38 cases, tumor growth was unicentric while histologically identifiable ones as multicentric in 44. Multicentricity mostly occurred in cases of macroscopically-identifiable nodes located in the central segments of the breast. Clinically-identifiable nodes of multicentric tumor growth measured more than 3 cm. Multicentric tumors were mostly grade III, featured lower expression of sex hormone receptors and positive Her2 status.

  13. You, Your Teenage Daughter and Breast Cancer.

    Science.gov (United States)

    Brateman, Libby

    1991-01-01

    Discusses breast cancer and teenagers, focusing on how parents can introduce the subject and encourage breast self-examination. The article provides information on breast cancer statistics, mammography, and American Cancer Society services. (SM)

  14. Braving Breast Cancer: Just Do It!

    Science.gov (United States)

    ... of this page please turn Javascript on. Feature: Breast Cancer Braving Breast Cancer: Just Do It! Past Issues / Spring - Summer 2010 Table of Contents Breast cancer survivor Jana Brightwell, pictured here on the NIH ...

  15. Breast cancer fear in African American breast cancer survivors.

    Science.gov (United States)

    Gibson, Lynette M; Thomas, Sheila; Parker, Veronica; Mayo, Rachel; Wetsel, Margaret Ann

    2014-01-01

    The purpose of this study was to describe breast cancer fear according to phase of survivorship, determine whether breast cancer fear levels differed among survivorship phases, and determine the relationship between fear and age in African-American breast cancer survivors. The study utilized secondary data analysis from the study, Inner Resources as Predictors of Psychological Well-Being in AABCS. A new subscale entitled, "Breast Cancer Fear" was adapted from the Psychological Well Being Subscale by Ferrell and Grant. There was no significant difference between fear and phase of survivorship. There was a significant positive relationship between age and fear.

  16. Sentinel lymph node biopsy in bladder cancer: Systematic review and technology update

    Directory of Open Access Journals (Sweden)

    Michael A Liss

    2015-01-01

    Full Text Available A sentinel lymph node (SLN is the first lymph node to drain a solid tumor and likely the first place metastasis will travel. SLN biopsy has been well established as a staging tool for melanoma and breast cancer to guide lymph node dissection (LND; its utility in bladder cancer is debated. We performed a systematic search of PubMed for both human and animal studies that looked at SLN detection in cases of urothelial carcinoma of the bladder. We identified a total of nine studies that assessed a variety of imaging techniques to identify SLNs in patients with urothelial carcinoma of the bladder. Eight studies investigated human patients while one looked at animal (dog models. Seven studies representing 156 patients noted the negative predictive value of the SLN to predict a metastasis free state was 92% (92/100. The SLN biopsy was less accurate in metastatic patients with a positive predictive value of only 77% (43/56 with a false negative range of in individual studies of 0-19%. Clinically, positive nodes routinely do not take up the pharmaceutical agent for SLN. Therefore, SLN biopsy is a promising concept with a 92% negative predictive value; however, the false negative rates are high which may be improved by standardizing populations and indications. Novel technologies are improving the detection of SLN and may provide the surgeon with an improved ability to detect micrometastasis, guide surgery, and reduce patient morbidity.

  17. Getting free of breast cancer

    DEFF Research Database (Denmark)

    Halttunen, Arja; Hietanen, P; Jallinoja, P

    1992-01-01

    Twenty-two breast cancer patients who were relapse-free and had no need for cancer-related treatment were interviewed 8 years after mastectomy in order to evaluate their feelings of getting free of breast cancer and the meaning of breast cancer in their lives. The study is a part of an intervention...... and follow-up study of 57 breast cancer patients. Half of the 22 patients still had frequent or occasional thoughts of recurrence and over two-thirds still thought they had not been 'cured' of cancer. More than half of the patients admitted that going through breast cancer had made them more mature. Women...... who had less thoughts of recurrence belonged to a group that had gone through an eight-week group psychotherapy intervention, were less depressed and had more other illnesses. Women who felt 'cured' had less limitations and restrictions due to cancer and belonged more often to higher social classes...

  18. 前哨淋巴结活检对乳腺癌患者腋窝淋巴结清扫的临床指导价值%The role of sentinel lymph node biopsy on advising axillary lymph node dissection in breast cancer

    Institute of Scientific and Technical Information of China (English)

    李志红

    2013-01-01

    目的 探讨前哨淋巴结活检(SLNB)对乳腺癌患者腋窝淋巴结(ALN)转移状态的预测价值,为乳腺癌患者是否行腋窝淋巴结清扫(ALND)提供科学指导.方法 选取2010-2012年于本院手术治疗的乳腺癌患者65例,术中行前哨淋巴结活检,随后行包括ALND在内的不同方式的根除术.结果 根据术中切片病理和术后腋窝淋巴结病理,SLN检出成功率为95.4%(62/65); SLN预测ALN转移的准确性为95.2%(59/62);灵敏度为88.9%(24/27);特异性为100%(35/35),假阴性率为11.1%(3/27),总阳性、总阴性预测值分别为100%(24/24)和9.2%(35/38).结论 亚甲蓝法和放射性示踪法联合应用能准确检测出SLN,SLN能反映腋窝淋巴结的状态.%Objective To explore the clinical value of sentinel lymph node biopsy(SLNB) to predictaxillary lymph nodemetastasis so as to perform axillary lymph node dissection(ALND) in breast canceroperation.Methods Sixty-five breast cancer patients with surgical treatment in our hospital from 2010 to 2012 were selected.Intraoperative sentinel lymph node biopsy,then eradication of the different ways and ALND were executed.Results According to intraoperative biopsy and postoperative pathologic axillary lymph node pathology,SLN detection success rate was 95.4 % (62/65),SLN prediction accuracy of ALN metastasis was 95.2% (59/62),sensitivity was 88.9% (24/27),specificity was 100% (35/35),false-negative rate was 11.1% (3/27),and the total positive and negative predictive value were 100% (24/24) and 9.2% (35/38).Conclusion Methylene blue method combined with radioactive tracer method could accurately detect the SLN.SLN could reflect the status ofaxillary lymph nodes.

  19. Molecular imaging of breast cancer

    NARCIS (Netherlands)

    Adams, A.L.L.

    2014-01-01

    Breast cancer is the most common type of cancer in women. Imaging techniques play a pivotal role in breast cancer management, especially in lesion detection, treatment planning and evaluation, and prognostication. These imaging techniques have however limitations such as the use of ionizing radiatio

  20. Molecular imaging of breast cancer

    NARCIS (Netherlands)

    Adams, A.L.L.

    2014-01-01

    Breast cancer is the most common type of cancer in women. Imaging techniques play a pivotal role in breast cancer management, especially in lesion detection, treatment planning and evaluation, and prognostication. These imaging techniques have however limitations such as the use of ionizing

  1. [Immediate breast reconstruction for breast cancer].

    Science.gov (United States)

    Yamamoto, Daigo; Tanaka, Yoshihito; Tsubota, Yu; Sueoka, Noriko; Endo, Kayoko; Ogura, Tsunetaka; Nagumo, Yoshinori; Kwon, A-Hon

    2014-11-01

    We performed immediate breast reconstruction after nipple-sparing mastectomy or skin-sparing mastectomy and evaluated the reconstruction procedure, cosmesis, and complications. Among the 30 patients included in the study, 6 received latissimus dorsi flaps, 1 received a transverse rectus abdominis myocutaneous flap, 7 received deep inferior epigastric perforator flaps, 1 received an implant, and 15 received tissue expanders. In addition, the results were excellent in 25 patients, good in 3 patients, and poor in 2 patients. As the number of patients with breast cancer is increasing, the demand for breast reconstruction will increase. Therefore, it is essential to choose an appropriate method of breast reconstruction for each case.

  2. Time trends in axilla management among early breast cancer patients

    DEFF Research Database (Denmark)

    Gondos, Adam; Jansen, Lina; Heil, Jörg;

    2016-01-01

    Background We examined time trends in axilla management among patients with early breast cancer in European clinical settings. Material and methods EUROCANPlatform partners, including population-based and cancer center-specific registries, provided routinely available clinical cancer registry data...... for a comparative study of axillary management trends among patients with first non-metastatic breast cancer who were not selected for neoadjuvant therapy during the last decade. We used an additional short questionnaire to compare clinical care patterns in 2014. Results Patients treated in cancer centers were...... younger than population-based registry populations. Tumor size and lymph node status distributions varied little between settings or over time. In 2003, sentinel lymph node biopsy (SLNB) use varied between 26% and 81% for pT1 tumors, and between 2% and 68% for pT2 tumors. By 2010, SLNB use increased to 79...

  3. The bignificance of 99mTc-SC combined methylere method in sentinel lymph node biopsy of breast cancer%99m锝硫胶体联合美蓝在乳腺癌前哨淋巴结活检中的应用价值

    Institute of Scientific and Technical Information of China (English)

    王宇; 崔志超; 赵亚婷; 胡继卫; 马杰; 张景华; 胡万宁

    2012-01-01

    Objective To study the feasibility,accuracy and clinical applied value of sentinel lymph node biopsy(SLNB) in early breast cancer. Methods In 68 cases T1-2N0M0 stage of breast cancer,sentinel lymph nodes identified by 99mTo-sulfur colloid ( 99m Tc-SC) combining methylene blue were excised for biopsy. SI.N was examined pathologically to acquaint the conionnance rate and the clinical value of the combination approach in SLNB of early breat cancer. Results SLN was identified in 67 cases, one case was failure examed by SPECT, in 10 cases axillary lymph node dissection had performed because of the SLNB positive, the sensitivity rate of 99mTc-SC and methylene blue method was 81. 8% and 72. 7% .respectively, the accuracy rate of 99mTc-SC and methylene blue method was 97. 1% and 95. 6% , respectively, the false negative rate of 99m Tc-SC and methylene blue method was 18.2% and 27. 3% , respectively. The sensitivi-ty rate of combination method was 90. 9% , and the accuracy rate was 98.5% ,the false negative rate was 9. 1% and the false positive rate was zero. Conclusion 99m Tc-SC combining methylene blue bviously decreased the false negative rate of SLNB in early breast cancer.%目的 探讨锝-99m硫胶体(99mTc-SC)联合美蓝在早期乳腺癌前哨淋巴结活检(SLNB)中的可行性、准确性及临床应用价值.方法 采用99mTc-SC联合美蓝对68例T1-2 N0M0乳腺癌患者进行SLNB,将切除的前哨淋巴结(SLN)行病理检查了解其符合率,探讨联合法在早期乳腺癌SLNB中的临床应用价值.结果 成功确定患者SLN 67例,1例术前单光子发射型计算机断层扫描(SPECT)未显影,10例SLN病理检测阳性并行腋窝淋巴结清扫(ALND),99mTc-SC灵敏度为81.8%,准确性为97.1%,假阴性率为18.2%.美蓝法灵敏度为72.7%,准确性为95.6%,假阴性率为27.3%.联合法灵敏度为90.9%,准确性为98.5%,假阴性率为9.1%.假阳性率为0.结论 99mTc-SC联合美蓝检测法可明显降低早期乳腺癌SLNB的假阴性率.

  4. Progress in breast cancer: overview.

    Science.gov (United States)

    Arteaga, Carlos L

    2013-12-01

    This edition of CCR Focus titled Research in Breast Cancer: Frontiers in Genomics, Biology, and Clinical Investigation reviews six topics that cover areas of translational research of high impact in breast cancer. These topics represent areas of breast cancer research where significant progress has occurred but also where very important challenges remain. The papers in this CCR Focus section are contributed by experts in the respective areas of investigation. Herein, key aspects of these contributions and the research directions they propose are reviewed.

  5. 99mTc-硫胶体淋巴结显像联合亚甲蓝在乳腺癌前哨淋巴结活检中的临床研究%Clinical study of the axillary conservative surgery by sentinel lymph node biopsy using preoperative lymphoscintigraph technique with 99mTc-SC and methylene blue in breast cancer surgical therapy

    Institute of Scientific and Technical Information of China (English)

    冯尧军; 吴新红; 潘翠萍; 马彪

    2011-01-01

    目的 探讨99mTc-硫胶体(99mTc-SC)淋巴结显像联合亚甲蓝行乳腺癌前哨淋巴结活检(SLNB),对前哨淋巴结(SLN)阴性者避免行腋窝淋巴结清扫(ALND)的可行性及其临床应用价值.方法 187例乳腺癌患者术前行99mTc-SC淋巴结显像,并进行体表定位,术中加用亚甲蓝示踪SLN,切除后快速冰冻切片.其中51例SLN转移患者行改良根治术,将136例SLN阴性患者分为两组,A组[为腋窝淋巴结阳性患者,58例为术中检测阳性,2例为SLNB术后淋巴结常规病理检查阳性,再次行ALND,共60例]行乳腺切除或象限切除加ALND,B组(术中检测阴性78例,除去术后检测阳性2例,共76例)行SLNB,未行ALND.结果 A组术后上肢麻木、上肢水肿、上肢功能障碍分别为36、8、45例,B组分别为2、0、0例,两组比较差异有统计学意义(P0.05).结论 99mTc-SC淋巴结显像联合亚甲蓝行SLNB方法 简便,准确率高,疗效确实可靠.%Objective To evaluate the clinical significance of the axillary conservative surgery by sentinel lymph node biopsy (SLNB) using preoperative lymphoscintigraph technique with 99mTc-SC and methylene blue in early-stage breast cancer patients. Methods The sentinel lymph node (SLN) of 187 patients were located with preoperative lymphoscintigraph technique with 99mTc-SC and labeled with methylene blue during the operations. The metastasis of SLN was detected using frozen section technique. There were 51 patients whose SLN were positive having been carried with modified radical mastectomy of breast cancer and axillary lymph node dissection (ALND), 136 patients' SLN were negative,58 patients of those were carried with mammectomy or partial mastcctomy and ALND (group A),while 78 patients were carried out with mammectomy or partial mastectomy only (group B). The sentinel lymph nodes were detected with HE stain after surgery. All the patients were treated with chemotherapy,and the patients with partial mastcctomy must be treated with

  6. 吲哚菁绿荧光导航技术联合亚甲蓝示踪在乳腺癌前哨淋巴结活检术的应用研究%Study of fluorescence navigation technology with indocyanine-green combined with mapping with methylene blue applied to sentinel lymph nodes biopsy in breast cancer patients

    Institute of Scientific and Technical Information of China (English)

    姬逸男; 蒋奕; 韦薇; 唐玮; 杨华伟; 刘剑仑

    2015-01-01

    目的:探讨吲哚菁绿荧光导航技术联合亚甲蓝示踪在乳腺癌前哨淋巴结活检术中的临床应用价值。方法将127例cT1~3 N0 M0乳腺癌患者按随机数字表法分为吲哚菁绿组62例及联合组65例,分别应用吲哚菁绿和吲哚菁绿联合亚甲蓝作为淋巴示踪剂进行前哨淋巴结活检术。结果吲哚菁绿组定位成功率为95.2%(59/62),联合组定位成功率为98.5%(64/65),两组比较,差异无统计学意义(P>0.05)。联合组检出前哨淋巴结(3.8±1.5)枚/例,多于吲哚菁绿组的(2.7±1.2)枚/例(P<0.01)。结论吲哚菁绿是一种可靠的、操作简单的淋巴结示踪剂,与亚甲蓝联合应用可提高前哨淋巴结检出数量。%Objective To investigate the clinical value of fluorescence navigation technology with indocyanine-green(ICG) combined with mapping with methylene blue applied to sentinel lymph nodes biopsy ( SLNB) in breast cancer patients .Methods One hundred and twenty-seven patients with cT1-3N0M0 breast cancer were randomly divided into ICG group (n=62) and combination group(n=65).IGG group underwent SLNB by mapping with ICG ,while combination group underwent SLNB by mapping with ICG and methylene blue .Results The success rates of location in the ICG group and combination group were 95.2%(59/62) and 98.5%(64/65),respectively,which showed no statistical difference (P>0.05).The average number of sentinel lymph nodes detected in the combination group was more than that in the ICG group((3.8 ±1.5)/case vs.(2.7 ±1.2)/case,P<0.01).Conclusion ICG is a reliable and simply lymphatic mapping tracer.The combination of ICG and methylene blue can increase the detection amount of the sentinel lymph nodes .

  7. [Organized breast cancer screening].

    Science.gov (United States)

    Rouëssé, Jacques; Sancho-Garnier, Hélèn

    2014-02-01

    Breast screening programs are increasingly controversial, especially regarding two points: the number of breast cancer deaths they avoid, and the problem of over-diagnosis and over-treatment. The French national breast cancer screening program was extended to cover the whole country in 2004. Ten years later it is time to examine the risk/benefit ratio of this program and to discuss the need for change. Like all forms of cancer management, screening must be regularly updated, taking into account the state of the art, new evidence, and uncertainties. All screening providers should keep themselves informed of the latest findings. In the French program, women aged 50-74 with no major individual or familial risk factors for breast cancer are offered screening mammography and clinical breast examination every two years. Images considered non suspicious of malignancy by a first reader are re-examined by a second reader. The devices and procedures are subjected to quality controls. Participating radiologists (both public and private) are required to read at least 500 mammographies per year. The program's national participation rate was 52.7 % in 2012. When individual screening outside of the national program is taken into account (nearly 15 % of women), coverage appears close to the European recommendation of 65 %. Breast cancer mortality has been falling in France by 0.6 % per year for over 30 years, starting before mass screening was implemented, and by 1.5 % since 2005. This decline can be attributed in part to earlier diagnosis and better treatment, so that the specific impact of screening cannot easily be measured. Over-treatment, defined as the detection and treatment of low-malignancy tumors that would otherwise not have been detected in a person's lifetime, is a major negative effect of screening, but its frequency is not precisely known (reported to range from 1 % to 30 %). In view of these uncertainties, it would be advisable to modify the program in order to

  8. Estrogens and breast cancer

    Directory of Open Access Journals (Sweden)

    HANKINSON SUSAN E

    1997-01-01

    Full Text Available In this review, we summarize the epidemiologic evidence for the associations of oral contraceptives and postmenopausal hormones with risk of breast cancer. We also describe the biologic plausibility of these relationships. Overall, there appears to be little, if any, increase in risk with oral contraceptive use in general, even among users for 10 or more years. However, compared to never users, current oral contraceptive users appear to have a modest elevation in risk that subsides within about 10 years after cessation of use. For postmenopausal hormones, the weight of the evidence suggests little or no increase in risk among users of short duration, or for use in the past. However, current longer term use is associated with an increased risk of breast cancer that increases with duration. This increase in risk is large enough, and well enough supported, to be considered along with the other risks and benefits of postmenopausal hormone therapy.

  9. Unemployment among breast cancer survivors.

    Science.gov (United States)

    Carlsen, Kathrine; Ewertz, Marianne; Dalton, Susanne Oksbjerg; Badsberg, Jens Henrik; Osler, Merete

    2014-05-01

    Though about 20% of working age breast cancer survivors do not return to work after treatment, few studies have addressed risk factors for unemployment. The majority of studies on occupational consequences of breast cancer focus on non-employment, which is a mixture of sickness absence, unemployment, retirement pensions and other reasons for not working. Unemployment in combination with breast cancer may represent a particular challenge for these women. The aim of the present study is therefore to analyze the risk for unemployment in the years following diagnosis and treatment for breast cancer. This study included 14,750 women diagnosed with breast cancer in Denmark 2001-2009 identified through a population-based clinical database and linked with information from Danish administrative population based registers for information on labour market affiliation, socio-demography and co-morbid conditions. Multivariable analyses were performed by Cox's proportional hazard models. Two years after treatment, 81% of patients were still part of the work force, 10% of which were unemployed. Increasing duration of unemployment before breast cancer was associated with an adjusted HR = 4.37 (95% CI: 3.90-4.90) for unemployment after breast cancer. Other risk factors for unemployment included low socioeconomic status and demography, while adjuvant therapy did not increase the risk of unemployment. Duration of unemployment before breast cancer was the most important determinant of unemployment after breast cancer treatment. This allows identification of a particularly vulnerable group of patients in need of rehabilitation.

  10. Proteomic classification of breast cancer.

    LENUS (Irish Health Repository)

    Kamel, Dalia

    2012-11-01

    Being a significant health problem that affects patients in various age groups, breast cancer has been extensively studied to date. Recently, molecular breast cancer classification has advanced significantly with the availability of genomic profiling technologies. Proteomic technologies have also advanced from traditional protein assays including enzyme-linked immunosorbent assay, immunoblotting and immunohistochemistry to more comprehensive approaches including mass spectrometry and reverse phase protein lysate arrays (RPPA). The purpose of this manuscript is to review the current protein markers that influence breast cancer prediction and prognosis and to focus on novel advances in proteomic classification of breast cancer.

  11. SELDI-TOF Serum Profiling for Prognostic and Diagnostic Classification of Breast Cancers

    Directory of Open Access Journals (Sweden)

    Christine Laronga

    2004-01-01

    Full Text Available Surface enhanced laser desorption/ionization (SELDI time-of-flight mass spectrometry has emerged as a successful tool for serum based detection and differentiation of many cancer types, including breast cancers. In this study, we have applied the SELDI technology to evaluate three potential applications that could extend the effectiveness of established procedures and biomarkers used for prognostication of breast cancers. Paired serum samples obtained from women with breast cancers prior to surgery and post-surgery (6–9 mos. were examined. In 14/16 post-treatment patients, serum protein profiles could be used to distinguish these samples from the pre-treatment cancer samples. When compared to serum samples from normal healthy women, 11 of these post-treatment samples retained global protein profiles not found in healthy women, including five low-mass proteins that remained elevated in both pre-treatment and post-treatment serum groups. In another pilot study, serum profiles were compared for a group of 30 women who were known BRCA-1 mutation carriers, half of whom subsequently developed breast cancer within three years of the sample procurement. SELDI protein profiling accurately classified 13/15 women with BRCA-1 breast cancers from the 15 non-cancer BRCA-1 carriers. Additionally, the ability of SELDI to distinguish between the serum profiles from sentinel lymph node positive and sentinel lymph node negative patients was evaluated. In sentinel lymph node positive samples, 22/27 samples were correctly classified, in comparison to the correct classification of 55/71 sentinel lymph node negative samples. These initial results indicate the utility of protein profiling approaches for developing new diagnostic and prognostic assays for breast cancers.

  12. Breast cancer risk factors

    Directory of Open Access Journals (Sweden)

    Marzena Kamińska

    2015-09-01

    Full Text Available Breast cancer is the most frequently diagnosed neoplastic disease in women around menopause often leading to a significant reduction of these women’s ability to function normally in everyday life. The increased breast cancer incidence observed in epidemiological studies in a group of women actively participating in social and professional life implicates the necessity of conducting multidirectional studies in order to identify risk factors associated with the occurrence of this type of neoplasm. Taking the possibility of influencing the neoplastic transformation process in individuals as a criterion, all the risk factors initiating the process can be divided into two groups. The first group would include inherent factors such as age, sex, race, genetic makeup promoting familial occurrence of the neoplastic disease or the occurrence of benign proliferative lesions of the mammary gland. They all constitute independent parameters and do not undergo simple modification in the course of an individual’s life. The second group would include extrinsic factors conditioned by lifestyle, diet or long-term medical intervention such as using oral hormonal contraceptives or hormonal replacement therapy and their influence on the neoplastic process may be modified to a certain degree. Identification of modifiable factors may contribute to development of prevention strategies decreasing breast cancer incidence.

  13. Interleukin-19 in Breast Cancer

    Directory of Open Access Journals (Sweden)

    Ying-Yin Chen

    2013-01-01

    Full Text Available Inflammatory cytokines within the tumor microenvironment are linked to progression in breast cancer. Interleukin- (IL- 19, part of the IL-10 family, contributes to a range of diseases and disorders, such as asthma, endotoxic shock, uremia, psoriasis, and rheumatoid arthritis. IL-19 is expressed in several types of tumor cells, especially in squamous cell carcinoma of the skin, tongue, esophagus, and lung and invasive duct carcinoma of the breast. In breast cancer, IL-19 expression is correlated with increased mitotic figures, advanced tumor stage, higher metastasis, and poor survival. The mechanisms of IL-19 in breast cancer have recently been explored both in vitro and in vivo. IL-19 has an autocrine effect in breast cancer cells. It directly promotes proliferation and migration and indirectly provides a microenvironment for tumor progression, which suggests that IL-19 is a prognostic marker in breast cancer and that antagonizing IL-19 may have therapeutic potential.

  14. International multicenter tool to predict the risk of nonsentinel node metastases in breast cancer

    DEFF Research Database (Denmark)

    Meretoja, Tuomo J; Leidenius, Marjut H K; Heikkilä, Päivi S;

    2012-01-01

    Background Axillary treatment of breast cancer patients is undergoing a paradigm shift, as completion axillary lymph node dissections (ALNDs) are being questioned in the treatment of patients with tumor-positive sentinel nodes. This study aims to develop a novel multi-institutional predictive too...

  15. Clinical application of sentinel lymph node biopsy under the guidance of contrast-enhanced ultrasound pins methylene blue in patients with breast cancer%超声造影结合亚甲蓝定位在乳腺癌前哨淋巴结活检中的应用

    Institute of Scientific and Technical Information of China (English)

    胡慧; 韦伟; 孙德胜; 刘荫华

    2013-01-01

    Objective To explore the application feasibility of contrast-emhanced ultrasound (CEUS) plus methylene blue in sentinel lymph node biopsy (SLNB) for breast cancer and determine the ultrasonographic features of sentinel lymph node (SLN).Methods The microbubbles of SonoVue were injected subcutaneously and intradermally into tumor side of areola.The images were observed to record the size,number,lymphatic door,aspect ratio,enhanced time and enhanced mode of SLN.Methylene blue was injected into SLN under the guidance of ultrasound.The marked SLNs were dissected for pathological examinations.Based upon the results,the specimens were divided into SLN metastasis and SLN nonmetastasis groups.Results A total of 34 breast cancer patients were recruited.Among them,SLN was detected preoperatively in 31 patients by CEUS and the rate was 91.2%.And the postoperative results showed that 14 were confirmed positive (metastasis group) and 17 negative (non-metastasis group).The sensitivity,specificity,accuracy and false negative rate of CEUS for detecting SLNs were 93.3% (14/15),100%(16/16),96.8% (30/31) and 6.7% (1/15) respectively.The model of stepwise regression analysis showed that lymphatic door,aspect ratio and enhanced mode were helpful to differentiate SLN metastasis and SLN nonmetastasis groups.Conclusions SLNB under the guidance of CEUS plus methylene blue offer prompt and accurate localization with a lower cost.It may enhance the detection rate of SLNB in breast cancer.%目的 探讨超声造影结合亚甲蓝行乳腺癌前哨淋巴结活检(SLNB)的可行性以及超声造影图像特征.方法 2011年10月至2012年5月北京大学深圳医院对34例乳腺癌患者在患侧乳晕区皮内及皮下注射造影剂,观察前哨淋巴结(SLN)超声造影增强情况,记录SLN大小、数量、淋巴门结构、纵横比、增强时间及增强模式;在B超声引导下对确定的SLN进行亚甲蓝定位后切除SLN,行病理检查,并根据有无肿瘤转移

  16. 吲哚菁绿联合亚甲蓝在乳腺癌前哨淋巴结活检术中的应用研究%Appl ication of Indocyanine green joint methylene blue for sentinel lymph node biophy in pa-tients with breast cancer

    Institute of Scientific and Technical Information of China (English)

    崔仁忠; 杨接辉; 潘承欣

    2016-01-01

    Objective:To discuss the value of Indocyanine green joint methylene blue in sentinel lymph node biophy for patients with breast cancer.Methods:A total of 200breast cancer patients were selected and randomly divided into test group and control group,with 100 cases in eachgroup.The test group received indocyanine green and methylene blue as the lymphatic mapping tracers and the control group received methylene blue only.Intraoperative frozen section was performed followed by conventional histopathology.Results:The positive rate,sensitivity,false negative rate,consistent rate and the Kappa values of the test group were 98.00% (98/100),95.74% (45/47),4.26% (2/47),96.94% (95/98)and 0.860,the corresponding data for the control group was 94.00% (94/100)and 86.96% (40/46),13.04% (6/46),93.62% (88/94)and 0.758 showing sig-nificant difference in positive rate,sensitivity,false negative rate,consistent rate and the Kappa values between the two groups (P <0.05 ).Conclusion:With advantages of real-time visual and accurate positioning,Indocyanine green joint methylene blue shows high positive rate,accuracy and low fake negative rate when it is used for sentinel lymph node biophy in patients with breast cancer.%目的::探讨吲哚菁绿联合亚甲蓝作为淋巴示踪剂在乳腺癌前哨淋巴结活检术(SLNB)中的应用价值.方法:选取于我院收治并确诊的原发性乳腺癌住院患者200例,随机分为实验组和对照组,各100例.实验组采用吲哚菁绿联合亚甲蓝作为淋巴示踪剂,对照组单用亚甲蓝为淋巴示踪剂,两组均先行常规 SLNB 再行腋窝淋巴结清扫术,两标本均送病理检查.结果:实验组检出率、灵敏度、假阴性率、一致率和 Kappa 值分别为98.00%(98/100)、95.74%(45/47)、4.26%(2/47)、96.94%%(95/98)和0.860;对照组检出率、灵敏度、假阴性率、一致率和 Kappa 值分别为94.00%(94/100)、86.96%(40/46)、13.04%(6/46)、93.62

  17. 单用亚甲蓝示踪剂行乳腺癌前哨淋巴结活检术(附47例报告)%Methylene Blue as Single Tracer for Sentinel Lymph Node Biopsy in Breast Cancer(a report of 4 7 cases)

    Institute of Scientific and Technical Information of China (English)

    周文斌; 麦玉嫦; 周冬仙; 钟才能; 许楠

    2014-01-01

    目的探讨单用亚甲蓝示踪剂在乳腺癌前哨淋巴结活检术(SLNB)中的临床应用效果。方法回顾性分析2010年7月至2012年6月年本科室收治的47例临床腋窝淋巴结阴性乳腺癌采用单用亚甲蓝示踪剂行 SLNB及腋窝淋巴结清扫术(ALND)的临床资料。结果47例患者中46例成功施行 SLNB,成功率97.8%;在前30例的学习曲线阶段,30例中有6例前哨淋巴结有癌转移,转移率20%;与 ALND术后结果比较,SLNB准确率100%,假阴性率0%。与行 ALND患者比较,行 SLNB患者术后患肢淋巴水肿、肩部不适、肩关节活动障碍等不良事件发生率明显降低。结论在规范操作的前提下,单用亚甲蓝示踪剂行乳腺癌 SL-NB简单可行、安全有效、可获得良好的成功率和准确率。%Obj ective]To explore the clinical efficacy of methylene blue as single tracer for sentinel lymph node biopsy(SLNB)in breast cancer.[Methods]Clinical data of 47 patients with clinical axillary lymph node-negative breast cancer undergoing SLNB and axillary lymph node dissection(ALND)in our department from July 2010 to June 2012 were analyzed retrospectively.[Results]Among 47 patients,46 patients underwent SLNB successfully,and the success rate was 97.8%.During the learning curve period of 30 patients,6 pa-tients had sentinel lymph node metastases,and the metastasis rate was 20%.Compared with the outcomes of ALND,the accuracy and false negative rate of SLNB were 100% and 0%,respectively.Compared with pa-tients undergoing ALND,the incidence rates of lymphedema of diseased limbs,shoulder discomfort,shoulder joint movement disorder and so on in patients undergoing SLNB were obviously reduced.[Conclusion]Based on the standard operation,methylene blue as single tracer for SLNB in breast cancer is simple,feasible,safe and effective,and can obtain good success rate and accuracy rate.

  18. Morbidade entre a pós-biópsia de linfonodo sentinela e a dissecção axilar no câncer de mama Morbidity after sentinel node biopsy and axillary dissection in breast cancer

    Directory of Open Access Journals (Sweden)

    Beatriz Pifano Soares Ferreira

    2008-12-01

    Full Text Available OBJETIVO: O objetivo deste estudo foi avaliar a morbidade cirúrgica pós-biópsia de linfonodo sentinela (BLS ou dissecção axilar com (DA-NP e sem preservação do nervo intercostobraquial (DA-NS. MÉTODOS: Fez-se estudo coorte prospectivo com 108 pacientes divididas em três grupos: BLS (n=35, DA-NP (n=36 e DA-NS (n=37. Foram avaliadas ocorrência de déficit sensorial, dor, linfedema, seroma e infecção no membro superior homolateral à cirurgia. Monofilamentos de Semmes-Weinstein foram usados para avaliar o déficit sensorial, perimetria braquial foi feita para avaliação da presença de linfedema e aplicado questionário de dor. Para análise estatística foram utilizados os testes ANOVA e Kruskal-Wallis. Foi feita análise bivariada e multivariada. RESULTADOS: Pelo menos uma complicação pós-cirúrgica, imediata ou tardia, ocorreu em 45/108 (41,7% pacientes avaliadas. A complicação mais comum foi dor. Houve diferença estatisticamente significante entre os três grupos somente quanto ao déficit sensorial (p=0,04. Dor, linfedema e déficit sensorial ocorreram com maior freqüência no grupo DA-NS. As pacientes dos grupos BLS e DA-NP não apresentaram diferenças estatisticamente significantes para nenhuma das variáveis analisadas. A pesquisa com os monofilamentos mostrou sensibilidade cutânea preservada em 28/35 pacientes do grupo BLS, em 25/36 pacientes do grupo DA-NP e em 10/37 pacientes do grupo DA-NS (pBACKGROUND: The aim of this study was to evaluate the morbidity after sentinel node biopsy (SNB and axillary dissection with (AD-NS or without sparing the intercostobrachial nerve (AD-NOS. Methods: A prospective cohort study was performed on 108 patients divided into three groups: SNB (n=35, AD-NS (n=36 and AD-NOS (n=37. We evaluated the incidence of sensory loss, pain, lymphedema, seroma formation and infection in the arm homolateral to the breast surgery. Semmes-Weinstein monofilaments were used to assess the sensory loss

  19. Increasing Breast Cancer Surveillance among African American Breast Cancer Survivors

    Science.gov (United States)

    2005-07-01

    Madam , The project entitled INCREASING BREAST CANCER SURVEILLANCE AMONG AFRICAN AMERICAN BREAST CANCER SURVIVORS includes activities involving human...B b- d § fr. Thomisonwill Work e .y .With’Dra) Vdldf naTir, W and y Bo • rganif Janidorf on data a"_`l- ssi reatihfiutfor pres~entatidns and publi

  20. The role of ultrasound and lymphoscintigraphy in the assessment of axillary lymph nodes in patients with breast cancer

    Directory of Open Access Journals (Sweden)

    Michał Nieciecki

    2016-03-01

    Full Text Available Breast cancer is the most common malignancy and the leading cause of death due to cancer in European women. Mammography screening programs aimed to increase the detection of early cancer stages were implemented in numerous European countries. Recent data show a decrease in mortality due to breast cancer in many countries, particularly among young women. At the same time, the number of sentinel node biopsy procedures and breast-conserving surgeries has increased. Intraoperative sentinel lymph node biopsy preceded by lymphoscintigraphy is used in breast cancer patients with no clinical signs of lymph node metastasis. Due to the limited sensitivity and specificity of physical examination in detecting metastatic lesions, developing an appropriate diagnostic algorithm for the preoperative assessment of axillary lymph nodes seems to be a challenge. The importance of ultrasound in patient qualification for sentinel lymph-node biopsy has been discussed in a number of works. Furthermore, different lymphoscintigraphy protocols have been compared in the literature. The usefulness of novel radiopharmaceuticals as well as the methods of image acquisition in sentinel lymph node diagnostics have also been assessed. The aim of this article is to present, basing on current guidelines, literature data as well as our own experience, the diagnostic possibilities of axillary lymph node ultrasound in patient qualification for an appropriate treatment as well as the role of lymphoscintigraphy in sentinel lymph node biopsy.

  1. Drugs Approved for Breast Cancer

    Science.gov (United States)

    This page lists cancer drugs approved by the Food and Drug Administration (FDA) for breast cancer. The list includes generic names, brand names, and common drug combinations, which are shown in capital letters.

  2. Detection and localization of sentinel lymph node with breast cancer using ultrasound%超声对乳腺癌前哨淋巴结的定位检测进展

    Institute of Scientific and Technical Information of China (English)

    张琴

    2010-01-01

    @@ 前哨淋巴结(sentinel lymph node,SLN)是指原发肿瘤引流区域中第一级接受淋巴引流的淋巴结.1994年Giuliano等~([1])在乳腺癌外科治疗引用SLN的概念,首创了乳腺癌术中淋巴结定位和前哨淋巴结活检(sentinel lymph node biopsy,SLNB)技术.乳腺癌SLNB是乳腺外科领域的一个极具意义的进展,也是当前乳腺外科领域的一个热点~([2,3]).

  3. 亚甲蓝染色法乳腺癌前哨淋巴结活检术158例分析%Analysis of 158 Cases of Sentinel Lymph Node Biopsy in Breast Cancer by Methylene Blue Staining Method

    Institute of Scientific and Technical Information of China (English)

    黄国兴; 苏国森; 李上芹; 湛建伟; 程少萍

    2016-01-01

    目的:分析研究亚甲蓝染色法乳腺癌前哨淋巴结活检术(SLNB)158例的检测结果,为临床手术治疗提供数据参考。方法选择乳腺癌患者158例,所有患者均给予亚甲蓝染色法 SLNB 术,观察并统计乳腺癌患者的年龄、肿瘤大小和位置、术前化疗情况以及腋窝淋巴结肿大情况。分析亚甲蓝染色法 SLNB 术对于乳腺癌前哨淋巴结(SLN)的检出情况,并分析影响乳腺癌 SLN 检出的危险因素。结果亚甲蓝染色法 SLNB 术检测乳腺癌SLN 的准确度为94.94%,敏感度为94.38%,特异度为95.65%,肿瘤大小>5 cm 及触及腋窝淋巴结肿大的 SLN 检出率均显著少于肿瘤大小≤5 cm 及未触及腋窝淋巴结肿大者(P 5 cm and hit axillary lymph node enlargement of SLN detection rate were significant-ly less than tumor size≤5 cm and not palpable axillary lymph nodes,the difference was statistically significant (P < 0. 05). Tumor size and axillary lymph nodes were the unfavorable factors for SLN detection in breast cancer. Conclusion Meth-ylene blue staining method was applied to SLNB operation,the detection value was higher,but the clinic should also pay at-tention to the unfavorable factors of SLN detection in breast cancer.

  4. Breast and Colon Cancer Family Registries

    Science.gov (United States)

    The Breast Cancer Family Registry and the Colon Cancer Family Registry were established by the National Cancer Institute as a resource for investigators to use in conducting studies on the genetics and molecular epidemiology of breast and colon cancer.

  5. Breast cancer screening in Korean woman with dense breast tissue

    Energy Technology Data Exchange (ETDEWEB)

    Shin, Hee Jung [Dept. of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul (Korea, Republic of); Ko, Eun Sook [Dept. of Radiology, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul (Korea, Republic of); Yi, Ann [Dept. of Radiology, Seoul National University College of Medicine, Seoul National University Hospital, Seoul (Korea, Republic of)

    2015-11-15

    Asian women, including Korean, have a relatively higher incidence of dense breast tissue, compared with western women. Dense breast tissue has a lower sensitivity for the detection of breast cancer and a higher relative risk for breast cancer, compared with fatty breast tissue. Thus, there were limitations in the mammographic screening for women with dense breast tissue, and many studies for the supplemental screening methods. This review included appropriate screening methods for Korean women with dense breasts. We also reviewed the application and limitation of supplemental screening methods, including breast ultrasound, digital breast tomosynthesis, and breast magnetic resonance imaging; and furthermore investigated the guidelines, as well as the study results.

  6. Overdiagnosis in breast cancer screening

    DEFF Research Database (Denmark)

    Lynge, Elsebeth; Beau, Anna-Belle; Christiansen, Peer

    2017-01-01

    Overdiagnosis in breast cancer screening is an important issue. A recent study from Denmark concluded that one in three breast cancers diagnosed in screening areas in women aged 50-69 years were overdiagnosed. The purpose of this short communication was to disentangle the study's methodology...

  7. Circadian clocks and breast cancer

    OpenAIRE

    Blakeman, Victoria; Jack L. Williams; Meng, Qing-Jun; Streuli, Charles H

    2016-01-01

    Circadian clocks respond to environmental time cues to coordinate 24-hour oscillations in almost every tissue of the body. In the breast, circadian clocks regulate the rhythmic expression of numerous genes. Disrupted expression of circadian genes can alter breast biology and may promote cancer. Here we overview circadian mechanisms, and the connection between the molecular clock and breast biology. We describe how disruption of circadian genes contributes to cancer via multiple mechanisms, an...

  8. Imaging inflammatory breast cancer.

    Science.gov (United States)

    Alunni, J-P

    2012-02-01

    Carcinomatous mastitis is a severe form of breast cancer and its diagnosis is essentially clinical and histological. The first examination to perform is still mammography, not only to provide evidence supporting this diagnosis but also to search for a primary intramammary lesion and assess local/regional spread. It is essential to study the contralateral breast for bilaterality. Ultrasound also provides evidence supporting inflammation, but appears to be better for detecting masses and analysing lymph node areas. The role of MRI is debatable, both from a diagnostic point of view and for monitoring during treatment, and should be reserved for selected cases. An optimal, initial radiological assessment will enable the patient to be monitored during neoadjuvant chemotherapy. Copyright © 2011 Éditions française de radiologie. Published by Elsevier Masson SAS. All rights reserved.

  9. What Is Breast Cancer in Men?

    Science.gov (United States)

    ... and bloodstream. At least 8 out of 10 male breast cancers are IDCs (alone or mixed with other types ... is much smaller than the female breast, all male breast cancers start relatively close to the nipple, so they ...

  10. General Information about Breast Cancer and Pregnancy

    Science.gov (United States)

    ... Breast Cancer Treatment and Pregnancy (PDQ®)–Patient Version General Information about Breast Cancer and Pregnancy Go to ... are linked by thin tubes called ducts. Enlarge Anatomy of the female breast. The nipple and areola ...

  11. Unemployment among breast cancer survivors

    DEFF Research Database (Denmark)

    Carlsen, Kathrine; Ewertz, Marianne; Dalton, Susanne Oksbjerg

    2014-01-01

    AIM: Though about 20% of working age breast cancer survivors do not return to work after treatment, few studies have addressed risk factors for unemployment. The majority of studies on occupational consequences of breast cancer focus on non-employment, which is a mixture of sickness absence......, unemployment, retirement pensions and other reasons for not working. Unemployment in combination with breast cancer may represent a particular challenge for these women. The aim of the present study is therefore to analyze the risk for unemployment in the years following diagnosis and treatment for breast...... cancer. METHOD: This study included 14,750 women diagnosed with breast cancer in Denmark 2001-2009 identified through a population-based clinical database and linked with information from Danish administrative population based registers for information on labour market affiliation, socio...

  12. Decline in breast cancer mortality

    DEFF Research Database (Denmark)

    Njor, Sisse Helle; Schwartz, Walter; Blichert-Toft, Mogens

    2015-01-01

    OBJECTIVES: When estimating the decline in breast cancer mortality attributable to screening, the challenge is to provide valid comparison groups and to distinguish the screening effect from other effects. In Funen, Denmark, multidisciplinary breast cancer management teams started before screening...... was introduced; both activities came later in the rest of Denmark. Because Denmark had national protocols for breast cancer treatment, but hardly any opportunistic screening, Funen formed a "natural experiment", providing valid comparison groups and enabling the separation of the effect of screening from other...... factors. METHODS: Using Poisson regression we compared the observed breast cancer mortality rate in Funen after implementation of screening with the expected rate without screening. The latter was estimated from breast cancer mortality in the rest of Denmark controlled for historical differences between...

  13. Statins and breast cancer prognosis

    DEFF Research Database (Denmark)

    Ahern, Thomas P; Lash, Timothy L; Damkier, Per

    2014-01-01

    Much preclinical and epidemiological evidence supports the anticancer effects of statins. Epidemiological evidence does not suggest an association between statin use and reduced incidence of breast cancer, but does support a protective effect of statins-especially simvastatin-on breast cancer...... recurrence. Here, we argue that the existing evidence base is sufficient to justify a clinical trial of breast cancer adjuvant therapy with statins and we advocate for such a trial to be initiated without delay. If a protective effect of statins on breast cancer recurrence is supported by trial evidence......, then the indications for a safe, well tolerated, and inexpensive treatment can be expanded to improve outcomes for breast cancer survivors. We discuss several trial design opportunities-including candidate predictive biomarkers of statin safety and efficacy-and off er solutions to the key challenges involved...

  14. Near-infrared fluorescence imaging with methylene blue for detecting sentinel lymph node in early breast cancer%荧光法联合染色法前哨淋巴结活检在早期乳腺癌中的应用

    Institute of Scientific and Technical Information of China (English)

    刘军; 王宁; 陈平; 黄林平

    2015-01-01

    Objective To explore the clinical value of indocyanine green near-infrared fluorescence imaging with methylene blue for the sentinel lymph node biopsy (SLNB) in early breast cancer.Methods SLNB was performed in forty patients by fluorescence navigation with methylene blue.Frozen section was performed,followed by conventional histopathology.Results The identification rate of SLN was 100%.100% of SLNs were fluorescent,with the average number being 2.88.92.5% of SLNs were stained blue,with the average number being 1.75.The presence of lymph node metastasis was observed in intraoperative biopsy in 7 patients,and a total dissection of the axillary lymph nodes was performed immediately.Metastatic lesions were not found in the identified lymph nodes by intraoperative biopsy and permanent pathological diagnosis in the other 33 patients.Conclusions Sentinel lymph nodes biopsy by fluorescence navigation with methylene blue was a feasible minimally invasive technology with high detection rate.%目的 探讨吲哚菁绿引导的荧光法联合染色法进行早期乳腺癌前哨淋巴结活检的临床应用价值.方法 40例早期乳腺癌患者通过荧光法联合染色法进行前哨淋巴结活检,全部前哨淋巴结均进行术中冰冻及术后石蜡切片病理检查.结果 40例患者均成功行前哨淋巴结活检,其中前哨淋巴结荧光显影率为100%,平均每例2.88枚;蓝染率为92.5%,平均每例1.75枚.7例患者术中冰冻检查发现前哨淋巴结转移癌并立即行腋窝淋巴结清扫.其余33例患者前哨淋巴结术中冰冻病理检查及术后石蜡切片病理检查均未发现转移癌.结论 染色法联合荧光法前哨淋巴结活检具备检出率高、创伤小等优势,适宜在临床推广.

  15. Sentinel node biopsy in head and neck cancer

    DEFF Research Database (Denmark)

    Ross, Gary L; Soutar, David S; Gordon MacDonald, D

    2004-01-01

    BACKGROUND: The aim was to determine the reliability and reproducibility of sentinel node biopsy (SNB) as a staging tool in head and neck squamous cell carcinoma (HNSCC) for T1/2 clinically N0 patients by means of a standardized technique. METHODS: Between June 1998 and June 2002, 227 SNB...

  16. Breast Cancer Diagnosed During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients.

    Science.gov (United States)

    Loibl, Sibylle; Schmidt, André; Gentilini, Oreste; Kaufman, Bella; Kuhl, Christine; Denkert, Carsten; von Minckwitz, Gunter; Parokonnaya, Anastasia; Stensheim, Hanne; Thomssen, Christoph; van Calsteren, Kristel; Poortmans, Philip; Berveiller, Paul; Markert, Udo R; Amant, Frederic

    2015-11-01

    Breast cancer during pregnancy (BCP), although rare, is becoming more common and treatment should be as similar as possible to that for nonpregnant young patients with breast cancer. A group of specialists convened to review current guidelines and provide guidance on how recent advances in breast cancer diagnosis and treatment can be adapted for pregnant patients. The majority of patients with BCP will be considered for treatment during the pregnancy. Premature delivery should be avoided whenever possible. Most treatments, including sentinel lymph node biopsy, systemic therapy with taxanes, platinum agents, or dose-dense treatment can be safely given during pregnancy, after careful risk/benefit assessment for mother and child. Chemotherapy is contraindicated during the first trimester because of a higher risk of fetal malformations but is feasible in the second and third trimesters. Other treatments such as radiation therapy or anti-human epidermal growth receptor 2 treatment are in general not indicated during pregnancy but might be considered in some instances. Patient data should be collected in a systematic way whenever possible.

  17. Pregnancy associated breast cancer and pregnancy after breast cancer treatment

    OpenAIRE

    Doğer, Emek; Çalışkan, Eray; Mallmann, Peter

    2011-01-01

    Breast cancer is one of the most common cancers diagnosed during pregnancy and its frequency is increasing as more women postpone their pregnancies to their thirties and forties. Breast cancer diagnosis during pregnancy and lactation is difficult and complex both for the patient and doctors. Delay in diagnosis is frequent and treatment modalities are difficult to accept for the pregnant women. The common treatment approach is surgery after diagnosis, chemotherapy after the first trimester and...

  18. Axillary Lymph Nodes and Breast Cancer

    Science.gov (United States)

    ... more likely to affect arm function and cause lymphedema. For this reason, sentinel node biopsy is the ... OR supraclavicular (above the clavicle) nodes have cancer Lymphedema Lymphedema [lim-fa-DEE-ma] is a build- ...

  19. Functional Magnetic Resonance Imaging in Assessing Affect Reactivity and Regulation in Patients With Stage 0-III Breast Cancer

    Science.gov (United States)

    2017-02-27

    Healthy Subject; Stage 0 Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer

  20. Optimal breast cancer pathology manifesto.

    Science.gov (United States)

    Tot, T; Viale, G; Rutgers, E; Bergsten-Nordström, E; Costa, A

    2015-11-01

    This manifesto was prepared by a European Breast Cancer (EBC) Council working group and launched at the European Breast Cancer Conference in Glasgow on 20 March 2014. It sets out optimal technical and organisational requirements for a breast cancer pathology service, in the light of concerns about variability and lack of patient-centred focus. It is not a guideline about how pathology services should be performed. It is a call for all in the cancer community--pathologists, oncologists, patient advocates, health administrators and policymakers--to check that services are available that serve the needs of patients in a high quality, timely way.

  1. Breast Tissue Composition and Susceptibility to Breast Cancer

    Science.gov (United States)

    Martin, Lisa J.; Bronskill, Michael; Yaffe, Martin J.; Duric, Neb; Minkin, Salomon

    2010-01-01

    Breast density, as assessed by mammography, reflects breast tissue composition. Breast epithelium and stroma attenuate x-rays more than fat and thus appear light on mammograms while fat appears dark. In this review, we provide an overview of selected areas of current knowledge about the relationship between breast density and susceptibility to breast cancer. We review the evidence that breast density is a risk factor for breast cancer, the histological and other risk factors that are associated with variations in breast density, and the biological plausibility of the associations with risk of breast cancer. We also discuss the potential for improved risk prediction that might be achieved by using alternative breast imaging methods, such as magnetic resonance or ultrasound. After adjustment for other risk factors, breast density is consistently associated with breast cancer risk, more strongly than most other risk factors for this disease, and extensive breast density may account for a substantial fraction of breast cancer. Breast density is associated with risk of all of the proliferative lesions that are thought to be precursors of breast cancer. Studies of twins have shown that breast density is a highly heritable quantitative trait. Associations between breast density and variations in breast histology, risk of proliferative breast lesions, and risk of breast cancer may be the result of exposures of breast tissue to both mitogens and mutagens. Characterization of breast density by mammography has several limitations, and the uses of breast density in risk prediction and breast cancer prevention may be improved by other methods of imaging, such as magnetic resonance or ultrasound tomography. PMID:20616353

  2. Exercise Intervention in Targeting Adiposity and Inflammation With Movement to Improve Prognosis in Breast Cancer

    Science.gov (United States)

    2017-08-19

    Cancer Survivor; Central Obesity; Estrogen Receptor Positive; Postmenopausal; Progesterone Receptor Positive; Stage I Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage III Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer

  3. Exercise in Targeting Metabolic Dysregulation in Stage I-III Breast or Prostate Cancer Survivors

    Science.gov (United States)

    2017-09-12

    Cancer Survivor; No Evidence of Disease; Obesity; Overweight; Prostate Carcinoma; Sedentary Lifestyle; Stage I Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage III Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer

  4. [Breast cancer in elderly].

    Science.gov (United States)

    Diab, Sami G

    2007-10-01

    The question of the breast cancer in elderly is enlightened by two constituted epidemiological data bases in the United-States: the data basis of San Antonio and the SEER (Surveillance Epidemology and End Results) which represent a follow-up of 26% of the American population. The listed data allow an approach of the clinical and biological constituents according to the age of the disease as well as the factors of comorbidity. The informations relative to the therapeutic choices are more fragmentary and must be developed first and foremost during the programs. double dagger.

  5. Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid

    Science.gov (United States)

    2016-07-12

    Estrogen Receptor-positive Breast Cancer; Invasive Ductal Breast Carcinoma; Progesterone Receptor-positive Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer

  6. [San Antonio Breast Cancer Symposium -- highlights 2004].

    Science.gov (United States)

    Rody, A; V Minckwitz, G; Loibl, S; Kaufmann, M

    2005-04-01

    The adjuvant therapy of postmenopausal, hormonereceptor positive breast cancer patients with aromatase inhibitors in ATAC, ABCSG 8/ ARNO 95 and IES trial revealed just a benefit in terms of disease-free survival, but not for over-all survival. Thus MA-17 trial is so far the only study which could demonstrate a survival benefit for node positive disease by "extended adjuvant" therapy with letrozole. Node- and receptorpositive, postmenopausal women show a higher benefit by anthracycline containing chemotherapy in combination with tamoxifen, than by endocrine therapy alone. But tamoxifen should given sequentially to chemotherapy (Intergroup 0100/ SWOG-8814 trial). Adjuvant chemotherapy with three cycles FEC followed by three cycles docetaxel reveals a survival benefit compared to six cycles FEC, especially in women older than 50 years (PACS 01 trial). Furthermore there is evolving evidence that dose-dense, interval shortened chemotherapy is superior to standard chemotherapy in adjuvant setting. The impaired survival of receptornegative, nodalpositive breast cancer patients seems to be converted to a survival improvement compared with receptorpositive patients by modern adjuvant cytotoxic regimens (metaanalysis CALGB 8541, 9344, 9741). In primary systemic chemotherapy survival is strongly associated with the rate of pathohistological complete remissions (NSABP B-27). The combination of cytotoxic drugs has no further influence on survival, but the sequential administration of taxane increases the rate of pCR. A difference in survival stratified by pCR and non-pCR in breast and positive nodal status could not be detected, so that the number of involved lymph nodes seems to be the strongest prognostic factor and is independent of tumor response in the breast. The sentinel node biopsy is a safe and reliable method, but the rate of false negative findings depends on the pathohistological methods (NSABP B-32). The morbidity of this method is low compared with conventional

  7. The role of sentinel node biopsy in gynecological cancer : a review

    NARCIS (Netherlands)

    Oonk, Maaike H. M.; van de Nieuwenhof, Hedwig P.; de Hullu, Joanne A.; van der Zee, Ate G. J.

    2009-01-01

    Purpose of review In early-stage vulvar, cervical and endometrial cancer, lymph node status is the most important prognostic factor. Surgical treatment is aimed at removing the primary tumor and adequately staging the regional lymph nodes. As morbidity of regional lymphadenectomy is high, sentinel n

  8. Effects of previous surgery on the detection of sentinel nodes in women with vulvar cancer.

    NARCIS (Netherlands)

    Ennik, T.A.; Allen, D.G; Bekkers, R.L.M.; Hyde, S.E.; Grant, P.T.

    2011-01-01

    BACKGROUND: There is a growing interest to apply the sentinel node (SN) procedure in the treatment of vulvar cancer. Previous vulvar surgery might disrupt lymphatic patterns and thereby decrease SN detection rates, lengthen scintigraphic appearance time (SAT), and increase SN false-negative rate. Th

  9. Detection of Sentinel Lymph Nodes in Patients with Papillary Thyroid Cancer

    Directory of Open Access Journals (Sweden)

    Hiroshi Takami

    2003-07-01

    Conclusions: Sentinel lymph node biopsy may allow discrimination between patients with true lymph-node-negative papillary thyroid carcinoma and those with non-palpable metastatic lymph nodes. It may also be helpful in diagnosing metastases and avoiding unnecessary lymph node dissection in thyroid cancer.

  10. The sentinel node procedure in early stage cervical cancer, taking the next step; a diagnostic review

    NARCIS (Netherlands)

    Tax, C.; Rovers, M.M.; Graaf, C. de; Zusterzeel, P.L.M.; Bekkers, R.L.M.

    2015-01-01

    OBJECTIVE: Recent reviews on the sentinel lymph node (SLN) procedure in cervical cancer have shown that bilateral SLN detection and ultra staging are safe and superior options compared to a unilateral detection, frozen section and H&E analysis. So far, nobody identified a subgroup of patients in who

  11. The role of sentinel node biopsy in gynecological cancer : a review

    NARCIS (Netherlands)

    Oonk, Maaike H. M.; van de Nieuwenhof, Hedwig P.; de Hullu, Joanne A.; van der Zee, Ate G. J.

    2009-01-01

    Purpose of review In early-stage vulvar, cervical and endometrial cancer, lymph node status is the most important prognostic factor. Surgical treatment is aimed at removing the primary tumor and adequately staging the regional lymph nodes. As morbidity of regional lymphadenectomy is high, sentinel n

  12. Sentinel node biopsy for early-stage oral cavity cancer: the VU University Medical Center experience

    NARCIS (Netherlands)

    Den Toom, I.J.; Heuveling, D.A.; Flach, G.B.; van Weert, S.; Karagozoglu, K.H.; van Schie, A.; Bloemena, E.; Leemans, C.R.; de Bree, R.

    2015-01-01

    Background Sentinel node biopsy (SNB) in head and neck cancer is recently introduced as the staging technique of oral squamous cell carcinoma. We report the results of SNB in patients diagnosed with a T1-T2 oral squamous cell carcinoma and clinically negative (N0) neck in a single center. Methods A

  13. Aluminium, antiperspirants and breast cancer.

    Science.gov (United States)

    Darbre, P D

    2005-09-01

    Aluminium salts are used as the active antiperspirant agent in underarm cosmetics, but the effects of widespread, long term and increasing use remain unknown, especially in relation to the breast, which is a local area of application. Clinical studies showing a disproportionately high incidence of breast cancer in the upper outer quadrant of the breast together with reports of genomic instability in outer quadrants of the breast provide supporting evidence for a role for locally applied cosmetic chemicals in the development of breast cancer. Aluminium is known to have a genotoxic profile, capable of causing both DNA alterations and epigenetic effects, and this would be consistent with a potential role in breast cancer if such effects occurred in breast cells. Oestrogen is a well established influence in breast cancer and its action, dependent on intracellular receptors which function as ligand-activated zinc finger transcription factors, suggests one possible point of interference from aluminium. Results reported here demonstrate that aluminium in the form of aluminium chloride or aluminium chlorhydrate can interfere with the function of oestrogen receptors of MCF7 human breast cancer cells both in terms of ligand binding and in terms of oestrogen-regulated reporter gene expression. This adds aluminium to the increasing list of metals capable of interfering with oestrogen action and termed metalloestrogens. Further studies are now needed to identify the molecular basis of this action, the longer term effects of aluminium exposure and whether aluminium can cause aberrations to other signalling pathways in breast cells. Given the wide exposure of the human population to antiperspirants, it will be important to establish dermal absorption in the local area of the breast and whether long term low level absorption could play a role in the increasing incidence of breast cancer.

  14. Breast Cancer Center Support Grant

    Science.gov (United States)

    1999-09-01

    also occur with increased frequency in gene carriers, such prostate cancer. First-degree relatives of individuals with a BRCA1 or BRCA2 mutation have...Tumor M 36 Asian Prostate Cancer M 52 Caucasian Ovarian Cancer F 56 Caucasian Cervical Cancer F 43 Caucasian Breast Cancer F 45 Caucasian Cancer of...address transportation barriers, alternate mechanisms were put in place for provision of parking and taxi vouchers. It was expected that many of the women

  15. Integrated Immunotherapy for Breast Cancer

    Science.gov (United States)

    2016-09-01

    Ivermectin-induced acute cytotoxicity through accumulation of lactate , the final product of glycolysis (Figure 6F). Excessive acidification in cancer cells...2 AD_________________ Award Number: W81XWH-12-1-0366 TITLE: Integrated Immunotherapy for Breast Cancer PRINCIPAL INVESTIGATOR: Peter P. Lee...TITLE AND SUBTITLE 5a. CONTRACT NUMBER Integrated Immunotherapy for Breast Cancer 5b. GRANT NUMBER W81XWH-12-1-0366 5c. PROGRAM ELEMENT

  16. The Pittsburgh Breast Cancer Consortium

    Science.gov (United States)

    2005-08-01

    Protein Autovac in Patients with Brest Cancer CPharmexa). This trial was initiated in June 2003. The PBCC accrued 5 of the planned 11 patients. This...AD_________________ Award Number: DAMD17-01-1-0374 TITLE: The Pittsburgh Breast Cancer Consortium...3. DATES COVERED 1 AUG 2001 - 31 JUL 2005 4. TITLE AND SUBTITLE The Pittsburgh Breast Cancer Consortium 5a. CONTRACT NUMBER 5b. GRANT

  17. Detection of sentinel nodes with radiopharmaceuticals

    Energy Technology Data Exchange (ETDEWEB)

    Yokoyama, Kunihiko; Michigishi, Takatoshi; Kinuya, Seigo; Konishi, Shota; Nakajima, Kenichi; Tonami, Norihisa [Kanazawa Univ. (Japan). School of Medicine

    2000-10-01

    Sentinel lymph nodes have been found to be an indicator of lymph node metastasis in breast cancer. In Japan, the theory and concept of sentinel lymph nodes in breast cancer have begun to be applied to carcinomas of the digestive system. Based on clinical experience in the detection of sentinel lymph nodes with radiopharmaceuticals, differences and similarities between the radiopharmaceuticals, methods, and techniques used to detect sentinel lymph nodes have been assessed in relation to breast cancer and carcinomas of the digestive system (including carcinomas of the esophagus and large intestine). The greatest difference between the methods used for breast and digestive cancers is the site of administration of the radiopharmaceutical. In breast cancer, the radiopharmaceutical is administered into a superficial organ (i.e., the mammary gland), whereas in carcinomas of the digestive system, it is administered into a deep organ (i.e., digestive tract). Another obvious difference is in lymph flow, i.e., the flow of the mammary glands is subcutaneous whereas lymph flow in the digestive tract is submucosal. Two radionuclide diagnostic methods are available to detect sentinel lymph nodes: sentinel lymphoscintigraphy with a gamma camera and a method that involves the use of a gamma probe intraoperatively. Radiopharmaceuticals used to detect sentinel lymph nodes must be smoothly transferred from the site of administration into the lymph, and uptake by the sentinel lymph node must continue for a long time without excessive flowing to lower reaches. The optimal particle size remains a matter of controversy, and no radiopharmaceuticals appropriate for lymphoscintigraphy have ever been approved in Japan. The authors compared the pharmacokinetics of three different radiopharmaceuticals used for sentinel lymphoscintigraphy in breast cancer ({sup 99m}Tc-labeled albumin, {sup 99m}Tc-labeled tin colloid, and {sup 99m}Tc-labeled phytic acid) and founded that the detection rate was

  18. Procedure guidelines for sentinel lymph node diagnosis; Verfahrensanweisung fuer die nuklearmedizinische Waechter-Lymphknoten-Diagnostik

    Energy Technology Data Exchange (ETDEWEB)

    Vogt, H. [Klinikum Augsburg (Germany). Klinik fuer Nuklearmedizin; Schmidt, Matthias [Universitaeten zu Koeln (Germany). Klinik fuer Nuklearmedizin; Bares, R. [Klinik fuer Nuklearmedizin, Tuebingen (DE)] (and others)

    2010-07-01

    The authors present a procedure guideline for scintigraphic detection of sentinel lymph nodes in malignant melanoma and other skin tumours, in breast cancer, in head and neck cancer, and in prostate and penile carcinoma. Important goals of sentinel lymph node scintigraphy comprise reduction of the extent of surgery, lower postoperative morbidity and optimization of histopathological examination focussing on relevant lymph nodes. Sentinel lymph node scintigraphy itself does not diagnose tumorous lymph node involvement and is not indicated when lymph node metastases have been definitely diagnosed before sentinel lymph node scintigraphy. Procedures are compiled with the aim to reliably localise sentinel lymph nodes with a high detection rate typically in early tumour stages. Radiation exposure is low so that pregnancy is not a contraindication for sentinel lymph node scintigraphy. Even with high volumes of scintigraphic sentinel lymph node procedures surgeons, theatre staff and pathologists receive a radiation exposure <1 mSv/year so that they do not require occupational radiation surveillance. (orig.)

  19. Histological and immunohistochemical evaluation of sentinel lymph ...

    African Journals Online (AJOL)

    [6,7] The technique is sensitive and specific to ... of sentinel lymph nodes in breast cancer at a tertiary hospital in ... tumour excision or simple mastectomy as well as SLN biopsies. All the ... [6,7] Significant resource implications of the increasing ...

  20. Diet and breast cancer

    Directory of Open Access Journals (Sweden)

    Isabelle Romieu

    2011-10-01

    Full Text Available Both diet and nutrition have been studied in relationship with breast cancer risk, as the great variation among different countries in breast cancer incidence could possibly be explained through the inflammatory and immune response, as well as antioxidant intake, among others.To date, no clear association with diet beyond overweight and weight gain has been found, except for alcohol consumption. Nonetheless, the small number of studies done in middle to low income countries where variability of food intake is wider,is beginning to show interesting results.Tanto la dieta como la nutrición han sido estudiadas en relación con el riesgo de cáncer de mama, dada la gran variación de incidencia de cáncer entre países, y la posibilidad de explicarla a través de la respuesta inflamatoria o inmune, así como ingesta de antioxidantes,entre otros.Hasta la fecha, ninguna asociación clara con la dieta ha sido encontrada, excepto para el consumo de alcohol, más allá del sobrepeso y del incremento de peso. Sin embargo, los estudios que se están realizando en países de mediano a bajo nivel de ingresos, con mayor variabilidad de ingesta de alimentos, comienzan a mostrar resultados interesantes.

  1. Epigenetics and Breast Cancers

    Directory of Open Access Journals (Sweden)

    An T. Vo

    2012-01-01

    Full Text Available Several of the active compounds in foods, poisons, drugs, and industrial chemicals may, by epigenetic mechanisms, increase or decrease the risk of breast cancers. Enzymes that are involved in DNA methylation and histone modifications have been shown to be altered in several types of breast and other cancers resulting in abnormal patterns of methylation and/or acetylation. Hypermethylation at the CpG islands found in estrogen response element (ERE promoters occurs in conjunction with ligand-bonded alpha subunit estrogen receptor (Erα dimers wherein the ligand ERα dimer complex acts as a transcription factor and binds to the ERE promoter. Ligands could be 17-β-estradiol (E2, phytoestrogens, heterocyclic amines, and many other identified food additives and heavy metals. The dimer recruits DNA methyltransferases which catalyze the transfer of methyl groups from S-adenosyl-L-methionine (SAM to 5′-cytosine on CpG islands. Other enzymes are recruited to the region by ligand-ERα dimers which activate DNA demethylases to act simultaneously to increase gene expression of protooncogenes and growth-promoting genes. Ligand-ERα dimers also recruit histone acetyltransferase to the ERE promoter region. Histone demethylases such as JMJD2B and histone methyltransferases are enzymes which demethylate lysine residues on histones H3 and/or H4. This makes the chromatin accessible for transcription factors and enzymes.

  2. Sentinel Lymph Node Biopsy in Uterine Cervical Cancer Patients: Ready for Clinical Use? A Review of the Literature

    OpenAIRE

    Viktoria-Varvara Palla; Georgios Karaolanis; Demetrios Moris; Aristides Antsaklis

    2014-01-01

    Sentinel lymph node biopsy has been widely studied in a number of cancer types. As far as cervical cancer is concerned, this technique has already been used, revealing both positive results and several issues to be solved. The debate on the role of sentinel lymph node biopsy in cervical cancer is still open although most of the studies have already revealed its superiority over complete lymphadenectomy and the best handling possible of the emerging practical problems. Further research should ...

  3. Breast Cancer Epigenetics: Review article

    Directory of Open Access Journals (Sweden)

    Bahareh Abbasi

    2016-11-01

    Full Text Available Stable molecular changes during cell division without change the sequence of DNA molecules is known as epigenetic. Molecular mechanisms involved in this process, including histone modifications, methylation of DNA, protein complex and RNA antisense. Cancer genome changes happen through a combination of DNA hypermethylation, long-term epigenetic silencing with heterozygosis loss and genomic regions loss. Different combinations of N-terminal changes cooperation with histone variants with have a specific role in gene regulation have led to load a setting histone that determine transcription potential of a particular gene or genomic regions. DNA methylation analysis in genome region using methylation-specific digital karyotyping of normal breast tissue detect gene expression patterns and DNA specific methylation can be found in breast carcinoma too. More than 100 genes in breast tumors or cell lines of breast cancer are reported hypermethylated. Important of DNA methylation on cancer has been concentrated CpG islands Hypermethylation. The most of the techniques are able to identify hypermethylated areas. Recent studies have showed the role of epigenetic silencing in the pathogenesis of breast cancer in which tumor suppressor genes have been changed by acetylation and DNA deacetylation. Histone deacetylase inhibitors have different roles in cancer cells and could show the ways of new treatment for breast cancer. In this review, various aspects of breast cancer epigenetics and its applications in diagnosis, prediction and treatment are described.

  4. [Current status and new applications of sentinel lymph node mapping in non-small cell lung cancer].

    Science.gov (United States)

    Minamiya, Yoshihiro; Ogawa, Jun-Ichi

    2009-03-01

    Sentinel lymph node (SLN) mapping has become a common procedure in the treatment of breast cancer and malignant melanoma. Its primary benefit is that it enables surgeons to avoid nontherapeutic lymph node dissection and the complications that may follow. All present evidence demonstrates the existence of SLNs in non-small cell lung cancer (NSCLC). However, SLN mapping is not widely used in the treatment of NSCLC for several reasons: first, special precautions are required to minimize exposure to radioisotopes; second, it is difficult to detect a dye within anthoracotic thoracic lymph nodes; and third, major complications comparable to the arm edema seen in breast cancer or the lymphedema and nerve injury seen in melanoma are not seen with mediastinal lymph node dissection. However, if the SLN mapping procedure were simplified, it could be used to avoid nontherapeutic mediastinal lymph node dissection in NSCLC. Recently, new applications of SLN mapping have been reported, such as the detection of lymph node micrometastases and segmentectomy for NSCLC. We expect SLN mapping to become a common clinical practice in the treatment of NSCLC in the near future

  5. Breast self examination and breast cancer: Knowledge and practice ...

    African Journals Online (AJOL)

    Medical students must possess the appropriate knowledge .... Table 2: Likert's scale scores on breast cancer-related knowledge levels. Variable. Preclinical. Clinical ... Routine alcohol consumption increases the risk of breast cancer. 50. 41. 9.

  6. Breast Cancer Chemotherapy and Your Heart

    Science.gov (United States)

    ... American Heart Association Cardiology Patient Page Breast Cancer Chemotherapy and Your Heart Christine Unitt , Kamaneh Montazeri , Sara ... cancer treatments. Breast cancer treatments include the following: Chemotherapy involves drugs that are intended to kill the ...

  7. Contrast enhanced ultrasound of sentinel lymph nodes

    Directory of Open Access Journals (Sweden)

    XinWu Cui

    2013-03-01

    Full Text Available Sentinel lymph nodes are the first lymph nodes in the region that receive lymphatic drainage from a primary tumor. The detection or exclusion of sentinel lymph node micrometastases is critical in the staging of cancer, especially breast cancer and melanoma because it directly affects patient’s prognosis and surgical management. Currently, intraoperative sentinel lymph node biopsies using blue dye and radioisotopes are the method of choice for the detection of sentinel lymph node with high identification rate. In contrast, conventional ultrasound is not capable of detecting sentinel lymph nodes in most cases. Contrast enhanced ultrasound with contrast specific imaging modes has been used for the evaluation and diagnostic work-up of peripherally located suspected lymphadenopathy. The method allows for real-time analysis of all vascular phases and the visualization of intranodal focal “avascular” areas that represent necrosis or deposits of neoplastic cells. In recent years, a number of animal and human studies showed that contrast enhanced ultrasound can be also used for the detection of sentinel lymph node, and may become a potential application in clinical routine. Several contrast agents have been used in those studies, including albumin solution, hydroxyethylated starch, SonoVue®, Sonazoid® and Definity®. This review summarizes the current knowledge about the use of ultrasound techniques in detection and evaluation of sentinel lymph node.

  8. Miscellaneous syndromes and their management: occult breast cancer, breast cancer in pregnancy, male breast cancer, surgery in stage IV disease.

    Science.gov (United States)

    Colfry, Alfred John

    2013-04-01

    Surgical therapy for occult breast cancer has traditionally centered on mastectomy; however, breast conservation with whole breast radiotherapy followed by axillary lymph node dissection has shown equivalent results. Patients with breast cancer in pregnancy can be safely and effectively treated; given a patient's pregnancy trimester and stage of breast cancer, a clinician must be able to guide therapy accordingly. Male breast cancer risk factors show strong association with BRCA2 mutations, as well as Klinefelter syndrome. Several retrospective trials of surgical therapy in stage IV breast cancer have associated a survival advantage with primary site tumor extirpation.

  9. Research progress on false negative reason of breast cancer sentinel lymph node biopsy%乳腺癌前哨淋巴结活检假阴性原因研究新进展

    Institute of Scientific and Technical Information of China (English)

    吕艳; 牛昀

    2013-01-01

    乳腺癌根治术常规进行腋窝淋巴结清扫术,往往给患者造成疼痛、水肿、运动和感觉功能障碍.前哨淋巴结活检(sentinel lymph node biopsy,SLNB)是一种微创的淋巴结活检方法,用前哨淋巴结评估整个腋窝淋巴结转移情况,有针对性的指导清扫腋窝淋巴结,减小清扫范围,减轻患者腋窝淋巴结清扫后遗症,但是前哨淋巴结活检存在一定比例的假阴性结果,影响其在临床的推广,主要原因有:适应证的选择不当、术前化疗影响、对内乳前哨淋巴结忽略、分子病理学方法利用不充分、单用示踪剂等.增强临床医生和病理医生对乳腺癌前哨淋巴结活检的临床指导作用以及腋窝淋巴结和内乳淋巴结解剖变异的认识,加强SLNB规范操作,借助术中冰冻切片,联合免疫组化,RT-PCR等方法,可降低SLNB假阴性率.%Conventional axillary lymph node dissection, as a part of radical mastectomy, usually lead to edema, motor and sensory function obstacle. The sentinel lymph node biopsy( SLNB) is a kind of minimally invasive lymph node biopsy method, used as the assessment of the armpit lymph node metastasis, guiding targeted cleaning the axillary lymph nodes. SLNB reduce cleaning scope of axillary lymph node, relieve patients sequela of axillary lymph nodes resection, but SLNB exists a certain proportion of false negative results,which hinder clinical promotion of SLNB,the main reasons are: improper selection of SLNB indication,preoperative neoadjuvant chemotherapy,and omit of internal mammary sentinel lymph node, unavailable of immunohistochemical method, unskilled detection technology, etc. Enhance the knowledge of clinical doctors and pathological doctor about sentinel lymph node biopsy and clinical guidance function of axillary lymph node dissection and internal mammary lymph node anatomical variations of understanding, strengthen SLNB standardized operation, with the aid of intraoperative frozen section

  10. Management of the axilla in women with breast cancer.

    Science.gov (United States)

    Benson, J R; Querci della Rovere, G

    2007-04-01

    There remain several outstanding questions relating to management of the axilla in women with early stage breast cancer. This paper summarises the outcome of a national debate aimed at discussing certain key issues including a) whether axillary dissection has any survival advantage b) is an axillary staging procedure always necessary c) what is the optimum method of staging the axilla and d) whether an axillary dissection is always necessary in cases of a positive sentinel node. Electronic voting was undertaken at the beginning and end of the debate and results are compared and presented herein.

  11. Consumer Health Education. Breast Cancer.

    Science.gov (United States)

    Arkansas Univ., Fayetteville, Cooperative Extension Service.

    This short booklet is designed to be used by health educators when teaching women about breast cancer and its early detection and the procedure for breast self-examination. It includes the following: (1) A one-page teaching plan consisting of objectives, subject matter, methods (including titles of films and printed materials), target audience,…

  12. Survivorship Care Plan in Promoting Physical Activity in Breast or Colorectal Cancer Survivors in Wisconsin

    Science.gov (United States)

    2017-05-01

    Cancer Survivor; Healthy Subject; Stage I Colorectal Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIA Colorectal Cancer; Stage IIB Breast Cancer; Stage IIB Colorectal Cancer; Stage IIC Colorectal Cancer; Stage IIIA Breast Cancer; Stage IIIA Colorectal Cancer; Stage IIIB Breast Cancer; Stage IIIB Colorectal Cancer; Stage IIIC Breast Cancer; Stage IIIC Colorectal Cancer

  13. 早期乳腺癌前哨淋巴结阴性患者行腋窝淋巴结清扫的预后分析%Prognosis of early breast cancer sentinel lymph node negative patients with axillary lymphadenec-t omy

    Institute of Scientific and Technical Information of China (English)

    曾云龙; 李俊

    2016-01-01

    目的:比较早期乳腺癌前哨淋巴结(SLN)阴性患者仅行前哨淋巴结活检术(SLNB)和SLNB后加腋窝淋巴结清扫术(ALND)的术后并发症及远期预后差异。方法回顾性分析2005年1月至2010年12月461例SLN阴性的早期乳腺癌患者的临床和病理资料,其中241例仅行SLNB的患者为非腋窝淋巴结清扫组(NALND组),220例加行ALND者为腋窝淋巴结清扫组(ALND组)。比较两组患者的术后并发症情况和远期疗效。结果 NALND组和ALND组术后平均住院天数为(5.2±1.3)d和(8.1±1.8)d(t=1.450,P=0.003),术后6个月患侧上肢感觉异常分别为3.7%(9/241)和73.2%(161/220)(χ2=283.239,P<0.0001),患侧上肢水肿发生率分别为0(0/241)和10.9%(24/220)(χ2=7.735,P<0.0001),差异均有统计学意义。两组5年无病生存率分别为95.4%和95.5%(χ2=0.231,P=0.902),差异无统计学意义。结论对于SLN阴性早期乳腺癌患者,不行ALND较ALND手术创伤小,术后并发症少,且远期疗效可与ALND相媲美,本研究结论支持SLN阴性的早期乳腺癌患者无须进行ALND术。%Objective To compare the prognosis of early breast cancer patients with negative sentinel lymph nodes (SLN) treated only by sentinel lymph node biopsy (SLNB) and SLNB plus axillary lymph node dissection (ALND). M ethods A retrospective analysis of early breast cancer patients in our hospital from January 2005 to December 2010 with negative SLN (only SLNB in 241 cases and SLNB+ALND in 220 cases) was carried out. According to the clinical and pathological data, we compared postop⁃erative complications and long-term prognosis in the two groups. Results The average postoperative hos⁃pital stay of NALND group and ALND group was (5.2±1.3) d and (8.1±1.8) d (t=1.450, P=0.003), respec⁃tively, upper extremity with abnormal sensation after resection was 3.7%(9/241) and 73.2%(161/220) (χ2=283.239, P<0.000 1

  14. Height and Breast Cancer Risk

    DEFF Research Database (Denmark)

    Zhang, Ben; Shu, Xiao-Ou; Delahanty, Ryan J

    2015-01-01

    BACKGROUND: Epidemiological studies have linked adult height with breast cancer risk in women. However, the magnitude of the association, particularly by subtypes of breast cancer, has not been established. Furthermore, the mechanisms of the association remain unclear. METHODS: We performed a meta......-analysis to investigate associations between height and breast cancer risk using data from 159 prospective cohorts totaling 5216302 women, including 113178 events. In a consortium with individual-level data from 46325 case patients and 42482 control patients, we conducted a Mendelian randomization analysis using...... a genetic score that comprised 168 height-associated variants as an instrument. This association was further evaluated in a second consortium using summary statistics data from 16003 case patients and 41335 control patients. RESULTS: The pooled relative risk of breast cancer was 1.17 (95% confidence...

  15. System delays in breast cancer

    African Journals Online (AJOL)

    2 Department of Specialised Surgery, Inkosi Albert Luthuli Central Hospital, Durban, South Africa ... Centralised multidisciplinary management of breast cancer occurs in .... published an updated position statement on quality indicators in the.

  16. Nonestrogenic drugs and breast cancer.

    Science.gov (United States)

    Danielson, D A; Jick, H; Hunter, J R; Stergachis, A; Madsen, S

    1982-08-01

    The relation between breast cancer and selected nonestrogenic drugs was evaluated in the Group Health Cooperative of Puget Sound, Seattle, Washington, a prepaid health care organization with computerized information on diagnoses and outpatient drug use. No important positive associations with breast cancer were found in a follow-up study of 302 women aged 35-74 years. These women were newly diagnosed with breast cancer in 1977-1980 and were studied in relation to exposure in the six months prior to diagnosis to one or more of the following drugs: diazepam, digitalis glycosides, medroxyprogesterone acetate, methyldopa, metronidazole, phenothiazines, tricyclic antidepressants, thiazides, thyroid/levothyroxine sodium, or spironolactone. A modest association between recent reserpine use and breast cancer was present (risk ratio = 1.7, 90% confidence interval 0.9-3.3).

  17. Management of male breast cancer

    Directory of Open Access Journals (Sweden)

    Nikolay V. Dimitro v

    2011-12-01

    Full Text Available The management of male breast cancer is still under discussion due to lack of information from prospective, randomized clinical trials and low incidence of this disease. Current management is based largely on extrapolation from data related to treatment of female breast cancer. Over the last two decades, several review articles have discussed mainly retrospective and anecdotal data related to hormonal and chemotherapy treatment modalities. In this review, we present the most recent information and future considerations related to the management of male breast cancer. In addition to the conventional treatment options we will discuss the possible role of targeted therapy. Establishing a national or global registry for male breast cancer will provide more precise information about the natural history of the disease and will facilitate the design and execution of prospective, randomized multicenter clinical trials.

  18. Bilateral synchronous male breast cancer

    National Research Council Canada - National Science Library

    Nwashilli, Nnamdi J; Ugiagbe, Ezekiel E

    2015-01-01

    .... The importance of this case report is to create more awareness that breast cancer can occur in males just as in females, though the incidence is rare in males. Early presentation and compliance with treatment modality provide a better outcome.

  19. Understanding your breast cancer risk

    Science.gov (United States)

    Skip navigation U.S. National Library of Medicine The navigation menu has been collapsed. ... page: //medlineplus.gov/ency/patientinstructions/000830.htm Understanding your breast cancer risk To use the sharing features ...

  20. Palbociclib for Advanced Breast Cancer

    Science.gov (United States)

    An interim analysis of the PALOMA3 trial shows that women with hormone receptor-positive metastatic breast cancer who received palbociclib plus fulvestrant had longer progression-free survival rates than women who received a placebo plus fulvestrant.

  1. Breast cancer. Part 3: advanced cancer and psychological implications.

    Science.gov (United States)

    Harmer, Victoria

    This is the last article in this 3-part series on breast cancer. The previous two articles have outlined the principles behind breast awareness and breast health, detailing common benign breast diseases, types of breast cancer and staging, and treatment for breast cancer, including surgery, chemotherapy, radiotherapy and endocrine treatment. The series concludes by giving information on advanced disease, including when a patient presents late with a fungating breast lesion, or if the disease has metastasized from the breast to other organs. Lymphoedema is also described and discussed, and the latter half of this article discusses psychological implications of breast cancer, from diagnosis through the individual treatments.

  2. Metals and breast cancer.

    Science.gov (United States)

    Byrne, Celia; Divekar, Shailaja D; Storchan, Geoffrey B; Parodi, Daniela A; Martin, Mary Beth

    2013-03-01

    Metalloestrogens are metals that activate the estrogen receptor in the absence of estradiol. The metalloestrogens fall into two subclasses: metal/metalloid anions and bivalent cationic metals. The metal/metalloid anions include compounds such as arsenite, nitrite, selenite, and vanadate while the bivalent cations include metals such as cadmium, calcium, cobalt, copper, nickel, chromium, lead, mercury, and tin. The best studied metalloestrogen is cadmium. It is a heavy metal and a prevalent environmental contaminant with no known physiological function. This review addresses our current understanding of the mechanism by which cadmium and the bivalent cationic metals activate estrogen receptor-α. The review also summarizes the in vitro and in vivo evidence that cadmium functions as an estrogen and the potential role of cadmium in breast cancer.

  3. Current status of sentinel lymph node mapping in the management of cervical cancer.

    Science.gov (United States)

    Rob, Lukas; Lukas, Rob; Robova, Helena; Helena, Robova; Halaska, Michael Jiri; Jiri, Halaska Michael; Hruda, Martin; Martin, Hruda; Skapa, Petr; Petr, Skapa

    2013-07-01

    The status of regional lymph nodes is the most important prognostic factor in early cervical cancer patients. Pelvic lymph node dissections are routinely performed as a part of standard surgical treatment. Systematic pelvic lymphadenectomy is associated with short- and long-term morbidities. This review discusses single components of the sentinel lymph node mapping (SLNM) technique and results of the detection of sentinel lymph nodes. SLNM biopsy performed by an experienced team for small volume tumors (<2 cm) has high specific side detection rate, excellent negative-predictive value and high sensitivity. Uncommon lymphatic drainage has been reported in 15% of cervical cancer patients. There is sufficient data now to suggest that SLNM with 99mTc plus blue dye in the hands of a surgeon with extensive experience should prove to be an important part of individualized cervical cancer surgery and increase the safety of less radical or fertility-sparing surgery.

  4. 99Tcm-硫胶体及其联合染色法对早期乳腺癌前哨淋巴结探测的比较%Comparison of radioactive sulfur colloid and combined methylene blue injection methods for detection of sentinel lymph node in early breast cancer

    Institute of Scientific and Technical Information of China (English)

    俞丹; 许林; 洪明; 吴华; 苏新辉; 陈贵兵

    2011-01-01

    Objective To compare the efficacy of 99Tcm-sulfur colloid and combined 99Tcm-sulfur colloid/methylene blue methods for detection of sentinel lymph node (SLN) in early breast cancer.Methods Seventy-six patients with early breast cancer were dived into two groups.In group 1 (n=25),99Tcm-sulfur colloid detection was used alone.In group 2 (n=51),both 99Tcm-sulfur colloid detection and methylene blue methods were used.The pathological findings of resected axillary lymph nodes were regarded as evaluation standard.Results In 76 patients SLN was successfully detected in 74 cases.The SLN detection rate,accuracy,sensitivity and the false negative rate for 99Tcm-sulfur colloid group and combined group were 92.0% vs.100%,95.7% vs.98.0%,90.0% vs.95.2%,and 10.0% vs.4.8% respectively.Conclusions SLN detection in early breast cancer may accurately predict axillary lymph node metastasis,thus providing important information for surgery.Combined use of 99Tcm-sulfur colloid and methylene blue methods may improve the SLN detection accuracy and reduce false negative rate.%目的 评价单用99Tcm-硫胶体和99Tcm-硫胶体与亚甲蓝联合应用探测早期乳腺癌前哨淋巴结(SLN)的效能.方法 76例早期乳腺癌患者分为单用99Tcm-硫胶体组(25例)和99Tcm-硫胶体与亚甲蓝联合组(51例),分别在术前进行乳腺癌SLN探测,以腋窝淋巴结病理检查结果作为评价标准.结果 76例患者中成功探测到SLN 74例,SLN的检出率、准确率、灵敏度和假阴性率在99Tcm-硫胶体组分别为92.0%、95.7%、90.0%、10.0%;在联合组分别为100%、98.0%、95.2%、4.8%.结论 乳腺癌SLN探测可较准确预测腋窝淋巴结的转移状况,为外科医生确定手术方式提供重要信息,联合应用99Tcm-硫胶体和亚甲蓝可提高SLN的检出率和准确率,降低假阴性率.

  5. Breast cancer epigenetics: review article

    Directory of Open Access Journals (Sweden)

    Bahareh Abbasi

    2016-11-01

    Full Text Available Stable molecular changes during cell division without any change in the sequence of DNA molecules is known as epigenetic. Molecular mechanisms involved in this process, including histone modifications, methylation of DNA, protein complex and RNA antisense. Cancer genome changes happen through a combination of DNA hypermethylation, long-term epigenetic silencing with heterozygosis loss and genomic regions loss. Different combinations of N-terminal’s changes cooperate with histone variants with a specific role in gene regulation. It have led to load a setting histone that determine transcription potential of a particular gene or genomic regions. DNA methylation analysis in genome region using methylation-specific digital karyotyping of normal breast tissue detect gene expression patterns and DNA specific methylation can be found in breast carcinoma too more than 100 genes in breast tumors or cell lines of breast cancer are reported hypermethylated. Important of DNA methylation on cancer has been concentrated CpG islands hypermethylation. Most of the techniques are able to identify hypermethylated areas. Often, methylated genes play important role in cell cycle regulation, apoptosis, metastasis and tissue invasion, angiogenesis and hormonal signaling. Cyclin D2 (CCND2 gene is an important regulator of cell cycle and increased of expression inhibits the transition from G1 to S cell cycle. This gene is frequently methylated in breast cancer and has been proposed as the first event. Other cell cycle regulator is p16ink4A / CDKN2A that methylated in a large number of human cancers, including breast cancer. Another regulator of the proliferation of breast cancer that methylated is tumor suppressor RAR-β cancer that has been found in lobular and ductal carcinoma. Recent studies have showed the role of epigenetic silencing in the pathogenesis of breast cancer in which tumor suppressor genes have been changed by acetylation and DNA deacetylation

  6. Advances in the surgical treatment of breast cancer and postoperative physiotherapy

    Directory of Open Access Journals (Sweden)

    Anna Opuchlik

    2016-07-01

    Full Text Available In recent years, radical surgical techniques have been replaced with conserving ones, and a sentinel lymph node biopsy was introduced in the case of routine lymphadenectomy. Subcutaneous amputation with an immediate breast reconstruction or radical breast amputation in Madden modification are used in advanced tumours. Breast conserving surgery and effective neoadjuvant therapy reduce the range of the operation and postoperative complications. Similarly, breast reconstructions do not increase the risk of cancer development, and they do not impede the detection of a local recurrence. This paper presents the most commonly used types of surgery used to treat breast cancer, and the possibility of a surgical reconstruction of the breast. The methods of physiotherapeutic management in particular stages of treating women both after radical surgeries and reconstructions, including the aspect of maintaining their physical activity and mental balance are discussed.

  7. Advances in the surgical treatment of breast cancer and postoperative physiotherapy

    Directory of Open Access Journals (Sweden)

    Anna Opuchlik

    2016-07-01

    Full Text Available In recent years, radical surgical techniques have been replaced with conserving ones, and a sentinel lymph node biopsy was introduced in the case of routine lymphadenectomy. Subcutaneous amputation with an immediate breast reconstruction or radical breast amputation in Madden modification are used in advanced tumours. Breast conserving surgery and effective neoadjuvant therapy reduce the range of the operation and postoperative complications. Similarly, breast reconstructions do not increase the risk of cancer development, and they do not impede the detection of a local recurrence. This paper presents the most commonly used types of surgery used to treat breast cancer, and the possibility of a surgical reconstruction of the breast. The methods of physiotherapeutic management in particular stages of treating women both after radical surgeries and reconstructions, including the aspect of maintaining their physical activity and mental balance are discussed.

  8. Breast cancer: origins and evolution.

    Science.gov (United States)

    Polyak, Kornelia

    2007-11-01

    Breast cancer is not a single disease, but rather is composed of distinct subtypes associated with different clinical outcomes. Understanding this heterogeneity is key for the development of targeted cancer-preventative and -therapeutic interventions. Current models explaining inter- and intratumoral diversity are the cancer stem cell and the clonal evolution hypotheses. Although tumor initiation and progression are predominantly driven by acquired genetic alterations, recent data implicate a role for microenvironmental and epigenetic changes as well. Comprehensive unbiased studies of tumors and patient populations have significantly advanced our molecular understanding of breast cancer, but translating these findings into clinical practice remains a challenge.

  9. Getting free of breast cancer

    DEFF Research Database (Denmark)

    Halttunen, Arja; Hietanen, P; Jallinoja, P

    1992-01-01

    who had less thoughts of recurrence belonged to a group that had gone through an eight-week group psychotherapy intervention, were less depressed and had more other illnesses. Women who felt 'cured' had less limitations and restrictions due to cancer and belonged more often to higher social classes...... and follow-up study of 57 breast cancer patients. Half of the 22 patients still had frequent or occasional thoughts of recurrence and over two-thirds still thought they had not been 'cured' of cancer. More than half of the patients admitted that going through breast cancer had made them more mature. Women...

  10. Iodide transport and breast cancer.

    Science.gov (United States)

    Poole, Vikki L; McCabe, Christopher J

    2015-10-01

    Breast cancer is the second most common cancer worldwide and the leading cause of cancer death in women, with incidence rates that continue to rise. The heterogeneity of the disease makes breast cancer exceptionally difficult to treat, particularly for those patients with triple-negative disease. To address the therapeutic complexity of these tumours, new strategies for diagnosis and treatment are urgently required. The ability of lactating and malignant breast cells to uptake and transport iodide has led to the hypothesis that radioiodide therapy could be a potentially viable treatment for many breast cancer patients. Understanding how iodide is transported, and the factors regulating the expression and function of the proteins responsible for iodide transport, is critical for translating this hypothesis into reality. This review covers the three known iodide transporters - the sodium iodide symporter, pendrin and the sodium-coupled monocarboxylate transporter - and their role in iodide transport in breast cells, along with efforts to manipulate them to increase the potential for radioiodide therapy as a treatment for breast cancer.

  11. Using the intraoperative hand held probe without lymphoscintigraphy or using only dye correlates with higher sensory morbidity following sentinel lymph node biopsy in breast cancer: A review of the literature

    Directory of Open Access Journals (Sweden)

    Travis Arlene

    2005-09-01

    Full Text Available Abstract Background There are no studies that have directly investigated the incremental reduction in sensory morbidity that lymphoscintigraphy images (LS and triangulated body marking or other skin marking techniques provide during sentinel lymph node biopsy (SLNB compared to using only the probe without LS and skin marking or using only dye. However, an indirect assessment of this potential for additional sensory morbidity reduction is possible by extracting morbidity data from studies comparing the morbidity of SLNB to that of axillary lymph node dissection. Methods A literature search yielded 13 articles that had data on sensory morbidity at specific time points on pain, numbness or paresthesia from SLNB that used radiotracer and probe or used only dye as a primary method of finding the sentinel node (SN. Of these, 10 utilized LS, while 3 did not utilize LS. By matching the data in studies not employing LS to the studies that did, comparisons regarding the percentage of patients experiencing pain, numbness/paresthesia after SLNB could be reasonably attempted at a cutoff of 9 months. Results In the 7 studies reporting on pain after 9 months (> 9 months that used LS (1347 patients, 13.8% of patients reported these symptoms, while in the one study that did not use LS (143 patients, 28.7% of patients reported these symptoms at > 9 months (P 9 months that used LS (601 patients, 12.5% of patients reported these symptoms, while in the 3 studies that did not use LS (229 patients, 23.1% of patients reported these symptoms at > 9 months (P = 0.0002. Similar trends were also noted for all these symptoms at ≤ 9 months. Conclusion Because of variations in techniques and time of assessing morbidity, direct comparisons between studies are difficult. Nevertheless at a minimum, a clear trend is present: having the LS images and skin markings to assist during SLNB appears to yield more favorable morbidity outcomes for the patients compared to performing

  12. Screening for Breast Cancer: Detection and Diagnosis

    Science.gov (United States)

    ... please turn JavaScript on. Feature: Screening For Breast Cancer Detection and Diagnosis Past Issues / Summer 2014 Table of Contents Screening ... Cancer" Articles #BeBrave: A life-saving test / Breast Cancer Basics and ... and Diagnosis / Staging and Treatment / Selected National Cancer Institute Breast ...

  13. Occupational exposure and risk of breast cancer

    OpenAIRE

    FENGA, CONCETTINA

    2016-01-01

    Breast cancer is a multifactorial disease and the most commonly diagnosed cancer in women. Traditional risk factors for breast cancer include reproductive status, genetic mutations, family history and lifestyle. However, increasing evidence has identified an association between breast cancer and occupational factors, including environmental stimuli. Epidemiological and experimental studies demonstrated that ionizing and non-ionizing radiation exposure, night-shift work, pesticides, polycyclic...

  14. 吲哚菁绿联合亚甲蓝在乳腺癌前哨淋巴结活组织检查中的应用价值%Indocyanine green combined with methylene blue for sentinel lymph node biopsy in breast cancer patients

    Institute of Scientific and Technical Information of China (English)

    苑龙; 周艳; 胡滢; 魏宏屹; 潘沁汶; 张孔涌; 姜军

    2016-01-01

    目的:探讨吲哚菁绿联合亚甲蓝在乳腺癌前哨淋巴结活组织检查( SLNB)中的应用价值。方法根据纳入、排除标准,选取2015年5~12月在第三军医大学西南医院乳腺外科住院行术前检查提示腋窝淋巴结阴性的104例乳腺癌患者进行前瞻性研究。按照随机数字表法将患者分成2组(每组均为52例),分别采用吲哚菁绿联合亚甲蓝(试验组)或者核素联合亚甲蓝(对照组)作为淋巴示踪剂对患者进行SLNB,术中根据冰冻检查结果决定是否行腋窝淋巴结清扫。比较两种方法在乳腺癌SLNB中检出率的差别。偏态分布的计量资料用M( P25~P75)表示。两组患者间前哨淋巴结( SLN)和转移性SLN检出率及检出数目的比较,采用χ2检验、Fisher确切概率检验或非参数检验。结果试验组52例患者中,皮肤淋巴管荧光显影者49例(94.2%,49/52),SLN荧光显影者52例(100%,52/52), SLN检出率为100%(52/52),而对照组的检出率为96.2%(50/52)。试验组转移性 SLN 检出率为32.7%(17/52),明显高于对照组的15.4%(8/52)(χ2=4.27,P=0.039)。试验组共检出SLN190枚,中位数为3(2~4)枚,对照组共检出SLN 158枚,中位数为2(1~4)枚,两组患者SLN检出数目相似(Z=-1.58,P=0.113)。试验组共检出转移性SLN 26枚,中位数为0(0~1)枚,而对照组共检出转移性SLN 9枚,中位数为0(0~0)枚,两组相比,差异有统计学意义(Z=-2.15,P=0.032)。结论在乳腺癌SLNB术中应用吲哚菁绿联合亚甲蓝法示踪,其SLN检出率与核素联合亚甲蓝双标法相当,且能提高转移性SLN的检出率,并可协助术者精准定位SLN的位置,降低手术难度,具有较高的临床应用价值。%Objective To evaluate the application value of indocyanine green ( ICG) combined with methylene blue (MB) for sentinel lymph node biopsy(SLNB) in breast cancer patients. Methods Totally 104 breast cancer patients with axillary node negative indicated by preoperative examination in Department

  15. Genomic profiling of breast cancer.

    Science.gov (United States)

    Pandey, Anjita; Singh, Alok Kumar; Maurya, Sanjeev Kumar; Rai, Rajani; Tewari, Mallika; Kumar, Mohan; Shukla, Hari S

    2009-05-01

    Genome study provides significant changes in the advancement of molecular diagnosis and treatment in Breast cancer. Several recent critical advances and high-throughput techniques identified the genomic trouble and dramatically accelerated the pace of research in preventing and curing this malignancy. Tumor-suppressor genes, proto-oncogenes, DNA-repair genes, carcinogen-metabolism genes are critically involved in progression of breast cancer. We reviewed imperative finding in breast genetics, ongoing work to segregate further susceptible genes, and preliminary studies on molecular profiling.

  16. Danish Breast Cancer Cooperative Group

    Directory of Open Access Journals (Sweden)

    Christiansen P

    2016-10-01

    Full Text Available Peer Christiansen,1 Bent Ejlertsen,2,3 Maj-Britt Jensen,3 Henning Mouridsen3 1Department of Surgery P, Breast Surgery Unit, Aarhus University Hospital/Randers Regional Hospital, Aarhus C, 2Department of Oncology, Rigshospitalet, Copenhagen University Hospital, 3DBCG-secretariat, Department 2501, Rigshospitalet, Copenhagen Ø, Denmark Aim of database: Danish Breast Cancer Cooperative Group (DBCG, with an associated database, was introduced as a nationwide multidisciplinary group in 1977 with the ultimate aim to improve the prognosis in breast cancer. Since then, the database has registered women diagnosed with primary invasive nonmetastatic breast cancer. The data reported from the departments to the database included details of the characteristics of the primary tumor, of surgery, radiotherapy, and systemic therapies, and of follow-up reported on specific forms from the departments in question. Descriptive data: From 1977 through 2014, ~110,000 patients are registered in the nationwide, clinical database. The completeness has gradually improved to more than 95%. DBCG has continuously prepared evidence-based guidelines on diagnosis and treatment of breast cancer and conducted quality control studies to ascertain the degree of adherence to the guidelines in the different departments. Conclusion: Utilizing data from the DBCG database, a long array of high-quality DBCG studies of various designs and scope, nationwide or in international collaboration, have contributed to the current updating of the guidelines, and have been an instrumental resource in the improvement of management and prognosis of breast cancer in Denmark. Thus, since the establishment of DBCG, the prognosis in breast cancer has continuously improved with a decrease in 5-year mortality from ~37% to 15%. Keywords: breast cancer, database, guidelines, quality control, research

  17. Functional performance of upper limb and quality of life after sentinel lymph node biopsy of breast cancer Desempenho funcional de membros superiores e qualidade de vida após biópsia de linfonodo sentinela para o tratamento do câncer de mama

    Directory of Open Access Journals (Sweden)

    Fernanda S. B. Velloso

    2011-04-01

    Full Text Available BACKGROUND: Sentinel lymph node biopsy (SLNB is commonly used for the treatment of breast cancer with minimal surgical intervention as well as with low morbidity rates of upper limbs. OBJECTIVES: The aim of the present study was to investigate possible impairments and functional performance of the upper limb on activities of daily living (ADL and health related quality of life (HRQL among women treated through SLNB in a Brazilian hospital and to study the association among these variables. METHODS: Forty-five women (58.9±9.3 years participated in this descriptive, cross-sectional and correlational study. The visual analogue scale (VAS was used to quantify pain intensity/discomfort, arm circumference and shoulder range of motion (ROM measurement were used to measure upper limb impairments. The Disabilites of Arm Shoulder and Hand questionnaire (DASH was used to quantify functional performance of upper limb during ADL and European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire - Cancer 30 (EORTC-QLQ-C30 and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Breast Cancer Module 23 (EORTC-BR23 were used to characterize HRQL. RESULTS: Results revealed a 75% prevalence of symptoms affecting upper limb (pain or discomfort in arm, shoulder or breast, although the severity of the symptoms was only mild. Only 4.4% exhibited lymphedema and no ROM restriction was observed. There was little limitation in functional performance of the upper limb, which was associated with Arm Symptoms scale (EORTC BR-23. Impairments and functional performance of upper limb did not interfere on HRQL perception, which was considered to be good. CONCLUSION: SLNB caused small impairments and limitation on the functional performance of the upper limb during ADL and did not influence HRQL in our sample.CONTEXTUALIZAÇÃO: A biópsia de linfonodo sentinela (BLS é um procedimento cirúrgico minimamente

  18. Paraneoplastic thrombocytosis in breast cancer.

    Science.gov (United States)

    Rajkumar, Anita; Szallasi, Arpad

    2013-10-01

    Elevated platelet count at the time of diagnosis has been suggested to identify a subset of patients with cancer (e.g. ovarian and lung adenocarcinoma) and poor prognosis. The evidence on the incidence and prognostic significance of thrombocytosis in breast cancer is, however, incomplete. We performed a retrospective analysis of 127 consecutive patients with breast cancer at our Institution. None of the 81 newly- diagnosed patients had an elevated platelet count (mean=252 × 10(6)/l). Out of the 31 patients with metastatic disease, one exhibited mild thrombocytosis (445 × 10(6)/l) but the mean value (239 × 10(6)/l) was similar to that seen in patients with localized disease. We conclude that thrombocytosis in breast cancer is rare and thus, unlike in other types of cancer, and has limited (if any) value in clinical decision making.

  19. Immunolymphoscintigraphy for metastatic sentinel nodes: test of a model

    DEFF Research Database (Denmark)

    Chakera, A H; Nielsen, Boye S.; Madsen, J;

    2011-01-01

    Aim. To develop a method and obtain proof-of-principle for immunolymphoscintigraphy for identification of metastatic sentinel nodes. Methods. We selected one of four tumour-specific antibodies against human breast cancer and investigated (1), in immune-deficient (nude) mice with xenograft human...... in healthy rabbits. Results and Conclusion. Our paper suggests the theoretical possibility of a model of dual isotope immuno-lymphoscintigraphy for noninvasive, preoperative, malignant sentinel node imaging....

  20. Microwaves for breast cancer treatments

    Directory of Open Access Journals (Sweden)

    Heba Abdelhamid Elkayal

    2015-12-01

    Full Text Available Hyperthermia is potentially an effective method for the treatment of cancer, especially breast cancer tumors. One of the most attractive attributes of hyperthermia is the possibility of providing therapeutic benefit noninvasively, minimizing side effects. To be effective, a hyperthermia treatment must selectively heat the cancerous tissue, elevating the temperature in the tumor without exposing healthy tissue to excessive temperature elevations. In this paper, a suggested simple model of Annular Phased Array (APA using eight half wavelength linear dipoles is presented. New software (COMSOL MULTIPHYSICS is used to calculate the temperature distribution inside a model of a three layered breast (skin, breast tissue, and tumor. In addition, the effect of changing the amplitude and phases of the array elements on the temperature distributions and the conditions on the values of the phases are demonstrated in order to achieve the objective of hyperthermia for breast tumor treatment.

  1. Lymphatic mapping and sentinel node biopsy in gynecological cancers: a critical review of the literature

    Directory of Open Access Journals (Sweden)

    Dursun Polat

    2008-05-01

    Full Text Available Abstract Although it does not have a long history of sentinel node evaluation (SLN in female genital system cancers, there is a growing number of promising study results, despite the presence of some aspects that need to be considered and developed. It has been most commonly used in vulvar and uterine cervivcal cancer in gynecological oncology. According to these studies, almost all of which are prospective, particularly in cases where Technetium-labeled nanocolloid is used, sentinel node detection rate sensitivity and specificity has been reported to be 100%, except for a few cases. In the studies on cervical cancer, sentinel node detection rates have been reported around 80–86%, a little lower than those in vulva cancer, and negative predictive value has been reported about 99%. It is relatively new in endometrial cancer, where its detection rate varies between 50 and 80%. Studies about vulvar melanoma and vaginal cancers are generally case reports. Although it has not been supported with multicenter randomized and controlled studies including larger case series, study results reported by various centers around the world are harmonious and mutually supportive particularly in vulva cancer, and cervix cancer. Even though it does not seem possible to replace the traditional approaches in these two cancers, it is still a serious alternative for the future. We believe that it is important to increase and support the studies that will strengthen the weaknesses of the method, among which there are detection of micrometastases and increasing detection rates, and render it usable in routine clinical practice.

  2. Endocrine determinants of breast density and breast cancer

    NARCIS (Netherlands)

    Verheus, M.

    2007-01-01

    Worldwide, breast cancer is the most common malignancy among females. The total breast area on a mammogram can be dived in a radiologicaly dense area (glandular and stromal tissue) and a non-dense area (mainly fat tissue). Women with a high proportion of dense breast tissue (percent breast density)

  3. Endocrine determinants of breast density and breast cancer

    NARCIS (Netherlands)

    Verheus, M.

    2007-01-01

    Worldwide, breast cancer is the most common malignancy among females. The total breast area on a mammogram can be dived in a radiologicaly dense area (glandular and stromal tissue) and a non-dense area (mainly fat tissue). Women with a high proportion of dense breast tissue (percent breast density)

  4. Propranolol and survival from breast cancer

    DEFF Research Database (Denmark)

    Cardwell, Chris R; Pottegård, Anton; Vaes, Evelien

    2016-01-01

    BACKGROUND: Preclinical studies have demonstrated that propranolol inhibits several pathways involved in breast cancer progression and metastasis. We investigated whether breast cancer patients who used propranolol, or other non-selective beta-blockers, had reduced breast cancer-specific or all......-cause mortality in eight European cohorts. METHODS: Incident breast cancer patients were identified from eight cancer registries and compiled through the European Cancer Pharmacoepidemiology Network. Propranolol and non-selective beta-blocker use was ascertained for each patient. Breast cancer-specific and all......-analysis techniques. Dose-response analyses by number of prescriptions were also performed. Analyses were repeated investigating propranolol use before cancer diagnosis. RESULTS: The combined study population included 55,252 and 133,251 breast cancer patients in the analysis of breast cancer-specific and all...

  5. Breast Cancer Risk Prediction Models

    Science.gov (United States)

    Developing statistical models that estimate the probability of developing breast cancer over a defined period of time will help clinicians identify individuals at higher risk of specific cancers, allowing for earlier or more frequent screening and counseling of behavioral changes to decrease risk.

  6. Lung cancer after treatment for breast cancer.

    Science.gov (United States)

    Lorigan, Paul; Califano, Raffaele; Faivre-Finn, Corinne; Howell, Anthony; Thatcher, Nick

    2010-12-01

    Breast cancer is the most common cancer in women, and the second most common cause of cancer death after lung cancer. Improvements in the outcome of breast cancer mean that more patients are living longer and are, therefore, at risk of developing a second malignancy. The aim of this review is to present the current understanding of the risk of lung cancer arising in patients previously treated for early stage breast cancer. We review data on the effect of treatment factors (ie, surgery type, radiotherapy technique, and adjuvant chemotherapy) and patient factors (ie, age and smoking) on the risk of developing a subsequent lung cancer. The evidence suggests that older radiotherapy techniques were associated with a substantially increased risk of developing lung cancer in the ipsilateral lung, but there is no clear evidence of an increased risk with modern techniques. Smoking is an important risk factor, and increases the risk of lung cancer in those receiving radiotherapy. Adjuvant chemotherapy is not significantly associated with an increased risk. The risk of developing lung cancer increases with time elapsed since treatment, but any effect of age at treatment is unclear.

  7. Hormone Therapy for Breast Cancer in Men

    Science.gov (United States)

    ... of testosterone and other androgens (male hormones). Most male breast cancers have androgen receptors that may cause the cells ... into estrogens in the body. Orchiectomy shrinks most male breast cancers, and may help make other treatments like tamoxifen ...

  8. Breast Cancer and the Environment Research Program

    Science.gov (United States)

    The Breast Cancer and the Environment Research Program supports a multidisciplinary network of scientists, clinicians, and community partners to examine the effects of environmental exposures that may predispose a woman to breast cancer throughout her life.

  9. Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy

    Science.gov (United States)

    2015-05-01

    Male Breast Cancer; Neurotoxicity; Peripheral Neuropathy; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer

  10. Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer

    Science.gov (United States)

    2017-02-17

    Estrogen Receptor Positive; Postmenopausal; Stage 0 Breast Cancer; Stage I Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer

  11. THERAPEUTIC OPTIONS FOR BREAST CANCER

    Directory of Open Access Journals (Sweden)

    Milena Georgescu

    2011-12-01

    Full Text Available Breast cancer remains a major public health problem, being the second cause of cancer death in women. There is a marked tendency to restrict the extension of surgical gesture, which directly leads to two different attitudes: radical surgery and conservative surgery, to which, at least in our country, there are still some delays. Prospective and retrospective studies have shown that, in 20 years, conservative and radical therapy had about the same rate of survival and disease-free interval, at least for stage I and II breast cancer, the only real counterargument against conservative surgery being that, in principle, the higher rate of recurrence local constraint can be solved by postoperative radiotherapy. Finally, the survival rate is the main parameter of evaluation, assessing the effectiveness of the treatment in breast cancer, and in all its other forms.

  12. Fluorescence agent and methylene blue in sentinel lymph node biopsy for patients with breast cancer%荧光剂联合亚甲蓝注射在早期乳腺癌前哨淋巴结活检中的应用

    Institute of Scientific and Technical Information of China (English)

    覃天; 吴永晓; 黄临凌

    2015-01-01

    Objective To analyze the value of sentinel lymph node biopsy (SLNB)in predicting axillary lymph node status by injection of fluorescence agent and methylene blue.Methods 156 breast cancer patients receiving surgery from Oct.2013 to Jun.2014 were studied and they were randomly divided into the experimental group(n =78) and the control group(n =78).The fluorescent agent combined with methylene blue and methylene blue were used respectively as tracers for SLNB.Axillary lymph nodes dissection was made during surgery and combined with pathology the status of sentinel lymph node(SLN) metastasis was distinguished between true negative,false negative,true positive,and false positive.Results A total of 164 SLNs were detected by the method of fluorescent agent combined with methylene blue with the detection rate of 97.44%.An average of 2.10 SLNs were detected for each patient.The accuracy rate was 97.44%,the sensitivity was 97.44%,the false negative rate and the false positive rate was 0% and 0%.A total of 139 SLNs were detected by the method of methylene blue with the detection rate of 89.74%.An average of 1.78 SLNs were detected for each patient.The accuracy rate was 89.74%,the sensitivity was 89.74%,the false negative rate and the false positive rate was 10.26% and 3.85%.There was statistical difference between the two groups in the average detection number and the false negative rate (P < 0.05)while no statistical difference was found in the detection rate,accuracy,or sensitivity between the two groups (P > 0.05).Conclusion Fluorescent agent combined with methylene blue as tracer for lymph nodes has the advantages of higher detection rate and less trauma,which is worth of clinical application.%目的 通过荧光剂和美蓝联合注射,进行乳腺癌前哨淋巴结活检(sentinel lymph node biopsy,SLNB),分析其预测腋窝淋巴结状态的应用价值.方法 2013年10月至2014年6月接受手术的156例女性乳

  13. The Epidemiology of Male Breast Cancer.

    Science.gov (United States)

    Ferzoco, Raina M; Ruddy, Kathryn J

    2016-01-01

    Male breast cancer is a rare disease, accounting for only 1% of breast cancer diagnoses in the USA. The current literature suggests that genetic factors including BRCA2 mutations, family history, age, androgen/estrogen imbalance, and environmental exposures may predispose to male breast cancer. In this manuscript, we will review known and possible risk factors for male breast cancer, as well as describe the clinical patterns of the disease.

  14. Prevention of ER-Negative Breast Cancer

    OpenAIRE

    Li, Yuxin; Brown, Powel H.

    2009-01-01

    The successful demonstration that the selective estrogen receptor modulators (SERMs) tamoxifen and raloxifene reduce the risk of breast cancer has stimulated great interest in using drugs to prevent breast cancer in high-risk women. In addition, recent results from breast cancer treatment trials suggest that aromatase inhibitors may be even more effective at preventing breast cancer than are SERMs. However, while SERMs and aromatase inhibitors do prevent the development of many estrogen-recep...

  15. A pesquisa do linfonodo sentinela para o câncer de mama na prática clínica do ginecologista brasileiro The sentinel lymph node biopsy in breast cancer in the practice of the Brazilian gynecologist: a revision

    Directory of Open Access Journals (Sweden)

    Luis Gerk de Azevedo Quadros

    2007-03-01

    Full Text Available O estudo histopatológico dos linfonodos axilares continua sendo o melhor parâmetro para a avaliação do prognóstico do câncer de mama. No entanto, como em cerca de 80% das pacientes com tumores de até 2 cm os linfonodos não apresentam comprometimento neoplásico, foi proposta, há alguns anos, a dissecção do linfonodo sentinela, reduzindo a morbidade cirúrgica nas pacientes com resultado negativo. Recentemente, esta técnica cirúrgica disseminou-se no Brasil, mas existem duas questões importantes: qual a probabilidade de resultado falso-negativo, ou seja, deixar de identificar um linfonodo comprometido pelo câncer, e se o subestadiamento pelo resultado falso-negativo exporia a paciente ao risco de recidiva axilar ou mesmo metástase a distância, pela utilização de terapia cirúrgica e adjuvante menos agressiva. A revisão da literatura mostra que a taxa de falsos-negativos varia de 5 a 10%, sendo o principal fator associado à falta de experiência do cirurgião. Embora as recidivas axilares sejam raras, não é ainda possível avaliar o efeito a longo prazo de deixar de retirar linfonodos comprometidos, devido ao curto período de seguimento. Portanto, a recomendação é que o linfonodo sentinela só seja realizado por cirurgiões com experiência comprovada pela pequena taxa de resultados falso-negativos.Axillary nodal metastasis is still the most important breast cancer prognostic factor. As in approximately 80% of the patients with tumors measuring less than 2 cm the axillary lymph nodes are negative, it has been proposed sentinel lymph node biopsy, reducing surgical morbidity in the patients with negative result. Recently, this technique has been widely used in Brazil, but there are two questions that need to be answered: what is the probability of a false-negative result (not diagnosing a positive lymph node and if the understaging by false-negative result exposes the patient to the risk of axillary recurrence or even

  16. Multi-epitope Folate Receptor Alpha Peptide Vaccine, Sargramostim, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer

    Science.gov (United States)

    2017-01-24

    Bilateral Breast Carcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage III Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Triple-Negative Breast Carcinoma; Unilateral Breast Carcinoma

  17. 乳腺癌前哨淋巴结活检染料选择的实验研究%Experimental study of the choice of vital dyes for sentinel lymph node biopsy in breast cancer

    Institute of Scientific and Technical Information of China (English)

    徐鲲; 刘晓安; 王水; 张小林; 陆辉

    2005-01-01

    目的:通过观察1%异硫蓝(isosulfan blue,IB)、1%专利蓝(patent blue,PB)及1%美蓝(methylene blue,MB)在大耳白家兔腋窝淋巴系统的运行特性,为乳腺癌前哨淋巴结活检(sentinel lymph node biopsy,SLNB)染料选择提供实验依据.方法:30只雌性成年大耳白家兔随机分为3组,每组10只.观察前哨淋巴结(sentinellymph node,SLN)和第二站淋巴结染色时间、染色枚数及褪色时间.结果:染料注射后到达SLN的时间IB组平均为20.6 s;PB组平均为16.8 s;MB组平均为14.7 s,组间比较差异明显(P=0.040).腋窝淋巴结染色枚数3组无明显差异(P=0.235).肉眼观,淋巴结染色以MB组最深,IB组次之,而PB组最浅.第二站淋巴结染色时间IB组平均为45.8 s,PB组为40.6 s,两者比较无差异(P=0.257),MB组为23.5 s,与前两者比较差异明显(均为P=0.000).蓝染淋巴结的褪色时间以PB组最短,(6.4±0.9)min明显褪色,于(32.3±3.3)min完全褪色;IB组次之,(33.9±2.8)min可见明显褪色,于(64.2±2.4)min完全褪色;MB组最长,至6 h淋巴结仍呈深染,组间比较差异明显(均为P=0.000).结论:三种染料各具优缺点,效果相仿.

  18. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01)

    DEFF Research Database (Denmark)

    Galimberti, Viviana; Cole, Bernard F; Zurrida, Stefano

    2013-01-01

    For patients with breast cancer and metastases in the sentinel nodes, axillary dissection has been standard treatment. However, for patients with limited sentinel-node involvement, axillary dissection might be overtreatment. We designed IBCSG trial 23-01 to determine whether no axillary dissection...... was non-inferior to axillary dissection in patients with one or more micrometastatic (≤2 mm) sentinel nodes and tumour of maximum 5 cm....

  19. Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)

    Science.gov (United States)

    2016-10-25

    Breast Tumor; Breast Cancer; Cancer of the Breast; Estrogen Receptor- Negative Breast Cancer; HER2- Negative Breast Cancer; Progesterone Receptor- Negative Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer; Triple-negative Breast Cancer; Triple-negative Metastatic Breast Cancer; Metastatic Breast Cancer

  20. Personalization of loco-regional care for primary breast cancer patients (part 1).

    Science.gov (United States)

    Toi, Masakazu; Winer, Eric P; Benson, John R; Inamoto, Takashi; Forbes, John F; von Minckwitz, Gunter; Robertson, John F R; Grobmyer, Stephen R; Jatoi, Ismail; Sasano, Hironobu; Kunkler, Ian; Ho, Alice Y; Yamauchi, Chikako; Chow, Louis W C; Huang, Chiun-Sheng; Han, Wonshik; Noguchi, Shinzaburo; Pegram, Mark D; Yamauchi, Hideko; Lee, Eun-Sook; Larionov, Alexey A; Bevilacqua, Jose L B; Yoshimura, Michio; Sugie, Tomoharu; Yamauchi, Akira; Krop, Ian E; Noh, Dong Young; Klimberg, V Suzanne

    2015-01-01

    ABSTRACT  Kyoto Breast Cancer Consensus Conference, Kyoto, Japan, 18-20 February 2014 The loco-regional management of breast cancer is increasingly complex with application of primary systemic therapies, oncoplastic techniques and genetic testing for breast cancer susceptibility. Personalization of loco-regional treatment is integral to optimization of breast cancer care. Clinical and pathological tumor stage, biological features and host factors influence loco-regional treatment strategies and extent of surgical procedures. Key issues including axillary staging, axillary treatment, radiation therapy, primary systemic therapy (PST), preoperative hormonal therapy and genetic predisposition were identified and discussed at the Kyoto Breast Cancer Consensus Conference (KBCCC2014). In the first of a two part conference scene, consensus recommendations for axillary management are presented and focus on the following topics: indications for completion axillary lymph node dissection in primary surgical patients with ≤2 macrometastases or any sentinel nodal deposits after PST; the timing of sentinel lymph node biopsy in the context of PST; use of axillary irradiation as a component of primary treatment plans and the role of intraoperative node assessment in the post-Z0011 era.

  1. Internet Use and Breast Cancer Survivors

    Science.gov (United States)

    Muhamad, Mazanah; Afshari, Mojgan; Mohamed, Nor Aini

    2011-01-01

    A survey was administered to 400 breast cancer survivors at hospitals and support group meetings in Peninsular Malaysia to explore their level of Internet use and factors related to the Internet use by breast cancer survivors. Findings of this study indicated that about 22.5% of breast cancer survivors used Internet to get information about breast…

  2. Search for new breast cancer susceptibility genes

    NARCIS (Netherlands)

    Oldenburg, Rogier Abel

    2008-01-01

    This thesis describes the search for new high-risk breast cancer susceptibility genes by linkage analysis. To date 20-25% of familial breast cancer is explained by mutations in the high-risk BRCA1 and BRCA2 breast cancer susceptibility genes. For the remaining families the genetic etiology is unknow

  3. Search for new breast cancer susceptibility genes

    NARCIS (Netherlands)

    Oldenburg, Rogier Abel

    2008-01-01

    This thesis describes the search for new high-risk breast cancer susceptibility genes by linkage analysis. To date 20-25% of familial breast cancer is explained by mutations in the high-risk BRCA1 and BRCA2 breast cancer susceptibility genes. For the remaining families the genetic etiology is

  4. Search for new breast cancer susceptibility genes

    NARCIS (Netherlands)

    Oldenburg, Rogier Abel

    2008-01-01

    This thesis describes the search for new high-risk breast cancer susceptibility genes by linkage analysis. To date 20-25% of familial breast cancer is explained by mutations in the high-risk BRCA1 and BRCA2 breast cancer susceptibility genes. For the remaining families the genetic etiology is unknow

  5. Theranostics Targeting Metastatic Breast Cancer

    Science.gov (United States)

    2016-10-01

    2016. Active Targeting of Cancer Cells, Masaryk University, CZECH REPUBLIC, May 2016. Websites or other Internet sites none Technologies or... trafficking , thus impacting the efficacy of receptor-mediated drug delivery for cancer therapy. These factors include the following: (i) the rate of ligand...The V, Labrie C, Belanger A, Simard J, Lin SX, Pelletier G. Endocrine and intracrine sources of androgens in women : Inhibition of breast cancer and

  6. Male breast cancer: a review of literature

    Directory of Open Access Journals (Sweden)

    Sodabe Shahidsales

    2017-05-01

    Full Text Available Studies have devoted relatively scant attention to male breast cancer compared with female breast cancer. Nevertheless, the incidence of male breast cancer has increased considerably in parallel manner with women. There is not comprehensive knowledge regarding the etiology of breast cancer in men. The environmental agents and genetic factors are proposed as the influential parameters in the pathogenesis of breast cancer. Invasive ductal carcinoma is the most frequent subtype of breast cancer in men and a palpable mass is the most common presentation. Breast masses might be identified at advanced stages of the disease, if undiagnosed, due to the lower prevalence and lack of awareness in men compared to women. There is not any large sample size trial or retrospective study regarding any specific treatment strategy; the routine treatments are based on existing data. In this review, we studied the risk factors, biological characteristics, and therapeutic strategies of breast cancer in men.

  7. Endocrine Therapy of Breast Cancer

    Science.gov (United States)

    2009-06-01

    inhibitor of both the src and abl kinases, selectively inhibits growth of basal -type/“triple-negative” breast cancer cell lines growing in vitro. Breast...Welch JN, Lu J, Liu A, Zhu Y, Davis N, Leonessa F, Brunner N, Wang Y, Clarke R. Association of interferon regulatory factor-1, nucleo - phosmin...nmol/L 4HT (within the range of clinically relevant concentrations; ref. 10) was designated SUM44/LCCTam (hereafter called LCCTam). The basal growth

  8. Angiogenesis in male breast cancer

    Directory of Open Access Journals (Sweden)

    Kanthan Rani

    2005-03-01

    Full Text Available Abstract Background Male breast cancer is a rare but aggressive and devastating disease. This disease presents at a later stage and in a more advanced fashion than its female counterpart. The immunophenotype also appears to be distinct when compared to female breast cancer. Angiogenesis plays a permissive role in the development of a solid tumor and provides an avenue for nutrient exchange and waste removal. Recent scrutiny of angiogenesis in female breast cancer has shown it to be of significant prognostic value. It was hypothesized that this holds true in invasive ductal carcinoma of the male breast. In the context of male breast cancer, we investigated the relationship of survival and other clinico-pathological variables to the microvascular density of the tumor tissue. Methods Seventy-five cases of primary male breast cancer were identified using the records of the Saskatchewan Cancer Agency over a period of 26 years. Forty-seven cases of invasive ductal carcinoma of the male breast had formalin-fixed paraffin-embedded tissue blocks that were suitable for this study. All cases were reviewed. Immunohistochemical staining was performed for the angiogenic markers (cluster designations 31 (CD31, 34 (CD34 and 105 (CD105, von Willebrand factor (VWF, and vascular endothelial growth factor (VEGF. Microvascular density (MVD was determined using average, centre, and highest microvessel counts (AMC, CMC, and HMC, respectively. Statistical analyses compared differences in the distribution of survival times and times to relapse between levels of MVD, tumor size, node status and age at diagnosis. In addition, MVD values were compared within each marker, between each marker, and were also compared to clinico-pathological data. Results Advanced age and tumor size were related to shorter survival times. There were no statistically significant differences in distributions of survival times and times to relapse between levels of MVD variables. There was no

  9. Epigenetic Testing for Breast Cancer Risk Stratification

    Science.gov (United States)

    2014-06-01

    breast cancer risk. Cancer epidemiology , biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the...markers optimized for fine-needle aspiration samples. Cancer epidemiology , biomarkers & prevention : a publication of the American Association for

  10. Secretory breast cancer. Case report.

    Science.gov (United States)

    Lombardi, A; Maggi, S; Bersigotti, L; Lazzarin, G; Nuccetelli, E; Amanti, C

    2013-04-01

    Secretory carcinoma of the breast is a rare tumor initially described in children but occurring equally in adult population. This unusual breast cancer subtype has a generally favorable prognosis, although several cases have been described in adults with increased aggressiveness and a risk of metastases. However, surgery is still considered the most appropriate treatment for this pathology. We describe the case of a 50 -year-old woman who has undergone a breast conservative surgery for a little tumor, preoperatively diagnosticated by a fine needle aspiration biopsy (FNAB) as a well differentiated infiltrating carcinoma.

  11. Problems and pitfalls in vulvar and cervical cancer sentinel node scintigraphy

    Directory of Open Access Journals (Sweden)

    Helmut Sinzinger

    2008-12-01

    Full Text Available After the introduction for penile cancer, the sentinel lymph node imaging is increasingly applied in various types of cancer. After the initial learning phase, 105 patients with vulvar and 24 with cervical cancer have been investigated. In vulvar cancer all the imaged sentinel nodes were discovered by the portable probe intraoperatively. No false negative sentinel node was observed. The most critical issue is the tracer application. Performed strictly intradermally, the sentinel node shows up immediately. Concomitant use of isosulfan blue dye did not improve the results and was stopped therefore. Similarly, more superficial (intra/subendothelial application brings up better results as compared to deeper injection in cervical cancer patients. No false negative results were seen. Apparently, an almost 100% detection is possible. Our findings clearly show that tracer application is the key for successful imaging. If not done properly, sentinel node may appear later or may even more likely be missed.Após a introdução para câncer do pênis, a imagem do linfonodo sentinela é cada vez mais aplicada nos diversos tipos de câncer. Após a fase inicial de aprendizagem, 105 pacientes com câncer vulvar e 24 com câncer cervical foram investigados. No câncer vulvar todas as imagens de nodos sentinela foram descobertas por sonda portátil durante o exame. Nenhum nodo sentinela falso negativo foi observado. A questão mais crítica é a aplicação do traçador. Realizada pela via intradérmica, o nodo sentinela surge imediatamente. O corante isosulfan blue não melhora os resultados e seu uso concomitante foi abandonado. Do mesmo modo, a aplicação mais superficial (intra/subendotelial apresenta melhores resultados quando comparada com a administração mais profunda em pacientes com câncer cervical. Não foram observados resultados falsos negativos. Aparentemente, uma detecção de aproximadamente 100% é possível. Nossos achados mostram claramente

  12. Video-assisted breast surgery and sentinel lymph node biopsy guided by three-dimensional computed tomographic lymphography.

    Science.gov (United States)

    Yamashita, K; Shimizu, K

    2008-02-01

    Video-assisted breast surgery (VABS) is a less invasive and aesthetically better option for benign and malignant breast diseases and for sentinel lymph node biopsy (SLNB). The authors have performed 150 VABS procedures since December 2001. They have examined the usefulness of three-dimensional computed tomographic (3D-CT) lymphography for detecting sentinel lymph nodes (SLNs) precisely, as well as the cosmetic and treatment results of VABS. In this study, VABS was performed with a 2.5-cm skin incision in the axilla or periareola (1 cm in the axilla for SLNB), using a retraction method, for mammary gland resection, SLNB, axillary lymph node dissection, and breast reconstruction under video assistance. On the day before the surgery, 3D-CT lymphography was performed to mark SLN on the skin. Above the tumor and near the areola, 2 ml of Iopamiron 300 was injected subcutaneously. A 16-channnel multidetector-row helical CT scan image was taken after 1 min and reconstructed to produce a 3D image. Sentinel lymph node biopsy was performed by the VABS technique using the Visiport. The VABS procedure was performed for 19 benign and 131 malignant diseases, and 115 SLNBs (74 with 3D-CT) were performed. The SLNs were shown precisely by 3D-CT lymphography, as proved by a case of lymph node metastasis, in which accurate relationships between lymph ducts and SLNs were shown. These were classified into four patterns: a single duct to single node (40 cases), multiple ducts to a single node (13 cases), a single duct to multiple nodes (1 case), and multiple ducts to multiple nodes (12 cases). The SLNB procedure can be performed safely by 3D-CT lymphography and less invasively by VABS. The findings show that 3D-CT lymphography is useful for performing precise SLNB using VABS.

  13. Breast cancer: an overview of nuclear medicine imaging and treatment

    Energy Technology Data Exchange (ETDEWEB)

    Munro, P. [QEII/Dalhousie School of Health Sciences, Halifax, Nova Scotia (Canada)

    2005-01-01

    The purpose of this overview is to introduce the diagnostic and therapeutic procedures routinely used in the management of the patient with breast cancer and includes what some may consider being the future of nuclear medicine, positron emission tomography. Imaging the breast with {sup 99m}Tc MIBI to lymphatic mapping and the search for the sentinel lymph node for biopsy purposes, as well as bone scans used in the search for metastases will be discussed. Wall motion and ejection fraction studies are discussed as a monitoring tool for patients requiring cardiotoxic chemotherapy. The final section of the synopsis deals with the treatment of bone metastases for the purpose of palliation of this often debilitating disease. (author)

  14. Educação a distância mediada pela internet: "Linfonodo sentinela, prevenção, diagnóstico precoce e biópsia - nova técnica de abordagem do câncer de mama" Internet-conducted distance education: "Sentinel lymph node, prevention, early diagnosis and biopsy - a new technique for approaching breast cancer"

    Directory of Open Access Journals (Sweden)

    Santuzza Kelmer

    2007-08-01

    Full Text Available OBJETIVO: O objetivo deste estudo é o desenvolvimento e a aplicação de um curso na modalidade "Educação a distância mediada pela internet". MATERIAIS E MÉTODOS: Foi utilizado o curso "Linfonodo sentinela, prevenção, diagnóstico precoce e biópsia - nova técnica de abordagem do câncer de mama" como modelo de aplicação. O material didático para a modalidade "Educação a distância" foi elaborado visando a um público composto por médicos envolvidos com o tratamento do câncer de mama. O curso foi estruturado em ambiente virtual de aprendizagem, um espaço virtual que permitiu a interação entre os participantes. RESULTADOS: A duração do curso foi de 12 semanas. Iniciou-se com nove participantes, médicos ginecologistas com pelo menos oito anos de experiência profissional. Todos os alunos participaram de alguma forma, dois realizaram exercícios e interagiram. O alcance do curso pelo método atingiu quatro estados e oito municípios. Não ocorreu adesão integral dos alunos, apesar de a maioria permanecer até o fim do curso. Possivelmente, não houve motivação suficiente para participação nas atividades propostas. CONCLUSÃO: Os resultados mostram que é necessário quebrar as barreiras da falta de cultura relacionada a esta forma de aprendizagem. É fundamental a participação facilitadora do coordenador para integração e mobilização dos participantes.OBJECTIVE: The present study was aimed at developing and delivering a course in the modality "Internet-conducted distance education". MATERIALS AND METHODS: The theme "Sentinel lymph node, prevention, early diagnosis and biopsy - a new technique for approaching breast cancer" was utilized as an application model, and the didactic material for distance-learning was targeted to a selected audience of physicians involved in the treatment of breast cancer. The course was structured in a virtual learning environment, allowing interaction among participating students. RESULTS

  15. 乳腺癌前哨淋巴结活检常用染料效果实验研究%Experimental study of the choice of vital dyes for sentinel lymph node biopsy in breast cancer

    Institute of Scientific and Technical Information of China (English)

    徐鲲; 刘晓安; 王水; 王振中

    2005-01-01

    目的通过动态观察国内外最常使用的3种生物活性染料:1%异硫蓝(isosulfan blue,IB)、1%专利蓝(patent blue,PB)及1%美蓝(methylene blue,MB)在大耳白家兔第二对乳腺至腋窝淋巴系统的运行特性,为临床选取理想的染料示踪剂行乳腺癌前哨淋巴结活检(sentinel lymph node biopsy,SLNB)提供实验依据.方法30只雌性大耳白家兔随机分为3组,每组10只.全麻后,首先分离皮瓣,暴露部分第二对乳腺、连接乳腺与腋窝淋巴结之间的淋巴管以及腋窝,向第二对乳腺注射不同染料0.1ml,取染料经淋巴管到达的第一站淋巴结为前哨淋巴结(sentinellymph node,SLN),观察SLN和第二站淋巴结染色的时间、淋巴结染色枚数以及淋巴结的褪色时间.结果注射后,染料到达腋窝第一站淋巴结的时间以IB组最长,平均为20.6秒;PB组其次,平均16.8秒;MB组最短,平均14.7秒,